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aso-PC     L-α-phosphatidylcholine from soybean, type IV-S 
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DMPC     1,2-dimyristoyl-sn-phosphatidylcholine 
DMSO     dimethyl  sulfoxide 
DNA     desoxyribonucleinacid 
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dNTP     desoxyribonucleitriphosphate 
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E. coli     Escherischia coli 
EDTA     ethylenediaminetetraacetic  acid 
e.g.     for  example 
EM     electron  microscopy 
ER     endoplasmic  reticulum 
ESI     electrospray  ionisation 
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ETA      endothelin A receptor 
ETB      endothelin B receptor 
et al.      and others 
EtBr     ethidium  bromide 
f-4-Ala-ET-1    fluorescein labelled 4 – alanine 1,3,11,15 mutant ET-1 
FM     feeding  mix 
FPLC      fast performance liquid chromatography 
Fos-12     n-dodecylphosphocholine 
Fos-16     n-hexadecylphosphocholine 
FRET      fluorescence resonance energy transfer 
g     gram 
GFP      green fluorescence protein 
GPCR      G-protein coupled receptor 
h     hour(s) 
HDM     n-hexadecyl-β-D-maltoside 
HEPES     4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC      high performance liquid chromatography 
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HSQC      heteronuclear single quantum coherence 
IB     inclusion  body 
IC50      half maximal inhibitory concentration 
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IMAC      immobilized metal affinity chromatography 
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L     liter(s) 
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NC     negative  control 
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nL     nanoliter(s) 
nm     nanometer 
NMR      nuclear magnetic resonance 
NTP     nucleotide  triphosphate 
NTR     neurotensin  receptor 
o. n.      over night 
P     pellet 
PAGE      polyacrylamide gel electrophoresis 
PC     phosphatidylcholine Abbreviations     VII 
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of hydrophobic substances 
PCR      polymerase chain reaction 
PE     phosphatidylethanolamine 
PEI     polyethyleneimine 
PEP     phosphoenol  pyruvate 
PG     phosphatidylglycerol 
PI     phosphatidylinositol 
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RM     reaction  mix 
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RT     room  temperature 
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S     supernatant 
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tRNA     transfer  RNA 
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Tween 20    polyoxyethylene-sorbitane-monolaurate 20 
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Summary 
 
G-protein coupled receptors (GPCRs) are the most abundant class of cell surface receptors 
encoded by the human genome. They are the key players in signal perception and transduction 
which makes them consequently to one of the currently most important class of drug targets. 
Approximately 50  % of market pharmaceuticals are directed against them. The majority of 
GPCRs is expressed at very low levels in native tissues rendering it virtually impossible to 
obtain amounts sufficient for the determination of their three-dimensional structure. 
Heterologous overexpression in cell-based systems as an indispensable prerequisite for 
structural analysis of most GPCRs has therefore been approached but remains a challenge now 
for decades. The recent few successful structural approaches result from sophisticated and 
elaborated strategies solely adapted to single targets. The major bottleneck for structural 
determination of GPCRs is hence to obtain milligram quantities of highly pure, homogenous 
and stable protein. 
Instead of using conventional in vivo expression hosts, I focused on the alternative 
cell-free (CF) expression strategy for the production and characterization of the human 
endothelin (ET) receptom in this study. The receptor associated system is one of the major 
modulators in cardiovascular regulation and plays a crucial role in mitogenesis. Many 
civilisatory disorders are associated with its dysfunction and ET antagonism is considered to be 
a possible treatment of diseases like heart failure, hypertension, diabetes, artherosclerosis and 
even cancer. 
CF expression has emerged as a highly competitive, powerful technique to overcome 
major restrictions of classical in vivo MP production as it eliminates the complexity of a living 
host cell. Its open nature and high versatility offers in addition a variety of valuable advantages 
that can be adapted to the needs of the target protein. 
As initial comparisons between self-made eukaryotic wheat germ CF extracts and a self-made 
prokaryotic E. coli CF expression system did not show any benefit of the eukaryotic background 
with regard to the productivity of the human endothelin B receptor (ETB) I chose the easier to 
handle prokaryotic source for further studies. 
The major task of this thesis was the development of preparative scale expression 
protocols for the endothelin A receptor (ETA) in qualities sufficient for structural analyses 
along with the set-up of target specific optimization protocols. The versatility of the CF 
expression system was used to modulate its sample quality by alteration of detergents hence 
presenting different solubilization environments to the synthesized protein at different stages of 
the production process. Sample properties after co- and post-translational solubilization have 2   Summary 
 
been analysed by the evaluation of homogeneity, protein stability and receptor ligand binding 
competence. 
After basic optimization I was able to produce up to 2-3 mg/mL of ETA in the precipitate 
generating continuous exchange (P-CF) mode. The resolubilization in LPPG was quantitative 
and resulted in a homogenous sample preparation as evaluated by BN-PAGE and size exclusion 
chromatography (SEC). Detergent-based expression (D-CF) in contrast showed an apparently 
lower homogeneity. Analysis of the initial P-CF ETA precipitate by solid-state NMR (Karsten 
Mörs, group of Prof. Clemens Glaubitz) already revealed an estimated amount of 30-40 % of 
α-helical secondary structure elements, only slightly lower than the determined and predicted 
values and supported further the use of P-CF expressed receptor. 
Highest purity with over 90 % along with the highest yield of up to 1 mg/mL were 
achieved upon purification by metal chelate chromatography coupled to a detergent exchange or 
to a reduction of detergent concentration from LPPG in LPPG, B35 and Fos-16. In those 
conditions, ETA showed a high degree of apparent homogeneity and stability at 4 °C for at least 
one week evaluated by its elution profiles in SEC analyses. By circular dicroism (CD) 
spectroscopy at 222  nm, the secondary structure of ETA was further characterized by a 
transition at ~85 °C under optimal conditions, indicating a very high thermostability in B35. 
Monodispersity of ETA was most prominent in B35 as supported by electron micrographs of 
negatively stained samples. BN-PAGE and SDS-PAGE analysis hinted to a potential formation 
of SDS-resistant dimers/oligomers of ETA which was supported by ESI mass spectrometry. A 
similar behaviour has been detected in native receptors in literature before. The equilibrium in 
between monomeric and dimeric CF expressed ETA could obviously be triggered by the 
surrounding micelles like multi angle light scattering (MALS) experiments suggested. Whereas 
in Fos-16 ETA seemed to be mostly monomeric, coexistent dimer and monomer fractions were 
obtained in B35. Moreover, first hints of a potential homo- or hetero-oligomerization behaviour 
of CF expressed ETA and ETB receptors were obtained by co-expression of full-length 
receptors with various designed truncated derivatives and subsequent pull-down assays. 
Negative controls which resulted in false positives pointed however at the need of 
complementary approaches to support these initial findings. 
Functional folding of ETA was evaluated by different approaches in present thesis. 
Classical post-translational in vitro reconstitution in artificial liposomes revealed homogenously 
distributed particles by freeze-fracture analysis. Equilibrium dissociation constants (KD) of 
1.4 nM for its circular ligand 
125I-endothelin 1 (ET-1) were determined and IC50 values of 
2.17 µM for homologous competition were obtained. Lipid-based CF (L-CF) expressed ETA 
used for co-translational reconstitution further showed preliminary ligand binding capacity. 
The ligand binding competence of detergent-solubilized ETA receptor was investigated by 
ligand affinity chromatography and fluorescence anisotropy. An efficient and reliable protocol Summary     3 
 
for the purification of ligand-bound CF expressed ETA was therefore developed based on a 
biotinylated ligand variant (b-ET-1) immobilized on monomeric avidin agarose beads. 
Dependent on different production modes and diverse micellar environments, different degrees 
of ligand binding competence were obtained. Binding of ETA to its ligand ET-1 at levels of up 
to 50  % in B35 resulted in the isolation of up to 0.5  mg/mL binding competent receptor. 
Fluorescence anisotropy of ETA in B35 further supported functional folding. A KD of the linear 
fluorescein-labelled mutant of ET-1 (f-4-Ala-ET-1) was determined at around 1.2 µM which is 
comparable to published values of crude membrane fractions. 
X-ray crystallization trials were started with ETA in B35 but in initial condition screens 
no crystals have been obtained yet. Tendencies towards the formation of microcrystals might 
however hint to a future potential under optimized conditions. 
As a basis to alternative structural analyses using nuclear magnetic resonance (NMR) 
spectroscopy the use of self-splicing split inteins for the segmental labelling of the 
transmembrane segment 1 was successfully approached by CF synthesis. However, as the final 
yield of the end product was very low, optimization of constructs as well as of the splicing 
reaction itself should be prime parameters before setting up NMR studies. 
The obtained results document the CF production of the ETA receptor in two different 
modes as an example of a class A GPCR in ligand-binding competent and non-aggregated form 
in quantities sufficient for structural approaches. The presented strategy could serve as basic 
guideline for the production of related receptors in similar systems. 
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Zusammenfassung 
 
G-Protein gekoppelte Rezeptoren (GPCRs), bilden mit etwa 3  % die größte Klasse an 
Zelloberflächenrezeptoren im menschlichen Proteom. Ihre Hauptaufgabe besteht in der 
Aufnahme einer Vielzahl externer Stimuli. Infolgedessen, meist durch dynamische Interaktion 
mit heterotrimeren G-Proteinen ausgelöst, werden diese Stimuli zu einer spezifischen 
intrazellulären Antwort umgesetzt. Durch ihre bedeutende Funktion bei der Verarbeitung 
vielfältiger Umweltsignale und bei der Steuerung physiologischer Abläufe im menschlichen 
Organismus ist es nicht verwunderlich, dass GPCRs mit einem Anteil von rund 50 % zu den 
wichtigsten Angriffspunkten heutiger Arzneimittel gehören und daher im Fokus der 
biochemischen und pharmakologischen Forschung stehen. 
Hochaufgelöste dreidimensionale Strukturen stellen nach wie vor die Grundlage für die 
Aufklärung der Funktionsweise dieser Proteine auf molekularer Ebene dar. Sie sind essentiell, 
um wirksame und spezifisch abgestimmte Medikamente zu entwickeln. Die Mehrheit der 
GPCRs wird allerdings auf sehr geringem Niveau in nativen Geweben produziert. Somit ist es 
nahezu unmöglich, ausreichende Mengen homogener und stabiler Proteine zu ihrer strukturellen 
Aufklärung zu gewinnen. Heterologe Überexpression wird daher als unabdingbare Voraus-
setzung für die strukturelle Analyse der meisten GPCRs angesehen und viele Systeme wurden 
intensiv auf ihre Anwendbarkeit untersucht. Die Überexpression der Zielproteine in 
konventionellen zell-basierenden Systemen ist aber seit Jahrzehnten schon eine 
Herausforderung, da sie oft mit einer zytotoxischen Wirkung auf den Organismus einhergeht 
und die funktionelle Extraktion aus den Zellmembranen in präparativen Mengen häufig große 
Schwierigkeiten bereitet. 
Die vorliegende Arbeit konzentrierte sich daher nicht auf die Anwendung klassischer in 
vivo Expressionsysteme für die Überproduktion von GPCRs, sondern auf die Entwicklung 
effizienter Syntheseprotokolle in alternativen selbst hergestellten zellfreien Expressions-
systemen. Als Zielproteine wurden die humanen Endothelin (ET)-Rezeptoren gewählt, die sich 
durch eine hohe pharmakologische Relevanz auszeichnen. Das humane ET-System ist einer der 
wichtigsten Modulatoren des kardiovaskulären Systems und spielt zudem eine essentielle Rolle 
bei Zellproliferation und Mitogenese. Es besteht aus zwei Rhodopsin-ähnlichen GPCRs, dem 
Endothelin A (ETA) und dem Endothelin B Rezeptor (ETB). Der prinzipielle Agonist des 
kardiovaskulären Systems ist das zyklische und hochkomplexe Peptid ET-1, das zu beiden 
Rezeptoren gleiche Affinität besitzt. Trotz einer Identität ihrer Aminosäuresequenz von 59 % 
unterscheiden sich die beiden Rezeptoren hinsichtlich ihres physiologischen Wirkspektrums. 
Eine Stimulation von ETA führt beispielsweise zur Vasokonstriktion während ETB eine 
vasodilatierende Wirkung zugeschrieben wird. Viele bekannte Zivilisationskrankheiten werden Zusammenfassung    5 
 
mit endothelialer Fehlfunktion assoziiert. ET-Rezeptor-Antagonismus wird daher unter anderem 
als potente Methode zur Behandlung von Herzinsuffizienz, Bluthochdruck, Diabetes, 
Atherosklerose und sogar von Krebs aufgefasst. 
Die zellfreie Expression hat sich zu einer hochkompetitiven, potenten Technik, 
insbesondere auch zur Produktion von Membranproteinen, entwickelt. Durch die Arbeit mit 
Zellextrakten wird die Komplexität lebender Zellen beseitigt, der Produktionsprozess 
vereinfacht, und somit einige Hauptprobleme konventioneller in vivo Membranprotein-
Expression umgangen. Toxische Effekte der synthetisierten Proteine auf den Expressions-
organismus treten nicht auf und die Geschwindigkeit der zellfreien Reaktion mit hohen 
Produktionsraten macht sie interessant für strukturelle Untersuchungen. Zusätzlich ermöglicht 
die zellfreie Synthese durch direkte Zugänglichkeit zur Reaktion eine individuelle, auf das 
jeweilige Zielprotein abgestimmte Optimierung. Frisch translatierte Proteine können durch eine 
Reihe fördernder Additive zu jedem Zeitpunkt des Syntheseprozesses stabilisiert werden. 
Das in dieser Arbeit verwendete zellfreie Expressionssystem beruht auf einem 
optimierten  E. coli S30-Extrakt, der alle wichtigen hochmolekularen Komponenten zur 
Translation enthält. Zusätzliche Bestandteile und Vorstufen für eine gekoppelte 
Transkriptions/Translations-Reaktion werden noch hinzugefügt. Ein effizientes System zur 
Energieregeneration ist ebenfalls integraler Bestandteil der zellfreien Synthese. Zur Herstellung 
der ET-Rezeptoren wurde die „continuous-exchange cell-free“ Konfiguration verwendet, die 
durch ein Dialyseverfahren eine Akkumulation inhibierender Nebenprodukte verhindert und 
gleichzeitig die weitere Versorgung der Reaktionslösung mit Substraten gewährleistet. Dieser 
Aufbau, der durch lange Reaktionszeiten charakterisiert ist, erlaubt eine effiziente Produktion 
der Zielproteine sowohl im analytischen (~50  µL) als auch im präparativen Maßstab von 
≥1 mL. 
Die Hauptaufgabe der vorliegenden Dissertation bestand in der Entwicklung 
Zielprotein-spezifischer, effizienter Syntheseprotokolle für GPCRs am Beispiel des humanen 
ET-Rezeptoms in zellfreien Expressionssystemen. Da initiale Mengenanalysen des zellfrei 
exprimierten ETB Rezeptors und Hinweise auf eine ähnliche Qualität keine ersichtlichen 
Vorteile in selbst hergestellten eukaryotischen Weizenkeimextrakten aufzeigten, wurde für 
weitere Untersuchungen das verlässlich etablierte auf E. coli basierende prokaryotische Zellfrei-
System angewandt. 
Im Speziellen sollte der ETA Rezeptor in diesem System in präparativen Mengen 
gewonnen und seine Qualität für funktionelle und strukturelle Charakterisierung optimiert 
werden. Die Vielseitigkeit der zellfreien Proteinsynthese wurde dazu genutzt, die Probenqualität 
von ETA durch Variation von Detergenzien zu beeinflussen, indem um ETA verschiedene 
mizellare Umgebungen zu unterschiedlichen Phasen des Produktionsprozesses generiert 
wurden. Die Probenqualität nach ko- und post-translationeller Solubilisierung wurde 6   Zusammenfassung 
 
anschließend anhand von Parametern wie Homogenität, Proteinstabilität sowie Liganden-
bindungs-Kompetenz analysiert. Zur funktionellen Analyse von zellfrei exprimiertem Rezeptor 
wurden hier verschiedene Methoden etabliert. 
Alternativ sollte ETA in artifizielle Liposomen rekonstituiert werden, um einen 
Vergleich zu in vivo exprimierten ET-Rezeptoren zu ermöglichen, deren Funktionalität 
üblicherweise in Membranfraktionen bestimmt wird. Entsprechende Radioliganden-
Experimente wurden zu diesem Zweck eingeführt. Einerseits wurde hierzu die klassische post-
translationelle Rekonstitution angewandt und deren Effizienz durch Optimierung spezifischer 
Parameter anhand von Messung der Funktionalität evaluiert. Zusätzlich wurde ein dritter 
zellfrei-spezifischer Modus zur Rekonstitution von ETA untersucht. Die direkte Zugabe von 
artifiziellen Liposomen im Lipid basierenden Modus (L-CF) wurde für ETA implementiert und 
vorläufige Untersuchungen zur Insertionseffizienz unternommen. 
Abschließend wurden Untersuchungen zum Oligomerisierungs-Potential der zellfrei 
synthetisierten ET-Rezeptoren durchgeführt. Da in der Oligomerisierung von GPCRs eine hohe 
pharmakologische Relevanz vermutet wird, sollte Aufschluss über das native Verhalten der 
zellfrei hergestellten Rezeptoren erhalten und mittels verkürzter Varianten der Rezeptoren 
Hinweise auf die mögliche Interaktionsfläche erlangt werden. 
Im P-CF Modus wurden nach Optimierung der Grundparameter präparative Mengen 
von ETA von bis zu 2-3 mg/mL erhalten. Die Resolubilisierung des Präzipitats im Detergenz 
LPPG erwies sich mit 100  % Löslichkeit als am erfolgreichsten. Analytische Gelfiltrations-
experimente der Direktsolubilisate zeigten zudem die höchste Homogenität in LPPG. Blau-
native Polyacrylamid-Gelelektrophorese ließ zusätzlich mono- und dimeren Charakter des 
Proteins in diesem Detergenz vermuten. 
Für die lösliche Produktion von ETA im D-CF Modus wurden der Polyoxyethylen-
Alkyl-Ether Brij 35 (B35) und das Steroid-Derivat Digitonin als geeignet gefunden. Allerdings 
erreichte Digitonin nur eine Solubilisierungseffizienz von 60  %. B35 erlaubte eine 
Produktionsmenge von ETA von maximal 1 mg/mL und lag demnach um durchschnittlich 50 % 
niedriger als die P-CF Expression. Eine Evaluierung der Homogenität der D-CF Probe nach 
Aufreinigung in B35 durch Gelfiltration und Negativfärbung zeigte eine geringere 
Probenqualität, so dass ETA infolgedessen bevorzugt im P-CF Modus synthetisiert wurde. 
Festkörper-Kernmagnetische Resonanz Analysen des P-CF exprimierten ETA 
Rezeptors (Karsten Mörs, Arbeitskreis Prof. Clemens Glaubitz) offenbarten bereits einen 
ungefähren Anteil von 30-40  % α-helikaler Sekundärstrukturelemente in den generierten 
Präzipitaten, so dass sich diese von den klassischen Einschlusskörperchen der in vivo 
Expression abgrenzen ließen. Der geschätzte Prozentsatz lag nur geringfügig niedriger als die 
vorhergesagten Werte von etwa 50 % und die durch Fern-UV CD-Spektroskopie ermittelten Zusammenfassung    7 
 
Werte von 46 % im Detergenz B35, die sich in den charakteristischen Minima bei 208 und 
222 nm widerspiegelten. 
Detergenzaustausch oder Verringerung der Detergenzkonzentration durch Reinigung mittels 
immobilisierter Metallchelat-Affinitätschromatographie wurde im Folgenden zur Modulation 
der mizellaren Umgebung von ETA verwendet, um deren Einfluss auf die Qualität des 
Rezeptors zu untersuchen. Die höchste Reinheit in Verbindung mit der höchsten Ausbeute von 
durchschnittlich 1 mg/mL wurde bei der Aufreinigung von ETA von LPPG zu LPPG (geringere 
Konzentration), B35 oder dem Phosphocholin-Derivat Fos-16 erreicht. Unter diesen 
Bedingungen zeigten Gelfiltrationsanalysen von ETA schlanke Elutionsprofile, die einen hohen 
Grad an Homogenität und zusätzlich eine Stabilität des Zielproteins von mindestens einer 
Woche bei 4 °C erkennen ließen. Negativfärbung unterstützte des Weiteren die Monodispersität 
der P-CF synthetisierten ETA Proben in B35 und LPPG. 
Thermostabilität als eine der Voraussetzungen für Röntgenstrukturanalyse wurde für 
ETA in unterschiedlichen Detergenzien mittels Fern-UV CD-Spektroskopie bei der festgelegten 
Wellenlänge von 222 nm untersucht. Hierbei wurde die Änderung der Elliptitizät während des 
Aufschmelzens der Sekundärstruktur im Temperaturbereich von 4-90 °C untersucht. Eine hohe 
thermische Sekundärstrukturstabilität von ~85 °C zeigte sich bei P-CF exprimiertem und in B35 
aufgereinigtem ETA. Selbst D-CF synthetisiertes ETA in B35 wies eine hohe Stabilität seiner 
Sekundärstrukturelemente mit einer klaren Transition bei 72 °C auf. 
Analysen durch native und denaturierende Gelelektrophorese deuteten des Weiteren auf 
die potentielle Bildung SDS-resistenter Dimere/Oligomere des ETA Rezeptors hin. Diese 
Annahme wurde durch ESI Massenspektrometrie von B35 solubilisiertem Protein unterstützt 
und ist übereinstimmend mit der in der Literatur diskutierten Theorie, dass in nativ gefalteten 
Rhodopsin-ähnlichen GPCRs Oligomere durch robuste hydrophobe Wechselwirkungen 
ausgebildet werden. Das Gleichgewicht zwischen monomerem und dimerem zellfrei 
exprimiertem ETA Rezeptor konnte offenbar zudem durch die den Rezeptor umgebende 
Mizelle gesteuert werden. Vielwinkel-Lichtstreuung (MALS: multi angle light scattering) zeigte 
beispielsweise, dass Fos-16 vorwiegend monomeres ETA generierte, während in B35 
vornehmlich monomere und dimere Formen des Rezeptors koexistierten. 
Erste Anzeichen auf ein natives Verhalten in Bezug auf Homo- und 
Heterodimerisierung beider ET-Rezeptoren wurden durch die lösliche Koexpression der 
kompletten Rezeptoren mit verschiedenen verkürzten Rezeptorderivaten mittels anschließenden 
Affinitäts-‚Pull-Down’ Analysen erlangt. Hierbei wurde einerseits auf die von Dr. Christian 
Klammt in seiner Dissertation hergestellten ETB Fragmente zurückgegriffen. Andererseits 
wurden zusätzlich ETA Fragmente unterschiedlicher Länge erstellt und erfolgreich zellfrei 
synthetisiert. Allerdings konnten mit dieser Methode bisher keine eindeutigen Aussagen zur 
Interaktionsfläche getroffen werden, da in Detergenzumgebung auch die gewählten 8   Zusammenfassung 
 
Negativkontrollen mit den ET-Rezeptoren interagierten. Somit konnte nicht zwischen 
unspezifischer Assoziation und spezifischer Interaktion differenziert werden. 
Klassische post-translationelle in vitro Rekonstitution in artifizielle Liposomen zeigten 
in elektronenmikroskopischen Gefrierbruchanalysen zwar eine sehr geringe, aber dennoch 
homogene Partikelverteilung, welche auf eine funktionelle Faltung von ETA schließen lässt. 
Weitere Funktionsanalysen in Lipidumgebung erfolgten durch in dieser Arbeit etablierte 
Radioliganden-Experimente. Gleichgewichtsdissoziationskonstanten (KD) von 1,4  nM für die 
Bindung des zirkulären Liganden 
125I-Endothelin 1 (ET-1) wurden bestimmt. Mittlere 
inhibitorische Konzentrationen (IC50) von 2,17  µM in homologer Kompetition wurden 
weiterhin erhalten, was für die funktionelle Faltung von zellfrei exprimiertem ETA spricht. 
Zusätzlich konnten mittels der Radioligandenanalysen vorläufige Daten zur 
Ligandenbindungsfähigkeit L-CF exprimierten ETA Rezeptors in Abhängigkeit der 
umgebenden Lipidzusammensetzung gewonnen werden. 
Die Ligandenbindungs-Kompetenz Detergenz-solubilisierten ETAs wurde durch 
Liganden-Affinitätschromatographie und Fluoreszenz-Anisotropie untersucht. Ein effizientes 
und verlässliches Protokoll für die Reinigung des Liganden-gebundenen Rezeptors wurde 
hierfür entwickelt. In Abhängigkeit unterschiedlicher zellfreier Produktionsarten und mizellarer 
Umgebungen wurden verschiedene Bindungskompetenzen erhalten. Die Bindung von P-CF 
exprimiertem ETA an seine Liganden mit bis zu 50  % in B35 erzielte unter optimalen 
Bedingungen eine Ausbeute an funktionellem Rezeptor von 0.5  mg/mL. Fluoreszenz-
Anisotropie von ETA in B35 deutete zusätzlich auf die funktionelle Faltung von ETA hin. Unter 
Verwendung einer Fluorescein markierten linearen Mutante von ET-1 wurde ein KD von 1,2 µM 
bestimmt, der sich gut mit publizierten Daten aus nativen Membranfraktionen vergleichen lässt. 
Initiale Röntenstrukturanalysen mit zellfrei exprimiertem ETA in B35 zeigten allerdings 
noch keinen Erfolg. Tendenzen zu der Ausbildung von Mikrokristallen deuten dennoch auf ein 
zukünftiges Potenzial unter optimierten Bedingungen hin. 
Als Basis zur alternativen Strukturanalyse mittels kernmagnetischer Resonanz wurde 
zusätzlich die initiale Einführung selbst-spleißender Inteine in die zellfreie Reaktion zur 
selektiven Markierung des Transmembransegments 1 des ETB Rezeptors gezeigt. Allerdings 
wurden nur so geringe Mengen an Endprodukt gewonnen, dass erst eine Optimierung einen 
Einsatz zur strukturellen Analyse rechtfertigen würde. 
Die erhaltenen Ergebnisse dokumentieren, dass der ETA Rezeptor mit wenigen mL 
Reaktionsvolumina sowohl im P-CF als auch im D-CF Modus in ausreichenden Mengen für 
strukturelle Analysen synthetisiert werden kann, wobei seine Qualität von der Expressionsart 
sowie von der finalen mizellaren Umgebung abhängig ist. Die präsentierte Strategie könnte als Zusammenfassung    9 
 
Orientierungshilfe dienen, auch die Qualität verwandter Rezeptoren in zellfreien Systemen zu 
optimieren. Pharmakologische Studien an zellfrei synthetisierten Rezeptoren sollten aufgrund 
teilweise deutlich unterschiedlicher Kinetiken aber immer mit in vivo Daten abgeglichen 
werden. 
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1.1.  Selecting expression systems for the large scale production of functional 
integral membrane proteins 
1.1.1.  Basic characteristics of membrane proteins 
Membrane proteins (MPs) represent essential mediators between cytosolic pathways and the 
cellular environment thus being vital to any living cell. They are responsible not only for 
numerous physiological but also for pathophysiological cell responses mediated by their diverse 
array of functions ranging from transport processes and transmission of signals to the control of 
intercellular contacts. Integral MPs are either spanning biological membranes completely with 
their transmembrane segments (TMSs) or are exposed to one side of the membrane. They are 
encoded by approximately 20–30 % of open reading frames of an averaged genome (Wallin and 
Von Heijne 1998) and are very diverse in their function since they include receptors, channels, 
pores, transporters, enzymes, proteins of energy transduction, accumulation and proteins for cell 
adhesion. They mostly follow the positive-inside rule as positively charged amino acids (aa) are 
more abundant in cytoplasmic regions (Von Heijne and Gavel 1988, Von Heijne 1992). 
Characterized by the structure of their transmembrane (TM) domains they can be classified into 
α-helical and β-barrel MPs. The latter class does predominantly exist in the outer membrane of 
Gram-negative bacteria, mitochondria, chloroplasts as well as in the cell wall of Gram-positive 
bacteria probably sharing an ancient evolutionary origin. α-helical MPs are prevalent as they are 
found in the inner and outer membranes of bacteria and the plasma membrane of eukaryotes and 
prokaryotes and constitute about 27 % of MPs in the human genome (Almen et al. 2009, Wallin 
and Von Heijne 1998). A typical α-helical TMS consists of 20–25 amino acids displaying an 
average tilt angle of 24° to the membrane normal as well as an intrinsic stability in their natural 
lipid environment. Hydrophobic amino acids such as alanine, isoleucine, leucine and valine 
have been shown to prevail in the TM domains with approximately 45  % abundancy 
(Ulmschneider et al. 2005). 
If compared with soluble cytoplasmic proteins, the expression of MPs requires a variety 
of special considerations. Integral MPs are not just released into the cytosol but must rather be 
targeted and translocated to their final destinations in membranes (Dalbey and Chen 2004, Drew 
et al. 2003, Schnell and Hebert 2003, Wagner et al. 2006). In particular in eukaryotes, the 
directed targeting through the endoplasmic reticulum (ER) and early and late Golgi apparatus to 
the plasma membrane requires sophisticated recognition and sorting mechanisms. The insertion 
of MPs into membranes usually does not occur spontaneously. It requires the cooperation of 
translating ribosomes with translocation machineries like the eukaryotic Sec61 complex or the Introduction 11 
 
homologous prokaryotic SecYEG machinery (White and Von Heijne 2008). Copy number and 
capacity of those systems are limited and translocation can be selective for distinct groups of 
MPs only (Drew et al. 2003, Facey and Kuhn 2004, Schnell and Hebert 2003). 
 
1.1.2.  Conventional cell-based expression of MPs 
In some cells or organisms, one or few MPs are highly abundant, for instance certain rhodopsin 
derivatives in Halobacterium salinarium and in bovine eye retina. It has been attempted to use 
naturally evolved high level expression systems for the production of closely related MPs 
(Junge et al. 2008). However, drawbacks were numerous as the efficiency of the expression 
pathway in H. salinarium appeared to be rather specific for bacteriorhodopsin and some of its 
derivatives. Other eukaryotic MPs even under control of the bacteriorhodopsin promoter were 
expressed only in spurious amounts (Sohlemann et al. 1997, Turner et al. 1999). Consequently, 
the homologous expression of MPs in their natural cellular environments, preferentially with 
increased copy numbers after genetic recombination, appears promising in order to achieve 
optimal folding conditions, targeting and translocation of the target MPs as all necessary 
machineries should in principle be present. Almost all established expression systems with clear 
emphasis on E. coli have been used for homologous expression. In a number of further not 
commonly used prokaryotes or lower eukaryotes, MPs in crystallization-grade quality could 
also be obtained by homologous expression but this was limited to individual targets (Lancaster 
et al. 1999, Luecke et al. 2001, Stroebel et al. 2003). A promising option could also be the 
expression of MPs in hosts that are very closely related to their origin. Overall, an estimate of 
45 % of the currently available MP structures originates from homologous expression systems 
(Junge et al. 2008). 
More critical in particular with regard to the availability of efficient accessory helper 
systems are heterologous expression approaches of MPs in non-related hosts or cellular 
backgrounds. However, powerful and efficient expression systems are difficult to establish and 
the necessary technical developments, e.g. the construction of strains, vectors and controllable 
regulation mechanisms, are very demanding. Few elaborated and well documented systems like 
their expression in E. coli, yeasts or in insect cells are therefore prevalent for MP production as 
their versatility, efficiency and the availability of reliable protocols dominates over potential 
disadvantages of not providing the optimal expression background (Table 1). 
The expression in E. coli is frequently the first and only choice for prokaryotic MPs, 
while eukaryotic MPs are often attempted to be produced in prokaryotic as well as in eukaryotic 
backgrounds. Reasons to switch to the latter more expensive and time consuming systems are 
almost exclusively the intention to improve functionality or the overall quality of the MP 
samples (Junge et al. 2008). 
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Table 1: General features of MP expression systems
1. 
 
  E. coli  L. lactis Yeast Insect  Mammalian E-CF/W-CF 
Basic properties
2  
Set  up  requirements  1 1  1 3 3    1/1 
Time  investment  1 1  2 3 3    1/3 
Costs  1 1  2 3 3    2/2 
Robustness  3 3  3 1 1    2/2 
Preparative  scale  3 3  3 2 1    3/3 
Bio-safety  risk  1 1  1 1-2  1-3    1/1 
 
Characteristics 
Throughput  option  + +  + – –    +/+ 
 
Expression environment 
Native  membranes  + +  + + +    ?/? 
Micelles  – –  – – –    +/+ 
Artificial  liposomes  – –  – – –    +/+ 
IBs/precipitate  +  ?  (+) (+) –    +/+ 
 
MP labelling 
Uniform  + +  + – –    +/+ 
Specific  + +  + – –    +/+ 
Combinatorial  (+) (+)  (+) –  –    +/+ 
 
PTMs 
Glycosylation  – –  + + +    –/? 
Prenylation  – –  + + +    –/? 
Disulfid  bonds  (+)  –  + + +    +/? 
1 IBs, inclusion bodies; PTMs, post-translational modifications; ?, not analysed yet, E-CF, E. coli 
cell-free, W-CF, wheat germ cell-free 
2 1, low; 2, medium; 3, high 
Central factors that could determine the yield, integrity, activity and stability of synthesized 
MPs are the availability of highly processive transcription and translation machineries, suitable 
folding environments, the lipid composition of cellular membranes, the presence of efficient 
targeting systems and appropriate pathways for post-translational modifications (PTMs) 
(Table 1). Differences in the codon usage of the target gene and the host’s translation machinery 
could result in premature termination of the polypeptide chain or in mis-incorporation of amino 
acids, both having severe effects on sample quality and functionality of the final MP (Kurland 
and Gallant 1996, Sorensen et al. 2003). Most PTMs of recombinant eukaryotic MPs are 
unlikely to occur in prokaryotic expression hosts like E. coli and Lactococcus lactis, which 
sometimes may hamper functional folding but in other cases could be beneficial for 
crystallization studies. In addition, bacterial MPs typically have a cytoplasmic location for both 
the N- as well as the C-terminus (Daley et al. 2005). The prevalent requirement of an 
N-terminus-out topology for eukaryotic MPs like G-protein coupled receptors (GPCRs) could 
therefore cause problems in their correct targeting and membrane insertion. 
Optimization of expression protocols is most demanding for the MP production in any 
system. Modifications of each little step like vector design and transfer, cultivation conditions, 
expression strategies, MP extraction or choice of detergents and buffer conditions can have Introduction 13 
 
significant impacts on the final yield and sample quality. Expression protocols have thus to be 
individualized according to the requirements of each particular MP. It should be realized that 
highest yield expression and best sample quality often exclude each other and protocols 
allowing satisfying compromises have to be established. Optimization strategies are usually 
based on iterative processes of trial and error and they can take many months (Junge et al. 
2008). 
 
1.2.  Cell-free expression of MPs 
Cell-free (CF) systems do not require sophisticated hardware and can easily be set up in 
standard biochemical labs. The CF technique has initially been used for deciphering the genetic 
code (Nirenberg and Matthaei 1961) and later for the analytical scale production of soluble 
proteins (Zubay 1973). Their preparative scale expression just evolved in line with the 
development of efficient new reaction protocols (Kigawa and Yokoyama 1991, Spirin et al. 
1988). Today, the expression and structural analysis of soluble proteins by CF systems is 
already routinely used with high success rates (Endo and Sawasaki 2003, Vinarov et al. 2004, 
Yokoyama 2003). 
Preparative scale CF expression of MPs is a relatively new approach with first reports 
starting in 2004 (Berrier et al. 2004, Elbaz et al. 2004, Klammt et al. 2004). Comprehensive 
protocols for the CF production of MPs have been published and the preparation of essential 
compounds has been described (Kigawa et al. 1999, Kim et al. 2006, Schwarz et al. 2007a, 
Spirin et al. 1988, Swartz et al. 2004, Zubay 1973). Evident advantages are that CF expression 
reactions are open systems allowing easy access at any time point (Fig. 1). Furthermore, several 
principle problems of MP overproduction commonly occurring in living host cells are 
eliminated by using CF extracts. Most toxic or growth inhibitory effects upon overexpression 
can be avoided. No transport or selection mechanisms through cellular membranes have to be 
considered. Moreover, the cellular metabolism pathways are largely reduced in cell extracts and 
metabolic conversion problems of supplemented compounds are minimized (Junge et al. 2008). 
A first X-ray structure involving a CF produced MP could be presented with the 
multidrug transporter EmrE (Chen et al. 2007) and most recently, crystals of the voltage-gated 
anion channel VDAC1 have be obtained from D-CF expressed protein (Deniaud et al. 2010, 
Nguyen et al. 2010). Furthermore, the structure of the CF produced C-terminal fragment of 
human presenilin 1 (CTF) has been solved by liquid-state nuclear magnetic resonance (NMR) 
spectroscopy (Sobhanifar et al. 2010), all reports pointing to the potential of CF expression for 
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1.2.1.  CF extract sources: Selection of the adequate expression environment 
Preparative scale expression achieving mg amounts of protein per mL of reaction mixture (RM) 
is currently most efficient if using prokaryotic E. coli or eukaryotic wheat germ extracts (WGE) 
(Endo and Sawasaki 2005, Zubay 1973). 
The quality of WGE highly depends on the origin of the wheat seeds and therefore 
enormous batch variations have to be considered. Preparing extracts from wheat germ embryos 
is relatively laborious and time-consuming (Endo and Sawasaki 2005, Erickson and Blobel 
1983, Madin et al. 2000). However, these extracts are of eukaryotic origin which might be 
advantageous, are highly stable and protein expression can even proceed for weeks if substrates 
and mRNA are continuously supplied with final protein yields of up to 10 mg/mL (Sawasaki et 
al. 2002). 
 
Fig. 1: Analytical and preparative scale configurations of transcription/translation CECF reactions. 
The S30 extract contains all necessary basic compounds for the translation process. The reactions can be 
incubated in individually designed dialyzers (Schneider et al. 2010) under vigorous stirring or shaking. 
Due to the open nature of the CF system any beneficial compound as well as labelled amino acids and 
necessary precursors can be added at any time point. CECF, continuous-exchange cell-free; FM, feeding 
mix; RM, reaction mix; T7RNAP, T7 RNA polymerase. 
Various strains like BL21 derivatives or strains deficient in endogenous RNAses such as A19 or 
D10 have been used for preparation of the commonly used S30 E. coli extract and protocols can 
be completed witin a day (Kim et al. 2006, Swartz et al. 2004, Zubay 1973). Endogenous 
mRNA as well as amino acids and other low molecular weight compounds are eliminated 
during extract preparation which minimizes background expression and allows control over the Introduction 15 
 
amino acid pool ensuring efficient labelling of the target proteins. E. coli CF systems are mostly 
operated as coupled transcription/translation systems and double stranded DNA or PCR 
products are applied as templates for the transcription (Fig. 1). E. coli as well as wheat embryo 
extracts have similar efficiencies in the production of prokaryotic and eukaryotic MPs and even 
proteins exceeding 100 kDa in size can be synthesized in both systems (Liguori et al. 2007, 
Schwarz et al. 2010). 
Other eukaryotic systems based on rabbit reticulocyte extracts (RRL) (Craig et al. 1992), insect 
cells (Ezure et al. 2006, Katzen and Kudlicki 2006) or the parasitic protozoan Leishmania 
(Mureev et al. 2009) may perform a variety of PTMs (Arduengo 2007, Ren et al. 1993, Tie et al. 
2005), but they can currently only be used for analytical scale productions. 
Alternatively to complex cell extracts, the PURE (Protein Synthesis Using Recombinant 
Elements) system has been developed in which the complete E. coli translation machinery is 
assembled out of the purified recombinant components (Ohashi et al. 2010, Shimizu et al. 
2001). The better defined expression environment could be beneficial in order to address 
specific aspects such as minimizing random proteolysis or the study of translation kinetics. 
 
1.2.2.  E. coli CF reaction compounds and major system configurations 
E. coli systems are coupled transcription/translation systems that are based on transcription by 
the highly processive T7 or SP6 RNA polymerase (Klammt et al. 2004, Matveev et al. 1996, 
Sawasaki et al. 2005). The target gene has therefore to be cloned under control of an appropriate 
promoter (see 3.1.3.). 
In contrast to E. coli, the wheat germ CF system does not work well as a coupled 
transcription/translation system since magnesium optima for transcription are higher (~15-
18 mM  Mg
2+) than those for translation (around 3 mM Mg
2+) (Sawasaki and Endo 2007). 
Translation systems are thus preferred with supplied mRNA as template. The translation 
efficiency of mRNA templates in wheat germ systems strongly depends on the nature of the 5’ 
and 3’ untranslated regions (UTR) and they represent prime targets for optimization strategies 
(Endo and Sawasaki 2003, Mignone et al. 2002, Sawasaki et al. 2002). Stable viral leaders 
mostly found in plant virus RNA genomes substitute for the otherwise required cap structures 
and poly(A)tails of eukaryotic mRNA (Endo and Sawasaki 2003). Popular 5’ enhancing 
elements contain AC-rich sequence elements mostly derived from the tobacco mosaic virus 
(TMV) like the OMEGA leader (Gallie et al. 1987) or its derivatives (Endo and Sawasaki 
2003). Alternatively, 5’  obelin RNA leader sequences from the hydroid polyp Obelia 
longissima have been used. The length of the 3’ UTRs is of primary importance in order to 
antagonize exosomes degrading mRNAs from their 3’ ends (Beelman and Parker 1995). 
CF extracts already contain all important factors for translation like ribosomes, 
aminoacyl-tRNA synthetases (ARSases) and translation factors as well as acetate kinase for 16   Introduction 
 
energy regeneration. Precursors for transcription and translation like amino acids, tRNAs, 
nucleoside triphosphates (NTPs), template nucleic acids and efficient energy regeneration 
systems have to be supplied to the CF reactions. Amino acids can be added in concentrations 
from 0.3 to 2 mM and highly unstable amino acids (R,C,W,M,D,E) are recommended to be 
supplemented in even higher concentrations to ensure productive expression. The efficient and 
long-lasting energy supply is one of the most critical parameters in CF expression. Commonly 
used components for the regeneration of ATP in continuous-exchange cell-free (CECF) 
reactions in E. coli extracts are phosphoenolpyruvate (PEP) (Zubay 1973), acetylphosphate 
(AcP) (Ryabova et al. 1995) or combinations of both (Klammt et al. 2006) together with their 
respective enzymes. Numerous modifications of E. coli CF reaction protocols have been 
published recently that mainly address variations in energy precursors and strategies for the 
extension of reaction times in batch systems (Calhoun and Swartz 2005, Jewett and Swartz 
2004, Kim and Swartz 2001, Sitaraman et al. 2004). 
The open nature and high versatility of CF expression allows a variety of new ways to 
rationally design and to optimize expression environments as well as to modulate folding 
kinetics for MPs independent of their origin, size, topology and function (Junge et al. 2010a). 
Stabilizers, protease inhibitors, ligands, chaperones and virtually any other compound that 
might improve the expression or folding of a particular MP can be directly added into the 
expression reaction (Fig. 1). Additional tRNA or the co-expression of rare codon tRNA might 
compensate for difficulties arising from heterologous codon usage. Disulfide bond formation in 
CF reactions might already occur during CF expression but can for instance also be modulated 
by providing appropriate redox systems or disulfide bond shuffling systems (Goerke and Swartz 
2008). CF systems based on prokaryotic sources like E. coli most likely lack the ability to 
introduce co- and PTMs in eukaryotic proteins and are further characterized by the absence of 
eukaryotic chaperone systems which may be necessary for their functional folding or their 
stability in membranes. Approaches in order to address those potential problems are to 
supplement extracts with chaperones or microsomal fractions isolated from eukaryotic cells 
(Jiang et al. 2002, Kolb et al. 2000, Ryabova et al. 1997). The operator can further provide 
specified amino acid mixtures with regard to amino acid biases of the target MP or in view of 
selective labelling approaches. The easy implementation of labelled amino acids in any 
combination is of particular value for structural approaches by NMR and by X-ray 
crystallography. Selenomethionine, isotope labelled amino acids or any other labelled amino 
acid might be added and the complete control over the low-molecular weight compounds 
ensures up to 100 % label incorporation and minimized scrambling backgrounds (Kainosho et 
al. 2006, Ozawa et al. 2005, Reckel et al. 2008, Torizawa et al. 2004, Trbovic et al. 2005). 
Two main configurations are commonly used in CF expression: batch or CECF formats 
(Fig. 2). Batch systems only contain one compartment and are particularly useful for analytical 
purposes as the reaction can be carried out in microplates with reaction volumes of just few µL. Introduction 17 
 
The whole process can be automated and is therefore suited for high-throughput applications. 
The disadvantage of this configuration are the reaction times that are limited to few hours since 
essential precursors for translation are exhausted until then or by-products reach inhibitory 
concentrations. Consequences are moderate expression yields, whereas it may be possible to 
obtain significantly increased production yields with specialized protocols (Jewett and Swartz 
2004, Kim et al. 2006, Sawasaki et al. 2002, Swartz et al. 2004). 
Extended reaction times and highest averaged levels of MP production can be obtained with 
CECF systems (Shirokov et al. 2007, Spirin et al. 1988). In the CECF set up, the reaction is 
divided into two compartments holding a RM and a feeding mixture (FM) with constant 
volumes (Fig. 2). The two compartments are separated by a semi-permeable membrane with a 
molecular weight cut-off (MWCO) of 10-50 kDa. The RM contains all high molecular weight 
compounds necessary for transcription and translation like ribosomes, nucleic acids and 
enzymes whereas the FM contains low molecular weight precursors like amino acids and 
nucleotides. 
 
Fig.  2: Batch and 
CECF configuration. 
The RM reservoir (grey) 
contains all necessary 
high molecular weight 
compounds in the CECF 
format and is separated 
from the FM (white) by 
a semi-permeable mem-
brane. Batch formats 
only have one compart-
ment. 
 
Volume ratios of RM to FM usually in between 1:10 and 1:50 are an important parameter for 
the final yield of the protein. Increasing the FM volume will also result in an increase of 
production efficiency. However, precursors are expensive and there is no linear correlation 
between ratio and yield since the capacity of CF extract is limiting. Therefore, compromises are 
found in between 1:10 and 1:20. Intensive stirring, rolling or shaking of the reaction device 
during incubation ensures an efficient exchange of fresh precursors from the FM against 
breakdown products from the RM through the membrane. CECF systems reach expression 
times of approximately 20 hours (h) and can yield amounts of up to several mg of target protein 
per mL of RM (Junge et al. 2008, 2010a). 
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1.2.3.  CF reaction modes for the production of MPs 
CF expression offers the opportunity to produce MPs in three new ways. The target proteins can 
be produced either in the precipitate forming (P-CF) mode without providing hydrophobic 
environments or in presence of supplied hydrophobic agents in the detergent based (D-CF) or in 
the lipid based (L-CF) mode (Fig. 3). 
In the P-CF mode, MP precipitation occurs instantly after translation as CF extracts are 
almost completely devoid of membranes. Only residual amounts of lipids of 50-100 µg/mL 
extract have been detected and those lipids might not even be accessible for the target MP. The 
P-CF precipitates can usually be solubilized efficiently by the addition of particular detergents 
within few hours without applying classical refolding procedures known for inclusion bodies 
(IBs). Detergents especially suited for an efficient resolubilization which still might allow 
functional folding include the lipid-like n-dodecylphosphocholine (Fos-12) and the lyso-
phosphoglycerols 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LMPG) and 
1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LPPG) (Klammt et al. 2004, 
2005). These detergents also enable structural investigations by NMR (Krueger-Koplin et al. 
2004). If initial MP precipitation should be prevented, selected detergents or lipids in various 
combinations can also be directly added into the reaction (Fig. 3). 
In D-CF systems, the operator creates artificial hydrophobic environments of defined 
composition directly in the reaction chamber, in which the nascent protein chain can 
immediately be integrated during or shortly after translation. The emerging full-length MPs can 
then stay in a soluble form. Solubilization efficiencies are MP specific and optimal 
detergent/MP combinations and ratios have to be identified individually for every target 
(Ishihara et al. 2005, Klammt et al. 2005). 
Few detergents like n-β-octyl-D-glucopyranoside (β-OG), Fos-12, sodium cholate or 3-[(3-
Cholamidopropyl)dimethylammonio]propanesulfonic acid (CHAPS) appear to inhibit protein 
expression in D-CF systems already at low concentrations hardly exceeding their critical 
micellar concentration (CMC). Other commonly used detergents like n-dodecyl-β-D-maltoside 
(DDM) or Triton X-100 are tolerated by CF systems up to 10 times of their CMC. Exceptionally 
suitable for the D-CF expression of even larger α-helical MPs like GPCRs are Brij detergents, 
relatively mild polyoxyethylene-alkyl-ethers, and the steroid derivative digitonin. The tolerance 
of CF systems for Brij detergents is very high and exceeds 100 times CMC (Klammt et al. 
2005). 
Alternatively, amphipols (Pocanschi et al. 2006, Popot 2010) or fluorinated surfactants 
(Park et al. 2007, Polidori et al. 2006) may be used for D-CF solubilization. They differ from 
classical detergents as they are do not disintegrate membranes (Krafft and Riess 1998, Park et 
al. 2007), are therefore very mild MP solubilizing agents and may even promote the rapid 
partitioning of MPs into lipid bilayers. Different detergents (mixed micelles) as well as lipids Introduction 19 
 
and detergents (lipomicelles) may be combined in order to create optimal individual 
hydrophobic environments (Fig. 3). These options might represent interesting alternatives to 
pure micelles since lipids often have chaperone-like effects on MPs (see 1.3.3. and 4.4.). 
Fig. 3: Versatility of the CF expression technique. Basic expression modes for the CF synthesis of MPs 
are illustrated. The protein is either expressed without any hydrophobic agents (P-CF mode) or in 
presence of detergents (D-CF mode) or lipids (L-CF mode). Processing of the different samples (indicated 
by arrows) results in a variety of primary MP sample environments. 
An important characteristic of D-CF expression is that the synthesized MPs are instantly 
available in detergent solubilized form. The critical and often inefficient step of MP extraction 
out of cellular membranes is therefore completely avoided (Klammt et al. 2005, 2007a, 
Opekarova and Tanner 2003, Schwarz et al. 2007b). 
Membrane integration of CF expressed MPs can be operated in two different ways. The 
post-translational reconstitution of P-CF or D-CF solubilized MPs is based on routine protocols 
adapted from cellularly expressed MPs and many CF expressed proteins have already been 
reconstituted successfully by these conventional methods (Berrier et al. 2004, Elbaz et al. 2004, 
Kamonchanok et al. 2008, Keller et al. 2008, Klammt et al. 2007a). Alternatively, the L-CF 
expression mode in presence of supplied lipids offers a unique option for the co-translational 
insertion of MPs. Lipids are the natural environment of MPs and often essential modulators of 
folding, stability and function (Opekarova and Tanner 2003). It is necessary to adapt the lipid 
composition to the target protein as well as to the CF expression process as the charge of the 20   Introduction 
 
used lipids can clearly effect transcription and translation efficiencies. While transcription is 
usually not affected in presence of any lipids, translation may be inhibited by cationic lipids. 
Lipid concentration may furthermore influence the expression level (Bui et al. 2008, Umakoshi 
et al. 2009). 
Lipids can be supplied into CF reactions in different formulations such as (I) preformed 
liposomes of defined compositions, (II) isolated fractions of cell membranes, (III) detergent 
solubilized lipo-micelles providing a mixed environment for MPs, (IV) bicelles consisting of 
planar bilayers surrounded by detergents and (V) nano-lipid particles or nanodiscs providing 
highly soluble and confined bilayer areas (Fig.  3). Mechanisms of co-translational MP 
translocation can thus be analysed in dependency of a large variety of lipid mixtures. MP 
integration into the provided bilayers may furthermore be more directed during L-CF mode 
expression if compared with the random orientation in classical post-translational reconstitution 
approaches which might support functional assays. In addition, the synthesized target will be the 
only MP inserted into the bilayers and measured activities could thus clearly be attributed. 
These characteristics can have considerable benefits for subsequent functional studies. 
The L-CF expression mode and its diverse modifications are emerging techniques and 
their potential as approaches for the preparative scale expression of MPs still have to be 
explored. The co-translational membrane insertion of functional bacteriorhodopsin was shown 
by using different lipids and lipid compositions (Kalmbach et al. 2007). A further efficient 
approach was to add cholate solubilized phosphatidylcholines into the RM of CECF reactions 
which easily dialyzes out during the reaction resulting in bacteriorhodopsin proteoliposome 
formation (Shimono et al. 2009). Combining detergent and lipids in lipomicelles might 
generally be an interesting approach in order to improve functional CF expression (Marques et 
al. 2007, Nozawa et al. 2007). MP integration in the L-CF mode was analysed upon addition or 
co-expression of chaperones (Nishiyama et al. 2006) as well as by addition of microsomes 
(Joseph et al. 1997, Lyford and Rosenberg 1999) or crude inner membrane vesicles as shown 
for the bacterial outer membrane secretin PulD or for E. coli transporters (Guilvout et al. 2008, 
Wuu and Swartz 2008). However, added chaperones did not increase the integration rate of 
functional aquaporin Z into synthetic liposomes, although a higher association of the MP to the 
lipid bilayer was noted (Hovijitra et al. 2009). Variation of lipid composition, lipid head group 
polarity and alkyl chain length to alter bilayer thickness or using different types of bilayers such 
as nano-lipoprotein particles are tools in order to improve MP integration in L-CF expression 
mode approaches (Cappuccio et al. 2008, Katzen et al. 2008, Nishiyama et al. 2006). 
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1.3.  G-protein coupled receptors – GPCRs 
1.3.1.  Diversity, evolution and topology of GPCRs 
GPCRs belong to the largest classes of cell surface receptors encoded by the mammalian 
genome, mediate their complex cellular responses by a vast array of different external stimuli 
responding to hormones and neurotransmitters and play a role in olfaction, taste and vision 
(Fredriksson et al. 2003, Rosenbaum et al. 2009). Understandably, approximately 50  % of 
modern pharmaceuticals target GPCRs (Klabunde and Hessler 2002). A recently performed 
detailed phylogenetic classification of human GPCRs revealed over 800 single human GPCRs 
with approximately 460 olfactory receptors representing the major sub-class within this receptor 
superfamily. On the basis of similarity in the seven TMSs the receptors could be clustered into 
five families which are the rhodopsin-like family (class A, 701 members), the adhesion family 
(24 members), the frizzled/taste family (24 members), the glutamate family (15 members) and 
the secretin-like family (15 members) (Fredriksson et al. 2003). The receptors of the rhodopsin-
like family are mostly characterized by specific highly conserved motifs such as the 
NPxxY(x)5,6F motif localized in TMS 7 (Fritze et al. 2003) or the E/DRY motif localized 
between TMS 3 and the intracellular loop (IL) 2 (Rovati et al. 2007). They furthermore often 
share a conserved disulfide bridge as receptor stabilizing element which links the first to the 
second extracellular loop (ECL) (Ji et al. 1998). 
So far, a large fraction of these 800 GPCRs has no defined physiological ligand initiating their 
activation and is therefore termed as orphan. Deciphering their function known as 
deorphanization is a very promising tool for the generation of novel drug targets in 
pharmaceutical research (Howard et al. 2001). 
GPCRs are structurally characterized by seven hydrophobic α-helical TMSs each 
commonly consisting of 20-27 amino acids. The TMSs are linked by three alternating ECLs and 
ILs, a fourth cytoplasmic loop arising upon palmitoylation at cysteine residues in the C-terminal 
segment. They furthermore share an extracellular N-terminal domain and a C-terminus which is 
exposed to the cytoplasm (Fig. 4). 
The most prominent diversity of GPCRs can be found in the soluble domains. The 
C-terminus varies between 12-360 and the N-terminus between 7-600 aa, its length weakly 
correlated to the ligand size (Ji et al. 1998). In peptide as well as in monoamine transporters the 
amino terminal domain consists of only few amino acids (10-50 aa) whereas it is much larger 
for glycoprotein hormone receptors (350-600 aa) and the receptors of the glutamate family. 
Receptors of the adhesion family have the largest N-terminal domains (Kobilka 2007). 
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Fig. 4: Schematic representation of common structural features of GPCRs (A) and the proposed 
modes of receptor-ligand interactions including the location of ligand binding sites (B-F). Adapted 
from Ji et al. 1998. 
 
1.3.2.  Ligand binding and GPCR activation 
Natural GPCR ligands are characterized by an immense structural diversity contrasting the 
structural similarity pattern of their receptors (Ji et al. 1998). The ligands range from subatomic 
particles (photons), ions (H
+ and Ca
2+), small organic molecules, to peptides and whole proteins 
(Kobilka 2007) and their respective binding domains have already been determined for a range 
of GPCRs (Fig. 4) (Ji et al. 1998). Ligand binding seems to be promoted by ion pairs, hydrogen 
bonds and hydrophobic contacts. Small organic molecules like biogenic amines, nucleosides as 
well as photons and some lipids tend to bind exclusively within the TMSs, peptides smaller than 
40 aa mostly interact with the ECLs and the upper parts of the TMSs whereas larger peptides 
and proteins mostly bind either solely to the N-terminus (glycoproteins) or to ECLs and the 
N-terminal sequence (Ji et al. 1998, Kobilka 2007). It is however impossible to devise a 
universal rule for the location of the ligand binding site by the size of the ligand alone. For 
instance, receptors of the glutamate/pheromone family, such as GABAB, are activated if the 
respective ligands such as the main neurotransmitters glutamate and γ-aminobutyric acid bind to 
the expanded N-terminal domain by interaction with the so-called Venus Flytrap module 
(Kristiansen 2004, Pin et al. 2005). It is also interesting to note that for a variety of GPCRs, 
although binding their agonists with their soluble extracellular domains, small molecular weight 
allosteric modulators have been identified which bind within the TMSs (Carroll et al. 2001, 
Knoflach et al. 2001). 
The common signal transduction mechanism shared by the majority of GPCRs is the 
mediation of intracellular signalling through coupling to specific heterotrimeric guanyl Introduction 23 
 
nucleotide-binding proteins (G-proteins) which consist of α-subunits plus the tightly associated 
heterodimeric βγ-complexes (Hepler and Gilman 1992). 
The βγ-complex interacts with a hydrophobic pocket present in the Gα-GDP subunit. Its release 
is triggered by the binding of GTP to Gα, consequently removing this hydrophobic interaction 
interface (Lambright et al. 1994). 
G-proteins can be classified into four major families based on the respective α-subunits. Gαs 
and Gαi/o either stimulate or 
inactivate adenylate cyclases. 
Gαq/11 activates phospholipase C 
and the Gα12/13 family stimulates 
the Na
+/H
+-exchanger pathway 
(Elefsinioti et al. 2004). The 
α-subunits possess an intrinsic 
GTPase activity domain necessary 
for the  hydrolysis of GTP in the 
G–protein cycle (Fig. 5). At least 
21 distinct α-subunits, five 
β-subunits and twelve γ-subunits 
have been identified so far 
(Cabrera-Vera et al. 2003, Hepler 
and Gilman 1992) accounting for 
a vast array of different combinations. 
In the basic G-protein cycle agonist activation leads to a conformational rearrangement 
within the receptor which might especially involve TMS 3 and TMS 6 (Ballesteros and 
Palczewski 2001, Gether et al. 1997). Subsequent interaction of the receptors with cytoplasmic 
G-proteins involves the second and third IL as well as the cytoplasmic ends of the adjacent 
TMSs (Kobilka 2007, Kristiansen 2004, Mirzadegan et al. 2003). The activated receptors serve 
as guanine nucleotide exchange factors and initiate GDP exchange to GTP at the respective 
α-subunit. This promotes the dissociation of the heterotrimeric G-protein from the receptors and 
its disintegration into the separately acting α-subunit and the βγ-dimer which further stimulate 
their downstream effectors. Subsequent auto-hydrolysis of GTP to GDP mediated by the 
α-subunit increases the affinity to the βγ-complex and leads to the reassociation of the 
heterotrimer and the termination of the G-protein cycle (Fig. 5). 
In contrast to the activation of GPCRs by the G-protein heterotrimer as demonstrated 
above, G-protein independent pathways have also been elucidated (Azzi et al. 2003, Lefkowitz 
and Shenoy 2005, Luttrell and Lefkowitz 2002). These involve PDZ scaffolding proteins as 
shown for instance for the β1-adrenergic receptor (Pak et al. 2002) or β-arrestin transducers as 
Fig. 5: Schematic representation of GPCR activation 
and initiation of downstream signalling. 24   Introduction 
 
monitored for the β2-adrenergic and the endothelin receptors which may stimulate cell 
proliferation through β-arrestin-1-Src-mediated pathways (Kristiansen 2004). Other interaction 
partners for GPCRs are molecular chaperones (e.g. Nina A or calnexin) mediating proper 
folding of the GPCR or its transport to the plasma membrane as well as activity modifying 
proteins such as RAMPs (reviewed in Brady and Limbird 2002). 
 
1.3.3.  Biological membranes and their composition: Necessary lipids for MPs, 
especially for GPCRs 
Biological membranes are essential for any living organism as they constitute specialized 
permeability barriers and compartimentalize cells in different functional units. Specific lipids or 
hydrophobic environments can play important roles in the functional folding or stabilization of 
MPs (Hunte 2005, Lee 2004, Opekarova and Tanner 2003). 
Many crystallized MP complexes show defined protein-lipid contacts and folding and 
function of bacterial MPs can also depend on the presence of specific lipids, as reported for the 
lactose permease in E. coli (Xie et al. 2006). Most observed lipid effects on MPs are still 
difficult to interpret. They could either take place on the molecular and supermolecular level 
between lipids and proteins like hydrogen bonding, hydrophobic effects and charge interactions 
or on the physical level such as altered membrane properties like changes in fluidity, 
hydrophobic thickness, lateral pressure and curvature. Lipids lead to the positioning of MPs in 
correct orientations within the membrane, to changes in their secondary structure and to 
structural stabilization by direct lipid-MP interactions but can also promote aggregation and 
misfolding if their composition is unfavourable for the embedded and affected proteins (Lee 
2004). The specific structure of lipids especially the charge of their headgroups as well as the 
length of their acyl chain was shown to be for instance of high importance for the potassium 
channel KscA which essentially needs anionic lipids for its activity (Heginbotham et al. 1998) 
as well as for the Ca
2+-ATPase (Starling et al. 1996). Acyl chain length effects of fatty acids on 
activity states were investigated for an array of proteins in terms of hydrophobic mismatch and 
phospholipids which match biological membrane thickness (mostly C18) were highly favoured 
(Lee 2004). 
The lipid compositions of host cells from the different expression systems vary 
considerably (Opekarova and Tanner 2003). Bacterial membranes are generally devoid of 
sterols, sphingolipids and polyunsaturated side chains. Phosphatidylethanolamine (PE) is one of 
the most abundant glycerolphospholipids in bacteria followed by phosphatidylserine (PS), 
phosphatidylglycerol (PG), cardiolipin and phosphatidylinositol (PI). In contrast, one of the 
major lipid classes in eukaryotic plasma membranes is phosphatidylcholine (PC). Sterols, that 
completely lack in bacteria, and sphingolipids are further components of eukaryotic membranes 
in which PS constitutes the predominant anionic lipid. Of major concern for the selection of an Introduction 25 
 
expression system or cellular background should therefore be the lipid composition of the host 
cell membranes in addition to specific codon usages and prevalent glycosylation patterns (Junge 
et al. 2008). 
Cholesterol is an essential compound of mammalian cells which is engaged in the 
organization of membranes, mostly by formation of lipid rafts or modulation of membrane 
fluidity or permeability (Burger et al. 2000) and it is often discussed as indispensable lipid for 
the functional expression of MPs, especially for GPCRs (Opekarova and Tanner 2003). Its 
molar ratio to phospholipids might even be as high as 1:1 supporting its importance for plasma 
membranes (Yeagle 1985). The interaction mechanism of cholesterol with GPCRs in order to 
modulate their function is individual to each receptor and can hardly be predicted. It might 
either act via direct specific lipid/protein interaction, alteration of physical properties of the 
membrane in which the receptor is localised or by binding to proposed ‘nonannular’ sites in the 
immediate proximity of the receptor (Paila and Chattopadhyay 2009). Cholesterol or its 
analogue cholesteryl hemisuccinate (CHS) promoted for instance proper function and thermal 
stability of the rat neurotensin receptor (Tucker and Grisshammer 1996), the oxytocin and brain 
cholecystokinin receptor (Gimpl et al. 1995, Gimpl et al. 1997, Harikumar et al. 2005) the 
human adenosine A2a receptor (Weiss and Grisshammer 2002) and the human β2-adrenergic 
receptor (AR) (Yao and Kobilka 2005) and proved essential in stabilizing the crystal-packing 
interface of the AR dimer and its thermal stability (Cherezov et al. 2007, Hanson et al. 2008). 
Several amino acid sequences or whole stretches in MPs are associated with an ability to form 
interaction interfaces with sterols such as the CRAC motif with its consensus pattern L/V–(x)1-5-
Y-(x)1-5-R/K (Li and Papadopoulos 1998), the sterol-sensing domain (SSD) which consists of 
~180 aa in five consecutive TMS (Kuwabara and Labouesse 2002) or the cholesterol consensus 
motif (CCM) found in the β2-AR and 21 % of other human GPCRs. The CCM displays the 
consensus sequence [4.39-4.43 (R,K)]-[4.50 (W,Y)]-[4.46 (I,L,V)]-[2.41 (F,Y)] after the 
Ballesteros-Weinstein numbering scheme. A revised CCM (rCCM) in which the aromatic 
amino acids in the second TMS are absent should interact with cholesterol in a similar fashion 
increasing the number of human class A GPCRs containing this motif to over 44 % (Hanson et 
al. 2008). 
 
1.3.4.  GPCR dimerization / oligomerization: An evaluation of current models 
Emerging evidence of GPCRs forming oligomeric structures which consist of at least two 
receptor subunits (dimers or oligomers) has grown, and more and more empirical data support 
these findings (George et al. 2002). Dimerization is a prominent mechanism for receptor 
activation of members of the glutamate family (Ji et al. 1998). For instance, only the 
simultaneous expression of two isoforms of the GABA receptor resulted in a functional receptor 
unit at the cell surface (Kaupmann et al. 1998, Kuner et al. 1999, White et al. 1998). 26   Introduction 
 
The role of dimerization in the rhodopsin-like family of GPCRs is just emerging. Data gained 
from atomic force microscopy and cryo-electron microscopy of discs from mouse rod outer 
segments suggest dimerization of rhodopsin (Liang et al. 2003) and of squid rhodopsin which 
clearly showed higher organisation of rhodopsin in membranes (Davies et al. 2001). A variety 
of functional implications for homo- as well as heterodimerization have been discussed so far 
which more and more gain in importance in pharmaceutical research. Homo-oligomerization is 
thought to already occur at the level of protein synthesis in the ER or during maturation of the 
GPCR therefore possibly influencing protein folding prior to cell surface delivery (Bulenger et 
al. 2005). A distinct role in protein folding has been determined for many GPCRs (reviewed in 
George et al. 2002, Milligan 2007). Mutant or truncated receptors act as dominant negatives and 
inhibit the transport of the native receptors to the cell membrane. Another function of homo-
oligomerization has been seen in altered signal transduction that might result in signal 
amplification as exemplified with rhodopsin (Chabre and Le Maire 2005, Jastrzebska et al. 
2006). Proposed functional consequences of hetero-oligomerization are altered G-protein 
selectivity as demonstrated for the dopamine D1 and D2 receptor dimer (Lee et al. 2004) in 
which adenylate cyclase signalling switched to phospholipase C stimulation or signal alteration 
upon allosteric molulation (Springael et al. 2007) which often results in an increased agonist 
potency transmitted by one of the protomers (Hilairet et al. 2003). 
Currently, two mechanistic models of interaction between the single protomers of an 
oligomeric complex exist (George et al. 2002, Milligan 2007). In ‘contact’ dimers each 
protomer folds independently and interacts with its partner involving TMS contacts. In the 
‘domain-swapped’ model the functional unit of each protomer is generated by its own first five 
TMS in combination with the last two TMS of the other protomer. This model is thought to be 
less likely. But investigations of the histamine H1 receptor suggest that both models might 
co-exist (Bakker et al. 2004). 
On the structural level, GPCR oligomers might be generated by disulfide bridge 
formation, by interactions between ILs as well as ECLs or by hydrophobic interactions between 
TM domains (George et al. 2002, Milligan 2007). In the rhodopsin-like family the model of 
robust hydrophobic interaction is favoured as SDS-resistant oligomers are often observed 
(Lemmon et al. 1992, Hebert and Bouvier 1998). A universal mechanism can however not be 
deduced so far. Involvements of almost all TMS (1, 2, 4, 5, 6) including parts of extracellular 
domains have been analysed for a variety of different GPCRs (Milligan 2007). The role of 
agonist-induced formation or disruption of oligomers in the rhodopsin-like GPCRs is also a 
matter of debate and far from consistency (Angers et al. 2002, Milligan 2007). The concept of 
bivalent ligands which possess two distinct receptor recognition sites, hence able to bridge 
between two receptor monomers, has been suggested for ET receptors (Harada et al. 2002) and 
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Pharmaceuticals based on those bivalent structures are already used in the treatment of 
migraines (George et al. 2002, Milligan 2007). 
GPCR oligomerization clearly provides a new platform for the treatment of diseases. 
Nevertheless, until now these applications are still restricted to trial and error since the exact 
mechanisms are not yet elucidated. It therefore remains important to investigate the ligand-
induced structural rearrangements of the individual GPCR monomers which contributes to the 
understanding of the complex GPCR physiology. 
 
1.3.5.  Expression systems for the functional and structural characterization of 
GPCRs 
High-level recombinant expression of active GPCRs is still a matter of trial and error and 
mostly restricted to individual targets whose crystallization success bases on excessive 
fundamental research. Vapour diffusion as well as lipidic mesophase techniques (Caffrey and 
Cherezov 2009) have been employed for X-ray crystallization of GPCRs. Five crystal structures 
comprising bovine rhodopsin and ligand-free opsin obtained from either highly abundant natural 
sources or heterologously expressed in vivo (Okada et al. 2004, Palczewski et al. 2000, Park et 
al. 2008, Scheerer et al. 2008, Standfuss et al. 2007), squid rhodopsin (Murakami and Kouyama 
2008, Shimamura et al. 2008) as well as various mutation-stabilized and engineered versions of 
the human β2-adrenergic receptor in which T4 lysozyme replaces the third IL (Cherezov et al. 
2007, Hanson et al. 2008, Rasmussen et al. 2007), mutation-stabilized turkey β1-adrenergic 
receptor (Warne et al. 2008) and the human adenosine A2a receptor in complex with a high 
affinity antagonist (Jaakola et al. 2008) are recent path-breaking achievements ranging from 2.2 
to 3.7 Å resolution. 
Major challenges to successful crystallization are (I) the choice and the stable set-up of 
a suitable and efficient expression technique yielding large amounts of receptor and (II) 
generating a homogenous, thermostable, purified active receptor population in detergent-
solubilized state by overcoming inherent problems of thermodynamic instability (Serrano-Vega 
et al. 2008) and proteolytic degradation especially of their ECL regions (Rosenbaum et al. 
2009). 
Functional studies on receptors are commonly performed in mammalian cells and 
production levels of 1.7 mg/L culture of the hamster β2-adrenergic receptor could be achieved 
(Chelikani et al. 2006). The structural genomics network MePNet recently screened 101 GPCRs 
using a combination of mammalian host cells and Semiliki Forest virus at high success rates of 
70 active GPCRs displaying expression levels compatible with structural investigations 
(Hassaine et al. 2006). 
Insect cells such as Sf9 or Hi5 (Standfuss et al. 2007) are suitable systems for the 
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folding, PTMs identical to mammalian cells and the supply of several Gα subunits (McCusker 
et al. 2007). The list of GPCRs expressed at high amounts for structural studies comprises for 
instance the human A2a adenosine, human α2a and α2b-adrenergic, histamine H1, β1- and 
β2-adrenergic and cannabinoid receptor CB1 (Akermoun et al. 2005) as well as many others 
(e.g. Massotte et al. 1999). Tremendous drawbacks are the time-consuming and laborious set-up 
and the necessity of high-titer viral stocks to infect the cultures (Lundstrom 2006, McCusker et 
al. 2007). 
Yeast expression systems combine prokaryotic as well as eukaryotic characteristics. Single 
cells, fast growth rates, inexpensive media, high cell-densities and the well developed variety of 
genetic tools make yeasts to an attractive eukaryotic host for mammalian GPCRs if controlled 
by inducible promotors such as the GAL or AOX1 promotor to overcome their toxicity to yeast 
cells (Bill 2001, Macauley-Patrick et al. 2005, McCusker et al. 2007, Romanos et al. 1992). 
Some eukaryotic specific PTMs such as proteolytic processing and lipidation can be performed 
in yeasts (Eckart and Bussineau 1996). However, significant differences exist in membrane 
composition, in particular due to the absence of cholesterol, which might influence the 
functionality of mammalian MPs (Opekarova and Tanner 2003) as well as the success of 
crystallisation trials (Long et al. 2005). PTMs are often not reliably performed thus increasing 
the inhomogeneity of the receptor (McCusker et al. 2007). Yeasts are nevertheless one of the 
preferred hosts for the production of GPCRs (Reiländer and Weiss 1998). In a concerted 
approach to express 100 different GPCRs, more than 90 % of the targets were successfully 
produced in P. pastoris (Lundstrom 2006). A systematic optimization screen was successful and 
8 of the 20 tested GPCRs were finally obtained in amounts of more than 0.35 mg/L culture 
(20 pmol per mg total membrane) (Andre et al. 2006). Oxygen supply and defined pH values 
were further found to be valuable for the expression of functional GPCRs (Sarramegna et al. 
2002). Supplementation of lipid derivatives like CHS during solubilization or purification has 
proven effective for the stabilization of the active conformation of the human adenosine A2a 
receptor resulting in 1 mg/mL functional purified receptor (O’Malley et al. 2007). 
Based on its long tradition as genetic model system the prokaryote E. coli can be 
considered as the oldest and still most popular host for the overproduction of MPs (Sorensen 
and Mortensen 2005). Major drawbacks for the expression of active GPCRs in E. coli cells are 
obvious, as they provide neither PTMs nor native G- or other accessory proteins for the 
functional expression and their lipid composition greatly differs from eukaryotic cells (e.g. no 
cholesterol). Despite those limitations a number of active GPCRs have been expressed in this 
prokaryotic host by implementing strategies such as fusions of E. coli signal peptide or maltose 
binding protein (MBP) to the termini of the target GPCR. It has been reported that GPCR 
expression without tags or fusion proteins resulted in only low or no expression yield 
(McCusker et al. 2007). Those strategies were successfully applied for instance to the human 
adenosine receptor A2a (Weiss and Grisshammer 2002), rat neurotensin receptor (White et al. Introduction 29 
 
2004), human 5-HT1a receptor (Bertin et al. 1992), human β2-adrenergic receptor (Hampe et al. 
2000) and the human cannabinoid CB2 receptor (Yeliseev et al. 2005). 
The expression of MPs in IBs in E. coli display attractive advantages as they are 
resistant to proteolytic degradation, reduce the toxicity of the target protein expression and can 
be harvested at high amounts. In vitro refolding has therefore also been exploited for GPCRs. 
However, refolding procedures for α-helical MPs are neither straightforward nor generally 
applicable techniques. So far, only the human leukotriene B4 receptor (Baneres et al. 2003), the 
human serotonin 5-HT4a receptor (Baneres et al. 2005) as well as the OR5 olfactory receptor 
(Kiefer et al. 1996) have been refolded from IBs. 
Recent crystallization success of GPCRs bases on the combination of different 
techniques adapted to the respective target and are designed to stabilize the active conformation 
as well as the thermal and proteolytic stability of the receptors (Rosenbaum et al. 2009). The 
binding of stabilizing ligands was a successful tool in recent submitted GPCR structures. 
Enhancing thermostability upon mutation of single amino acids was an important parameter 
towards crystallization of recombinant bovine rhodopsin and human adenosine A2a receptor, 
respectively (Magnani et al. 2008, Standfuss et al. 2007). Alteration of receptors by point 
mutation also enhanced the thermostability of the β1-adrenergic receptor and of the neurotensin 
1 receptor compared with its highest stability in ligand bound native form (Serrano-Vega et al. 
2008, Shibata et al. 2009). Addition of lipids during solubilization and purification and high salt 
concentrations as well as low pH might also increase receptor stability (Rosenbaum et al. 2009, 
Vogel et al. 2001). Engineering of the receptors by removal of glycosylation sites in line with 
truncation of disordered and flexible regions such as the C-terminus were applied. Introduction 
of well-folded fusion protein domains from T4 lysozyme into the unstable third IL or complex 
formation with an antibody Fab fragment which enhanced the formation of crystal-lattice 
contacts and stabilized the region of TM5/6 were further successfully used for the determination 
of the crystal structures of human β2-adrenergic receptor and the human adenosine A2a receptor 
(Cherezov et al. 2007, Hanson et al. 2008, Jaakola et al. 2008, Rasmussen et al. 2007). 
However, the approach to mutate and to engineer GPCRs always involves the risk of changing 
their native pharmacological behaviour. Reliable active states for drug design strategies will 
only be obtained in their natural form, favorably in complex with adequate G-proteins 
(Rosenbaum et al. 2009). 
 
1.4.  Structural and functional investigations on CF expressed MPs and GPCRs 
To date not only diverse prokaryotic but also eukaryotic MPs have been successfully studied in 
CF systems of different sources and functional investigations as well as structural 
determinations are more and more brought into focus (Table 2). Members of a wide array of MP 
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either extensive MP library screens (Schwarz et al. 2010) or CF expression followed by 
subsequent functional and structural investigations (Junge et al. 2010b). 
So far, only two CF expressed MPs have been reported to crystallize. The small 
multidrug resistance protein EmrE was P-CF produced as selenomethionine-labelled variant and 
employed for crystallographic phasing (Chen et al. 2007). Conditions for the crystallization of 
the human β-barrel VDAC1 have been extensively evaluated and first crystals of D-CF 
expressed MP could be achieved (Deniaud et al. 2010, Nguyen et al. 2010), however still 
displaying a limited diffraction (Deniaud et al. 2010). 
Studies of around 20 GPCRs synthesised in CF systems have been published to date 
(Table 2) (Ishihara et al. 2005, Junge et al. 2010a, Kaiser et al. 2008, Kamonchanok et al. 2008, 
Klammt et al. 2005, 2007b, 2007c, Schneider et al. 2010). They were either expressed in P-CF 
or D-CF mode and their respective yields have been found to be enhanced considerably by 
addition expression tags like the T7-tag (14 aa) or thioredoxin (Trx) fused to the N-terminus. 
Expression screens without any further functional or structural investigations of the respective 
receptors have already highlighted the CF potential in synthesizing twelve rhodopsin-like 
GPCRs without extensive optimization in yields ranging from 10 µg up to >500 µg/mL RM. 
Table 2: Cell-free expressed G-protein coupled receptors (adapted from Junge et al. 2010a) 
 
GPCR Origin  GPCR 
class 
Size 
(kDa) 
CF-
mode 
Extract 
source 
Quality 
control 
Funtional 
Assay 
β2AR-
GαS 
Human A  94  D-CF  E. coli  Activity Filter 
binding 
AChM2 Human  A  52  D-CF  E. coli  - - 
CRF Rat  B  47  D-CF  E. coli  Reconstitution - 
ETA Human  A  51  P-CF  E. coli  Activity SPR 
ETB Human  A  52  D-CF  E.coli  Activity SPR,  co-
elution, 
TIRFS 
HRH1 Human  A  55  P-CF  E. coli  Activity Filter 
binding 
MTNR1A Human  A  39  P-CF  E. coli  - - 
MTNR1B Human  A  40  D-CF  E.coli  - - 
NPY2R Human  A  43  P-CF  E. coli  - - 
NPY4R Human  A  45  D-CF  E. coli  - - 
NPY5R Human  A  50  P-CF  E. coli  - - 
NTR Rat A  59  D-CF  E. coli  - - 
OR17-4 Human  A  36  D-CF  wheat  Activity  SPR 
OR23 Mouse  A  34  D-CF wheat -  - 
S51 Mouse  A  18  P-CF  wheat  -  - 
SSTR1 Human  A  43  P-CF  E. coli  - - 
SSTR2 Human  A  42  P-CF  E. coli  - - 
V1BR Human  A  47  P-CF  E. coli  - - 
V2R Human  A  43  D-CF  E.coli  Reconstitution  
V2R Porcine  A  42  D-CF  E. coli  Reconstitution  
-, not analysed 
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1.5.  The endothelin system 
1.5.1.  Evolution of the endothelin core system in the animal kingdom: Gene 
phylogeny indicates its vertebrate specific origin 
The endothelin (ET) ligands and their respective receptors are known to play essential roles as 
regulators of the cardiovascular system (La and Reid 1995, Yanagisawa et al. 1988) as well as 
in the development of the neural crest and its derivatives (Pla and Larue 2003). Both systems 
represent hot spots of diversity especially in vertebrates and therefore participated in their 
evolutionary success (Braasch et al. 2009). Bioinformatic analyses in combination with 
phylogenetic reconstructions throughout the whole animal kindom suggest that the ET ligands 
as well as their receptors can be classified as a vertebrate specific innovation having emerged 
before the divergence of gnathostomes and lampreys. However, the ET system might also be 
even more diverse and older than anticipated since the genomes of lower vertebrates are far less 
analysed (Braasch et al. 2009, Hyndman et al. 2009). 
So far, three ET receptor gene subfamilies designated as endothelin A (ETA), 
endothelin B (ETB) and endothelin C (ETC) extended by lineage-specific duplications in 
teleosts (ETA3/4, ETB1/2) and Xenopus laevis (ETA1/2, ETC1/2) as well as four ET ligand 
subtypes ET-1, -2, -3 and -4 have been identified. It is assumed that the ET core system has 
been created by two rounds of whole-genome duplications in an early gnathostome resulting in 
four ligands and receptors that were secondarily rearranged by gene losses and co-evolution 
events. The fourth ligand exclusively persisted in teleost fish and has completely been lost in 
tetrapods while the ETC receptor has only been lost in therian mammals possibly due to 
chromosomal deletion (Braasch et al. 2009, Hyndman et al. 2009). 
 
1.5.2.  The human ET system: Receptors, ligands and binding kinetics 
Summarizing gene phylogeny studies, the human ET core system can be concentrated to the two 
class A GPCR subtypes ETA (Arai et al. 1990) and ETB (Sakurai et al. 1990) characterized by 
an extracellular N-terminus including a signal sequence and a cytoplasmic C-terminal part. 
They consist of seven TMSs each composed of around 20-27 hydrophobic amino acids. Both 
native receptors, that are approximately 50  kDa in mass, are primarily located in vascular 
smooth muscles and in the endothelium (Davenport and Battistini 2002). Downstream 
signalling of ETA is primarily mediated by the activation of G-proteins of the Gαq/11 family but 
also of GαS, Gαi2 and Gi/0. ETB further couples to Gαq/13 (Douglas and Ohlstein 1997, 
Simonson 2001, Takigawa et al. 1995) stimulating phospholipase Cβ, an increase of the 
intracellular Ca
2+concentration and immediate early genes (Douglas and Ohlstein 1997). 
Despite 59  % amino acid identity, the signalling function and targeting mechanisms of the 
activated ETA and ETB receptors are quite different (Cramer et al. 2001, Sakurai et al. 1992). 32   Introduction 
 
Vasoconstriction and cardiac inotropy is a result of ETA stimulation whereas vasodilatation can 
be attributed to ETB (Haynes and Webb 1998). 
Identified natural agonists of the ET receptors are the three 21 aa isopeptides ET-1, ET-2 and 
ET-3 (Inoue et al. 1989, Yanagisawa et al. 1988). Their synthesis involves two enzymatic 
cleavage steps forming the mature peptides out of biologically inactive precursors (Davenport 
and Maguire 2006). 
ET-2 and ET-3 differ in their mature forms in two and six amino acids from ET-1, 
respectively (Fig. 6). Major features of these three peptides reside in their highly hydrophobic, 
α-helical C-terminus and their bicyclic structure created by two disulfide bridges linking 
cysteine residues 1 and 15 and 3 and 11 (Janes et al. 1994, Kedzierski and Yanagisawa 2001). 
The principal natural agonist in the 
human cardiovascular system is ET-1 
that carries out a long-lasting 
vasoconstriction in human blood 
vessels. ET-1 is controlled by a dual 
secretory pathway. Besides being 
constitutively released from vascular 
endothelial cells thereby maintaining the 
endogenous vascular tonus by 
constriction of the adjacent smooth 
muscle cells, it can be induced by 
external stimuli being subsequently 
released by endothelial Weibel-Palade 
bodies in order to specifically increase 
its vasoconstrictory effect (Russell et al.
1998). 
Due to its low concentrations in the plasma of approximately 1 pM (Battistini et al. 1993) 
ET-1 can rather be classified as locally acting than circulating hormone. 
ET-2 is also attributed to cardiovascular tissues while mature ET-3 has been 
detected in plasma as well as brain and heart tissues (Davenport and Battistini 2002). 
Although all three native peptide ligands display picomolar to low nanomolar binding to 
both receptors in vivo (Davenport et al. 1995, Maguire and Davenport 1995, Saeki et 
al.1991) the receptors differ in their relative affinities to the respective ligands. Whereas 
ETB binds all three peptides with similar affinities, ETA is characterized by its relative 
insensitivity to ET-3 stimulation if compared with the other two ligands (Davenport and 
Battistini 2002). The C-terminal tryptophan 21 (Doherty et al. 1991) as well as the disulfide 
bridges (Saeki et al. 1991) have further been classified as essential binding residues of the 
ET-1 for high affinity binding to its receptors, especially with respect to ETA. Whereas 
Fig. 6: Schematic representation of the three native 
ET-peptides with structure of  human ET-1 (right). 
The changes in the amino acid sequence compared to 
ET-1 are highlighted in dark green. Disulfide bridges 
between involved cysteines are indicated. The crystal 
structure of ET-1 was modified after PDB 1EDN 
(Janes et al. 1994) in Pymol and shows the two 
disulfide bridges stabilizing α-helical secondary 
structure elements. Introduction 33 
 
high affinity binding of 4-Ala-ET-1 to ETB is not disturbed by mutation of all four 
cysteines to alanines, ETA displays a significant reduction in its sensitivity to the mutated 
ligand of approximately 2000-fold (Saeki et al. 1991). 
Evidently, the complex structure of the ET peptides in combination with their 
hydrophobicity render these ligands a very challenging tool for in vitro studies. However, 
structural studies by liquid-state NMR or X-ray crystallography require detergent-
solubilized receptors. High background in ligand binding experiments might therefore be 
considered due to unspecific interaction of the hydrophobic ligands with hydrophobic 
micelles or liposomes. Furthermore, their bicyclic structure has to be sustained outside the 
cellular environment and their reactive cysteines have to be kept in an oxidized state to 
prevent aggregation as well as unspecific intermolecular disulfide bridges with the receptor 
cysteines. So far, most studies of the ET system have been conducted in vivo with the 
receptors surrounded by their natural environment therefore avoiding the aforementioned 
difficulties (see 5.3.1. and 5.3.3.). 
 
1.5.3.  Physiology and pathophysiology of the human ET system 
The human ET system displays a very diverse expression pattern (Fig. 7) clearly related to 
the wide array of physiological and pathophysiological functions (Yanagisawa et al. 1988). 
Fig. 7: Exemplary overview of the human ET systems’ expression pattern. Illustrated are the 
expression, processing and release of the ET ligands by endothelial cells and their influence on the 
ETA ETB receptors on a selection of different cell types and tissues. Examples of respective 
physiological as well as pathophysiological responses are listed below. 34   Introduction 
 
The system generally acts as a major modulator in cardiovascular regulation and shows a 
striking diversity in biological responses affecting vasoconstriction, neurotransmission, 
embryonic development involved in the correct formation of neural crest-derived structures 
(Kedzierski and Yanagisawa 2001), renal function and hormone production. It is even involved 
in cancer by its mitogenic effects promoting aberrant cell proliferation, apoptotic escape and 
metastatic dissemination (Nelson et al. 2003). It is therefore not surprising that its components’ 
expression has been found associated to a variety of different tissues. These include blood 
vessels, the cardiovascular system, renal cells, glial cells and neurons in the central as well as 
peripheral nervous system, pituitary, adrenal, immune, hepatic, genitourinary and endocrine 
tissues (reviewed in Watts 2009). 
ET receptors are present on a variety of different cell types. Both receptors exist on smooth 
muscle cells on which ETA represents the major subtype with >85 %, whereas ETB is the 
predominant receptor subtype in kidney tissue and human cortex (Davenport and Maguire 2006, 
Kedzierski and Yanagisawa 2001). 
On vascular smooth muscle cells the human ETA exhibits vasoconstriction upon its activation. 
ETB, being the main receptor subtype in kidney tissue, is supposed to act as prevalent clearing 
receptor for ET-1 in a variety of organs including lung, kidney and heart. This conception of 
ETB’s clearing function bases on an empirically perceived significant rise in ET-1 levels if ETB 
is blocked by adequate antagonists (Davenport and Maguire 2006). Supporting its supposed role 
as ETA counter-regulatory receptor, activation of ETB stimulates endothelial cells to release 
muscular relaxing factors such as nitric oxide or prostacyclin resulting in a ETB-mediated 
transient vasodilatation (Berti et al. 1993, De Nucci et al. 1988, Verhaar et al. 1998). ET 
antagonism could be a possible clinical treatment for many civilisatory disorders including 
chronic heart failure, different types of pulmonary hypertension, diabetes, pain, renal failure, 
artherosclerosis and cancer (Watts 2009). The ET-1/ETA interaction constitutes the primary 
target in fighting those diseases whereas ETB antagonism only plays an inferior role in most of 
the pathophysiologies (Davenport and Maguire 2006, Kedzierski and Yanagisawa 2001). A 
variety of different subtype specific agonists and antagonists have been evaluated in clinical 
development by conventional drug design, bosentan (Tracleer) being the first combined 
ETA/ETB antagonist approved in human clinical treatment for pulmonary artery hypertension 
(Davenport and Battistini 2002, Davenport and Maguire 2006). 
ETA antagonists show for instance beneficial effects by decrease of blood pressure in 
the treatment of hypertension (Miyauchi et al. 1993), in cardiac ischemia and congestive heart 
failure (Grover et al. 1993, Sakai et al. 1996) and attenuated the detrimental symptoms in renal 
failure (Chan et al. 1994, Gellai et al. 1995). Blockage of ETA receptors by specific antagonists 
further significantly reduced cell proliferation in prostate, cervical and ovary cancer cells, 
whereas ETB antagonism did not show any remarkable effect (Nelson et al. 2003) which 
underlines ETA’s high pharmacological relevance (Kedzierski and Yanagisawa 2001). Introduction   35 
 
1.5.4.  Lipid composition of mammalian ET receptor membranes: Requirement 
of essential lipids? 
Since ET receptors have been classified as vertebrate specific innovation (see 1.5.1.) essential 
lipids as well as lipid composition of the surrounding natural membranes are characterized by 
their eukaryotic origin. 
For some of the mammalian ET receptor cell types their lipid composition has been 
elucidated. In human cultures of endothelial cells PC represents the most abundant lipid class 
accounting for approximately 60 % of total phospholipid content. Cholesterol constitutes around 
40-45 µg/mg of cell protein. Predominant fatty acids were found to be mostly of the saturated 
and monounsaturated type with oleate, stearate and palmitate representing the predominant 
molecular species (Cansell et al. 1997). 
PC and PE constitute the predominant phospholipids in rat liver cells, heart cells and 
neuronal cell bodies from cultured dorsal root ganglia (Calderon et al. 1995, Christie 1985). 
Latter are further characterized by a relatively high content of cholesterol and esters thereof at 
approximately 20 %. 
As discussed for the GPCR family of receptors above they are often characterized by a 
special need of cholesterol (see 1.3.3.). Regarding the ET receptors no specific requirement of 
cholesterol or any other sterol derivative in terms of direct interaction has been investigated so 
far. However, an enrichment of ET receptors in caveolae or caveolae-like domains characterized 
by a high cholesterol content and the presence of the structural cholesterol-binding protein 
caveolin along with an intrinsic caveolin-binding motif might already point to an interplay of 
the ET receptors with this lipid (Burger et al. 2000, Couet et al. 1997). An analysis of the amino 
acid sequence of both ETA and ETB receptors further revealed a stretch of L-(x)3-Y-(x)2-K in 
the first IL that might act as a putative CRAC motif (see 1.3.3.). The rCCM motif (see 1.3.3.) 
was additionally found in the ETB receptor implying that cholesterol might also exhibit 
pharmacological relevance for the human ET receptors. 
 
1.5.5.  Homo- and heterodimerization of ET receptors 
The traditional assumption of GPCRs solely acting as monomers in signalling processes has 
nowadays been corrected (see 1.3.4.) and corresponding investigations have also been 
performed with both ET receptors. 
In 1997 Ozaki and coworkers suggested a cross-talk between ETA and ETB receptors in 
human Girardi heart cell cultures stably expressing ETB and subsequently transfected with 
human ETA cDNA. They could demonstrate that ETA stimulation by ET-1 resulted in a 
significantly lowered affinity of ETB for its selective agonist BQ-3020 and for its selective 
antagonist BQ-788 than in cells solely expressing ETB. They assumed a characteristic change in 
the ETB receptor upon stimulation of ETA. This interaction between both receptors influenced 36   Introduction 
 
downstream effects such as intracellular Ca
2+ and cAMP levels (Ozaki et al. 1997). In the rat 
anterior pituitary gland, a tissue expressing both ETA and ETB receptors, Harada and 
colleagues suggested by quantitative autoradiography the formation of a heterodimer, which is 
mediated by the bivalent ligand ET-1 bridging between both receptors. In their ligand-
dependent model of ET receptor interaction based on the message-address concept initially 
drawn by Portoghese (1989), the bivalent ET-1 binds to the address-recognition domain via its 
N-terminal address domain whereas the C-terminal message sequence recognizes the message 
subdomain of ETB (Harada et al. 2002). 
Both ETA and ETB receptors have further been investigated for their ability to form homo– as 
well as heterodimers in cell cultures of HEK293 cells by fluorescence resonance energy transfer 
(FRET) and co-immunoprecipitation. Independently, stable FRET efficiencies between 12 % 
and 27  % indicated robust, constitutive homo- as well as heterodimerization of ETA/ETA, 
ETB/ETB and ETA/ETB. Furthermore, co-immunoprecipitation of the respective receptors was 
not altered by preincubation with agonists or antagonists indicating that the ligands directly 
neither promote dimer formation nor dissociation (Evans and Walker 2008, Gregan et al. 2004a, 
2004b). This finding is in clear contrast to the supposed model of Harada and coworkers and 
differs from receptor tyrosine kinases which need ligands for their dimerization (Ottensmeyer et 
al. 2000). It is further supposed that homodimerization might already be promoted during 
biosynthesis in the ER and that heterodimer formation is a reversible process and depends on 
receptor ETB sequestration whose onset is retarded in heterodimers (Gregan et al. 2004a, 
2004b). 
Possible physiological implications of ET receptor interaction were found in sustained 
Ca
2+-signalling controlled by heterodimers as the increase in intracellular Ca
2+ concentration 
could only be reversed by antagonizing both receptor subtypes whereas single antagonists did 
not show the ability to convert the sustained to a transient signal (Evans and Walker 2008). 
These investigations underline the necessity to understand ligand binding and downstream 
signalling of the ET receptors as a very complex and diverse process which might require not 
only the investigation of single, monomeric receptors and their kinetics but should also include 
solving receptor interaction interfaces. 
 
1.6.  CF characterization of the human ETB receptor 
Optimized CF expression of the ETB receptor in P-CF mode resulted in high preparative yields 
of 3  mg/mL RM that could be obtained as well after D-CF expression in 1  % B78 and 
1.5 % B58. Further detergent evaluations revealed that B35 and digitonin reduced the final yield 
of soluble receptor to less than 500 µg/mL of RM suggesting long-chain Brij derivatives as 
favourable detergents for the production of ETB. P-CF produced ETB precipitate resolubilized 
completely in 1 % LMPG and its subsequent reconstitution into E. coli total liposomes resulted Introduction   37 
 
in homogenously distributed particles. Purification of the receptor either out of P-CF or D-CF 
mode was performed by immobilized metal affinity chromatography (IMAC) yielding 1.8 mg of 
purified receptor per mL RM (Klammt et al. 2007b, 2007c). 
The quality of the detergent-solubilized ET receptor was analysed by a variety of 
complementary approaches. Size exclusion chromatography (SEC) and negative staining 
electron microscopy (EM) concomitant with single particle analysis of D-CF expressed ETB in 
B78 revealed monodisperse receptor preparations displaying dimensions comparable to the 
rhodopsin dimers suggesting also dimeric character of the receptor. In contrast, P-CF produced 
ETB resolubilized in LMPG resulted in high aggregation (Klammt et al. 2007c). Further 
evaluation of dimer formation capacity for the ETB receptor indicated Brij  derivatives and 
digitonin as prominently able to produce SDS-resistant dimers (Klammt et al. 2007b) which 
seems to be a characteristic feature for many in vivo expressed GPCRs (see 1.3.4.). It has 
therefore been assumed that dimerization of ETB in different hydrophobic environments might 
account for native folding. Summarizing, the ETB receptor quality was found to be highest if 
produced in D-CF mode preferably in B78. Most of the binding studies were therefore 
performed using the aforementioned conditions. 
Ligand binding studies on detergent-solubilized full-length ETB receptor was analysed 
by total internal reflection fluorescence spectroscopy with a f-4-Ala-ET-1 mutant as well as 
surface plasmon resonance (SPR) measurements with biotinylated ET-1 (b-ET-1). Equilibrium 
dissociation constants (KD) of 29 nM and 6.2 nM respectively pointed at a considerably reduced 
receptor affinity if compared with KD values of 50-300 pM determined in vivo in native lipid 
membranes (Hara et al. 1998). The reduction in binding affinity was speculated to result from 
potentially different receptor kinetics in an artificial hydrophobic micellar environment or the 
lack of G-proteins stabilizing the receptor (Klammt et al. 2007b, 2007c). 
Further ligand binding studies were performed by co-elution of a Cy3-labelled ET-1 
variant with different solubilized ETB receptor preparations in combination with SEC. D-CF 
expressed ETB in B78 revealed the highest degree of ligand binding of approximately 50 % 
comparable to values obtained by conventional insect cells expression. P-CF ETB resolubilized 
in LMPG showed no potency in binding of the ligand (Klammt et al. 2007c). 
In order to confine the ligand binding and homodimerization interfaces, different truncated 
derivatives of the full-length receptor were designed and D-CF expressed in B78 achieving high 
final yields. By use of affinity pull-down experiments of either individually or co-expressed 
full-length strep-tagged ETB and single poly(His)10-tagged truncations, the TMS 1 was found to 
be essential for the homodimerization of ETB. SPR measurements on truncations as well as 
affinity pull-down experiments of ETB truncations in B78 by b-ET-1 further suggested that this 
segment might also be essential for ligand binding (Klammt et al. 2007c). 
However, SPR measurements with ET-1 might be delicate to interpret since it was demonstrated 
in the present study that by using SPR ET-1 also bound to related GPCRs with almost the same 38   Introduction 
 
affinity (see 4.8.2. and 5.3.3.). 
 
1.7.  Aim of this project 
CF expression approaches overcome major limitations of conventional in vivo expression 
systems and are thus a competing alternative for the large-scale production of MPs. Instead of 
using classical approaches for the synthesis of MPs, CF expression systems with focus on the 
prokaryotic S30 E. coli extract, were therefore to be used for the production of the human ET 
receptors. Based on previous studies on ETB, accomplished by Dr. Christian Klammt, CF 
synthesis was to be extended to and optimized for the ETA receptor as basis for the 
characterization of the whole human ET receptom. 
Individual preparative scale production protocols along with the evaluation of rational 
purification and quality control strategies were to be developed as essential prerequisite for 
functional analyses of ETA and -to some extent- of ETB in detergent-solubilized and in co- and 
post-translationally liposome-reconstituted form. The intrinsic versatility of the CF expression 
system should be used to modulate the quality of the target protein at different stages of the 
production process. Parameters, compounds and processes able to modify ETA sample 
properties after solubilization should be identified and analysed by evaluation of homogeneity 
and protein stability. As complementary approach for analysing the functional folding of CF 
produced GPCRs these quality control strategies should finally allow the set-up of optimized 
production protocols for the generation of high quality ETA receptor samples which could serve 
as future guidelines for the CF preparation of GPCRs. 
The implementation and development of straightforward biochemical or biophysical 
assays for CF synthesized GPCRs to readily assess their ligand binding competence in different 
in vitro environments represented a further major aim of the present study. Ligand binding 
experiments with liposome-reconstituted receptor were intended to compare CF produced ETA 
binding kinetics to in vivo expressed membrane-embedded receptor. In particular, the new L-CF 
mode should be approached as promising alternative to the conventional in vitro reconstitution 
of MPs in lipid environments. 
Studies of homo– and hetero-oligomerization between ETA and ETB should further be initiated. 
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2.  Materials 
 
2.1.  Equipment 
CF extract and T7 RNA polymerase preparation: 
Cell disruptor Constant Systems      IUL Instruments GmbH (Germany) 
Fermenter, 10-liter      B. Braun Biotech GmbH (Germany) 
French pressure cell disruptor      SLM Aminco Instruments Inc. (USA) 
DNA template preparation and analysis: 
Agarose gel electrophoresis system    Peqlab Biotechnologie GmbH (Germany) 
Midi DNA preparation kit      Macherey-Nagel GmbH+Co. KG (Germany) 
QIAquick gel extraction kit      Qiagen GmbH (Germany) 
QIAquick PCR purification kit      Qiagen GmbH (Germany) 
Thermocycler     Biometra  AG  (Germany), Eppendorf (Germany) 
General equipment: 
Autoclave      Tecnomara AG (Switzerland),  
Gettinge AB (Sweden) 
Centrifuge Sorvall Evolution RC      Sorvall Instruments (Germany) 
Centrifuge Sorvall RC 5B, C      Sorvall Instruments (Germany) 
Cooled table top centrifuge Micro 22R      Hettich GmbH +Co.KG (Germany) 
Incubating shakers      Infors AG (Germany), New Brunswick 
Scientific Inc. (USA) 
MS2 Minishaker      IKA Werke GmbH+Co. KG (Germany) 
NanoDrop 1000     Peqlab Biotechnologie GmbH (Germany) 
Protein expression and analysis: 
Dialysis tubes type 27/30, MWCO      Spectrum Laboratories Inc. (USA) 
12-14 kDa 
Immobilon-P PVDF membrane    Millipore GmbH (Germany) 
Lumi Imager F1
     Roche Diagnostics GmbH (Germany) 
Mini-Protean Electrophoresis system      Bio-Rad GmbH (Germany) 
Slide-A-lyzer dialysis cassette, MWCO      Thermo Fisher Scientific GmbH (Germany) 
10 kDa 
Waterbath shaker      New Brunswick Scientific Inc. (USA) 
Protein processing, quality and functional analysis: 
Äkta purifier FPLC system      GE Healthcare (Germany) 
BAF 060 freeze-fracturing unit      Bal-Tec Inc. (Principality of Lichtenstein) 
Bandelin Sonorex Super RK 510    SCHALLTEC  GmbH  (Germany) 
Biobeads  SM-2      Bio-Rad  GmbH  (Germany) 40   Materials 
 
Cobra II Auto gamma        PerkinElmer (Germany) 
Columns (Superdex 200 3.2/30,      GE Healthcare (Germany) 
Superdex 200 10/300, Q-sepharose) 
Freeze-fracture  EM       Bal-Tec  Inc. (Principality of Lichtenstein) 
HPLC unit          Jasco Labortechnik GmbH (Germany) 
Mini Dawn Treos (3 angles)      Wyatt Technology Europe GmbH (Germany) 
Mini-Extruder      Avanti  Polar  Lipids  Inc.  (USA) 
MultiScreen HTS GF/B filter    Millipore  GmbH  (Germany) 
MultiScreen HTS vacuum filtration    Millipore GmbH (Germany) 
Optilab rex (RI detector)      Wyatt Technology Europe GmbH 
(Germany) 
Spectrofluorometer, FP-6500      Jasco Labortechnik GmbH (Germany) 
Spectropolarimeter, J-180      Jasco Labortechnik GmbH (Germany) 
Sonifier Labsonic U      B. Braun Biotech GmbH (Germany) 
Ultracentrifuges (L-70, Optima TLX,       Beckman Coulter GmbH (Germany) 
Optima LE-80K) 
Ultra-Clear Centrifuge Tubes      Beckman Coulter GmbH (Germany) 
2.2.  Software 
ASTRA 5.3.4.13        Processing and evaluation software for 
multi angle light scattering (MALS) data 
Chromas  lite      Processing software for DNA sequencing 
chromatogram files 
Graph Pad Prism 5        Software for biostatistics, graph fittings and 
scientific graphing 
UNICORN 5.11         Software package for control, supervision of 
chromatograpy systems and processing of  
chromatograms 
2.3.  Reagents and chemicals 
Antibodies: 
Anti-biotin goat pAb Peroxidase  Calbiochem, MERCK chemicals 
conjugate  KG aA (Germany) 
Anti-mouse IgG HRP conjugate   Sigma-Aldrich Chemie GmbH (Germany) 
from goat 
Anti-penta His IgG from mouse  Qiagen GmbH (Germany) 
T7 tag antibody HRP conjugate  Novagen, MERCK chemicals KG (Germany) 
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Detergents: 
Sigma-Aldrich Chemie GmbH (Germany): 
B35, Brij 35, polyoxyethylene-(23)-lauryl-ether 
B58, Brij 58, polyoxyethylene-(20)-cetyl-ether 
B78, Brij 78, polyoxyethylene-(20)-stearylether 
B98, Brij 98, polyoxyethylene-(20)-oleyl-ether 
Carl Roth GmbH+Co.KG (Germany): 
CHAPS, 3-[(3-Cholamidopropyl) dimethylammonio]-1-propansulfonat 
SDS, sodium dodecylsulfate 
Anatrace, Affymetrix Inc. (USA): 
DDM, n-dodecyl-β-D-maltoside (also Applichem GmbH, Germany) 
DPC, Fos-12, n-dodecylphosphocholine 
Fos-16, n-hexadecylphosphocholine 
HDM, n-hexadecyl-β-D-maltopyranoside 
LMPC, 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac(1-choline)] 
LMPG, 1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] 
LPPG, 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] 
TDM, n-tetradecyl-β-D-maltopyranoside 
General reagents and chemicals: 
1,4-Dithiotreitol (DTT)  Carl Roth GmbH+Co.KG (Germany) 
2-Mercaptoethanol  Carl Roth GmbH+Co.KG (Germany) 
Acetyl phosphate lithium potassium salt  Sigma-Aldrich Chemie GmbH (Germany) 
Adenosine 5’-triphosphate (ATP)  Roche Diagnostics GmbH (Germany) 
Amino acids (unlabelled)  Sigma-Aldrich Chemie GmbH (Germany) 
Antifoam Y-30 emulsion  Sigma-Aldrich Chemie GmbH (Germany) 
Bactotryptone  Carl Roth GmbH+Co.KG (Germany) 
Bovine serum albumin Fraction V  Sigma-Aldrich Chemie GmbH (Germany) 
Complete Protease Inhibitor Cocktail  Roche Diagnostics GmbH (Germany) 
Cholesteryl hemisuccinate tris salt  Sigma-Aldrich Chemie GmbH (Germany) 
Cytidine 5’ triphosphate di-sodium salt  Fluka, Sigma-Aldrich Chemie GmbH (Germany) 
Dimethylsulfoxide  Carl Roth GmbH+Co.KG (Germany) 
Ethidiumbromide  Carl Roth GmbH+Co.KG (Germany) 
Folinic acid calcium salt  Sigma-Aldrich Chemie GmbH (Germany) 
Gene ruler 100bp, 1kb DNA ladder  Fermentas GmbH (Germany) 
Glucose monohydrate  Carl Roth GmbH+Co.KG (Germany) 
Guanosine 5’ triphosphate di-sodium salt  Fluka, Sigma-Aldrich Chemie GmbH (Germany) 
HEPES, Imidazole, IPTG, K2HPO4, KCl, KH2PO4 Carl Roth GmbH+Co.KG (Germany) 
Magnesium acetate tetrahydrate  Sigma-Aldrich Chemie GmbH (Germany) 42   Materials 
 
NaCl  Carl Roth GmbH+Co.KG (Germany) 
NaN3  Fluka, Sigma-Aldrich Chemie GmbH (Germany) 
Ni-NTA Agarose  Qiagen GmbH (Germany) 
Nonidet P-40, P-40 alternative  MERCK chemicals (Germany) 
PEG8000  Sigma-Aldrich Chemie GmbH (Germany) 
Peptone, tryptic digest  Carl Roth GmbH+Co.KG (Germany) 
Phenylmethylsufonyl fluoride (PMSF)  Sigma-Aldrich Chemie GmbH (Germany) 
Phosphoenol pyruvic acid (PEP),  Sigma-Aldrich Chemie GmbH (Germany) 
monopotassium salt 
PIERCE Monomeric Avidin Agarose  Thermo Fisher Scientific (Germany) 
Potassium acetate  Sigma-Aldrich Chemie GmbH (Germany) 
Pyruvate kinase  Roche Diagnostics GmbH (Germany) 
Restriction enzymes  New England Biolabs GmbH (Germany) 
RiboLock RNase Inhibitor  Fermentas GmbH (Germany) 
Spermidine    Fluka, Sigma-Aldrich Chemie GmbH (Germany) 
T4 DNA-ligase  New England Biolabs GmbH (Germany) 
TCEP  PIERCE, Thermo Fisher Scientific (Germany) 
Tris-(hydroxymethyl)-aminomethane  Carl Roth GmbH+Co.KG (Germany) 
tRNA E. coli MRE 600  Roche Diagnostics GmbH (Germany) 
Turbo-Pfu DNA polymerase  Stratagene AG (Germany) 
Uridine 5’ triphosphate tri-sodium salt  Fluka, Sigma-Aldrich Chemie GmbH (Germany) 
VentDNA Polymerase  New England Biolabs GmbH (Germany) 
Yeast extract  Carl Roth GmbH+Co.KG (Germany) 
Lipids: 
Avanti Polar Lipids Inc. (USA): 
DMPC, 1,2-dimyristoyl-sn-phosphatidylcholine 
DOPE, 1,2-dioleyl-sn-glycero-3-phosphoethanolamine 
DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
E. coli total lipid extract 
E. coli polar lipid extract (Chloroform) 
POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (sodium salt) 
Sigma-Aldrich Chemie GmbH (Germany): 
L-α-Phosphatidylcholine from soybean, Type IV-S 
Cholesterol 
Plasmid vectors with T7 regulatory elements: 
pET21a(+), pET28a(+)  Novagen, MERCK chemicals KG (Germany) 
pIVEX  Roche Diagnostics GmbH (Germany) Materials   43 
 
2.4.  Labelled chemicals and ligands 
4-Ala-endothelin-1  (ET-1)    Dr.  Michael Beyermann, FMP (Berlin) 
L-[
35S]- methionine, 2 mCi      Hartmann Analytic GmbH (Germany) 
Biotin [Lys9]-ET-1        Dr. Michael Beyermann, FMP (Berlin) 
Cy3-ET-1          Dr. Michael Beyermann, FMP (Berlin) 
ET-1  (Human,  Porcine),     PerkinElmer  (Germany) 
[
125I]-ET-1, [
125I]Tyr
13-; 5, 10, 50 µCi 
ET-1, ET-3          Dr. Michael Beyermann, FMP (Berlin) 
Fluorescein-4-Ala-ET-1 (f-4-Ala-ET1)    Dr. Michael Beyermann, FMP (Berlin) 
The ligands, their aa sequences and labels are illustrated in the Appendix (see 7.3.). 
 
2.5.  Microbial strains 
 
Strain Relevant  genotype  Reference 
E. coli DH5α [F
-,endA1, hsdR17 (rk
-mk
-), supE44, thi-1, 
recA1, gyrA (Nal
r), relA1, ∆(lacZYA-
argF)U169, Φ80lacZ∆M15] 
(Hanahan et al. 1983) 
E. coli BL21 
(DE3) 
hsdS,  gal  [λcI,  ts857,  cnd1,  hsdR17,  recA1, 
endA1, gyrA96, thi-1, relA1] 
(Studier and Moffat 
1986) 
E. coli K-12 strain 
A19 
[rna19 gdh A2 his95 relA1 spoT1 metB1]  E. coli Genetic stock 
center, New Haven, 
CT 
 
2.6.  Oligonucleotides 
All primers were ordered from MWG Biotech AG or Biospring if not stated otherwise. 
Sequences as well as melting temperatures are provided in the Appendix (see 7.1.). 
 
2.7.  Common buffers, media and reagents 
All solutions are prepared with Milli Q water and kept at –20  °C if not stated otherwise. 
Sterilization by filtering is performed using 0.22 µm filters. 
2.7.1.  General buffers and media for the preparation of cell-free extract, T7 
RNA polymerase and bacterial growth 
Ampicillin stock, 1000-fold: 150 mg/mL Na
+-ampicillin salt in 50 % EtOH. 
DB salt: 5.22 mM NH4H2PO4, 0.05 mM MgSO4 x 7H2O, 0.2 mM KCl, 44 % glycerol (w/v) in 
H2O. Mix thoroughly on a stirring device for 20 minutes (min) and sterilize by autoclaving. 
Store at room temperature (RT). 44   Materials 
 
Dialysis buffer for T7RNAP: 10 mM K2HPO4, pH 8.0, 10 mM NaCl, 0.5 mM EDTA, 1 mM 
DTT. 
IPTG stock: 1 M in H2O. 
Kanamycin stock, 1000-fold: 75 mg/mL kanamycin sulfate in H2O. 
LB medium (1 liter): 10 g bactotryptone, 5 g yeast extract, 10 g NaCl. Sterilize by autoclaving. 
M9 T7-TG medium (1 liter): Combine 900 mL TG medium and 100 mL 10x M9 stalts; add 
0.2 % glucose, 1 mM MgSO4, 0.1 mM CaCl2, stock solutions of latter mentioned solutions 
have to be sterilized by filtering. 
10 x M9 salts (1 liter): 382 mM Na2HPO4, 220 mM KH2PO4, 186 mM NH4Cl, 855 mM NaCl. 
Dissolve in H2O, sterilize by autoclaving and store at 4°C. 
Protease inhibitor cocktail: 1.197  mg/mL AEBSF, 0.238  mg/mL leupeptin, 0.154  mg/mL 
bestatin, 0.098 mg/mL aprotinin, 0.089 mg/mL E-64, 0.034 mg/mL pepstatin. 
Q sepharose buffer A for T7RNAP: 30 mM Tris, pH 8.0, 50 mM NaCl, 1 mM EDTA, 10 mM 
β-mercaptoethanol, 5 % glycerol. Store at 4°C. 
Q sepharose buffer B for T7RNAP: 30 mM Tris, pH 8.0,1 M NaCl, 1 mM EDTA, 10 mM 
β-mercaptoethanol, 5 % glycerol. Store at 4°C. 
Resuspension buffer for T7RNAP: 30 mM Tris-HCl, pH 8.0, 50 mM NaCl, 10 mM EDTA, 
10 mM β-mercaptoethanol, 5 % glycerol, protease inhibitor cocktail 
SOC medium (1 liter): 20 g bactotryptone, 5 g yeast extract, 0.5 g NaCl. Adjust to pH 7.0 with 
NaOH and sterilize by autoclaving. Add final concentrations of 25 mM KCl, 10 mM MgCl2 
and 20 mM glucose solution. All latter mentioned solutions have to be sterilized by filtering 
before addition. Store at 4 °C. 
S30 A buffer:  10 mM Tris-acetate, pH 8.2, 14 mM Mg(OAc)2, 60 mM KCl, 6 mM 
β-mercaptoethanol. Sterilize by filtering and store at 4°C. 
S30 B buffer: 10 mM Tris-acetate, pH 8.2, 14 mM Mg(OAc)2, 60 mM KCl, 1 mM DTT and 
0.1 mM PMSF. It is recommended to prepare a 50-fold stock solution S30 A/B buffer out of 
Tris-acetate, Mg(OAc)2 and KCl. Sterilize by filtering and store at 4°C. Add 
β-mercaptoethanol, DTT and PMSF freshly to the 1-fold buffers. 
S30 C buffer: 10 mM Tris-acetate, pH 8.2, 14 mM Mg(OAc)2, 60 mM KOAc, 0.5 mM DTT. 
Store at 4°C. It is recommended to prepare a 50-fold stock without DTT. Add DTT freshly 
to the 1-fold buffer. 
TG medium (1 liter): 10 g bactotryptone, 0.2 % glycerol (v/v). Dissolve in H2O and sterilize by 
autoclaving. Store at RT. 
WGE buffer 40 mM HEPES-KOH pH, 7.6, 5 mM Mg(OAc)2, 100 mM KOAc, 4 mM DTT, 
0.3 mM of each of the 20 amino acids. Dissolve in H2O and sterilize by filtering. 
2 x YTPG medium (10 liters of aqueous solution): 22 mM KH2PO4, 40 mM K2HPO4, 100 mM 
glucose, 160 g bactotryptone, 100 g yeast extract, 50 g NaCl. Sterilize glucose separately by 
filtering. Sterilize phosphate buffer components separately by autoclaving. Dissolve 
remaining media components in distilled water and sterilize by autoclaving. The 
components should all be freshly prepared. Store at RT. 
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2.7.2.  Reagents and buffers for cell-free expression and mRNA preparation 
Acetyl phosphate lithium potassium salt, AcP: 1 M stock solution, pH 7.0, adjusted with 10 M 
KOH. 
Amino acid stock: 20 amino acids containing stock solution at a final concentration of 8 mM 
each and dissolve in H2O. Adjust pH to 8.0 with 10 M KOH. Suspensions are pipetted to the 
cell-free reaction set-up. 
Complete® protease inhibitors cocktail with EDTA: 50-fold stock solution in H2O. 
Creatine kinase: 10 mg/mL stock in H2O. 
DTT: 500 mM stock in H2O. 
Folinic acid calcium salt: 10 mg/mL stock in H2O. Completely dissolve by incubation at 37°C. 
HEPES: 2.4 M stock. Adjust to pH 8.0 with 10 M KOH. 
Lithium chloride, LiCl: 14 M stock solution in distilled RNase free water. Sterilize by filtering. 
Store at RT. 
Magnesium acetate tetrahydrate, Mg (OAc)2: 1 M solution in H2O. 
NTP mix: 75-fold stock containing 90 mM ATP, 60 mM each GTP, CTP and UTP, pH 7.0 
adjusted with NaOH. 
Phospho(enol)pyruvic acid monopotassium salt, PEP: 1 M stock. Adjust to pH 7.0 with 10 M 
KOH. 
Polyethylenglycol 8000, PEG8000: 40 % (w/v) solution dissolved in H2O by shaking over night 
(o. n.) at 37°C. 
Potassium acetate, KOAc: 4 M in H2O. 
Pyruvat kinase (Roche Diagnostics): Stock of 10 mg/mL.Commercial, no separate preparation 
necessary. 
RiboLock
TM RNase inhibitor (Fermentas): Stock of 40 U/µL. Commercial, no separate 
preparation necessary. 
Sodium acetate, NaOAc: 3 M stock in distilled RNase free water, pH 5.5 adjusted with NaOH. 
Sterilize by filtering. Store at 4°C. 
Sodium azide, NaN3: 3 % and 10 % (w/v) stocks in H2O. 
Spermidine: 100 mM stock solution in H2O. 
Transcription buffer, 5-fold: 400 mM HEPES-KOH, pH 7.6, 90 mM MgCl2. Sterilize by 
filtering. 
Translation pre-mix, 20-fold: 500 mM HEPES-KOH, pH 7.6, 30 mM DTT, 5 mM spermidine, 
8 mM GTP, 20 mM ATP. Sterilize by filtering. 
tRNA E. coli MRE 600: 40 mg/mL stock in H2O. 
tRNA from brewer’s yeast: 2 mg/mL stock in H2O. 46   Materials 
 
WGE-NTP mixture:100 mM stock of 25 mM each ATP, UTP, GTP and CTP in distilled RNAse 
free water, pH 7.0 adjusted with NaOH. Sterilize by filtering. 
 
2.7.3.  Buffers for DNA-Agarose gels, SDS-PAGE and immunodetection by 
Western Blotting 
Agarose: e.g. 1 % (w/v) agarose boiled in 1-fold TAE buffer. Store at RT. 
Ammoniumperoxid sulfate, APS: 10 % stock solution by dissolving 100 mg/mL 
ammoniumperoxid sulfate in H2O. Store at 4°C. 
Blotting buffer (Towbin): Dissolve 25 mM Tris, 192 mM Glycin, 3.5 mM (1 %) SDS, 15 % 
MeOH in H2O. pH should self-adjust to pH 8.3. Store at 4 °C. 
Coomassie brilliant blue-staining solution for SDS gels: 50 % (v/v) ethanol (96 %), 10 % (v/v) 
acetic acid (100 %) and 0.1 % (w/v) Coomassie Brilliant Blue G250. Dissolve in H2O and 
store at RT in a dark bottle to avoid exposure to light. 
DNA-loading dye, 6-fold: 40 % (w/v) sucrose, 0.25 % (w/v) bromphenol blue and 0.25  % 
xylene cyanol FF. Dissolve in H2O and store at 4°C. 
EtBr-stock solution: 10 mg/mL stock in H2O. 
ECL 1: 100 mM Tris-HCl, pH 7.5, 2.9 mM Luminol, 0.4 % p-coumaric acid in H2O. Store at 
4°C. Luminol and p-coumaric acid are dissolved in 100 % DMSO. 
ECL 2: 100 mM Tris-HCl, pH 8.0, 0.06 % H2O2 in H2O. Store at 4°C. 
PBS wash buffer for western blots (10-fold): Dissolve 1.37 M NaCl, 0.03 M KCl, 80 mM 
Na2HPO4 and 15 mM KH2PO4 in H2O. Add 0.05 % Tween 20 to the 1-fold dilution. Store at 
4°C. 
Rotiphorese Gel 30: 30 % (v/v) acrylamide, 0.8 % (v/v) bisacrylamide. Store at 4 °C. 
Rotiphorese Gel 40: 40 % (v/v) acrylamide, 1 % (v/v) bisacrylamide. Store at 4 °C. 
SDS gel buffers: 
Running buffer: 25 mM Tris-HCl, pH 8.0, 0.1 % (w/v) SDS and 200 mM glycine. Store at 
RT. 
Stacking gel buffer: 0.4 % (w/v) SDS, 0.5 M Tris-HCl, pH 6.8. Store at 4°C. 
Separating gel buffer: 0.4 % (w/v) SDS, 1.5 M Tris-HCl, pH 8.9. Store at 4°C. 
SDS-PAGE sample buffer, 5-fold: 25 % (w/v) glycerol, 25 % (v/v) β-mercaptoethanol, 
7.5 % (w/v) SDS, 0.1 % (w/v) coomassie G250, 300 mM Tris-HCl, pH 6.8. Store at RT. 
TAE buffer, 50-fold: Dissolve 2 M Tris , 5.7 % acetic acid (v/v) and 50 mM EDTA in H2O. 
Store at RT. 
Tricine gel buffers: 
Anode buffer, 10-fold: 1 M Tris-HCl, pH 8.9. Store at RT. 
Cathode buffer, 10-fold: 1 M Tris, 1 M tricine, 1 % SDS (w/v). The pH should self-adjust to 
8.25. Store at RT. 
Gel buffer, 3-fold: 3 M Tris-HCl, pH 8.45, 0.3 % SDS (w/v). Store at RT. Materials   47 
 
Table 3: Pipetting scheme for two 10 % Tricine separating and two 4 % stacking gels. 
 
 
2.7.4.  Buffers for protein purification and protein analysis 
Biotin Blocking buffer for MAM: 100 mM Na2HPO4, 150 mM NaCl, pH 7.0. Add 2 mM biotin 
as reversible competitor. 
CD buffer: 10 mM sodium phosphate, pH 7.5. The required pH is adjusted by combination of 1 
M Na2HPO4 and 1 M NaH2PO4. 
Elution buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM biotin as reversible competitor. 
Add the appropriate detergent used for protein purification. 
Filter binding / wash buffer for radioactive activity measurements on proteoliposomes: 20 mM 
potassium phosphate, pH 7.5, 150 mM NaCl, 0.1 % BSA. The pH is adjusted by 
combination of 1 M K2HPO4 and 1 M KH2PO4. 
Fluorescence anisotropy buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % B35. 
IMAC buffers for ETA and truncations: 
Equilibration buffer: 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 10 mM imidazole. 
Wash 1 buffer: 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 30 mM imidazole. 
Wash 2 buffer: 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 80 mM imidazole. 
Wash 3 buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl. 
Elution buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 350 mM imidazole. 
Add the appropriate detergent at a concentration of 5-10 times above CMC. 
IMAC buffers for ETB and truncations: 
See: IMAC buffers for ETA and truncations. Instead of Tris, 50 mM NaH2PO4 was used as 
buffer substance. 
Inteine cleavage buffer: 50 mM Tris-HCl, pH 6.5, 0.5 M NaCl, 1 mM EDTA. Alternatively, 2 
mM DTT were added to the buffer and the pH was adjusted to 7.0. 
Liposome reconstitution buffer, 1-fold: 20 mM potassium phosphate, 150 mM NaCl. The pH is 
adjusted by combination of 1 M K2HPO4 and 1 M KH2PO4. 
PBS buffer for MAM, 1-fold: 100 mM Na2HPO4, 150 mM NaCl. Adjust pH to 7.0. 
Regeneration buffer for MAM: 100 mM glycine, adjust pH to 2.8 with HCl. 
Compounds  Separating gel (10 %) [mL]  Stacking gel (4 %) [mL] 
Rotiphorese Gel
 30 (37.5:1)  4.5  0.5 
Gel buffer, 3-fold  4.5  1.3 
Glycerol (98 %)  1.1  - 
H2O 3.0  2.0 
APS (10 %)  0.135  0.08 
TEMED 0.015  0.005 48   Materials 
 
Resolubilization buffer for IMAC purification: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
TCEP, 1 % of the respective detergent. 
Resolubilization buffer for reconstitution, 5-fold: 100 mM potassium phosphate, 0.75 M NaCl. 
The required pH (pH 7.0, pH 7.5) is adjusted by combination of 1 M K2HPO4 and 1 M 
KH2PO4. 
SEC buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.04 % DDM or 0.1 % B35. Sterilize and 
degase by filtering. Store at 4 or 16 °C. 
SEC buffer for inteines: 50 mM Tris-HCl, pH 7.0, 100 mM NaCl, 2 mM DTT, 1 mM EDTA 
and 0.08 % Fos-12. Store at 4 or 16 °C. 
StrepII-tag affinity purification buffer: 
Equilibration and wash buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % B35 / 0.1 % 
Fos-12. 
Elution buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % B35 / 0.1% Fos-12, 2.5 mM 
desthiobiotin as a reversible binding specific competitor. 
Tris-HCl: Prepare a 1 M stock solution of Tris and adjust the required pH at RT with HCl. For 
measurements at higher temperatures a ∆pKa/°C of -0.03°C was assumed. 
Wash buffer for MAM: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl. Add the appropriate detergent 
used for protein purification. 
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3.  Methods 
 
3.1.  Standard methods of molecular biology and microbiology 
3.1.1.  DNA techniques: Conventional polymerase chain reaction (PCR) and 
cloning 
The coding region of the human ETA full-length receptor (Gene Bank accession number: 
AY275462) was amplified by conventional PCR (Mullis and Faloona 1987, Saiki et al. 1988) 
from cDNA obtained from the UMR cDNA Resource Center (www.cdna.org) by using 
VentDNA-polymerase (New England Biolabs, Frankfurt, Germany) and the oligonucleotide 
primers ETA_up: 5’-CGA AGA TCT ATG GAA ACC CTT TGC CTC AGG GCA TCC-3’ and 
ETA_low: 5’-CCG CTC GAG CAT GCT GTC CTT ATG GCT GCT CCG-3’. Restriction sites 
for the enzymes BglII, an isoschizomere of BamHI, and XhoI were introduced by suitable 
linkers. PCR fragments were purified, restriction digested and ligated with a BamHI and XhoI 
digested derivative of the vector pET21a(+) (Merck, Darmstadt, Germany) (see 7.2.) encoding 
for a poly(His)10-tag. Further coding regions of the human ETA resulting in truncations of the 
receptor were PCR-amplified using the corresponding oligonucleotide primers (see 7.1.4.), 
VentDNA-polymerase and the full-length ETA receptor construct in pET21a(+)poly(His)10 as a 
template (see above). The PCR products were either cleaved with BglII and XhoI or BglII and 
NcoI in order to achieve cloning into pET21a(+)polyHis10 or pET21a(+)strepII, another 
derivative of pET21a(+) encoding for a strepII-tag that was introduced by quick change 
mutagenesis. PCR products were purified, restricted and ligated either with a BamHI and XhoI 
cleaved pET21a(+)poly(His)10 or a BamHI and NcoI cleaved pET21a(+)strepII, respectively. 
The coding region of the human ETB receptor without its signal peptide (ETB-sign) 
was PCR-amplified using a full-length receptor containing plasmid as template (see PhD thesis 
Dr. Christian Klammt) and the oligonucleotide primers ETB1-bam_up: 5’-CGG GGA TCC 
GAG GAG AGA GGC TTC CCG CCT GAC AGG-3’ and ETBlow: 5’-CGG CTC GAG AGA 
TGA GCT GTA TTT ATT ACT GGA ACG-3’. Restriction sites for the enzymes BamHI and 
XhoI were introduced by appropriate linkers. PCR fragments were purified, restriction digested 
and ligated with a BamHI and XhoI digested derivative of the vector pET21a(+)poly(His)10. 
The ETB intein fusion constructs pVSO 4.1 and pVSO 4.2 were kindly provided by 
Prof. Dr. Henning Mootz (Technical University Dortmund, Germany). Both constructs were 
restriction digested with BamHI and XhoI and subsequently ligated into the equivalently cleaved 
vector pET21a(+)poly(His)10. pVSO  4.1 harbors the coding sequence for TMS1 of ETB 
full-length receptor starting at amino acid position 93 and ending at position 130 fused to the 
split intein DnaE
N from Nostoc punctiforme. pVSO 4.2 contains the split intein DnaE
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N. punctiforme fused to the coding sequence for the following two TMS (TMS 2+3) starting at 
amino acid position 131 and ending at position 203. The intein fusion proteins were further 
termed ETB 4.1 and ETB 4.2 after their respective plasmids pVSO 4.1 and pVSO 4.2. 
ETA and ETB as well as their truncations and intein fusions were expressed from these 
constructs with a N-terminal T7-tag and a C-terminal poly(His)10-tag.  
The ETB full-length construct pObe-ETB-TMV for the expression in the WGE 
harboring a poly(His)6-tag at its C-terminus was a pleasant gift of Dr. Vladimir A. Shirokov 
(Institute of Protein Research, Russian Academy of Science, Pushchino, Moscow Region, 
Russia). It was cloned into a pUC18-modified vector containing a 5’  UTR obelin leader 
sequence as well as a 3’ UTR TMV sequence under the control of a T7 promotor. The 
pObe-ETB-TMV was expressed from this constructs with a C-terminal poly(His)6-tag. 
Standard PCR reactions were performed using plasmid DNA as template and a reaction 
volume of 100 µL if not stated otherwise. Analysis of the amplification reaction was carried out 
with volumes of 5-10 µL on 1 % agarose gels in 1-fold TAE buffer. PCR reaction samples were 
subsequently purified with Nucleospin PCR purification kits (Macherey-Nagel, Düren, 
Germany) and eluted either in water or in 10 mM Tris-HCl, pH 7.5 (Table 4). 
Purification of plasmid DNA was achieved by modified alkaline/SDS lysis. Plasmid 
DNA resulting from molecular cloning procedures for sequencing–grade purity was commonly 
purified with NucleoSpin Plasmid (Macherey-Nagel, Düren, Germany) using a 3  mL o. n. 
culture. Plasmid DNA used as template for CF expression was isolated with NucleoBond 
AX100 commercial kits (Macherey-Nagel, Düren, Germany) using 150  mL o. n. culture 
according to manufacturer’s recommendations. 
Table  4: Composition of a standard PCR with program set-up. The annealing temperature was 
adjusted dependent on the melting temperature of the respective oligonucleotides. The elongation time 
was chosen dependent on the length of the target fragment. 
 
  *, dNTP mixture (10 mM): 2.5 mM dATP, 2.5 mM dCTP, 2.5 mM dGTP, 2.5 mM dTTP 
 
 
Compounds [stock]  Final 
concentration 
Program 
Template DNA  50 -300 ng  Initial denaturation: 
1 x                                                  95°C, 7 min 
5’-oligonucleotide 
[10 µM] 
10 pmol  Denaturation:  
                                                       95°C, 1 min 
3’-oligonucleotide 
[10 µM] 
10 pmol  Annealing:  
                                              42°C – 65°C, 30 s 
dNTP mixture* 
[10 mM] 
200 µM  Elongation: 
                                          72°C, 1 – 1min 30 s 
Polymerase buffer, 
10-fold 
1-fold  Final elongation: 
1 x                                                  72°C, 7 min 
VentDNA polymerase  2 U  ∞                                                                  4°C 
MgSO4 [100 mM]  2 – 6 mM   
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DNA concentration in aqueous solution was spectrophotometrically measured at λ = 260 nm 
using a NanoDrop 1000 Spectrophotometer (Peqlab Biotechnologie GmbH, Erlangen, 
Germany) assuming with Lambert-Beer’s law that an absorption of 1 corresponds to a 
concentration of 50 µg/mL of double-stranded DNA. 
 
3.1.2.  Site-directed mutagenesis: Replacement of essential cysteines involved in 
disulfide bridge formation 
To exchange the relevant codons of cysteines 158 and 239 involved in putative disulfide bridge 
formation in the ETA full-length receptor by bases coding for alanines site-directed mutagenesis 
by PCR was performed using the oligonucleotide primers ETA C/A 158_up 5’-GGC GTA TTT 
CTT GCC AGG CTG TTC CCC-3’ and ETA C/A 158_low 5’-GGG GAA CAG CTT GGC 
AAG AAA TAC GCC-3’ as well as ETA C/A 239_up 5’-CAG CAT AAA ACC GCT ATG 
GGC-3’ and ETA C/A 239_low 5’-GCC ATT GAG CAT AGC GGT TTT ATG CTG-3’ 
(see 7.1.3.). Therefore, either 25 or 50 ng of template plasmid DNA were combined with 1-fold 
PfuUltra buffer, 15 pmol of each primer, 200 µM dNTPs (Table 4), 2.5 U PfuUltra polymerase 
and water to give a final reaction volume of 50 µL. 
The cycler program was chosen as given in Table 5. Directly after amplification 40 U of the 
restriction enzyme DpnI per 50  µL reaction volume were added to the PCR sample and 
incubated at 37 °C for 2 h in order to completely digest the parental methylated DNA template. 
Subsequently, 10  µL of digested sample were transformed (see 3.1.4.) into chemically 
competent  E. coli DH5α cells, grown at 37  °C in SOC medium without antibiotics for an 
additional hour and finally plated on agar plates containing the appropriate antibiotic. The plates 
were incubated o. n. at 37 °C and colonies were picked the following day for the cultivation of 
bacteria and subsequent DNA preparation. Clones were sequenced in order to verify the success 
of site-directed mutagenesis. 
Table 5: Site-directed mutagenesis cycler program. The annealing temperature was set empirically at a 
minimum of 55 °C independent of the respective oligonucleotides melting temperatures. The elongation 
time was adapted to the length of the target plasmid DNA and the performance of PfuUltra polymerase of 
1kb / 2min. 
 
 
 
 
 
 
 
 
Site-directed mutagenensis cycler 
program 
Initial denaturation:
1 x                                            95°C, 1 min 
Denaturation: 
        95°C, 30 s 
Annealing: 
20 x                                            55°C, 30 s 
Elongation:
72°C, 14 min 
Final elongation:
1 x                                          72°C, 10 min 
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3.1.3.  Template design for CF expression using E. coli S30 extracts 
Plasmid DNA that was used as template for the E. coli CF expression was provided under the 
control of a strong promoter recognized by the phage T7 RNA polymerase. Essential T7 
regulatory sequences were therefore present to ensure optimal transcription efficiency such as 
the T7-promotor, ε-enhancer, ribosome binding site and a T7-terminator region (Fig.  8). 
Suitable vectors fulfilling the aforementioned conditions belong to the pET (Novagen) or 
pIVEX series (Roche Diagnostics) series. However, not only transcription but also translation 
efficiency had to be taken into account. Protein expression productivity in prokaryotic 
backgrounds strongly depends on the efficient initiation of translation which primarily depends 
itself on the first codons of a reading frame. Inappropriate codon structure can therefore cause 
failure of expression, in particular of eukaryotic MPs. 
 
 
 
 
Fig. 8.: DNA template design for CF expression in E. coli extracts. T7 regulatory sequences are listed 
and highlighted in grey. Optional translated elements like N- as well as C-terminal tag are indicated. 
Codon-optimized N-terminal tags like T7-tag or small fusion proteins such as Trx can help to 
avoid this problem and might even enhance expression (Junge et al. 2008, Murthy et al. 2004, 
Schwarz et al. 2007b).Therefore, all full-length constructs of the ET receptors as well as their 
respective truncations were cloned in a derivative of the standard expression vector pET21a(+) 
harbouring a N-terminal T7-tag and a poly(His)10-tag strepII-tag at its C-terminus (Novagen, 
Darmstadt, Germany) for purification and immunodetection. 
 
3.1.4.  Basic working with E. coli: Transformation of plasmids, growth and 
storage 
All heat resistant solutions as well as heat stable glassware were sterilized by autoclaving for 30 
min at 120 °C and 2 bars. Other temperature sensitive reagents and solutions were sterilized by 
filtering through filters with a pore size of 0.22 µm. 
For transformation of plasmid DNA into chemical competent DH5α cells (Inoue et al. 
1990) 50-100 µL of cells initially stored at -80 °C were thawed on ice. Either 10 µL of a ligation 
sample or 50-200 ng of plasmid DNA were directly added to the cells and incubated on ice for 
5 min followed by a heat shock of 42 °C for 45 s. Subsequently, cells were incubated on ice for 
additional 5 min. 750 µL of prewarmed SOC medium without antibiotics was added and cells 
were grown at 37 °C for 1 h. To concentrate bacteria, cells were centrifuged at 5,000 x g for 
5-10 min at RT and resuspended in 1/5 of the supernatant. 100-200 µL of cell suspension was Methods   53 
 
finally plated on agar plates containing the appropriate antibiotic and incubated at 37 °C over 
night. Single colonies were picked and grown in LB-medium. DNA was isolated (see 3.1.1.), 
subjected to a test restriction and promising clones were sent to the sequencing service Seqlab 
Sequence Laboratories (Göttingen, Germany). 
All used E. coli strains for standard techniques were grown in LB medium o. n. at 37 °C 
in shaking incubators at a speed of 170-190 rpm. Depending on the encoded antibiotic 
resistance of the used plasmid vector the appropriate antibiotic was added at a dilution of 
1:1,000 with final concentrations of 100 µg/mL for ampicillin and 30 µg/mL for kanamycin. 
An aliquot of bacterial suspension was plated on agar plates for single colony growth at 37 °C 
o. n.. Subsequently, a colony was picked, streaked on a separate agar plate and incubated again 
at 37 °C. Using inoculation loops, bacteria were finally transferred from these plates to 1 mL of 
DB salt and stored long-term at -80 °C. 
 
3.2.  Preparation of T7 RNA polymerase for cell-free expression 
The T7 RNA polymerase (T7RNAP) is one of the most essential and most expensive 
compounds for the CF synthesis of proteins and can be purchased commercially (e.g. Roche 
Diagnostics GmbH, Penzberg, Germany). However, for efficient transcription high amounts 
combined with high concentrations of T7RNAP are needed and commercial polymerases are 
often too low in concentration. 
The T7RNAP is characterized by a molecular mass of 98 kDa, a pI of 6.77 and is highly 
dependent on Mg
2+ ions that are not only required as co-factors but also for the stabilization of 
RNA conformation and the interaction of the two subcomplexes in the 70S ribosome complex. 
Since it has been shown that it is efficient to overexpress and purify this compound (Li et al. 
1999), an individual protocol for the preparation of T7RNAP was set up (Schwarz et al. 2007a, 
Schneider et al. 2010). Overproduction of the T7RNAP in BL21 (DE3) star cells was achieved 
from the plasmid pAR1219 carrying ampicillin resistance (Davanloo et al. 1984). An overnight 
culture was prepared in LB medium including the adequate antibiotic at 37 °C. The following 
day, 1 L of M9 T7-TG medium containing ampicillin was inoculated 1:100 in a culture flask 
with the freshly prepared overnight culture and incubated at 37 °C with vigorous shaking to 
reach an OD600 of 0.6-0.8. Expression of the T7RNAP was subsequently induced by addition of 
1 mM IPTG. After induction cells were further grown for additional 5 h at 37 °C and finally 
harvested by centrifugation at 4,500 x g and 4 °C for 15 min. At this step, cell pellets could 
either be stored at –80 °C for aproximately four weeks until further use or directly be subjected 
to cell disruption and purification procedures. The generated cell pellet was resuspended in 
30 mL per L culture of resuspension buffer for T7RNAP. Cell disruption was achieved by 8 
sonication cycles of 1 min each, interrupted by 30 s incubation on ice. The cell debris was then 
removed by centrifugation at 20,000 x g and 4 °C for 30 min. The supernatant was subsequently 54   Methods 
 
kept on ice and adjusted dropwise to a final concentration of 2  % streptomycin sulfate to 
precipitate DNA. In order to gently mix after each addition of streptomycin sulfate the mixture 
was inverted six to eight times. DNA precipitate was removed from the turbid supernatant by a 
second centrifugation step at 20,000 x g and 4 °C for 30 min. The DNA-free supernatant was 
subjected to purification by anion exchange chromatography and further treated as mentioned in 
3.5.2. 
Analysis of the catalytic activity and of the concentration units of the prepared T7RNAP was 
either achieved by CF synthesis of the reporter green fluorescent protein (GFP) or by in vitro 
transcription in comparison to a commercial polymerase. Plasmid DNA containing the target 
gene under the control of a T7 promotor was first linearized at the 3’ end of the open reading 
frame with an appropriate restriction enzyme to generate a transcript of defined size by run-off 
transcription. The linear plasmid template was purified by phenol/chloroform extraction. 
Subsequently, the transcription reactions were set up containing 50  ng of template DNA, 
0.1 U/µL RiboLock, 2 mM NTPs and 1-fold transcription buffer (40 mM Tris-HCl (pH 8.0), 
12 mM MgCl2, 5 mM DTT, 1 mM spermidine; prepared as 10-fold stock) and T7RNAP in 
different concentrations. The mixture was incubated for 2 h at 37 °C and terminated by addition 
of 2 mM EDTA. Transcripts were analysed and quantified by eye on RNA-free agarose gels and 
equipment. 
 
3.3.  Cell-free expression of MPs 
3.3.1.  Preparation of an individual E. coli S30 extract 
The extract preparation of the individual S30 extract of E. coli principally bases on the protocol 
developed by Zubay in the early 70s (Zubay 1973) but utilizes a modified run-off step. An 
additional heatshock that should induce the production of heatshock chaperones was 
occasionally introduced before cooling of the E. coli cells (see second day). 
The CF extract constitutes the most essential basic compound for the CF expression of 
proteins and contains all indispensible components for the translational process (see 1.2.2.). It 
may furthermore harbor some residual E.coli lipids or membrane fragments of approximately. 
50-100 µg/mL of S30 extract (see 1.2.3.). Other essential compounds for the complete 
expression process were supplemented individually. 
In this work the RNAse deficient E. coli strain A19 was used for extract preparation 
(Schwarz et al. 2007a, Schneider et al. 2010). 
The whole procedure takes three days and yields in between 70-100 mL of S30 extract out of 
10 L 2 x YPTG medium. The first day concentrates on the preparations such as sterilization of 
media and buffers, supply of necessary working material and the inoculation of the pre-culture 
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For this purpose 100  mL of LB medium were prepared and sterilized by autoclaving. The 
medium was subsequently carefully inoculated with E. coli cells of strain A19 from a fresh plate 
without any supply of antibiotics. The pre-culture was then incubated o. n. at 37  °C with 
vigorous shaking. Preparation of 2 x YTPG medium was followed as described in 2.7.1.. Yeast 
extract and bactotryptone were dissolved in 7 L of distilled water, filled into the fermenter and 
sterilized by autoclaving. Sterilized glucose and phosphate buffer were added the following day 
before initial inoculation. 50-fold stock solutions of S30 A/B buffer and S30 C buffer as well as 
5 M NaCl were prepared, sterilized by filtering and stored at 4 °C until further use. 
The second day started with the completion of the 2 x YTPG medium and its pre-
heating to 37 °C under good aeration. Subsequently, the A19 pre-culture was inoculated to the 
oxygen enriched medium at a ratio of 1:100. Cells were then incubated at 37 °C under vigorous 
stirring at 500 rpm until an OD600 of 4.0-4.5 (mid-logarithmic phase) was reached. 
An optional heat shock for the induction of chaperone formation was introduced at an 
OD600 of 3.5-4.0. Cells were heated up to 44 °C and grown at this temperature for 20 min, 
followed by cooling to 37 °C and further incubation for 20 min. 
Cells were subsequently rapidly chilled below 12 °C in the fermenter by using internal 
and external cooling sources. The chilling should not exceed 45 min. The broth was then filled 
into centrifuge beakers that were constantly kept at 4 °C and cells were subsequently harvested 
by centrifugation at 5,000 x g and 4 °C for 15 min. 
The pellet was resuspended in 300 mL of pre-cooled 1-fold S30 A buffer supplemented with β-
mercaptoethanol and centrifuged for 15 min at 5,000 x g and 4 °C. This washing step was 
repeated twice with the same buffer but at an extended final centrifugation for 30 min. The 
resulting cell pellet was weighted and resuspended in 110 % (v/w) of pre-cooled 1-fold S30 B 
buffer supplemented with PMSF and DTT for cell lysis. The wet weight from a 10-liter 
fermentation was in between 50 and 70 g. 
Cells were subsequently lysed either once by a pre-cooled French press cell disruptor (SLM 
Aminco Instruments Inc., USA) using a constant pressure of 20,000 psi or two to three times 
with a high-pressure homogenizer at 1.5-1.7  kbar (IUL Instruments GmbH, Germany). The 
disrupted cells were centrifuged at 30,000 x g for 30 min at 4 °C. The non-turbid upper part of 
the supernatant (~ 2/3 to 3/4 of the supernatant) was collected and subjected to a second 
centrifugation step at the aforementioned conditions. The supernatant was again judged by its 
turbidity. Only non-turbid extract was kept for following steps. 
Subsequently, the modified run-off step was performed to remove endogenous mRNA. 
Therefore, the supernatant was adjusted to a final concentration of 400 mM NaCl and the extract 
was incubated in a waterbath at 42 °C for 45 min, resulting in a cloudy solution. The turbid 
extract was transferred to dialysis tubes with a MWCO of 12-14 kDa and was dialysed once 
against 5 L of cold S30 C buffer for at least 2 h at 4 °C. Then, the dialysis buffer was exchanged 
and the dialysis continued o. n. at 4 °C. 56   Methods 
 
On the third day of preparation the dialysed extract was separated from precipitates by 
centrifugation at 30,000 x g for 30 min at 4 °C. The supernatant was immediately aliquoted to 
appropriate volumes and shock-frozen in liquid nitrogen. The frozen extract was stored at 
-80 °C for several months. 
 
3.3.2.  Continuous exchange cell-free configurations using E. coli extracts 
CECF expression reactions in P-CF, D-CF as well as L-CF mode were basically performed as 
previously described in detail (Schwarz et al. 2007a, Schneider et al. 2010). 
All reaction components for the CF expression of the ET receptors are listed in Table 9. A 
pipetting scheme for analytical scale reactions and salt optimization are given in Table  6. 
Analytical scale reactions for the optimization of expression conditions were carried out in 
24-well microplates in Mini-CECF reactors. Appropriate dialysis membranes, type 27/32, 
having a MWCO of 12-14 kDa (Roth, Karlsruhe, Germany) were used to separate RM from 
FM. The RM volume was 55 µL with a RM to FM ratio of 1:15. Preparative scale expression 
was accomplished in Maxi-CECF reactors (Schneider et al. 2010) in RM volumes from 1 to 
3 mL and with a RM to FM ratio of 1:17. CF reactions were incubated for 16 to 20 h with gentle 
shaking at 30 °C (Schwarz et al. 2007a). Optimal concentrations of Mg
2+ and K
+ ions for each 
S30 extract batch were analysed in analytical scale reactions in the P-CF mode. CF expressed 
protein was harvested as precipitate (P-CF) by centrifugation at 18,000 x g for 10 min at 4 °C. 
Successful P-CF synthesis resulted in a turbid RM after expression due to the precipitation of 
the target MPs. Those precipitates were subsequently washed and finally either resuspended in 
water or resolubilized in appropriate detergents equal to the volume of the initial RM for further 
analysis (see 3.5.1.). 3 µL or 1 µL of P-CF or D-CF overexpressed protein were analysed by 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) or western blotting, respectively (see 
3.4.1.). 
For soluble expression in the D-CF mode, detergents were added at the following final 
concentrations: Brij 35 (B35, 0.05 %, 0.1 %, 0.5 %), Brij 58 (B58, 1 %), Brij 78 (B78, 1 %), 
Brij 98 (B98, 1  %), digitonin (0.4  %), Triton X-100 (TX-100, 0.1  %), Fos-12 (0.1  %), 
n-hexadecyl-β-D-maltopyranoside (HDM, 0.05  %), n-tetradecyl-β-D-maltopyranoside (TDM, 
0.01 %), DDM (0.1 %), CHAPS (2 %). Stock solutions of the relevant detergents were prepared 
in distilled water at a concentration of at least 10-fold to the working concentration and stored at 
20 °C until further use. Stocks of Brij derivatives had to be completely solubilized at 60 °C for 
at least 1 h. 
To express target proteins in the D-CF mode mastermixes were prepared as stated in Table 6 
with minor changes. The appropriate detergents were added in desired amounts and their 
volumes were subtracted from the final water volume. D-CF expressed protein mainly stayed in 
the supernatant and was harvested by centrifugation at 18,000 x g for 10 min at 4 °C. Since Methods   57 
 
many soluble E. coli proteins also remain in the supernatant D-CF expressed protein displayed 
much less purity and could often only be identified by western blotting. 
Table 6: Analytical scale pipetting scheme for P-CF mode expression. A pipetting scheme for two 
analytical scale reactions is given for RM volumes of 55 µL and 850 µL of  FM. 
 
 Concentration  Unit  Mastermix  FM  RM 
 stock  final    [µL]  [µL]     [µL] 
NaN3 10  0.05  %  9.1 
PEG8000 40  2  %  90.5 
KOAc 4000  110  mM  49.8 
Mg(OAc)2 1000  11.1  mM  20.1 
HEPES buffer  24  1  x  66.4 
Complete 50  1  x  36.2   
Folinic acid  10  0.1  mg/mL  18.1 
DTT 500  2  mM  7.2 
NTP mix  75  1  x  24.1 
PEP 1000  20  mM  36.2 
AcP 1000  20  mM  36.2 
AA-mix 8  0.6  mM  135.8  128 
RCWMDE-mix 16.7  1  mM  108.6 
 
Mastermix      638  599.2  38.8 
S30 buffer  100  35  %    595 
 
Pyruvate kinase  10  0.04  mg/mL      0.44 
tRNA E.coli  40 0.5  mg/mL      1.38 
T7RNAP 3.8  0.05  mg/mL     1.45 
RiboLock
TM 40  0.3  U/µL      0.83 
Template DNA  200  0.03  µg/mL      16.5 
S30 extract  100  35  %      38.5 
 
MilliQ H2O              378  12.1 
 
Total       1810  1700.2  110 
a, Value for reaction with 270 mM K
+ and 16 mM Mg
2+ final concentration 
b, A, Carl Roth GmbH & Co. KG, Karlsruhe, Germany; B, Roche Diagnostics, Penzberg, Germany  
   C, Sigma-Aldrich, Steinheim, Germany; D, MBI Fermentas, St. Leon-Rot, Germany 
Alternatively, ET receptors were expressed in presence of preformed liposomes in the lipid 
based CF expression mode (L-CF). Liposomes composed of E. coli polar lipids/cholesterol 
(see 3.9.2.) or L-α-phosphatidylcholine from soybean, type IV-S, (aso-PC) were destabilized by 
detergents and subsequently added to the RM in final concentrations of 2 mg/mL for E. coli 
polar lipids/cholesterol and 4.5 mg/mL for soybean lipids. The proteoliposomes were harvested 
by centrifugation at 23,000 x g and 4 °C for 30 min. The pellet was washed once and finally 
resuspended in 1-fold Tris buffer or S30 C buffer equal to the RM volume and either analysed 
by ultracentrifugation (see 3.9.2.) or filter binding assays (see 3.9.3.). 
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3.3.3.  Preparation of an individual S30 wheat germ extract 
The isolation of wheat germ embryos as well as the subsequent preparation of the WGE was 
supervised by Dr. Vladimir A. Shirokov (Institute of Protein Research, Russian Academy of 
Science, Pushchino, Moscow Region, Russia) and accomplished according to initial protocols 
(Erickson and Blobel 1983, Madin et al. 2000, Sawasaki et al. 2007, Shirokov et al. 2007). 
 
3.3.4.  Preparation of mRNA templates for the cell-free translation in WGEs 
To achieve efficient translation initiation in the WG system without eukaryotic 5’-cap structure 
appropriate 5’ UTR as well as 3’ UTR sequences were introduced to the coding sequence of the 
target gene (see 3.1.1.). The mRNA preparation and purification steps are of great importance 
for the subsequent translation reaction. If the quality of the prepared mRNA is not sufficient no 
or only minor translation will occur. Therefore, all steps were performed with RNase free 
material and solutions. 
To increase the efficiency of the transcription reaction the ETB plasmid template was 
first linearized by the restriction endonuclease Bsp120I and subjected to DNA precipitation. The 
linear plasmid was subsequently used as template for the transcription reaction that was 
performed in volumes of 500 µL. Final concentrations of 50 µg/mL DNA, 1-fold transcription 
buffer, 20 mM WGE-NTP mixture, 2 mM spermidine and 40 mM DTT and RNase free water 
were combined and mixed thoroughly by vortexing. 0.5 U/µL RNase inbibitor and 40 U/µL 
T7RNAP were supplemented to the transcription reaction and the mixture was incubated for 3 h 
at 37  °C. Milky white precipitate due to pyrophosphate formed as by-product indicated 
successful transcription. 
The mRNA was subsequently harvested by phenol/chloroform extraction. Therefore, 
the transcription reaction was terminated by the addition of 0.5 volumes of phenol/chloroform 
mixture (1:1, v/v), vortexed thoroughly and subjected to centrifugation at 18,000 x g and RT for 
10 min. The aqueous phase was carefully harvested and transferred to a new tube. The yield of 
aqueous phase was increased by addition of 0.5 volumes of chloroform to the remainder of the 
previous step and repetition of the centrifugation. The mRNA was subsequently precipitated by 
addition of 0.5 volumes of saturated 14 M LiCl, mixed thoroughly and incubated on ice for at 
least 40 min. The mRNA was harvested by centrifugation at 18,000 x g and 4 °C for 20 min. 
The pellet was reconstituted in 200 µL of RNase free water followed by an addition of 0.1 
volumes of 3 M NaOAc, pH 5.5 and 2.5 volumes of precooled 96 % ethanol. The mixture was 
mixed by vortexing and incubated o. n. at -20 °C. The sample was pelleted by centrifugation at 
18,000 x g and 4 °C for 20 min. Washing steps at 18,000 x g and 4 °C for 5 min were repeated 
twice in 300 µL pre-cooled 75 % ethanol. The remaining pellet was dried at RT for at least 
15  min and finally reconstituted in 30-40  µL of RNase free water. The concentration was 
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3.3.5.  Continuous exchange cell-free expression using WGE 
The CF expression protocol set-up in WGE basically resembles expression of MPs in the E. coli 
extract (see 3.3.2.). Target proteins were expressed in analytical as well as preparative scale 
reactions. Dialysis membranes, type 27/32, with a MWCO of 12-14  kDa (Roth, Karlsruhe, 
Germany) were provided to separate RM from FM in the CECF reactions. For analytical scale 
and preparative scale reactions ratios of RM : FM of 1:14 or 1:17 were used, respectively. 
However, uncoupled transcription/translation was performed since magnesium optima for 
transcription in the wheat germ system are considerably higher (~15-18 mM Mg
2+) than those 
for translation (~ 3 mM Mg
2+) (Sawasaki and Endo 2007). Therefore, mRNA template was 
prepared beforehand (see 3.3.4.) which additionally renders the reaction more stable since the 
expression process is less susceptible to mRNA degradation. 
For a 70  µL analytical scale translation reaction the final concentrations and the required 
volumes of the individual components are listed in Table 7. 
Table 7: P-CF expression protocol in wheat germ extracts. Essential compounds as well as their stock 
and final concentrations in RM and FM are listed. A pipetting scheme for one analytical scale reaction is 
given for RM volumes of 70 µL and 1000 µL of FM. 
 
       Concentration    
Compound  [unit]     Stock   Final  concentration   Volume  [µL] 
Feeding mix (FM): 1000 µL 
Translation  pre-mix  [x]    20  1        50 
NaN3  [%]      3  0.03        10 
Glycerol  [%]      40  2        50 
Creatine phosphate [mM]    500  16        32 
AA-mix  [mM]    4   0.2     50 
Mg(OAc)2  [mM]    100   1.5     30 
KOAc  [M]    2.5   0.05     20 
MilliQ H2O           7 5 8  
Reaction mix (RM): 70 µL 
mRNA template [mg/mL]    ≥ 4  0.2        ≤ 3.5 
Wheat germ extract [%]    100  30        21 
RiboLock
TM  [U/µL]      40  0.5     0.88 
Creatine kinase [mg/mL]  10  0.1        0.7 
NaN3  [%]     3  0.03     0.7 
tRNA (yeast) [mg/mL]    2  0.05        1.75 
Translation  pre-mix  [x]    20  1     3.5 
Glycerol  [%]     40  2     3.5 
MilliQ H2O           a d j u s t   t o   7 0   µ L  60   Methods 
 
All reaction compounds were thawed at RT and stored on ice except creatine kinase, T7RNAP, 
tRNA and the S30 WGE that were constantly kept on ice. The FM was prepared first, 
thoroughly mixed and incubated at 25 °C until further use. The RM was prepared on ice by 
pipetting in inverse order to Table 7. All components were well vortexed except creatine kinase, 
RNase inhibitor and the extract itself which were added after mixing. The required amount of 
WGE was added and the RM was subsequently incubated for 2 min at 25 °C before the reaction 
was completed by addition of mRNA. All the components were gently mixed and RM and FM 
were transferred to their respective compartments. The reactions were and incubated for 16-20 h 
at 25 °C with gentle shaking. The target proteins were harvested and subjected to SDS-PAGE or 
western blotting as described in 3.4.1.. 
 
3.4.  Protein analysis 
3.4.1.  Electrophoresis and immunoblotting 
Protein samples analysed by SDS-PAGE were supplemented 1:3 with SDS-PAGE sample 
buffer, 5-fold. Samples of full-length ETA and ETB receptors were separated on 12 % (w/v) 
Tris-Glycine-SDS gels (Laemmli et al. 1970) at 100 V for 15 min followed by 200 V for 45 min 
with constant current. For truncations and co-expression of ETA and ETB 16 % gels were used. 
Commonly, 2-3 µL of resuspended protein pellet or supernatant as well as 1 µL of RM were 
loaded on SDS-PAGE gels. 
As Tris-Tricine-PAGE is better suited for the separation of proteins less than 30 kDa 
due to a higher resolution at lower molecular weights (Schägger and Von Jagow 1987) the 
smaller inteins and cleavage products were analysed by 10 % or 12 % Tris-Tricine-SDS gels 
(Table 3). 
Gels were either stained with Coomassie blue or analysed by western blotting. For 
immunodetection of the poly(His)10-tag, protein samples were transferred on an activated 
0.45  µm Immobilon-P (polyvinylidene difluoride, PVDF) membrane (Millipore, Eschborn, 
Germany) and blotted in a wet western blot apparatus for 30-40 min at 340 mA (MiniProtean 
IV, Bio-Rad, München, Germany). The membrane was subsequently blocked for 1 h in 1-fold 
PBS supplemented with 8 % skim milk powder and 0.05 % Tween-20 followed by incubation 
with the first antibody at a dilution of 1:2,000 against the C-terminal His-tag (PentaHis 
Antibody, QIAGEN, Hilden, Germany) in 1-fold PBS / 0.05 % Tween 20 / 0.6 % skim milk 
powder. Incubation of the first antibody was performed at 4 °C o. n. with gentle shaking. As a 
second antibody an anti-mouse IgG HRP conjugate (Sigma-Aldrich, Germany) was added after 
two washing steps with 1-fold PBS and 0.05 % Tween-20 at a dilution of 1:5,000 for 1 h at RT 
(1-fold PBS / 0.05 % Tween 20 / 0.6 % skim milk powder). After extensive washing, the 
membranes were analysed by chemiluminescence in a Lumi-Imager F1
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Science, Mannheim, Germany) using each 5 mL ECL 1 and 2 solutions with an incubation time 
of 1 min, respectively. 
To analyse the integrity of the receptors both tags had to be detected. Therefore, a T7-tag 
antibody directly conjugated to horseradish-peroxidase (Merck, Darmstadt, Germany) was used 
at a dilution of 1:10,000 in 1-fold PBS / 0.05 % Tween 20 / 0.6 % BSA and incubated with the 
membrane for 1 h at RT to detect the N-terminal T7-tag of the target proteins. Blocking as well 
as subsequent washing steps and chemiluminescence were performed as mentioned above. 
 
3.4.2.  Determination of protein concentration 
Table 8: Molecular weights and molecular extinction coefficients necessary for the measurement of 
the protein concentration by NanoDrop. Listed are all parameters of the different ETA receptor 
constructs, truncations and of the ETB receptor minus signal sequence (ETB-Sign) with tags. All ligands, 
that were kindly provided by Dr. Michael Beyermann (FMP, Berlin), are included. Molecular weights and 
molar extinction coefficients were calculated on the ExPASy Proteomics Server using the Protparam 
Tool. 
 
Protein/Peptide 
 
Vector Tag  Number  of 
amino acids
Molecular 
weight 
[g/mol] 
Molar  ε280 
[M
-1 cm
-1], 
oxidized state 
ETB-Sign cHx  pET21a N-term  T7 
C-term H10 
441 49790.6 
 
71485 
 
ETA cHx  pET21a N-term  T7 
C-term H10 
453 
 
51716.5 
 
66110 
 
ETA strep  pET21a N-term  T7 
C-term strepII 
451 51426.2  77110 
ETA197cHx  pET21a N-term  T7 
C-term H10 
221 24740.5 
 
25815 
 
ETA197strep  pET21a N-term  T7 
C-term strepII 
219 24450.3 
 
36815 
 
ETA198strep  pET21a N-term  T7 
C-term strepII 
258 29988.1  40295 
 
ETA107cHx  pET21a N-term  T7 
C-term strepII 
133 14990.0 
 
11710 
 
ETA107strep  pET21a N-term  T7 
C-term strepII 
131 14699.8 
 
22710 
 
ET-1  - -  21  2490.6  7240 
ET-3  - -  21  2641.5  10220 
b-ET-1  - -  21  2716.1  7240 
4-Ala-ET-1  - -  21  2366.2  6990 
f-4-Ala-ET-1 -  -  21 2698.5  6990 
The concentration of purified proteins was routinely determined via Lambert-Beer’s law by 
correlation of their respective absorptions at 280 nm using a NanoDrop 1000 Spectrophotometer 
(Peqlab Biotechnologie GmbH, Erlangen, Germany) to the known extinction coefficients (ε) 
and molecular weight of the target protein (Table 8). 
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3.4.3.  Acetone precipitation 
Precipitation of protein samples with acetone was used to precipitate and simultaneously 
concentrate the respective target protein if initial concentrations were to low to be detected by 
conventional SDS-PAGE or immunoprecipitation. 
Final concentrations of 90 % pre-cooled (-20 °C) acetone were added to the respective protein 
samples, mixed by vortexing and incubated for at least 20 min at -20 °C. Protein / acetone 
mixtures were then subjected to a cetrifugation step at 18,000 x g and 4  °C for 15  min. 
Discarding the supernatant had to follow very quickly on ice in order not to loose the 
precipitated protein. Pellets were subsequently dried at 50 °C for 20 min to completely remove 
residual acetone and were finally dissolved in desired volumes of water and SDS-PAGE sample 
buffer, 5-fold. 
 
3.5.  Protein purification and analysis of sample homogeneity 
3.5.1.  Resolubilization of MP precipitates 
For resolubilization of P-CF produced precipitates, all tested detergents were supplied at a final 
concentration of 1 % in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl with addition of 1 mM Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) (PIERCE, Thermo Scientific, Bonn, Germany). 
P-CF produced MP precipitate was collected by centrifugation at 18,000 x g for 10  min 
followed by two washing steps in distilled water and resuspension buffer (20 mM Tris-HCl, pH 
7.5 and 150 mM NaCl) or liposome buffer (20 mM potassium phosphate, 150 mM NaCl, pH 
7.0). The precipitate was subsequently resuspended in resuspension buffer supplemented with 
1  % detergent. The volume of resuspension was kept equal to the RM volume of the 
corresponding reaction. ETA solubilization was achieved by incubation for 2 h at 30 °C with 
gentle shaking. Residual precipitate was removed by centrifugation at 18,000 x g for 10 min and 
resuspended in a water volume equivalent to the supernatant for SDS-PAGE analysis. Routinely 
analysed detergents for resolubilization were LPPG, 1-myristoyl-2-hydroxy-sn-glycero-3-
[phospho-rac(1-choline)] (LMPC) (Avanti Polar Lipids, Alabaster, AL), Fos-12, 
n-hexadecylphosphocholine (Fos-16) (Anatrace, Maumee, OH) and sodium dodecylsulfate 
(SDS) (Roth, Karlsruhe, Germany). 
 
3.5.2.  Anion exchange chromatography: Purification of individually prepared 
T7RNAP 
The purification of the T7RNAP was performed at 16 °C and a flow rate of 2-4 mL/min using a 
self-packed fast flow Q-sepharose column with an approximate volume of 75 mL and a pressure 
limit set to 0.3 MPa on an Äkta purifier system (GE Healthcare Europe, München, Germany). 
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Q  sepharose buffer A for T7RNAP. Subsequently, half of the lysate obtained from 1  L 
expression was loaded onto the column at a flow rate of 2 mL/min by an external pump. Before 
gradient set-up, buffer A was applied until a stable baseline was reached. Since the T7RNAP 
elutes at very low salt concentrations, the continuous gradient was set to moderate steepness 
from 50-500 mM NaCl in 90 min at a flow rate of 4 mL/min using Q-sepharose buffers A and 
B. The purification was followed by consecutive measurements of conductivity and absorption 
at 280 nm. To analyse most valuable fractions with high T7RNAP concentration and moderate 
to low contents in impurities a 12  % SDS-PAGE was performed prior to dialysis and 
concentration. 
It is necessary to note that the T7RNAP does elute widely spread without being highly 
pure. Best fractions were pooled and dialyzed at 4 °C o. n. against dialysis buffer for T7RNAP. 
A final concentration of 10 % glycerol was added to the dialyzed protein solution followed by 
its concentration to 1-4 mg/mL of total protein. The T7RNAP preparation was finally adjusted 
to 50 % glycerol and stored in 500 µL aliquots for up to one year at -80 °C or at -20 °C for short 
term storage. 
 
3.5.3.  IMAC: Ni – and Co - NTA chromatography 
IMAC was applied to purify the poly(His)10- as well as poly (His)6-tagged receptors and for the 
optional exchange of the first detergents used for solubilization against the second detergents 
used for analysis. Its principle is based on the reversible interaction between consecutive 
histidine side chains and immobilized metal ions (Porath et al. 1988). 
For the purification of the ET receptors in batch mode either Ni
2+-NTA (QIAGEN, 
Hilden, Germany) or self-loaded Co
2+-NTA agarose beads were used. The advantage of the 
cobalt ions over nickel ions is their higher selectivity resulting in a higher purity of the eluted 
proteins since nickel-based IMAC resins tend to bind to host proteins’ exposed hisitine side 
chains with a higher affinity than cobalt-based resins (Kasher et al. 1993). Therefore, proteins 
can already be eluted using less stringent conditions that might be beneficial for the stability of 
the target protein. 
Resolubilized protein produced in the P-CF mode or RMs from D-CF reactions were 
centrifuged at 18,000 x g for 10 min prior to loading onto the IMAC agarose resins to remove 
residual precipitated proteins. The supernatant containing the detergent-solubilized MP was then 
diluted 1:5 or 1:10 in IMAC equilibration buffer in order to reduce the initial concentrations of 
detergent (e.g. starting from 1 % LPPG of resolubilized protein to 0.05 % LPPG) and reducing 
agents and was subsequently mixed with pre-equilibrated NTA-agarose beads (QIAGEN, 
Hilden, Germany) loaded with Ni
2+ or Co
2+ ions. 300-400 µL resin per 1 mL of diluted RM 
were employed. The mixture was incubated for 5-12 h at 4 °C on a shaker followed by the 
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on ice with ice-cold buffers. Bound protein was washed with 10 (CV) wash 1 buffer, followed 
by a second washing step with 10 CV of wash 2 buffer. The NaCl concentration was reduced to 
150 mM by washing in 10 CV of wash 3 buffer to allow for direct application of the protein to 
ligand-binding studies. Immobilized protein was finally competitively eluted with 350 mM 
imidazole in IMAC elution buffer and collected in 4-5 fractions of 1 CV each with the first 
fraction having a volume of 0.5 CV. 10 µL aliquots of each fraction were analysed by 12 % 
SDS-PAGE. 
 
3.5.4.  Streptavidin affinity chromatography 
ET full-length receptors in pET21a(+) as well as their truncations harboring a strepII-tag at the 
C-terminus were purified according to a slightly modified protocol based on the commercially 
available Strep-tag
® Purification kit (IBA GmbH, Göttingen, Germany). As a modification, self-
prepared buffers with the desired detergent were used. 
The strepII epitope consists of eight consecutive amino acids W, S, H, P, Q, F, E and K 
and displays intrinsic affinity to streptavidin. The purification was performed by batch binding 
to pre-equilibrated streptavidin beads in a plastic gravity flow chromatography column. Prior to 
loading applied protein was treated as mentioned for IMAC purification (see 3.5.3.) to dispose 
residual precipitates. 500 µL resin were used per 1 mL of RM. Protein supernatant was diluted 
1:5 in strepII-equilibration buffer in order to reduce the initial concentrations of the detergent 
and then incubated for 12 h or o. n. at 4 °C on a shaker. The protein was subsequently washed 
with 5  CV of strepII- wash buffer. The protein was finally competitively eluted in 
strepII-elution buffer containing 2.5 mM desthiobiotin in three to five fractions of 1 CV each. 
10 µL aliquots of each fraction were analysed by SDS-PAGE. 
 
3.5.5.  Size exclusion chromatography: A basic method to study homogeneity 
and stability 
SEC with prepacked columns (GE Healthcare Europe, München, Germany) was used in order to 
assess the homogeneity and the stability of the ET receptor samples produced. Protein 
preparations were centrifuged at 18,000 x g and 16 °C for 10 min prior to loading. Samples of 
10 to 30 µg of purified solubilized or resolubilized receptor were separated on a pre-equilibrated 
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.1 % B35 or 0.04 % DDM) analytical Superdex 
200 column (3.2  mm/30  cm) (GE Healthcare Europe, München, Germany) at a flowrate of 
50 µL/min on an Äkta Purifier station (GE Healthcare Europe, München, Germany). SEC was 
conducted at 16 °C and the absorption at 280 as well as at 260 nm was monitored during the 
run. 
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3.5.6.  Multi angle light scattering: A more refined method for the calculation of 
protein mass and its oligomerization state in detergent 
SEC is well suited as basic means to analyse protein homogeneity as well as its stability over 
time. However, it does not easily allow for the calculation of molecular masses of integral MPs 
since the amount of detergent associated with the protein in the protein / detergent micelle 
complex is usually not known. By using multi angle light scattering (MALS) it is possible to 
determine the absolute molecular mass as well as the oligomerization state of MPs by 
correlating molecular mass and concentration of the protein to the amount of scattered light. 
This technique does not take into account the shape of proteins nor does it need initial 
knowlegde of the amount of detergent bound to the protein (Slootboom et al. 2008). 
Combined SEC-light scattering analysis was performed on a Superdex 200 10/300 column (GE 
Healthcare Europe, München, Germany) at a flow rate of 0.5 mL/min on a Jasco HPLC unit 
(Jasco Labor- und Datentechnik GmbH, Gross-Umstadt, Germany) connected to a light 
scattering detector measuring at three angles (mini Dawn Treos, Wyatt Technology Europe 
GmbH, Dernbach, Germany) and a refractive index detector (Optilab rex, Wyatt Technology 
Europe GmbH, Dernbach, Germany). The column was equilibrated for at least 16 h with SEC 
buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 0.005 % Fos-16 or 20 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 0.1 % B35, filtered through 0.1 µm pore size VVLP filters (Millipore, Eschborn, 
Germany). 200  µL of protein samples (0.5-1  mg/mL) were separated on the column. Data 
analysis was accomplished using the ASTRA software package 5.3.4.13 (Wyatt Technology 
Europe GmbH, Dernbach, Germany). 
 
3.6.  Affinity chromatography: Immobilization as a means to study receptor-
receptor interaction and ligand binding competence 
3.6.1.  Ligand affinity chromatography 
Assessing the binding competence of a CF expressed receptor in proteomicelles is an essential 
tool for further structural studies by X-ray crystallography or liquid state NMR spectroscopy. 
Ligand-bound receptor tends to display a higher degree of homogeneity and stability, thereby 
increasing the possibility of one distinct receptor population and minimizing measurement 
disturbances. 
The ligand-binding competent fraction of the CF-produced protein was isolated by 
binding to peptide ligands immobilized on monomeric avidin agarose beads (PIERCE, Thermo 
Scientific, Bonn, Germany). The matrix was prepared following the manufacturer’s 
recommendations and subsequently incubated with 100 µg of biotinylated ET-1 or with 30 µg 
of biotinylated vasopressin per 100 µL (=1 CV) matrix. The peptide loading was conducted for 
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selected detergent). Unbound ligand was removed by a washing step of 3 CV of matrix buffer. 
Residual bound ligand was estimated to approximately. 13 nmol per 100 µL matrix in case of 
b-ET-1. A volume of 200 µL of a 2 to 3 µM stock of MP was diluted 1:3 in matrix buffer and 
subsequently loaded onto the ligand affinity matrix. The loaded total amounts of MP were in 
between 0.33 and 0.67 nmol, resulting in an excess of bound ligand of 20 to 40-fold. The matrix 
was then incubated for 2 h at RT with gentle shaking. The flow-through of monomeric avidin 
agarose loaded with protein was collected and stored for western blot analysis. Unbound protein 
was removed by 10 washing steps (1 CV each) in matrix buffer. Elution of the ligand bound 
receptor was finally performed in one step of 0.5  CV followed by further 1  CV steps by 
releasing the immobilized peptide with 2 mM biotin dissolved in matrix buffer. Aliquots of 
32.5  µL from fractions ≤1  CV and of 55  µL of fractions >1  CV were analysed by 12  % 
SDS-PAGE analysis followed by western blotting. The obtained percentages of ligand bound 
MP were normalized according to the initially loaded amounts of MP sample. 
 
3.6.2.  Analysis of homo- and heterodimerization by affinity chromatography 
pull-down 
To investigate the homo- and heterodimerization potential of CF expressed ET receptors and 
their truncated derivatives, possessing either poly(His)10-tag or strepII-tag, pull-down analysis 
was performed in batch binding on either co-expressed or separately expressed proteins by 
streptavidin or Co
2+-NTA chromatography. Plastic gravity flow columns were used for this 
purpose. The pull-down assay is based on the assumption that proteins that do not harbour the 
necessary tag can be co-eluted nonetheless if they are exhibiting interaction to a protein 
equipped with the relevant affinity tag. 
Samples analysed by pull-down were expressed in analytical scale either in D-CF mode 
(0.5 % B35) or P-CF mode (resolubilized in 1 % LPMC or LPPG) and volumes of 100 µL 
co-expressed or 50 µL individually expressed receptor, that were combined to a final volume of 
100 µL, were diluted 1:5 in strepII- equilibration buffer and subsequently applied to 70 µL of 
pre-equilibrated affinity resins. As negative controls (NCs) 50 µL of single receptors with the 
non-cognate tag were loaded on the resins to rule out any cross reactivity. 
After an initial incubation for 2 h at RT with gentle shaking, pull-down samples were 
transferred to 4 °C and additionally incubated o. n.. For pull-down analyses using the strepII-
tag, washing was performed in steps of 3 times 1 CV, followed by two times 2 CV with strepII- 
wash buffer. Elution was achieved by competition with 2.5 mM desthiobiotin in the elution 
buffer with volumes of once 0.5 CV, twice 1 CV and once 2 CV. For pull-down studies using 
the poly(His)10 epitope, washing was performed with 10 CV wash 1 buffer, followed by10 CV 
wash 2 buffer. The NaCl concentration was reduced to 150 mM by washing in 10 CV of wash 3 
buffer. Immobilized protein was finally competitively eluted with 350 mM imidazole in IMAC Methods   67 
 
elution buffer with 0.5 CV for the first fraction and 1 CV for the five subsequent fractions. All 
fractions were subjected to precipitation with acetone and analysed by immunoblotting or 
SDS-PAGE. 
 
3.7.  Spectroscopical and spectrometrical methods 
3.7.1.  Far-UV spectroscopy: Secondary structure analysis and thermostability 
ETA samples to be measured by circular dicroism (CD) spectroscopy were purified by IMAC 
(see 3.5.3.) using suitable detergents. Peak elution fractions were pooled to give a concentration 
in between 0.5 to 0.7 mg/mL and they were subsequently dialysed at 4 °C against 10 mM 
sodium phosphate buffer, pH 7.5 (CD-buffer), containing the appropriate detergent. CD 
spectrometry and melting curves were measured with a Jasco J-180 spectropolarimeter (Jasco 
Labortechnik, Gross-Umstadt, Germany) in 10 mM CD-buffer. Experiments were carried out at 
standard sensitivity with a band width of 1 nm and a response of 1 s. The data pitch was set to 
0.1 nm and a scanning speed of 100 nm/min was used. CD spectra were recorded from 190 to 
260 nm at 20 °C in a cuvette of 1 mm cell length. The data represent an average of three 
accumulations and were baseline corrected by subtraction of a buffer spectrum recorded under 
identical conditions. Melting curves were measured with a band width of 1 nm, a response of 1 s 
and a data pitch set to 0.1 °C at a wavelength of 222 nm with a slope of 2 °C/min from 4 °C to 
90 °C. 
 
3.7.2.  Ligand binding of detergent solubilized ETA monitored by fluorescence 
anisotropy 
Fluorescence anisotropy measurements with detergent-solubilized ETA were performed using a 
Jasco spectrofluorometer FP-6500 (Jasco Labortechnik, Gross-Umstadt, Germany). ETA was 
expressed in the P-CF mode, resolubilized in 1 % LPPG and subsequently purified in 0.1 % 
B35. Residual imidazole was removed by over night dialysis against assay buffer (20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.1 % B35). Protein samples purified by monomeric avidin matrix 
bound b-ET-1 ligand were measured without dialysis to retain the receptor-ligand complex. 
Ligand binding analysis was carried out with the fluorescein-labelled linear derivative 
1,3,11,15-Ala-ET-1 (f-4-Ala-ET-1). Excitation and emission maxima of the f-4-Ala-ET-1 have 
been determined at 498 nm and 520 nm, respectively. The G-factor of the ligand was measured 
in assay buffer with a value of 1.50. For saturation binding, 30  nM of f-4-Ala-ET-1 was 
incubated with increasing concentrations of free (0-5  µM) or ligand-bound ETA-receptor 
(0-1 µM) for 1.5 h at RT in a final volume of 500 µL. Anisotropy was determined as mean 
value of seven repetitions per data point. The observed anisotropy signal was normalized by 
subtraction of the anisotropy values of 0.038 gained from free f-4-Ala-ET-1 in assay buffer. 68   Methods 
 
Data were processed by non-linear regression curve fitting using GraphPad Prism 5 (GraphPad 
Software, Inc., San Diego, CA). 
 
3.7.3.  Liquid-state NMR 
CF expression of MPs offers a high potential for their structural analysis by NMR spectroscopy. 
The set-up is ideally suited for rapid screens of optimal expression and resolubilization 
conditions and highly concentrated protein samples can be obtained in less than 24 h. In order to 
study protein structure and dynamics by NMR spectroscopy, the backbone of a protein must 
first be assigned. However, the often large size of MPs results in slow rotational tumbling and 
concomitant broad linewidth. This problem is aggravated by the fact that MPs have to be 
solubilized in micelles, which contribute to the overall molecular weight. Furthermore, α-helical 
proteins tend to display narrower chemical shift dispersions, resulting in peak overlap, and the 
TM sections of these proteins consist predominantly of hydrophobic amino acids often leading 
to clustering of identical amino acids with very similar chemical shifts (Junge et al. 2010a). 
The first TMS of the ETB receptor was analysed with respect to possible interaction and 
titration studies with unlabelled ET-1 as well as for comparison with split intein constructs 
(see 3.11.). Therefore, [
15N
1H]-TROSY HSQC of ETB-TMS1 were recorded in cooperation 
with Dr. Frank Löhr (Institute of Biophysical Chemistry, Goethe University, Frankfurt/Main) as 
reference spectra at 800 MHz and 303  K. The protein was uniformly 
15N- labelled by CF 
expression in the P-CF mode. For NMR measurements the same conditions were chosen as 
found for successful cleavage of ETB inteins. The pellet was washed two times in water and 
was finally resolubilized for 2 h at 32 °C in 2 % Fos-12, 50 mM Tris pH 7.0, 1 mM EDTA and 
10 mM TCEP. 
 
3.7.4.  Mass spectrometry: Peptide mass fingerprinting (PMF) 
Mass spectrometry of CF-expressed ETA was performed in cooperation with Dr. Julian Langer 
(group of Prof. Michel, Department of Molecular Membrane Biology, Max-Planck Institute of 
Biophysics, Frankfurt/Main). 
Identification of SDS-PAGE separated ETA full-length receptor and its supposed dimer was 
performed on reduced and alkylated, trypsin- -digested samples prepared by standard mass 
spectrometry protocols (Proteoextract Digestion kit, CalBiochem). 
Proteolytic digests were loaded (Proxeon easy-nLC) on reverse phase columns (trapping 
column: particle size 5  µm, C18, L=20mm; analytical column: particle size 5  µm, C18, 
L=10 cm; NanoSeparations, Nieuwkoop, The Netherlands) using a nano-HPLC, and eluted in 
gradients of water (0.1 % formic acid, buffer A) and acetonitrile (0.1 % formic acid, buffer B). 
Peptides eluting from the column were ionised online via a Bruker Apollo ESI-source with a Methods   69 
 
nanoSprayer emitter and analysed in a quadrupole time-of-flight mass spectrometer (Bruker 
micrOTOF-Q-II and Bruker maXis). Mass spectra were acquired over the mass range of 
50-2200m/z, and sequence information was acquired by computer-controlled, data-dependent 
automated switching to MS/MS using collision energies based on mass and charge state of the 
candidate ions. 
The data sets were processed by means of a standard proteomics script with the software Bruker 
DataAnalysis 4.0 Service Pack 1 Build 253 and exported as mascot generic files. Proteins were 
identified by matching the derived mass lists against the NCBInr database on a local Mascot 
server (Version 2.2.2, Matrix Science, UK). These data and the results from re-sequencing the 
open reading frames were analysed and validated using the BioTools 3.1 software package 
(build 2.22, Bruker Daltonics). 
 
3.8.  Electron microscopy: Assessing sample dispersity and reconstitution 
efficiency 
3.8.1.  Negative staining electron microscopy 
The negative staining EM micrographs were provided by André Krüger from the group of Prof. 
Engel (Department of Structural Biology, M.E. Müller Institute for Microscopy, Biocenter, 
University of Basel, Switzerland). 
Aliquots of 5  µL of different concentrations of purified ETA receptor preparations were 
adsorbed to glow-discharged 200 mesh carbon-film coated copper grids, washed with water and 
negatively stained with 2 % (w/v) uranyl acetate. Images were recorded using a Philips CM10 
transmission electron microscope (Philips, Eindhoven, The Netherlands) operated at an 
acceleration voltage of 80 kV. Negatives were recorded and digitized on a 2000 x 2000 pixel 
charge coupled device camera (Veleta, Olympus Soft Imaging Solutions, Münster, Germany). 
 
3.8.2.  Freeze-fracture electron microscopy 
The freeze-fracture EM micrographs were kindly performed by Friederike Joos (group of Prof. 
Kühlbrandt, Department of Structural Biology, MPI of Biophysics, Frankfurt/Main. 
Proteoliposomes in sample holders were frozen in ethane precooled to -180 °C under liquid 
nitrogen. The fracturing at -120  °C and replication at a shadowing angle of 45° with 
platinum/carbon was performed with a BAF 060 freeze-fracturing unit from Bal-Tec Inc. 
(Principality of Liechtenstein). The enlargement of the respective fracture images were achieved 
from a x 16k-x 25k primary magnification to a final magnification of x 116,800-x 194,500 and 
digitized in a 1024 x 1024 pixel format. 
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3.9.  Analysing the functionality of cell-free produced ET receptors 
3.9.1.  Peptide labelling of the linear mutant 4-Ala-ET-1 with radioactive 
125 iodine 
For radioactive binding assays of the ET receptors with the mutant ET-1 ligand the peptide was 
labelled chemically with 
125 iodine at its tryrosine residue 13 by a redox reaction mediated by 
the oxidizing agent chloramin T and the corresponding reducing agent sodium–metabisulfite 
(Hunter and Greenwood 1962). 
17 µg of 4-Ala-ET-1 (Dr. Michael Beyermann, FMP, Berlin) in 1-fold PBS buffer and 
DMSO, pH 7.0 were gently mixed with 10 µL [
125I]NaI (1mCi) and 10 µL of chloramine T 
(1 mg/mL, in PBS) followed by an incubation of 5 min at RT. The reaction was terminated by 
the addition of 10  µL of sodium-metabisulfite solution (0.67  mg/mL, in PBS) and bound 
radioactivity was immediately separated by gel filtration on Sephadex G-10 spin columns with 
1 mL bed volume, pre-equilibrated in PBS buffer. The whole reaction volume (approximately 
60 µL) was subsequently loaded onto the column and the elution of the radioactively labelled 
ligand was performed in eight steps of 50 µL of PBS buffer, each followed by centrifugation at 
500 x g for 10 s. 2 µL of each elution were measured on a gamma counter (Cobra II Auto 
gamma, PerkinElmer, Rodgau-Jügesheim, Germany) and fractions displaying highest counts 
were pooled. The radioactive ligand was finally adjusted to a total concentration of 10 µM by 
addition of cold ligand and stored at -20 °C until further use. 
 
3.9.2.  Following traditional tracks: Post-translational reconstitution of P-CF 
produced ETA and ETB receptors 
Reconstitution of proteoliposomes was done with P-CF produced MP samples directly after 
resolubilization with 1  % LPPG in liposome reconstitution buffer at a concentration of 
approximately. 1.5 mg/mL. E. coli polar lipids and cholesterol at a ratio of 20:1 (w/w) were 
solubilized in 100  % chloroform, evaporated under vacuum to a thin film using a rotary 
evaporator and completely dried under vacuum over night. The film was resuspended in 
liposome reconstitution buffer to a concentration of 20 mg/mL, rotated and vortexed until a 
homogenous suspension was obtained. Finally, they were extruded to a size of 0.2 µm (Mini-
Extruder, Avanti Polar Lipids Inc., USA). Solubilized protein samples were subsequently mixed 
at molar ratios of 1:350 or 1:1,000 with the prepared E. coli polar liposomes supplemented with 
5 % cholesterol. The reconstitution mixture was incubated for 1  h at 30  °C. Detergent was 
removed by addition of 500 mg Biobeads SM-2 (Bio-Rad, München, Germany) pre-equilibrated 
with liposome buffer. After gentle agitation for 1 h at RT, Biobeads were refreshed and the 
mixture was further incubated for up to 48 h at 18 °C. Proteoliposomes were finally separated 
from empty liposomes in a discontinuous sucrose gradient of 10-20-30-40  % sucrose in 
liposome buffer by ultracentrifugation at 83,000 x g (SW28 swing bucket rotor, Beckman Methods   71 
 
Coulter, Krefeld, Germany) for 16 h at 4 °C. Proteoliposome layers were harvested and sucrose 
was removed by two subsequent washes with liposome buffer by centrifugation at 195,000 x g 
(rotor Type 70Ti, Beckman Coulter, Krefeld Germany) for 1  h at 4  °C. The pelleted 
proteoliposomes were resuspended in liposome buffer, shock frozen in liquid nitrogen and 
stored at -80 °C for functional analysis or freeze-fracture EM (see 3.8.2.). 
Optionally, the P-CF expressed ETA receptor was purified in presence of 2  mM of the 
fluorinated surfactants F6-TAC or F8-TAC and subsequently reconstituted either into E. coli 
polar lipids/cholesterol or in liposomes of aso-PC at a molar protein-to-lipid ratio of 1:1,500. 
 
3.9.3.  Radioligand binding assay: Analysis of ET receptor proteoliposomes 
Sucrose gradient purified and pelleted proteoliposomes of ETA were resuspended and 
concentrated in liposome reconstitution buffer. For competition studies, suitable aliquots of 
proteoliposomes (approximately. 6 µg protein/mL) were incubated in 96-well microplates with 
500 pM [
125I]Tyr
13 ET-1 (specific activity 2200 Ci/mmol) (PerkinElmer, Rodgau-Jügesheim, 
Germany) in the presence of unlabelled ET-1 (10
-10–10
-4 M) in a final volume of 50 µL of 
binding buffer (20 mM potassium phosphate, 150  mM NaCl, 0.1  % (w/v) bovine serum 
albumine, pH 7.0) for 1 h at RT. Competition was stopped by addition of 100 µL ice-cold 
binding buffer to the reaction and samples were transferred to GF/B glass fibre filters 
(Millipore, Eschborn, Germany) that were pre-treated with 0.3 % polyethyleneimine (PEI) for 
10 min and washed with 500 µL of binding buffer before use. Unbound ligand was removed by 
washing the filters 3 times with 150 µL of binding buffer. Dry filters were finally collected and 
the retained radioactivity was determined in a gamma counter (Cobra II Auto gamma, 
PerkinElmer, Rodgau-Jügesheim, Germany). Nonspecific binding was determined by 
preincubation of the proteoliposomes with 4 µM of unlabelled ET-1. Data were analysed by 
non-linear regression curve fitting using GraphPad Prism 5 (GraphPad Software, Inc., San 
Diego, CA) and represent the mean value of three independent experiments. 
 
3.9.4.  Centrifugation-assisted gel filtration: Ligand binding competence of 
detergent solubilized ET-receptors 
Saturation binding of individually labelled 
125I-4-Ala-ET-1 to soluble ET receptors was assayed 
by centrifugation-assisted gel filtration (Grisshammer et al. 1999). 
Approximately 50  nM of D-CF expressed ETA receptor purified in 0.04  % DDM were 
incubated at RT for 1 h with increasing concentrations of labelled ligand ranging from 0 to 
2 µM in a total volume of 25 µL in assay buffer (20 mM Tris-HCl, 150 mM NaCl, 0.04 % 
DDM and 0.01 % CHS). Non-specific binding was determined in presence of a 100-fold excess 
of unlabelled 4-Ala-ET-1. Separation of bound from free ligand was achieved by gel filtration 
on 1  mL columns (illustra MicroSpin G-50 columns, GE Healthcare, Europe, München, 72   Methods 
 
Germany) of Sephadex G-50 matrix material. Columns were pre-equilibrated in assay buffer by 
three consecutive centrifugation steps of 400 µL buffer at 2,000 x g and 4 °C for 1 min each. 
Aliquots of 16 µL of the total reaction mixture were loaded onto the columns. Receptor and 
bound ligand were collected in the void volume by centrifugation at 740 x g and 4 °C for 3 min. 
The amount of bound radioactive ligand was analysed by gamma counting (Cobra II Auto 
gamma, PerkinElmer, Rodgau-Jügesheim, Germany). All data were analysed by non-linear 
regression curve fitting using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA). 
 
3.9.5.  Surface Plasmon Resonance measurements with detergent-solubilized 
ETB receptor 
SPR measurements of the ETB receptor either CF-expressed in E. coli or in WGE were kindly 
carried out by the group of Dr. Michael Beyermann (FMP, Berlin) using a Biacore 2000 
instrument (Biacore Intl. AB, Uppsala, Sweden). CM-5 chips (research grade, Biacore AB) 
were coated with ET-1 by amide coupling at different response units (RU) ranging from 700 to 
1400 RU depending on the respective experiments. The control peptides urocortin and 
sauvagine were coupled to the chips via available cysteine residues. Subsequent interaction 
studies with ETB at dilutions of 2-120 µg/mL were performed in running buffer (20 mM Tris, 
100mM NaCl, 0.005 % P-20 surfactant, pH 8.0) at 25 °C at a flow rate of 2 µL/min. Unspecific 
binding was subtracted using blank runs without ET-1 bound to the chip surface. Kinetic 
constants were calculated using BIAevaluation software 3.1 (Biacore). 
 
3.10. Automated robotic screening of buffer conditions for X-ray crystallography 
Under defined conditions proteins can be forced to crystallize. Undersaturated solutions of 
homogenous, stable, purified protein are supersaturated by the addition of protein precipitating 
agents like salts and polyethylene glycols. Precipitation and aggregation as a result of optimal 
conditions in this unstable supersaturated state might lead to the alignment of individual protein 
molecules in a repeating series of “unit cells” by adopting uniform orientations. Non-covalent 
interactions stabilize the crystal lattice. Crystallization of a protein serves as basis for the 
determination of its three-dimensional structure by X-ray diffraction. A variety of conditions 
and combinations have to be screened initially in order to find the optimal parameters for the 
crystallization of the respective target protein. 
In cooperation with Dr. Yvonne Thielmann (group of Prof. Michel, Department of 
Molecular Membrane Biology, Max-Planck Institute of Biophysics, Frankfurt/Main) initial 
sitting drop crystallization of classical vapour diffusion as well as cubic phase series on the 
96-well format robotic platform “CrystalMation” (Rigaku, Berlin, Germany) were performed on 
the ETA receptor. The advantage of automation on CrystalMation clearly resides in a very fast Methods   73 
 
experimental set-up combined with small sample sizes of 100  nL of concentrated protein 
solution overlaid with 100 nL buffer volumes. 
ETA was therefore P-CF expressed, resolubilized in 1  %  LPPG and exchanged by 
IMAC purification to 0.1  %  B35 in 20  mM Tris and 150  mM NaCl. A protein purity of 
estimatedly >95 % was achieved. Gel filtration was not performed as second purification step 
since protein homogeneity was judged to be sufficient for initial trials. The purified protein was 
subsequently concentrated with or without addition of equal moles of ET-1 ligand to final 
volumes of 150  µL of around 5-8  mg/mL using an ultrafiltration device with a MWCO of 
10  kDa (Millipore GmbH, Eschborn, Germany). Initial experiments designed for soluble 
proteins or MPs were performed in sitting drop with commercial as well as custom MPI screens 
available from the database of the CrystalTrak software (see 7.5.). Incubation within the robotic 
unit for the vapour diffusion plates was performed at 4 °C and 18 °C. Cubic phase plates were 
incubated externally at 22  °C. Imaging was carried out automatically twelve times at fixed 
intervals within a time window of three months. 
 
3.11. Self-cleavage of ETB split intein constructs 
The intein self-cleavage / fusion reactions of the ETB split intein constructs pVSO 4.1 and 
pVSO 4.2 (see 3.1.1.) were adapted to the CF reaction and modified from Hong et al. 2008. The 
intein constructs were separately expressed in P-CF mode, centrifuged at 18,000 x g and 4 °C 
for 10 min and resolubilized in 2 % LPPG, Fos-12, Triton X-100 or diC6PC (solubilized in 
cleavage buffer) for 1 h 30 min at 30 °C. Resolubilization efficiency was analysed by western 
blotting of 1.5 µL of protein sample. The protein products further termed ETB 4.1 and ETB 4.2 
were subsequently mixed 1:1 (v/v) in a final reaction volume of 30 µL. The mixture was 
incubated at different temperatures (16 °C, 23 °C and 40 °C) and samples were analysed for 
their self-cleavage efficiency after 1, 2, 4, 18 and 42 h. Therefore, 2.5 µL of collected samples 
were loaded on 12 % Tris-Tricine-SDS gels and subjected to western blotting (see 3.4.1.). 
Alternatively, either ETB 4.1 or ETB 4.2 were CF expressed in presence of 125 µCi 
L-[
35S]- methionine (RM) and 40 µCi in the FM and cleavage was followed on 12 % Tris-
Tricine-SDS autoradiographs after 45 min, 1, 3 and 65 h at 23 °C. Therefore, gels were dried for 
1 h 30 min at 80 °C and finally incubated on phosphoimager plates from o. n. to 24 h. 
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4.  Results 
 
4.1.  Cell-free expression optimization of the human endothelin A receptor 
4.1.1.  Basic parameters for the expression of ETA in the E. coli CECF system 
analysed in the P-CF mode 
The coding sequence of the human ETA receptor was successfully cloned into the expression 
vector pET21a(+)poly(His)10 (see 3.1.1.). Full-length protein synthesis resulted in the protein 
construct T7-ETA-poly(His)10, further abbreviated ETA or ETAcHx, (453 aa, 51.72  kDa) 
(Fig. 9). The abbreviation cHx for poly(His)10-tagged receptors simplifies their differentiation 
from the strep-tagged variants. The N-terminal T7-tag was chosen as expression enhancer as it 
already proved highly beneficial especially for the expression of GPCRs since almost no 
expression was observed without this tag for the porcine GPCR vasopressin 2 receptor (V2R) as 
well as for three other GPCRs (Klammt et al. 2005). Addition of the poly(His)10-tag should 
ensure efficient IMAC purification. The strepII-tag, resulting upon expression of the protein 
construct T7-ETA-strep, abbreviated ETAstrep, was chosen for purification by streptavidin 
matrix and for homo- and heterodimerization pull-down experiments (Fig. 9). A list with all 
used ET constructs is available in 3.4.2.. 
Fig. 9: Predicted secondary structure of the human ETA receptor. Highlighted in light blue and green 
are the N-terminal T7-tag as expression enhancing element and the C-terminal purification sequences 
poly(His)10-tag or strepII-tag, respectively. Restriction site inserted amino acids are visualised by dark 
blue and green circles written in white. The internal signal sequence is depicted in yellow. 
All three terminal extensions were furthermore used as immunotags for quantification and 
verification of the expression success. Expression of ETA was first performed by P-CF Results   75 
 
synthesis using the optimized protocol for the standard control protein GFP. Production of ETA 
was subsequently analysed either by SDS-PAGE followed by Coomassie staining or 
immunodetection with poly(His)6-tag or T7-tag antibodies. 
Without addition of detergent, the ETA receptor precipitated quantitatively. After 
centrifugation of the RM at 18,000 x g and 4 °C for 10 min the whole synthesized protein was 
harvested in the pellet fraction of which 3 µL and 1.5 µL were loaded on SDS-PAGEs for either 
Coomassie or immunostaining, respectively (Fig. 10). ETAcHx or ETAstrep constructs were 
detected in 12 % SDS-gels at an apparent mass of approximately 40 kDa running faster than 
expected (Fig. 10 A) which might be explained by incomplete denaturation as already seen for 
the V2R as well as for many other MPs (Klammt et al. 2005). To investigate their full-length 
expression and to exclude the possibility of premature termination, ETA samples were subjected 
to immunodetection of both termini in parallel. Full-length synthesis could be verified from 
both ends for ETAcHx (Fig.10 B) as well as for ETAstrep (data not shown). 
 
Fig. 10:  Verification  of  ETA 
construct expression and full-length 
synthesis of ETAcHx. (A) Sample 
volumes of 3  µL of P-CF expressed 
ETAcHx or ETAstrep were loaded on 
12  % SDS-Tris-glycine gels and 
subsequently stained with Coomassie 
Blue. (B) 1.5  µL of resuspended 
protein pellet or detergent-solubilized 
ETAcHx were separated by 12  % 
SDS-Tris-glycine PAGE and immu-
nodetected by either His- or strep-tag 
specific antibodies. Arrows indicate 
ETA bands. M, marker proteins; P, 
pellet; F, soluble fraction; cHx, 
poly(His)10-tag. 
CECF reactions commonly display a very defined optimum for Mg
2+ and K
+ ions which usually 
is in between 15-23  mM and 250-300  mM, respectively. This optimum is highly batch-
dependent and individual to every target MP. Especially Mg
2+ ensures highest yields if 
optimized in CECF systems. 
Therefore, optimal concentrations of Mg
2+ and K
+ ions for every S30 extract batch were 
analysed in analytical scale reactions in the P-CF mode. In case of ETA, optimal concentrations 
were found in between 16–22 mM Mg
2+ and 270–300 mM K
+. Depending on the extract batch 
Mg
2+ optima might be broader or more distinct (Fig. 11). The concentrations of other reaction 
components were optimized and finally kept constant for all further experiments with ETA as 
illustrated in Table 9. 
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Table 9: CF expression protocol for the optimized expression of ETA in the CECF configuration. 
 
        Concentration   
Compound [unit]  Stock  Final (RM)  Final (FM)  Supplier
b/Ref. 
NaN3 [%]  10  0.05  0.05  A 
PEG 8000 [%]  40  2  2  A 
KOAc [mM]  4000  110
a 110
a A 
Mg(OAc)2 [mM]  1000  11.1
a 11.1
a A 
HEPES buffer, pH 8.0 [M]  24  1  1  A 
Complete [x]  50  1  1  B 
Folinic acid [mg/mL]  10  0.1  0.1  C 
DTT [mM]  500  2  2  A 
NTP-mix [x]:  75  1  1 
   ATP [mM]  360  4.8  4.8  B 
UTP [mM]  240  3.2  3.2  C 
GTP [mM]  240  3.2  3.2  C 
CTP [mM]  240  3.2  3.2  C 
PEP [mM]  1000  20  20  C 
AcP [mM]  1000  20  20  C 
AA-mix [mM]  4  0.6  1.2  C 
RCWMDE-mix [mM]  16.7  1  1  C 
S30 C buffer [%]
c  100  -  35  (Schwarz et al. 2007a) 
Pyruvat kinase [mg/mL]  10  0.04  -  B 
Plasmid DNA [mg/mL]  0.2  0.03  -  - 
RiboLock
TM [U/µL]  40  0.3  -  D 
T7RNAP [mg/mL]  3.8  0.05  -  (Schwarz et al. 2007a) 
tRNA E. coli [mg/mL] 40  0.5  -  B 
S30 extract [%]  100  35  -  (Schwarz et al. 2007a) 
a, Value for reactions with 270 mM K
+ and 16 mM Mg
2+ final concentration 
b, A, Carl Roth GmbH & Co. KG, Karlsruhe, Germany; B, Roche Diagnostics, Penzberg,  
   Germany; C, Sigma-Aldrich, Steinheim, Germany; D, MBI Fermentas, St. Leon-Rot, Germany 
c, S30 C buffer (10 mM Tris-acetate, 14 mM Mg(OAc)2, 0.6 KOAc, 0.5 mM DTT, pH 8.2),  
   prepared according to (Schwarz et al. 2007a) 
Using the optimized basic protocol with a good quality of the prepared S30 extract batch, 
expression rates in between 1-3 mg ETA per mL RM could be obtained in the P-CF mode. Results   77 
 
Fig. 11: Mg
2+ and K
+ optimization screen in the CECF configuration for two different S30 extract 
batches. Protein samples of 3 µL volume each of analytical scale P-CF reactions were loaded on 12 % 
SDS-Tris-glycine gels and stained with Coomassie Blue. Arrows point at ETA receptor bands. (A) 
Analysed Mg
2+ concentrations in dependence of K
+ ions kept in a concentration range of 270-290 mM. 
(B) Different extract batch, displaying a more distinct optimum for Mg
2+ than (A). M, marker proteins. 
 
4.1.2.  Evaluation of detergents for co- and post-translational solubilization of 
ETA 
The co-translational solubilization in the D-CF mode as well as its post-translational 
solubilization starting from P-CF mode were analysed for ETAcHx. Specific sets of detergent 
families which are either frequently used for MP solubilization out of membranes (e.g. DDM, 
Triton X-100, digitonin) or which already proved efficient especially for the expression of 
GPCRs (Brij  derivatives, digitonin) (Klammt et al. 2005) were investigated in each mode 
(Fig. 12). 
ETA precipitates produced in the P-CF mode in analytical reaction volumes were 
recovered by centrifugation at 18,000 x g and 4 °C for 10 min and subsequently washed twice, 
once with water, once in resuspension buffer (see 3.5.1.), to reduce the remaining impurities of 
E. coli extract proteins which co-precipitate with the target protein. ETA could completely be 
solubilized in 1 % final concentration of either the long-chain phosphoglycerol LPPG, the long-
chain phosphocholine LMPC, SDS or Fos-16. Fos-12 in the same concentration was less 
effective and solubilized only estimated 10 % of ETA (Fig. 12 A). Even 5 % DDM did not 
resolubilize ETA at all. The harsh denaturing agent SDS was used as a standard for complete 
resolubilization. As already shown for ETB and V2R (Klammt et al. 2005, 2007b) the relatively 
mild long-chain phosphoglycerols like LMPG or LPPG appear to be highly efficient for 
complete solubilization of GPCRs including ETA. 78   Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Solubilization screen of CF expressed ETA. Sample volumes of 1-1.5 µL (Western Blot) and 
3 µL (Coomassie) were loaded on 12 % SDS–Tris–glycine gels and subsequently immunodetected by 
anti-His-tag antibodies or stained by Coomassie Blue. (A) Resolubilization of P-CF produced ETA 
precipitates. All detergents were supplied in 1 % (w/v). (B) Detergent screen for the D-CF expression of 
ETA (partially adapted from the diploma thesis of Laura Luh under supervision of Friederike Junge, 
Institute of Biophysical Chemistry, Goethe University, Frankfurt/Main). The protein was synthesized in 
presence of various detergents at the indicated final concentrations (w/v). M, marker proteins; P, pellet; S, 
supernatant. 
D-CF expression offers an alternative approach to the post-translational solubilization of MPs as 
it directly enables the production of soluble MP targets during protein synthesis. If protein 
quality of samples derived from post-translational solubilization, in which yields are usually 
higher, is not efficient, the operator can switch to the D-CF mode. For the evaluation of the 
adequate hydrophobic environment, different detergent families were tested in analytical scale 
reactions with respect to their effects on the overall CF production efficiencies and their 
solubilization capacity of ETA as well as with respect to their use in functional and structural 
approaches. Especially Brij derivatives and digitonin were promising as they were already used 
in the functional production of GPCRs as shown for the ETB receptor (Klammt et al. 2007b) 
and human olfactory receptors (Kaiser et al. 2008). All detergents were tested above their 
specific CMC. 
In the D-CF screen highest yields of the ETA receptor of around 1 mg/mL RM were 
only achieved with polyoxyethylene derivatives (Brijs). B35 at final concentrations of 0.5 % 
corresponding to approximately 46  x  CMC appeared to be most effective in the complete 
solubilization of the synthesized ETA. The related detergents B58 and B78 at final Results   79 
 
concentrations of 1 % also resulted in complete ETA solubilization. However, these detergents 
appeared to reduce the expression efficiencies significantly (Fig. 12 B). 
Table 10. Efficiencies of CF expression protocols for the production of solubilized ETA. 
CF mode   1
st Detergent   (%)  Solubilization
a (%) 2
nd Detergent (%)  Yield
b 
P-CF -    -  -    +++  (E) 
 LPPG  1  100  -    +++  (S) 
 LPPG  1  100  B35  0.1  +++  (P) 
 LPPG  1  100  DDM  0.04  +/-  (P) 
 LPPG  1  100  LPPG  0.05  +++  (P) 
 LPPG  1  100  Fos-12  0.1  ++  (P) 
 LPPG  1  100  Fos-16  0.005  +++  (P) 
 LPPG  1  100  F6-TAC 0.35  +++  (P) 
 LPPG  1  100  F8-TAC 0.37  ++  (P) 
 LPPG  1  100  CHAPS  1  -  (P) 
 LPPG  1  100  DHPC  1  -  (P) 
 LPMC  1  100  -    +++  (S) 
 SDS 1  100  -    +++  (S) 
 Fos-16  1  100  -    +++  (S) 
 Fos-12  1  30  -    ++  (S) 
D-CF B35  0.5  100  -    +++  (E) 
 B35 0.5  100  B35  0.1  ++  (P) 
 B35 0.5  100  DDM  0.04  +  (P) 
 B58 1  100  -    +  (E) 
 B78 1  100  -    +  (E) 
 B98 1  -  -    -  (E) 
 Digitonin  0.4  60  -    ++  (E) 
 Fos-12  0.1  -  -    -  (E) 
 TX-100  0.1  -  -    +/-  (E) 
 DDM  0.1  -  -    +  (E) 
 HDM  0.05  -  -    +  (E) 
 TDM  0.01  -  -    ++  (E) 
a, solubilization efficiency in the 1
st detergent judged by immunodetection. 
b, E, expression yield; S, yield after solubilization; P, yield after IMAC purification. 
Thus, the number of polyoxyethylene moities as well as the chain length of the alkyl group 
seemed to be an important parameter for the efficiency of soluble ETA expression. The shortest 
of the investigated long chain Brij  derivatives -possessing only a lauryl moiety (C12H20)- 
displayed best solubilization effects without any reduction in CF protein production yield. The 
steroid detergent digitonin at 0.4 % final concentration solubilized approximately 60 % of the 80   Results 
 
produced ETA. Increased digitonin concentrations however inhibited the expression system 
(Kaiser et al. 2008, Klammt et al. 2007b). 
The alkyl glycoside detergents DDM, HDM and TDM as well as TX-100 were 
ineffective in ETA solubilization, although no inhibitory effect on the expression level could be 
observed. In contrast, addition of 0.1  % Fos-12 or 1  % B98 completely inhibited ETA 
production (Fig. 12 B). In summary, a list of detergents suitable for the production of soluble 
ETA in the D-CF mode (B35 > digitonin > B58, B78) as well as in the P-CF mode (LPPG, 
LMPC, SDS, Fos-16 > Fos-12) could be defined as basis for subsequent quality control 
approaches and their efficiencies are given in Table 10. 
 
4.2.  Quality control of cell-free expressed human ETA 
Fig.  13: Schematic flow-chart of protocol development for the CF expression of MPs. After 
successful template and target design, the expression screening can be organized into the three illustrated 
levels focussing on protein yield (level I), protein solubility (level II) and protein purity (level III). The 
obtained list of determined final preparation protocols provides the basis for subsequent quality 
evaluation screens implementing complementary techniques. 
Integrity, homogeneity and monodispersity amongst other parameters of protein sample quality 
are clearly high-end aims if aiming at structural investigations. The strength of CF expression 
resides in the possibility to individualize expression protocols and to adapt them to the 
requirements of the target protein (Fig. 13). As for any other expression system, the effect of 
basic compounds, specific additives or of the provided detergent on the target after CF synthesis 
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for its production. An advantage of the CF system is the fast feed-back response possible from 
any level of the production process since the reaction volumes are small and the expression rates 
fast. A comprehensive strategy of sample quality analysis of ETA in different CF modes has 
therefore been developed and might finally serve as basic guideline for the production of related 
receptors in similar expression systems. 
 
4.2.1.  Evaluation of buffer conditions for the resolubilization and purification 
of ETA 
Two different buffer substances Tris(hydroxymethyl)methylamine (Tris) and sodium phosphate 
at a near physiological pH of 8.0 were tested with respect to receptor homogeneity. 
Homogeneity was taken as a first hint to receptor quality which was assessed by SEC using a 
Superdex 200 3.2/30 column (Fig.  14). Sodium phosphate was analysed since it already 
generated stable and ligand binding competent ETB receptor (Klammt et al. 2007b, 2007c). 
Medium concentrations of Tris were chosen due to their common applicability in crystallization 
trials and their common use in functional assays for ETA membrane receptor preparations (De 
Leon and Garcia 1995, Tessier et al. 2005). 
Compared to sodium phosphate, Tris buffer generated a less aggregated D-CF 
expressed ETA receptor in 0.5 % B35 purified to 0.1 % B35 with higher apparent homogeneity. 
The peak maximum of ETA purified in Tris buffer centred at about 1.34 mL corresponding to a 
molecular mass of approximately 280 kDa with a shoulder at around 1.51 mL (120 kDa). The 
sodium phosphate-buffer generated profile of ETA resulted in a much broader peak pattern, 
indicating a multitude of different oligomeric or aggregated states of ETA in those buffer 
conditions. Most pronounced states could be detected at 1.13 and 1.25 mL corresponding to 
approximately 780  kDa and 430  kDa, respectively with a shoulder at 1.51  mL (120  kDa) 
(Fig. 14.). 
Fig.  14: Choice of optimal 
buffer substances for the 
purification of ETA. SEC 
elution profiles of IMAC 
purified ETA in 0.1  % B35 
under different buffer 
conditions. Samples con-
taining 10–15  µg of protein 
were analysed on a Superdex 
200 3.2/30 column. Protein 
absorbance was recorded at 
280 nm. The bold arrow 
indicates the void volume of 
the column in between 0.9 and 
1.0 mL. The retention volume, 
indicated by an asterisk, 
corresponds to approximately 
125 kDa (Fig. 62 A). 
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Tris buffer was therefore chosen as promising buffer and applied in subsequent functional and 
structural analyses. Lowering the pH to 6.5 of this buffer during purification decreased the final 
receptor yield to a minimum. Optimal purification of the ETA receptor was performed at pH 7.4 
with decreasing salt concentrations from 500  mM for equilibration and washing steps to 
150 mM sodium chloride in the elution fractions. 
 
4.2.2.  Characterization of resolubilized receptor sample quality by size 
exclusion chromatography 
Analysing elution profiles of proteins on size exclusion columns is a first and general tool in 
order to detect aggregates or apparent heterogeneities in protein samples. P-CF produced ETA 
precipitates (Fig. 12 A) were directly applied to SEC analysis on a Superdex 200 3.2/30 column 
after resolubilization in 1  % of the indicated detergents (Fig.  15  A). To evaluate possible 
aggregation or oligomerization of native protein samples without any reducing and denaturing 
agents, 3-5 µg of freshly resolubilized samples of ETA in 1 % LPPG, LMPC as well as samples 
in SDS as a control were further subjected to gradient Blue Native-PAGE (BN-PAGE) analysis 
in cooperation with Dr. Sebastian Richers (Institute of Biophysical Chemistry, Goethe 
University, Frankfurt/Main) (Fig. 15 B). 
Best elution profiles with highest yield and lowest degree of apparent receptor 
aggregation were achieved in LPPG and LMPC supplemented with 0.5  mM TCEP. A 
symmetric peak shape centred at 1.4 mL of retention volume corresponding to a molecular mass 
of approximately 250 kDa was obtained with the sample in 1 % LPPG (10
3 x CMC). Upon 
BN-PAGE separation, the resolubilized ETA receptor in LPPG behaved mostly monomeric at a 
molecular weight of around 50 kDa which is in accordance with its calculated mass of ~52 kDa. 
A faint band at estimated 100 kDa might possibly account for a minor dimerization potential in 
LPPG. Addition of 0.02 % CHS during the resolubilization process does however not seem to 
influence the running behaviour of ETA (Fig. 15 B). Pronounced bands at 440 and 880 kDa 
very likely represent impurities from the E. coli extract as they also occur in non related P-CF 
expressed proteins (data not shown). The resolubilization of ETA in 1 % LMPC (500 x CMC) 
generated a much broader peak presumably resulting from a mixture of lower and higher order 
ETA oligomers (Fig. 15 A). 
ETA in LMPC showed monomeric as well as dimeric folding on BN-PAGE since two 
prominent bands at approximately 60 and 120 kDa could be detected. The slower migration of 
ETA in LMPC might result from a slightly different running behaviour in LMPC as compared 
to LPPG (Fig. 15 B). 
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Fig.  15: Sample quality of CF expressed ETA samples by 
direct resolubilization. (A) SEC elution profiles of resolubilized 
P-CF expressed ETA without detergent exchange. Samples 
containing 10–30 µg of protein were analysed on a Superdex 200 
3.2/30 column. Protein absorbance was recorded at 280 nm. Solid 
lines demonstrate fresh sample preparations. The elution peaks of 
ETA are indicated by arrows or brackets. The bold arrow indicates 
the void volume of the column in between 0.9 and 1.0 mL. The 
retention volume indicated by an asterisk corresponds to 
approximately 150 kDa (Fig.  62  B). (B). 3-5  µg of freshly 
resolubilized ETA samples were loaded on BN-PAGE 4  % to 
18  % gradient gels. Arrows indicate ETA bands. ETA in 
1 % LPPG  with/without  CHS  and  in 1  %  LMPC shows mostly 
monomeric character with an additional potentially dimeric faint 
band. CHS, cholesteryl hemisuccinate; M, marker proteins. 
 
SDS seemed to completely aggregate the ETA receptor as only bands at very high molecular 
weight occurred in this detergent (Fig.   15  B). After resolubilization in 1  % Fos-16 
(2 x 10
3 x CMC; 1 mM TCEP) a prominent fraction of ETA eluted within the void volume of 
the column, indicating complexes of >800 kDa. ETA resolubilized in 1 % Fos-12 (20 x CMC) 
also showed a broad elution profile indicating a high degree of receptor heterogeneity 
(Fig. 15 A). 84   Results 
 
According to its SEC elution profile, 1  % LPPG was therefore chosen as most promising 
resolubilization detergent for P-CF produced ETA precipitates analysed in subsequent 
purification and detergent exchange steps (Fig. 15 A). 
 
4.2.3.  Purification of ETA by IMAC: Evaluation of chelating ions and 
secondary detergents 
Purification of detergent solubilized receptors was approached by IMAC based on binding of 
the C-terminal poly(His)10-tag at Co
2+ loaded NTA-agarose beads (see 3.5.3.). First evaluations 
of IMAC purification demonstrated that the commonly used Ni
2+ ions generated high initial 
yields of eluted ETA, however concomitant with significant impurities (Fig. 16). 
 
Fig.  16: Evaluation of 
chelating ions for the puri-
fication of ETA. Sample 
volumes of 10  µL fractions 
were separated on 12  % 
SDS-Tris-glycine gels, 
stained with Coomassie 
Blue. Chelated cobalt ions 
produced purer receptor than 
nickel ions, however with a 
more pronounced loss in the 
flow-through fraction. M, 
marker proteins; FT, flow-
through; E, elution; B35, Brij 
35. 
Although final receptor yields were significantly lower, Co
2+ ions were preferably employed 
since their use already resulted in a very high degree of final receptor purity of estimated 
90-95 % in the first purification step (Table 11). Thereby, the need of gel filtration as a second 
purification step could be avoided. 
Immobilization of MPs upon IMAC purification was used to modify the initially 
selected hydrophobic environment either by decreasing detergent concentrations or by 
exchanging the primary detergent with a second detergent having better properties for 
downstream processes. A selection of detergents frequently used in structural as well as in 
functional GPCR studies was evaluated with respect to their effects on ETA homogeneity and 
stability. LPPG and in particular Fos-12 as well as its derivative Fos-16 were chosen for their 
applicability in liquid-state NMR spectroscopy (Arora et al. 2001, Krueger-Koplin et al. 2004). 
B35, F6-TAC and F8-TAC as representatives of very mild detergents or surfactants (Klammt et 
al. 2005, Park et al. 2007) were analysed for their ability to retain or to increase the functionality 
of the ETA receptor. Their applied final concentrations are listed in Table 10. Results   85 
 
Fig. 17: Purification profiles of ETA in different detergents. Sample volumes of 10 μL were loaded on 
12 % SDS-Tris-glycine gels and subsequently stained with Coomassie Blue. (A) Detergent exchange of 
resolubilized ETA from 1 % LPPG to the respective detergents was performed upon IMAC purification. 
ETA elution fractions are already apparently pure after the first purification step out of P-CF mode. (B) 
Unsuccessful detergent exchange from P-CF expressed ETA in 1  % LPPG. Quantitative detergent 
exchange to DDM can only be achieved from Fos-16 resolubilized ETA. (C) Detergent exchange or 
concentration reduction of D-CF expressed ETA in 0.5 % B35 to the respective detergents. M, marker 
proteins; P, pellet; FT, flow-through; E, elution. 
P-CF produced ETA subsequently resolubilized in 1 % LPPG could be purified to a high degree 
in all tested detergents (Fig. 17 A) with highest average yields in 0.05 % LPPG. Exchange to 
B35, Fos-12 or Fos-16 resulted in comparably high amounts as seen with LPPG (Table 11). 
Exchange to some detergents like DDM, CHAPS or 1,2-dihexanoyl-sn-glycero-3-
phosphocholine (DHPC, diC6PC) considerably reduced the ETA yield in the elution fractions 
since most of the protein was already lost during the low stringency washing steps (Table 11). 
For 2  % CHAPS and 1  % DHPC losses of up to 100  % were even detected. To achieve 
quantitative detergent exchange from P-CF synthesized protein to DDM, ETA had to be 
resolubilized in 1 % Fos-16 as its resolubilization in 1 % LPPG hardly allowed an exchange to 
DDM on column (Fig. 17 B). D-CF expressed ETA in 0.5 % B35 purified to 0.1 % B35 or 
0.04  % DDM always displayed a significantly increased degree of impurities due to the 
presence of remaining soluble proteins of the E. coli extract (Fig.  17  C). Therefore, 
resolubilization out of P-CF mode can already be considered as efficient pre-purification step. 86   Results 
 
Table 11: Purification efficiencies of Co
2+-IMAC for ETA. Final estimated protein purity as well as 
final minimal and maximal yields in mg/mL determined by NanoDrop measurements at 280 nm (see 
3.4.2.) are listed. Highlighted in bold are those conditions most promising for further studies. 
 
CF mode   1
st Detergent / 2
nd Detergent  Average loss  Purity  Yield
1 
  (FT / wash) (%)  (%)  (mg/mL) 
P-CF -  -  50  1-3 
 LPPG/LPPG  40  95  0.9-1 
 LPPG/B35  60  95-98  0.25-1.25 
 LPPG/Fos-12  80  95  0.25 
 LPPG/Fos-16  54  95  0.25-1 
 LPPG/F6-TAC 60 95  0.25-0.6 
 LPPG/F8-TAC 70 95  0.25 
 LPPG/CHAPS  100  -  0 
 LPPG/DDM  95  -  0.025 
 LPPG/DHPC  100  -  0 
 Fos-16/DDM  80  95  0.2 
D-CF B35/B35  60  85  0.5-0.6 
 B35/DDM  80  75-80  0.05-0.5 
 B35/Fos-12  90  95  0.15 
 
1, mg ETA out of 1 mL RM after IMAC purification 
Dependent on the detergent used for exchange upon IMAC purification, varying final receptor 
yields were achieved. Highest final amounts of purified ETA were approximately 1 mg/mL RM 
from the P-CF mode (LPPG/LPPG) and 0.5  mg/mL RM from the D-CF mode (B35/B35). 
Implementing the two expression modes in combination with variations in the 1
st and 2
nd 
detergent, a dozen conditions, some of them resulting in the preparative scale production of 
solubilized ETA, could be determined in total (Table 11). Subsequent quality controls as well as 
ligand binding analyses were performed without removing N-terminal and C-terminal peptide 
tags from the receptors. 
 
4.2.4.  Evaluation of receptor sample quality after IMAC purification by size 
exclusion chromatography 
Those detergents which proved efficient for the purification of ETA (see 4.2.3.) and which are 
frequently used in structural as well as in functional GPCR studies were further evaluated with 
respect to their effects on ETA homogeneity and stability. Therefore, either LPPG resolubilized 
P-CF produced or D-CF expressed ETA in 0.5 % B35 was purified in the respective detergents 
by Co
2+-IMAC and the elution fractions were directly loaded on an analytical Superdex 200 
3.2/30 column. In parallel, their stability was assessed by storing freshly purified proteins for 
one to two weeks at 4 °C before SEC analyses (Fig. 18, dashed lines). Results   87 
 
The most homogenous elution profiles centred at approximately 1.35 mL (~300 kDa) could be 
achieved after exchange to 0.1 % B35 (~10 x CMC) as well as to 0.005 % Fos-16 (~10 x CMC) 
(Fig.  18  A, C solid lines). ETA was detected by immunoblotting against the C-terminal 
poly(His)10-tag in both preparations after gel filtration (Fig. 18 B, D). For LPPG/B35 samples 
second order differentiation of the peak curve using the Unicorn software resulted in two main 
protein mass fractions, represented as minima, suggesting two oligomeric states in this receptor 
preparation (Fig. 18 A, inset, red curve). The same evaluation for LPPG/Fos-16 showed only 
one major protein mass fraction under the peak which might correspond to a distinct oligomeric 
or even monomeric state (Fig. 18 C, inset, red curve). 
Furthermore, ETA showed a high degree of stability after storage in either of the two 
detergents at 4 °C. Only minor N-terminal degradation by the rightward shift of the peak tail 
and no aggregation of ETA in 0.1 % B35 might be expected after one week (Fig. 18 A, dashed 
lines). ETA exchanged from LPPG to 0.1  % Fos-12 (2  x  CMC) also showed a reasonable 
profile eluting with its peak maximum at around 1.38 mL (~275 kDa) and a small shoulder at 
approximately 1.26 mL (~500 kDa) (Fig. 18 C). ETA in Fos-12 exhibited good stability with 
only little aggregation after one week, indicated by the small arrow in Fig.  18  C at 
approximately 1  mL of retention volume. Subjecting the Fos-12 curve to second order 
differentiation (Fig. 18 C, inset, red curve) one main minimum at ~1.38 mL and a small second 
minimum under the shoulder at 1.26 mL were calculated suggesting two multimeric ETA states 
in Fos-12. The immunodetection however resulted in only one clear band (Fig. 18 D). 
Resolubilized ETA in 0.05  % LPPG (~50  x  CMC) eluted at 1.41  mL (~230  kDa) 
retention volume with a shoulder at around 1.50 mL (~150 kDa) when loaded directly onto the 
column after purification (Fig. 18 A, solid line). ETA could furthermore be detected in the peak 
by immunoblotting (Fig. 18 D). When stored at 4 °C for two weeks, the profile shifted to a 
major peak at around 1.55 mL (~120 kDa) (Fig. 18 A, dashed line). Fractions of protein masses 
in the LPPG/LPPG sample by differentiation (Fig.  18 A, inset, red line) verified two major 
multimeric states for ETA in the fresh sample which disintegrated over time at 4° C to only one 
prominent state of lower apparent molecular weight (Fig. 18 A, dashed line). 88   Results 
 
Fig.  18: Sample quality of P-CF expressed ETA samples exchanged from LPPG to different 
detergents upon IMAC purification. (A, C) SEC elution profiles of purified receptor samples 
solubilized in LPPG and B35 (A) and Fos-16 and Fos-12 (C). Grey boxes: The insets comprising blue and 
red curves represent initial smoothed curves (blue) subjected to second order differentiation (red) in the 
Unicorn 5.11 software. The analysed detergents are indicated (1
st  detergent/2
nd detergent). Samples 
containing 10–30 µg of protein were analysed on a Superdex 200 3.2/30 column. Protein absorbance was 
recorded at 280 nm. Solid lines: fresh sample preparations; dashed lines: samples after storage at 4 °C for 
1–2 weeks. The elution profiles of ETA are indicated by small arrows. The bold arrow indicates the void 
volume of the column in between 0.9 and 1.0  mL. The retention volume indicated by an asterisk 
corresponds to approximately 150 kDa (Fig. 62 B). (B, D) Elution fraction samples collected during SEC 
of the ETA preparations depicted above. 50  µL of 100  µL fractions were subjected to acetone 
precipitation, completely loaded on 12 % SDS-Tris-glycine gels and analysed by immunodetection with 
specific His-tag antibodies. M, marker proteins; 1-6, elutions fractions; 1.1-1.6, retention volume of the 
respective elution fractions [mL]. 
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Samples of ETA D-CF produced in 0.5  % B35 (~50  x  CMC) and exchanged to 0.1  %  B35 
(~10 x CMC) started to elute right after the determined void volume and showed a symmetric 
but considerably broader elution profile centred at approximately 1.21 mL corresponding to a 
theoretical size of ~640 kDa already hinting at potential higher average aggregation of ETA 
from D-CF mode expressed in 0.5 % B35 (Fig. 19 A, solid line). ETA could be verified as 
monomers without apparent aggregation in the SEC elution fractions by immunodetection 
against the C-terminal poly(His)10-tag (Fig. 19 B). However, second order differentiation of the 
D-CF sample peak resulted in the detection of four different oligomeric states within the profile 
suggesting inhomogenous sample quality (Fig. 19 A, inset, red curve). The sample appeared to 
be stable when stored at 4 °C for one week (Fig. 19 A, dashed line). 
As delineated above quantitative detergent exchange from P-CF synthesized protein to 
DDM was only possible from 1 % Fos-16 (see 4.2.3.). 
Fig.  19: Quality of D-CF (left) or P-CF (right) expressed ETA samples exchanged to different 
detergents upon purification. (A) SEC elution profiles of purified ETA solubilized in B35 and DDM. 
Grey boxes: The insets comprising blue and red curves represent initial smoothed curves (blue) subjected 
to second order differentiation (red) in the Unicorn 5.11 software. The analysed detergents are indicated 
(1
st detergent/2
nd detergent). Samples containing 5–20 µg of protein were analysed on a Superdex 200 
3.2/30 column. Protein absorbance was recorded at 280 nm. Solid lines: fresh sample preparations; 
dashed lines: samples after storage at 4 °C for one week. The elution peaks of ETA are indicated by small 
arrows. The bold arrow indicates the void volume of the column in between 0.9 and 1.0  mL. The 
retention volume indicated by an asterisk corresponds to approximately 150 kDa (Fig. 62 B). (B) Elution 
fractions collected during SEC of the ETA preparations in 0.1 % B35. 50 µL of 100 µL fractions were 
subjected to acetone precipitation, completely loaded on 12 % SDS-Tris-glycine gels and analysed by 
immunodetection with anti-His-tag antibodies. M, marker proteins; 1-6, elutions fractions; 1.1-1.4, 
retention volume of the respective elution fractions [mL]. 
The ETA sample Fos-16/DDM showed a relatively symmetric elution profile centred at 
1.36  mL (~295  kDa) with a shoulder oriented to higher molecular weights at 1.27  mL 
(~470 kDa) (Fig. 19 A, solid line). Due to the concomitant dilution effect its low absorbance of 
19  mAU at 280  nm rendered the immunodetection of the protein in the elution fractions 90   Results 
 
impossible. Upon differentiation two major oligomeric states were calculated supporting the 
peak shape with shoulder (Fig. 19 A, inset, red curve). 
 
4.2.5.  Molecular mass determination of ETA/detergent complexes 
MALS coupled to semi-preparative SEC on a Superdex 200 10/300 was employed in order to 
further analyse ETA sample qualities. The molecular mass of protein/detergent complexes as 
well as of the individual complex components can be analysed by this technique. SEC elution 
profiles of P-CF expressed ETA, resolubilized in 1 % LPPG and exchanged to 0.1 % B35 as 
well as to 0.005 % Fos-16 revealed the highest apparent degree of homogeneity (Fig. 18 A, C). 
These sample preparation conditions were therefore selected for analysis. P-CF produced ETA 
was changed to the respective detergents upon IMAC purification (Fig. 20 C, D) with a high 
degree of purity. From both preparations the second elution fractions were further subjected to 
MALS. Representative sections of the profiles depicted as red boxes were processed (Fig. 20 C, 
D). 
Fig. 20: Molecular mass analysis of P-CF produced ETA samples in different detergents by MALS. 
ETA precipitates were resolubilized in 1 % LPPG and exchanged to the indicated secondary detergents 
upon IMAC purification (C, D). MALS was coupled to SEC on a Superdex 200 10/300 column in 
HEPES buffered Fos-16 (A) or Tris buffered B35 (B). Relevant sections (thin arrows) used for the 
molecular mass calculation of the detergent-protein complexes are shown by red boxes in the gel filtration 
profiles (C, D). The void volume at 8 mL is represented by bold arrows. 
Using the Astra software 5.3.4.13, the molecular mass of the whole ETA/detergent complex in 
Fos-16 micelles was calculated with a retention volume of 11.4 mL at approximately 151 kDa, 
resulting from a protein mass of ~60 kDa and a mass contribution of the Fos-16 detergent of 
~91 kDa (aggregation number of ~220) which corresponds very well to the aggregation number Results   91 
 
found in literature of ~180 in pure water. ETA therefore appeared to be monomeric under those 
conditions since its calculated molecular mass including the terminal tags is 52 kDa. 
In B35 micelles, two major peak fractions had to be evaluated (Fig. 20 D). In the first 
peak at around 10.4  mL of elution volume, the mass of the ETA/detergent complex was 
determined at 163 kDa. The mass contributions of ETA were calculated at 102 kDa and of the 
B35 detergent at 61  kDa (aggregation number of ~50), respectively. The determined 
aggregation number is again comparable with the average aggregation number in water of 40 
resulting in a pure micelle of 50 kDa. The second peak, eluting at approximately 11.3 mL, had a 
molecular mass of the ETA/detergent complex of 114 kDa, resulting from a protein mass of 
70 kDa and a mass contribution of the B35 detergent of 44 kDa (aggregation number of ~36) 
(Fig.  20  B). However, the relative calculation errors were higher if compared with the 
ETA/Fos-16 sample. Considering the calculated molecular mass of the ETA monomer, it can be 
assumed that ETA in 0.1  %  B35 
shows monomeric as well as dimeric 
character. 
The relative mass 
contributions of ETA and B35 to the 
ETA/detergent complex from D-CF 
expressed receptor in 0.5 % B35 could 
not be determined. On the Superdex 
200  10/300 the whole receptor 
preparation generated a shark fin 
elution profile with a peak maximum 
at 8  mL corresponding to the 
determined void volume of the 
column (Fig. 21). Molecular weight determinations according to the calibration proteins resulted 
in a mass of 1 MDa for the D-CF expressed ETA receptor (Fig. 62 C). This observation is well 
in accordance with the broad elution profile of a comparable sample on the Superdex 200 3.2/30 
(Fig. 19) hinting to unsatisfactory homogeneity and overall receptor quality of D-CF produced 
ETA exchanged to lower concentrations of B35. 
 
4.2.6.  Characterization of ETA receptor sample dispersity by negative staining 
electron microscopy 
Negative staining EM was used as a complementary approach to support the proposed receptor 
quality in different detergents explored by SEC analysis. These experiments were kindly 
performed in cooperation with André Krüger (group of Prof. Andreas Engel, Department of 
Structural Biology at the M.E. Müller Institute for Microscopy, Biocenter, University of Basel, 
Fig.  21: Size exclusion profile of D-CF expressed 
ETA generated during MALS analysis. ETA is highly 
aggregated and almost completely elutes in the void 
volume indicated by a bold arrow. 92   Results 
 
Switzerland). 5  µL of P-CF expressed and subsequently purified ETA receptor at different 
concentrations in 0.05 % LPPG and 0.1 % B35, as well as D-CF expressed ETA exchanged to 
0.1 %  B35 upon IMAC, were analysed. Prior to the negative staining experiments the purity of 
the samples was explored by 12 % SDS-Tris-glycine PAGE. 
Fig. 22: Electron micrographs of negatively 
stained purified ETA. ETA was either P-CF 
expressed and exchanged to different detergents or  
reduced in detergent concentrations by IMAC 
purification (A, B) or D-CF expressed sample was 
reduced in detergent concentration upon IMAC 
purification (C). Scale bars represent 200  nm. 
P-CF generated protein displays homogenous and 
monodisperse character in B35 with only partial 
aggregation in LPPG (A, B). D-CF synthesized 
ETA shows different small to large aggregation 
states (C). 
 
 
The electron micrographs of negatively stained purified ETA receptor showed different degrees 
of sample homogeneity depending on which expression mode and which final detergent was 
used. The negatively stained ETA particles from P-CF expressed protein purified to lower 
concentrations of LPPG or purified to B35 displayed equal sizes and therefore exhibited 
homogenous and monodisperse character. This indicated high sample quality from these 
preparation methods (Fig.  22  A, B). Upon reduction of the final concentration of LPPG to 
0.05 % during IMAC purification only partial aggregation could be detected but the overall size 
distribution remained homogenous (Fig.  22  A). ETA expressed in 0.5  %  B35 reduced to 
0.1  %  B35 resulted in differently sized particles with an apparently high degree of varying Results   93 
 
aggregational states ranging from small to large structures assuming lower overall sample 
quality (Fig. 22 C). These findings are in accordance with the MALS and SEC results. 
 
4.2.7.  Characterization of secondary structure and its thermostability by 
far-UV CD spectroscopy 
Far-UV CD spectroscopy with ETA was conducted to analyse the formation of its secondary 
structure elements in the best conditions supported by SEC, MALS and negative staining 
(see 4.2.4. to 4.2.6.). CD spectra were thus recorded of P-CF produced ETA samples which 
were resolubilized in 1 % LPPG and exchanged to 0.1 % B35 and 0.005 % Fos-16, respectively. 
All spectra showed minima at 208 and 222  nm characteristic for α-helical proteins. The 
maximum at 190 nm which is typical for α-helical structure as well could not be detected due to 
high noise interference during the measurements under those buffer and detergent conditions 
(Fig. 23 D). 
Fig. 23: Characterization of ETA by far-UV CD spectroscopy. ETA samples were expressed either in 
P-CF mode without detergent (A, B, D) or in D-CF mode in presence of 0.5 % B35 (C). They were 
IMAC purified and exchanged to the respective detergents at final concentrations of 12 µM (A), 14 µM 
(B) and 11.5 µM (C). The samples were analysed in 10 mM sodium phosphate buffer, pH 7.5, including 
the respective detergents and measured in a cuvette of 1 mm path length at 22 °C. Melting curves were 
performed at a fixed wavelength of 222 nm from 4 °C to 90 °C with reversed temperature screens back to 
4  °C for A and B (light orange and light blue curves). Tm values of ~85  °C and ~72  °C could be 
determined for LPPG/B35 (A) and B35/B35 (C), respectively. LPPG/Fos-16 did not show any significant 
transition. (D) CD spectra of LPPG/B35 and Fos-16 respectively displayed the typical minima at 208 nm 
and 222 nm known for α-helical proteins. Insets: Coomassie stained SDS–PAGE of analysed samples. 
The determined α-helical content could be processed to final values of 61 % in 0.005 % Fos-16 
and 46  % in 0.1  % B35 according to the method of Chen (Chen et al. 1974). These 94   Results 
 
determinations correspond well to the predicted α-helical percentage of around 51 % performed 
by the secondary structure analysis servers PsiPred and APSSP2. Especially ETA in 0.1 % B35 
of 46 % is comparable to CD data of other groups which claim an α-helical content of lower 
than 50 % for refolded ETA (Orry and Wallace 2000). Apparently, different detergents induce 
various degrees of α-helical folding in the ETA receptor as already seen for V2R and Tsx 
(Klammt et al. 2005). 
The thermostability of the secondary structure elements of ETA was further analysed by 
far-UV CD spectroscopy as a change in ellipticity at 222  nm by thermal denaturation in a 
temperature range from 4 to 90 °C (Fig. 23 A, B, C). For ETA in LPPG/B35 (Fig. 23 A) two 
transitions could be detected. The minor one having its midpoint at ~40 °C might be caused by 
incomplete detergent exchange or a very small fraction of thermally instable elements as the 
ellipticity change only covers a range of 7 mdeg units. The major transition started at 60° C with 
an assumed endpoint to -5 mdeg at 90 °C. A Tm value for secondary structure melting could be 
determined at ~85 °C. Cooling down the denatured sample back to 4 °C did not show any 
refolding indicating complete denaturation at 90 °C, which was further supported by protein 
precipitates in the cuvette (Fig.  23  A). Denaturation of the B35/B35 treated ETA sample 
resulted in only one defined transition (Fig. 23 B). The melting curve showed a very clear shift 
from 60 °C towards a complete loss of secondary structure at 90 °C. Precipitation of ETA after 
heating was further observed. A Tm value of ~72°C was determined for this sample. 
Measurements with assay buffer containing only Brij detergent did not show any transition (data 
not shown). For both samples a highly stable secondary structure can be assumed in 0.1 % B35 
micelles. 
For ETA in LPPG/Fos-16 no significant changes in ellipticity and therefore no relevant 
decomposition of its secondary structure up to 90 °C could be detected. Only a minor fraction of 
structural elements might have started to melt at around 30 °C as the loss of ellipticity might 
indicate upon backward cooling (Fig. 23 C). This leads to the assumption that ETA in Fos-16 
micelles seems to be heat resistant up to 90 °C. Heating this sample to higher temperatures 
would possibly allow a better understanding of its secondary structure melting behaviour. 
 
4.2.8.  Preliminary indication of ETA folding in P-CF precipitates by solid-state 
NMR 
In the P-CF mode, no hydrophobic compounds are added into the reaction and translated 
hydrophobic MPs will consequently form a precipitate. This process apparently resembles the 
IB formation in E. coli cells. Increasing numbers of reports already indicate that even complex 
MPs can be functionally reconstituted from CF precipitates (Ishihara et al. 2005, Kamonchanok 
et al. 2008, Keller et al. 2008, Klammt et al. 2004). This might give evidence that some 
structural parts remain folded in the P-CF produced MP precipitates. Results   95 
 
Since ETA was processed from P-CF precipitates for further functional and structural analyses, 
insights in its initial quality is of high relevance and might provide further strategies of quality 
improvement already during the production process. An indication of precipitate quality might 
be given by magic angle spinning solid-state NMR spectroscopy as in particular CαCβ chemical 
shifts are dependent on secondary structure elements (Wang and Jardetzky 2002, Wishart and 
Sykes 1994). 
Solid-state experiments of ETA precipitates were performed in cooperation with 
Karsten Mörs (group of Prof. Glaubitz, Institute of Biophysical Chemistry, Goethe University, 
Frankfurt/Main) and preliminary data, results and discussion were kindly provided by him. 
 
Fig. 24.:  2D 
13C-PDSD of ETA precipi-
tates. The protein was expressed in the 
P-CF mode and selectively 
15N 
13C- alanine 
and -isoleucine-labelled. The spectrum was 
acquired on a Bruker Advance 600 
spectrometer using a 4  mm MAS-DVT 
probe at 260 K and 10 KHz spinning rate. 
Random coil structures of the respective aa 
are indicated by the red and blue horizontal 
and vertical lines. 
 
ETA was selectively 
15N 
13C- alanine 
and -isoleucine-labelled by CF 
expression in the P-CF mode. 3 mg of 
pellet was subsequently harvested, 
washed with 150  mM KCl, 5  mM 
EDTA, pH 7.3 and subjected to solid-
state measurements at 260 K and 10 KHz spinning rate (Fig. 24). The sample was then loaded in 
a 4 mm MAS rotor. The 2D 
13C-PDSD experiment was recorded with 50 ms mixing time and 
240 increments of 336 scans each. A SPINAL-64 pulse with a field strength of 125 KHz was 
applied during data acquisition. 
Taking the lines for random coil chemical shifts as starting point in the lower half of the 
spectrum (blue and red dashed lines) the observed CαCβ cross-peaks of alanine and isoleucine 
displayed secondary chemical shifts in the ω1-dimension to higher parts per million (ppm) and 
in the ω2-dimension to lower ppm values which indicates α-helical structures, whereas shifts to 
lower (ω1-dimension) and higher ppm values (ω2-dimension) account for β-sheet content. Both 
structural elements were present in the ETA precipitate with potential α-helical folding at an 
estimated amount of 30-40  % as judged by the intensity of both alanine and isoleucine 
cross-peaks (Fig. 24). From this spectrum the assumption seems likely that partial α-helical 
folding already characterizes P-CF derived ETA precipitates. 96   Results 
 
4.3.  Functional analyses of ETA by in vitro reconstitution into lipid bilayers 
Due to the lack of published data and further information on the functional characteristics of in 
vivo expressed ETA receptor in detergent-solubilized form, in vitro reconstitution into 
proteoliposomes was implemented for the CF expressed ETA. As a wealth of binding studies 
have already been performed on membrane-inserted ETA receptor from in vivo material, 
evaluation of the ligand binding activity and thus the quality of CF produced receptor compared 
with in vivo produced receptor in lipid bilayers was approached. 
In order to prove the quality of CF expressed ETA in liposomes and to finally confirm its ligand 
specific activity, different reconstitution conditions were tested and subjected to radioactive 
ligand binding experiments. 
The specificity of the 
implemented radioactive assay was 
initially verified by a commercially 
purchased membrane preparation of 
Chem1 mammalian cells containing 
recombinant human ETA receptor 
(ChemiScreen
TM GPCR Membrane 
Preparation, Millipore, Eschborn, 
Germany). Therefore, 5  µg of positive 
control membranes were incubated with increasing concentrations of 
125I-ET-1-labelled ligand. 
Unspecific binding was determined in presence of 4 µM unlabelled ET-1. High specificity of 
the assay and of the utilized ligands was shown and very low background binding could be 
detected upon pre-incubation of the membrane-incorporated ETA with unlabelled ligand 
(Fig. 25). 
 
4.3.1.  Evaluation of reconstitution parameters: Lipids, detergents and protein-
to-lipid ratio 
A variety of ETA receptor preparations were initially tested with a selection of natural lipids or 
artificial lipid mixtures in liposome buffer (20 mM KPi, 150 mM NaCl, pH 7.0 or pH 7.5) to 
achieve reconstitution (see 3.9.2.). Proteoliposomes were harvested either with or without 
sucrose gradient ultracentrifugation (Fig.  26) and subsequently subjected to ligand binding 
assays (Table 12). Alternatively, they were stored at -80 °C until further use. 
 
 
 
Fig. 25: Specificity of the radioactive binding test 
verified by commercially purchased membrane-
inserted ETA. Results   97 
 
 
Fig.  26: Sucrose gradient 
analysis of ETA proteoliposomes. 
ETA was P-CF expressed, 
resolubilized in 1  % LPPG and 
subsequently reconstituted at 
different protein-to-lipid ratios 
(1:1,000, 1:2,000) and subjected to 
sucrose gradient ultracentri-
fugation. EPL/C, E. coli polar 
lipids plus cholesterol. Arrows 
indicate EL, empty liposomes and 
PL, proteoliposomes. 
 
 
Best reconstitution with highest radioactive signal conservation of ET-1 specific binding was 
accomplished if empty liposomes were pre-destabilized with final concentrations of either 
3.5 mM DDM or 4 mM Triton X-100 for 30 min at RT prior to the addition of the respective 
protein preparations. Destabilization by Triton X-100 especially proved valuable for the ETA 
incorporation purified in the fluorinated surfactant F6TAC, while destabilization by DDM 
significantly decreased the observed specific binding (Fig. 27). Proteoliposome formation was 
performed by incubation of the liposome/protein mixture for 30 min at RT with an optional 
addition of 1 % glycerol. The removal of the detergents was conducted with sequential addition 
of Biobeads for 2 h at RT. Further incubation with Biobeads over night resulted in considerably 
higher apparent activity at 4 °C than at 16 °C or RT. 
All parameters were evaluated by determination of the relative ligand binding activity of 
radioactively labelled 
125I-ET-1 to the proteoliposomes (Table  12). Successful reconstitution 
with a high incorporation rate was assumed if an adequate radioactive signal over background 
binding was achieved. For the measurements, different proteoliposome preparations were 
incubated with 0.5  nM to 1  nM of 
125I-ET-1 and background binding was determined by 
blocking the same sample with an excess of unlabelled ET-1 prior to 
125I-ET-1 addition 
(unspecific binding, background). 
Separation of bound from unbound ligand was performed upon transfer of the samples 
to GF/B glass fibre filters and subsequent washing steps. Radioactivity retained on the filters 
was measured in a gamma counter (see 3.9.3.). 
 
 
 
 
 
 
 98   Results 
 
Table 12:  Analysed  reconstitution conditions for the ETA receptor by radioactive ET-1 ligand 
binding. The first detergent refers to the detergent used for either expression or resolubilization of ETA 
exchanged to the second detergent upon IMAC purification. %-ranges were determined by multiple 
independent experiments. 100  % correspond to the measured total radioactive signal for separate 
determinations. 
 
Expression 1
st detergent  2
nd detergent  Lipids  P/L-ratio
a Destab.  Activity
b 
mode (%)  (%)    detergent  (%) 
D-CF  B35 (0.5)  B35 (0.1)  EPL
c/C
d 1:1,200  DDM  0 
P-CF LPPG  (0.5)  -  EPL
c/C
d 1:350  DDM  40-60 
P-CF LPPG  (1)  -  EPL
c/C
d
  1:700 DDM 10 
P-CF LPPG  (1)  -  EPL
c/C
d
  1:1,000 DDM  30-40 
P-CF LPPG  (1)  -  EPL
c/C
d 1:1,000  Triton  20 
P-CF LPPG  (1)  -  EPL
c/C
d 1:2,000  DDM  n.a. 
P-CF LPPG  (1)  Fos-12  (0.1)  EPL
c/C
d 1:2,500  DDM  20 
P-CF LPPG  (1)  F6-TAC (0.35)  EPL
c/C
d  1:1,500  Triton  50 
P-CF LPPG  (1)  F6-TAC (0.35)  EPL
c/C
d   1:1,500  DDM  25 
P-CF LPPG  (1)  -  PC/PE
e/C
d
  1:1,000 DDM  50 
P-CF  LPPG (1)  LPPG (0.05)  PC/PE/PS
e/C
d 1:2,900  DDM  0 
P-CF  Fos-16 (1)  DDM (0.05)  EPL
c/C
d   1:1,500  DDM  30 
P-CF LPPG  (1)  -  aso-PC
f
   1:1,000 DDM  60 
P-CF LPPG  (1)  -  aso-PC
f
   1:1,000 Triton  30 
P-CF LPPG  (1)  F6-TAC (0.3)  aso-PC
f   1:1,500 DDM  20 
a, P/L-ratio, protein-to-lipid ratio 
b, percentage of specific binding calculated from total measured signal and background binding 
determined by an excess of cold ET-1 ligand 
c, EPL, E. coli polar lipids; 
d, C, cholesterol; 
e, PC, phosphatidylcholine; PE, phosphatidylethanolamine; 
PS, phosphatidylserine; 
f, aso-PC, asolectin-phosphatidylcholine, type IV-S 
n. a., not analysed 
bold writing, most promising conditions chosen for saturation and competition radioligand assays 
The initial screening of different reconstitution conditions by radioactive ligand binding allowed 
to determine the most promising combinations which could further be subjected to saturation as 
well as competition experiments (Fig. 27). 
D-CF expressed ETA in 0.5 % B35 and exchanged to 0.1 % B35 did not show any 
remarkable hint of specific ligand binding activity in E. coli polar lipids supplemented with 
cholesterol. Therefore, D-CF expression of ETA in B35 was classified as inefficient for the 
quantitative reconstitution of active receptor right at the beginning (Fig. 27, first bar, left). 
This decision also based on previous quality control by SEC and MALS which reported minor 
homogeneity for the B35 D-CF ETA preparation (see 4.2.4. and 4.2.5.). Results   99 
 
 
Fig. 27:  Tested 
combinations for 
the  in vitro recon-
stitution of ETA. 
Below the diagram 
the used lipids and 
the destabilizing 
detergents are listed. 
Above the bars the 
P/L-ratios are 
indicated. The 
expression mode 
and the final protein 
detergent are 
additionally given in 
brackets below the 
respective bars. 
 
ETA was P-CF expressed and resolubilized in 1 % LPPG in most of the reconstitution trials. 
1 % Fos-16 was only chosen for ETA sample preparation in DDM as IMAC purification to 
DDM was impossible using LPPG-resolubilized receptor (see 4.2.3.). High apparent binding 
was observed in E. coli polar lipids (EPL) and artificial PC/PE mixtures supplemented with 
cholesterol by using resolubilized ETA receptor directly without any further purification or 
detergent exchange step at protein-to-lipid ratios (P/L-ratios) of either 1:350 (40-60 % activity) 
or 1:1,000 (30-40 % activity) (Table 12). This leads to the assumption that dilution of initial 
protein concentration due to purification reduces the overall reconstitution efficiency, as ratios 
higher than 1:1,500 on average resulted in considerably decreased activity (Fig.  27). Very 
efficient also proved to be the application of the very mild fluorinated surfactant F6-TAC which 
is supposed not to induce disintegration of liposomes (Park et al. 2007) and can be removed by 
Biobeads thus presumably allowing easier incorporation of MPs into liposomes. However, using 
F6-TAC as protein detergent, the liposome-destabilizing detergent seemed to have a tremendous 
influence on total protein incorporation. While 50 % binding above background was detected 
with Triton X-100, DDM only generated low specific binding of ETA (Fig. 27). 
A remarkable radioactive signal/background-ratio of 60 % was achieved using extracted 
eukaryotic PCs from soybean (aso-PC type IV-S) for the formation of proteoliposomes from 
LPPG resolubilized ETA receptor (Fig. 27). 
To further determine the equilibrium dissociation constant KD in saturation binding 
experiments as well as half maximal inhibitory concentration values (IC50) in homologous 
competition experiments of in vitro reconstituted receptor with radioactively labelled and 
unlabelled ET-1, the most promising conditions were chosen (highlighted in bold writing in 
Table 12). 
In addition to the evaluation of reconstitution efficiency by activity measurements, one 
sample of ETA reconstituted into EPL enriched with 5 % cholesterol at a protein-to-lipid ratio 100   Results 
 
(P/L-ratio) of 1:700 could be further analysed by freeze-fracture EM in cooperation with 
Friederike Joos (MPI of Biophysics, Frankfurt/Main) to determine the incorporation efficiency 
of ETA (Fig. 28). 
 
Fig.  28: Freeze-fracture analysis of 
ETA proteoliposomes. Freeze-fracture 
EM was performed with P-CF produced 
ETA reconstituted into E. coli polar 
liposomes enriched with cholesterol after 
sucrose gradient purification. Liposomes 
are indicated by black arrows. White 
arrows indicate reconstituted protein 
particles. Inset: Immunodetection of ETA 
in the analysed proteoliposome sample by 
western blotting using anti-His-tag 
antibodies after separation by 
SDS-PAGE. M, marker; PL, 
proteoliposome sample (10 µL). 
 
Freeze-fracture analysis of reconstituted ETA revealed relatively low but detectable 
reconstitution efficiency with some 5–10 particles per liposome in approximately 10 % of total 
liposomes. The homogenously dispersed particles indicated non-aggregated insertion as should 
be expected for a functional reconstitution. The ETA receptor incorporation into the 
proteoliposomes was further verified by immunodetection of the C-terminal poly(His)10-tag 
(Fig.  28). This observed low incorporation along with the likewise low activity (Table  12) 
illustrates the necessity of extensive optimization. 
 
4.3.2.  Ligand binding of ETA reconstituted into lipid bilayers: Homologous 
competition 
According to the experimental set-up (see 3.9.2. and 3.9.3.) and to the evaluation of the most 
promising reconstitution conditions, ETA was reconstituted into E. coli polar lipids 
supplemented with cholesterol at P/L-ratios of 1:1,000 and 1:350 (see 4.3.1.). 
The functional reconstitution of ETA into proteoliposomes was analysed in radioassays 
by homologous competition experiments with unlabelled wild type ET-1. Three independent 
data sets were analysed to calculate the IC50 of cyclic wild type ET-1, needed to displace a 
given concentration of 
125I-ET-1 on CF produced ETA receptors. 
Unlabelled ET-1 was able to inhibit 
125I-ET-1 binding to the ETA proteoliposomes in all 
three experiments. By using non-linear regression and a one-site binding model, half- maximal 
inhibition could be observed resulting in individual IC50 values of 1.675 µM, 2.218 µM and 
2.614 µM with consistent R
2 values from 0.98 to 0.99, indicating that the used model fits well 
the data. By combination of the three data sets a final IC50 value of 2.17 µM ± 0.471 for the 
ETA receptor was determined (Fig. 29). Results   101 
 
 
Fig.   29: Radioligand compe-
tition binding of CF produced 
ETA receptor. Homologous 
competition experiments were 
performed with P-CF produced 
ETA receptors reconstituted into 
E. coli polar lipids enriched with 
cholesterol. Proteoliposome 
preparations were incubated with 
500 pM 
125I-ET-1 and with 
increasing concentrations of 
unlabelled ET-1 for 1 h at 22 °C. 
Data points out of three 
independent determinations. 
 
This calculated value is approximately 10
3 times higher as compared with competition observed 
in experiments with in vivo produced, membrane-integrated human ETA, ranging in between 
0.01-10 nM (Desmarets and Frelin 1999, Sakamoto et al. 1993). 
As the specificity of the experimental set-up itself was already verified by an 
appropriate positive control (see 4.3.) a possible source of this low IC50 was associated with the 
quality of used competitor. In order to exclude experimental errors such as miscalculation of the 
competitor stock concentration caused by degradation, aggregation or misfolding due to false 
intra- and intermolecular cysteine bridges of the unlabelled ET-1, HPLC analysis of the peptide 
on an RP-18 column was conducted in cooperation with the group of Prof. Tampé (Institute of 
Biochemistry, Goethe University, Frankfurt/Main) (Fig. 30). 
 
Fig.  30: HPLC analysis of un-
labelled ET-1 competitor. The 
relevant peak for ET-1 is 
highlighted by a red frame. The 
additional peaks could be verified 
as column impurities by an empty 
control gradient. 25 µg of peptides 
were analysed in each run. 
 
 
 
Non-aggregated, pure peptide ligand should elute at around 25 min (personal communication 
from Dr. Michael Beyermann, FMP, Berlin) which could be verified (Fig. 30). No aggregation 
and degradation were observed as the additional peaks at 29.303 min and 35.653 min were 
allocated to column impurities by an empty buffer gradient. Comparison of the peak areas under 
the curve of ET-1 with a standard peptide further supported the calculated stock concentration 
of the unlabelled ET-1. 102   Results 
 
4.3.3.  Ligand binding of ETA proteoliposomes: Saturation binding of 
125I-ET-1 
Saturation binding of 
125I-ET-1 to proteoliposomes was performed to investigate the equilibrium 
binding constant KD of CF produced and in vitro reconstituted ETA. Significant unspecific 
background binding presumably caused by the hydrophobicity of the ligand ET-1 tremendously 
decreased the detected signal-to-noise ratio which caused problems during measurements and 
evaluation. However, three different in vitro reconstitution protocols (Fig.  27) resulted in 
signal/background ratios sufficient for further analysis (see 4.3.1.). Respective samples were 
generated of P-CF produced ETA, either resolubilized in LPPG or further detergent-exchanged 
to F6-TAC upon IMAC purification. ETA was subsequently reconstituted at a P/L-ratio of either 
1:350 (LPPG) and 1:1,500 (F6-TAC) into EPL/C or at 1:1,000 (LPPG) into aso-PC liposomes 
from soybean. Increasing concentrations of radioactively labelled ET-1 from 0.05-5 nM were 
incubated with fixed amounts of ETA proteoliposomes. 
Unspecific binding was determined in presence of 2 µM unlabelled ET-1 and subtracted from 
total 
125I-ET-1 binding observed in the absence of ET-1 (Fig. 31). 
Fig.  31: Saturation binding assays of CF 
produced in vitro reconstituted ETA receptor. 
Saturation binding experiments were performed 
with P-CF produced ETA receptors reconstituted 
into either E. coli polar lipids enriched with 
cholesterol (A, B) or asolectin-PC from soybean 
type IV-S (C). Fixed proteoliposome amounts 
were incubated with increasing concentrations of 
125I-ET-1 and 2  µM unlabelled ET-1 for 1  h at 
22 °C. A one-site binding model with Hill slope 
was used for curve fitting. Data points out of 
triplicate (total) and duplicate (unspecific) 
binding. 
 
The three data sets were analysed by non-linear regression using a one-site model for specific 
binding in Graph Pad Prism 5. R
2 values of the determinations representing the reliability of the 
fit ranged from 0.89 (Fig. 31 B) to 0.99 (Fig. 31 A, C). Low values are likely due to the high 
calculated standard deviations. For all three preparations Hill slopes of ~1.6 were observed Results   103 
 
indicative of positive cooperativity (Fig. 31 A-C). Models which do not account for a positive 
cooperative effect could not be used for reliable data processing. The individually calculated KD 
of 1.23  nM (A), 1.47  nM (B) and 1.49  nM (C) were highly consistent among one another 
supposing that the ETA receptor displays similar binding characteristics in the three evaluated 
conditions. An average KD of 1.39 nM± 0.14 could finally be determined which is comparable 
to data gained with in vivo crude membranes of human tissue, still being on average one to two 
orders of magnitude higher. 
The detected positive cooperativity not present in human tissues, in which one ligand is 
supposed to bind to one receptor molecule, might hint to altered binding kinetics and 
characteristics of the CF produced ETA receptor in these artificial environments (see 5.3.1.). 
 
4.4.  Co-translational reconstitution of ETA by cell-free expression in presence of 
lipids: L-CF mode 
The L-CF expression mode in presence of supplied lipids or whole preformed liposomes offers 
a unique option for the co-translational insertion of MPs. Like shown for lipid molecules which 
are the natural environment of MPs and which are known to often act as essential modulators of 
folding, stability and function (Opekarova and Tanner 2003), model biomembranes (liposomes) 
have recently been reported to induce a variety of potential functions under variable 
environmental conditions such as chaperone-like behaviour and membrane fusions. They were 
even shown to reactivate enzyme activity under oxidative stress (Tuan et al. 2008, Umakoshi et 
al. 2009). 
MP integration into the provided bilayers may be more directed during L-CF mode 
expression if compared with the random orientation in classical post-translational in vitro 
reconstitution approaches. In addition, the synthesized target will be the MP inserted into the 
bilayers and measured activities could thus clearly be attributed. These characteristics can have 
considerable benefits for subsequent functional studies (Junge et al. 2010a). Due to these 
potential advantages preliminary investigations of the L-CF mode as an alternative for the in 
vitro reconstitution of ETA were hence started. Initial optimization trials of co-translational 
reconstitution were performed and co-precipitation of ETA and lipids after expression was 
analysed by sucrose gradient ultracentrifugation. An indication of functional insertion of L-CF 
samples was finally gained by radioactive ligand binding as described in 3.9.3.. 
 
4.4.1.  L-CF expression set-up and analysis of co-translational reconstitution of 
ETA 
Different basic considerations have been made concerning the application of the L-CF mode for 
the synthesis of ETA. To address the inherent problem of low functional insertion often 
encountered if adding pure artificial liposomes which might result from inefficient translocation 104   Results 
 
(Kalmbach et al. 2007), detergent-destabilized liposomes were supplemented only to the RM 
and incubated under standard conditions (Table  9). The addition of detergents to the 
liposomesprior to use is thought to relax the tightly packed liposome structure without complete 
disintegration thereby lowering the energy barrier for a spontaneous incorporation of MPs into 
an artificial lipid composed environment (Shimono et al. 2009). Lipids were supplied at final 
concentrations of 3.5 or 4.5 mg/mL. To destabilize the liposomes prior to their addition to the 
RM, final concentrations of 1 % CHAPS supplemented with 0.2 % CHS were mixed with the 
preformed liposomes and incubated for 30 min at RT before use. Due to its high CMC of 0.5 % 
and its small micellar size, CHAPS can be dialysed out during the reaction leaving pure 
proteoliposomes as shown for bacteriorhodopsin (Shimono et al. 2009). 
The influence of the lipid head group’s charge was also considered for the 
co-translational reconstitution of ETA as translation might be considerably inhibited by cationic 
lipids (Bui et al. 2008, Umakoshi et al. 2009). Neutral as well as anionic lipids were furthermore 
necessary for the functional tetramerization of the potassium channel KscA (Van Dalen et al. 
2002). Therefore, different lipids from natural sources have been analysed such as E. coli polar 
lipids and aso-PC which already proved effective in the in vitro reconstitution of ETA (see 
4.3.2. and 4.3.3.). Pure artificial PC (DPPC) and a mixture of natural aso-PC with neutral PE 
(DOPE) and anionic PG (POPG) were tested as well. 
ETA proteoliposomes of aso-PC were harvested at 23,000 x g for 30 min at 4 °C and 
subsequently subjected to sucrose gradient ultracentrifugation (Fig. 32). As positive control a 
GFP-fused small multidrug resistance protein SugE was L-CF expressed in parallel with ETA. 
Proteoliposomes of ETA and SugE were supplemented with sucrose to a final concentration of 
60 % and overlaid with decreasing sucrose concentrations of 40-30-20 %. Liposome-associated 
SugE could easily be verified by the fluorescence of the GFP-tag in the liposome layer (data not 
shown). P-CF produced ETA which was expressed as NC to visualize the behaviour of ETA 
precipitates in absence of lipids totally accumulated at the bottom of the tube. Empty aso-PC 
liposomes moved to the top of the gradient. Proteoliposome ETA floated to the barrier between 
40 and 60  % sucrose while non-associated ETA precipitated. The layer displayed a more 
dispersed character than the layer of SugE presumably indicating different intergration rates 
(Fig.  32  A). Immunoblotting of 5  µL of the respective sucrose gradient fractions further 
confirmed that it was possible to separate precipitated ETA from liposome-integrated or 
-associated protein. Taking the intensity of the western blot signal as a measure, 30 % of total 
ETA were estimated to be in liposome contact (Fig. 32 B). 
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Fig. 32: Co-translational reconstitution of ETA in aso-PC liposomes. ETA was L-CF expressed in 
presence of 4.5  mg/mL aso-PC lipids, destabilized by 1  %  CHAPS/0.2  %  CHS. (A) Sucrose gradient 
ultracentrifugation of L-CF samples. SugE and ETA showed proteoliposome layers between 60 and 40 % 
sucrose. P-CF expressed ETA totally precipitated. Empty liposomes floated to the top of the tube. Insets: 
Maginification of respective sample tubes. (B) Verifcation of ETA in pellet and layer fractions by 
immunoblotting against the C-terminal poly(His)10-tag. 5 µL were loaded on 12 % SDS-Tris-glycine gels 
and subsequently subjected to western blotting. By sucrose gradient ultracentrifugation it was possible to 
separate liposome-associated from free ETA. aso-PC, phosphatidylcholine from soybean, type IV-S; EL, 
empty liposomes; M, marker proteins; P, precipitate; PL, proteoliposomes. 
 
4.4.2.  Evaluation of co-translational reconstitution by ligand binding of 
125I-ET-1 
A variety of L-CF expressed ETA samples were investigated by ligand binding in order to get 
information on the functional reconstitution efficiency. Since it has been experienced that the 
activity of ETA in proteoliposomes can significantly be decreased by sucrose gradient 
ultracentrifugation, samples for functional assays were only treated with centrifugation at 
23,000 x g for 30 min at 4 °C. Precipitates were resuspended in either Tris buffer as used for 
purification (20 mM Tris, 150 mM NaCl, pH 7.0) or S30 C buffer (pH 8.2) used in the CF 
reaction (see 3.3.2.) to analyse the binding behaviour of ETA in dependency of pH and 
liposome composition (Fig. 33). Empty liposomes used in L-CF reactions served as NCs to 
determine the unspecific binding of the ligand to the liposomes themselves. ETA in vitro 
reconstituted into aso-PC-DDM (Fig. 27) characterized by a high signal/background-ratio was 
used as positive control. This sample displayed significantly lower specific binding after two 
weeks which might account for the fact that long-time storage at -80  °C might reduce the 
functionality of the ETA proteoliposomes (Fig. 33, first bar). 106   Results 
 
Fig. 33:  Influence  of 
lipid combinations and 
pH on the binding 
activity of L-CF 
expressed ETA. The 
abscissa describes the 
used lipids for the L-CF 
expression of ETA. A 
combination of neutral 
(PC and PE) with 
anionic (PG) at pH 7.0 
generated the highest 
specific binding. 
 
 
Highest specific binding was achieved for L-CF expressed ETA at pH 7.0 with a mixture of 
aso-PC, PG and PE which could be calculated to 30 % over background followed by E. coli 
polar lipids (26 %), DPPC (19 %) and aso-PC (17 %). 
However, compared to the NCs of the empty liposomes the background binding showed 
significant values in all tested samples. As no sucrose gradient was performed in order to retain 
full binding activity, this high unspecific binding might be due to the remaining ETA 
precipitate. Sucrose gradient ultracentrifugation (see 4.3.1.) could serve as a means to separate 
precipitate from liposome-inserted receptors. ET-1 potentially displayed unspecific binding to 
non-integrated ETA. The resuspension of the proteoliposomes in S30 C buffer (pH 8.2) even 
aggravated the problem of high background delineated before. A high pH should therefore be 
avoided for the determination of ligand binding from L-CF produced ETA. Competition or 
saturation binding studies were excluded at this point since the observed signal/background 
ratio was too low to determine reliable activity data. 
 
4.5.  Functional analyses of the detergent-solubilized ETA 
4.5.1.  Ligand affinity chromatography of detergent-solubilized ETA receptor 
Affinity chromatography of solubilized GPCRs with immobilized ligands is a key tool to 
quantify and to isolate the homogenous, ligand binding competent fraction of a sample. 
Amounts of 0.33-0.67 nmol of ETA samples were incubated with monomeric avidin agarose 
beads pre-coated with b-ET-1 ligand. The receptor was produced in the P-CF or in the D-CF 
mode, purified, subsequently incubated with the prepared b-ET-1 affinity material and 
competitively eluted with biotin after incubation for 2 h at 22 °C with gentle shaking at 180 rpm 
(Fig. 34). Results   107 
 
Fig. 34: Flowchart of the ligand affinity chromatography with biotinylated ligand and solubilized 
receptor. Firstly, monomeric avidin agarose beads were saturated with biotinylated ligand. Unbound 
ligand was subsequently washed out and the matrix was incubated with selected protein preparations. 
Unbound protein is removed by washing steps followed by the competitive elution of ligand-bound 
protein with an excess of biotin. 
An array of NCs were performed to ensure the specificity of the binding assay prior to 
evaluation of different ETA receptor preparations. Those control experiments were focused on 
binding of the receptor to the empty matrix material, binding of unrelated MPs to b-ET-1 or 
interaction of ETA with unrelated biotinylated ligands (Fig. 35 A). ETA resolubilized in 1 % 
LPPG and IMAC purified in 0.1  % B35 did not bind to the empty, non-ligand saturated, 
monomeric avidin agarose beads since all protein could only be detected in the flow-through 
and the wash fractions. Therefore, unspecific cross-interaction of the matrix with the receptor 
could be excluded (Fig. 35 A, 1
st line). The seven TMS containing light-driven proton pump 
proteorhodopsin (PR), kindly provided by Sina Reckel (AK Dötsch, Institute of Biophysical 
Chemistry, Goethe University, Frankfurt/Main), was D-CF produced in presence of its cofactor 
retinal, and exchanged to 0.04 % DDM. Functional folding of the obtained proteorhodopsin 
sample was indicated by its purple colour (data not shown). In two independent experiments the 
PR sample did not bind to the immobilized b-ET-1 peptide and the protein quantitatively eluted 
in the flow-through and wash fractions (Fig. 35 A, 2
nd line). Accordingly, ETA P-CF expressed, 
LPPG resolubilized and IMAC purified to 0.1%  B35 did not bind to the immobilized 
biotinylated peptide vasopressin (b-vasopressin) specific for the vasopressin receptor (Fig. 35 A, 
3
rd line). P-CF expressed ETB, generating low quality receptor (Klammt et al. 2007b, 2007c), 
was resolubilized in 1  % LPPG and exchanged to 0.1  % B78 upon IMAC purification. An 
estimate of only 5–10 % of the ETB sample bound to the column. The major unbound fraction 
was observed in the flow-through and in the washes (Fig. 35 A, 4
th line). 
Depending on the selected conditions for the ETA preparation, different degrees of 
apparent binding competence could be observed upon detergent evaluation (Fig. 35 B). High 
apparent ETA binding competences of approximately 50 % were found after D-CF expression 
in presence of 0.5 % B35 followed by exchange to 0.04 % DDM/0.0005 % CHS (Fig. 35 B, 1
st 
line) and after P-CF expression and resolubilization in 1 % LPPG followed by an exchange to 
0.1 % B35 (Fig. 35 B, 2
nd line). In two and six independent experiments, respectively, about half 
of the receptor was removed in the flow-through fraction and during the washing steps, while 
the other half was competitively eluted with biotin. No elution at all was detected after D-CF 108   Results 
 
expression in 0.5 % B35 and reduced to 0.1 % B35 upon IMAC purification (Fig. 35 B, 3
rd 
line). This experiment was repeated twice with different receptor preparations. The sample 
presumably remained on the matrix due to its apparent high aggregation state (Fig. 19 A, 21, 
22). P-CF generated ETA, resolubilized in 1  % LPPG and exchanged to 0.005  % Fos-16 
showed a binding competence of approximately 20-30 % (Fig. 35 B, 5
th line). 
Fig. 35: Ligand binding immunodetection of CF produced ETA (51 kDa) and ETB (49 kDa). ETA 
was either expressed in the P-CF or in the D-CF mode and detergent exchanged upon IMAC purification. 
PR and ETB were both D-CF expressed and exchanged to the indicated 2
nd detergent. Samples of 32.5 
and 55 µL were separated by 12 % SDS–PAGE followed by western blotting and immunodetection with 
anti-His-tag antibodies. (A) lines 1–4: Controls for the specificity of the experimental conditions. Line 1: 
P-CF expressed ETA in 1 % LPPG/0.1 % B35 incubated with empty matrix material. Line 2: D-CF 
expressed proteorhodopsin (27 kDa) in 0.04 % DDM. Line 3: P-CF expressed ETA in 1 % LPPG/0.1 % 
B35 incubated with immobilized b-vasopressin. Line 4: P-CF expressed ETB in 1 % LPPG/0.1 % B78. 
(B) lines 1-7: ETA ligand binding efficiency after different CF expression and solubilization conditions 
(1
st detergent/2
nd detergent). Line 1: D-CF expressed ETA in 0.5 % B35/0.04 % DDM/0.0005 % CHS. 
Line 2: P-CF expressed ETA in 1 % LPPG/0.1 % B35. Line 3: D-CF expressed ETA in 0.5 % B35/0.1 % 
B35. Line 4: P-CF expressed ETA resolubilized in 1 % LPPG/0.05 % LPPG. Line 5: P-CF expressed 
ETA in 1 % LPPG/0.005 % Fos-16. Line 6-7: ETA P-CF expressed and resolubilized in 1 % LPPG/ 
2 mM fluorinated surfactants, F6-TAC and F8-TAC, respectively. M, marker; FT, flow-through; CHS, 
cholesteryl hemisuccinate; PR, proteorhodopsin. 
The binding competence decreased if the 1 % LPPG of the P-CF produced ETA receptor was 
reduced to 0.05 % LPPG upon purification. The vast majority of P-CF produced ETA in 0.05 % 
LPPG did not bind to the affinity material and was washed out before elution which was 
verified by two repetitions. Only an estimate of 1-2 % of the sample could be recovered in the 
elution fractions (Fig. 35 B, 4
th line). The very mild fluorinated surfactants F6-TAC and F8-TAC 
did only allow a low binding competence of P-CF expressed ETA and resolubilized in 1 % 
LPPG. In two independent experiments a maximum of estimated 5 % of ETA was found to bind 
specifically to the ligand (Fig. 35 B, 6
th and 7
th line). Results   109 
 
Fig. 36: Ligand binding competence of the ETA receptor with different expression protocols. Upon 
calculation of expression and purification efficiencies in mg/mL the relative amount of active receptor in 
the three best conditions was determined. 
Considering initial optimal yields of purified ETA of approximately 1  mg/mL after P-CF 
expression and 0.5 mg/mL after D-CF expression, corresponding amounts of some 500 and 
250  µg ligand-binding competent ETA could finally be isolated out of 1  mL RM with the 
described optimal conditions (Fig. 36). 
The difference in SDS-PAGE stability of the CF expressed ETA or ETB receptor/ET-1 
complex which has been discussed in literature (Takasuka et al. 1992, 1994) was further 
analysed after ligand affinity chromatography. Therefore, selected elution fractions of both 
receptors were subjected to SDS-PAGE followed by 
immunoblotting against the biotin label of the ligand 
ET-1. In contrast to the CF expressed human ETB 
receptor, which formed a stable complex during 
SDS-PAGE with the b-ET-1 peptide as observed in 
present work, the ETA/b-ET-1 complex eluting from the 
monomeric avidin matrix could not be verified (Fig. 37). 
This observation is in accordance with published data 
suggesting a complex of higher stability during gel 
separation for ETB/ET-1 than for ETA/ET-1 and even the 
two bands appearing in the D-CF expressed ETB sample 
occurred by separation of native ETB receptor (Takasuka 
et al. 1992, 1994). These findings might point at a 
comparable behaviour of detergent-solubilized ET 
receptors obtained from either in vivo m a t e r i a l  o r  C F  
expression. 
 
Fig.  37: Analysis of ligand-
bound receptor complexes by 
immunodetection of the biotin-
label.  Elution fractions of 
momomeric avidin matrix affinity 
chromatography were subjected to 
12 %  SDS-Tris-glycine-PAGE 
and subsequently immunoblotted. 
M, marker proteins. 110   Results 
 
4.5.2.  Iodination of the linear peptide 4-Ala-ET-1 with 
125I: Binding 
experiments with detergent-solubilized ETA by centrifugation-assisted 
gel filtration 
A further aim was to determine the equilibrium binding constant of detergent-solubilized 
ETA/ET-1 complexes in order to compare CF synthesized protein to published functional data 
of ETA from in vivo crude membrane preparations. Centrifugation-assisted gel filtration with 
radioactive ligands appeared to be a promising approach for the ETA receptor as it was already 
successfully used GPCRs (Grisshammer et al. 
1999). 
Introduced into iodination and 
supervised by PD Dr. Rupert Abele and 
Christian Schölz (group of Prof. Tampé, 
Institute of Biochemistry, Goethe University, 
Frankfurt/Main) the linear mutant of ET-1 in 
which all cysteines are replaced by alanines 
(4-Ala-ET-1) was iodinated with 
125I at the 
single tyrosine 13 of the ligand. In the 
iodination reaction, 4-Ala-ET-1 was chosen 
instead of wild type cyclic ET-1 as disulfide bridges were likely to be modified during the 
procedure which could introduce heterogeneity (see 3.9.1.). 
125I-4-Ala-ET-1 was separated from free 
125I by gel filtration on Sephadex G-10 spin columns 
and fractions with highest radioactive counts were pooled (Fig. 38). The initially applied ligand 
achieved a radioactive concentration of approximately 25-60  µCi/mL. The radioactively 
labelled 4-Ala-ET-1 was used for saturation binding experiments of detergent-solubilized ETA 
by centrifugation-assisted gel filtration. 
50 nM of D-CF expressed ETA receptor purified in 0.04 % DDM supplemented with 
CHS were incubated with increasing concentrations of 
125I-4-Ala-ET-1 as delineated in detail in 
experimental procedures (see 3.9.4.). 
The parameters for centrifugation such as speed and time were optimized with fluorescently 
labelled 4-Ala-ET-1 (data not shown). Proteomicelles in complex with bound ligand were 
separated from free ligand. While the free ligand should be retained on the matrix the 
receptor/ligand complex was expected in the flow-through of the centrifugation. 
Using non-linear regression and a one-site binding model, total binding as well as unspecific 
binding could be determined in only one representative experiment resulting in a KD of 614 nM 
which is in the range of literature values (Fig. 39). All the other attempts remained unsuccessful 
due to the tremendous background noise. 
 
Fig. 38: Iodination of 4-Ala-ET-1. 2 µL of each 
collected elution fraction was measured in a 
gamma counter. Fractions with highest detected 
counts were pooled (green). Results   111 
 
 
Fig. 39:  Evaluation  of 
125I-4-Ala-
ET-1 binding to ETA/DDM/CHS 
proteomicelles. 50  nM of protein 
were incubated with increasing 
concentrations (0.03-1.5  µM) of 
labelled ligand. Unspecific binding 
was determined with 100-fold excess 
of unlabelled ligand. Each data point 
was determined in duplicates. 
 
 
 
The observed specific binding over background was extremely low with high standard 
deviations resulting in R
2 values of 0.95 limiting the reliability of the acquisitioned data. This 
might on the one hand be attributed to a tremendously reduced amount of binding active 
receptor in DDM/CHS which is unlikely as around 50 % of ETA could be purified by ligand 
affinity chromatography (see 4.5.1.). More likely, experimental errors are causative for such a 
loss of signal intensity as this assay highly depends on the interplay of a variety of parameters 
like centrifugation efficiency and possible cross-interaction of proteomicelles or the 
hydrophobic ligand with the used matrix material which leads to ineffective harvesting of 
binding active receptor. Therefore, centrifugation-assisted  gel filtration was not continued as it 
does not constitute a fast evaluation method of binding activity for the ETA receptor which is 
needed for quality control. 
 
4.5.3.  Ligand binding of detergent-solubilized ETA monitored by fluorescence 
anisotropy 
Binding of fluorophore-containing ligands to their receptors should restrict the mobility of the 
ligand and consequently of the fluorophore label resulting in increasing anisotropy signals upon 
titration of receptor molecules. 
The binding affinity of the linear fluorescein-labelled ligand f-4-Ala-ET-1 was 
determined by using non-linear regression and a one-site binding model for total binding 
without subtraction of the background (Fig. 40). A constant amount of 30 nM f-4-Ala-ET-1 was 
incubated at RT for 1.5  h with increasing concentrations of P-CF expressed ETA receptor 
purified in 0.1 % B35. Anisotropy control measurements were performed in presence of ETA 
receptor in 0.1 % B35 presaturated with b-ET-1 upon binding to b-ET-1 loaded monomeric 
avidin agarose. The ETA in the eluted ETA/b-ET-1 complex was controlled by Western blot 112   Results 
 
analysis against the C-terminal poly(His)10-tag of ETA (Fig.  40). The observed anisotropy 
signal was normalized by subtraction of the anisotropy value of 0.038 obtained from free 
f-4-Ala-ET-1 in assay buffer. 
The increase of anisotropy upon titration of ETA to the ligand enabled the calculation of 
an equilibrium dissociation constant KD of 2.25 µM. Considering that approximately 50 % of 
ETA is in a ligand binding conformation, the corresponding binding constant could be corrected 
to a value of about 1.2 µM. Only a minor increase in anisotropy was detected with the b-ET-1 
presaturated ETA sample. 
 
 
 
 
 
 
 
 
Fig.  40: Ligand binding competence of ETA/B35 proteomicelles analysed by fluorescence 
anisotropy. 30 nM of fluorescein-labelled 4-Ala-ET-1 was incubated with increasing concentrations of 
free (0-5.5 µM) (circles) or ligand-bound ETA receptor eluted from monomeric avidin agarose (0-1 µM) 
(triangles) for 1.5 h at RT in a final volume of 500 µL. Each data point represents a mean value of 7 
repetitions. Fluorescence signals were normalized by subtracting the anisotropy value 0.038 from 30 nM 
of free fluorescein-labelled 4-Ala-ET-1 in assay buffer. The inset shows the detection of ETA in the 
elution fraction of the ligand binding column by western blotting. 
 
4.6.  Structural investigations of ETAcHx on an automated platform in 96-well 
formats 
Crystallization trials of the CF expressed ETA receptor was performed in cooperation with Dr. 
Yvonne Thielmann (group of Prof. Michel, Department of Molecular Membrane Biology, Max-
Planck Institute of Biophysics, Frankfurt/Main). The receptor was expressed and quality 
optimized by the author. The automated platform as well as crystallization expertise was 
provided by Dr. Yvonne Thielmann. 
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4.6.1.  Concentration and homogeneity of CF expressed ETA 
Basic crystallization parameters of ETA were analysed in 0.1 % B35 as highest yields were 
obtained after IMAC purification in this detergent. Therefore, starting from 6  mL P-CF 
reactions ETA was purified by Co
2+-NTA. An additional purification step by SEC or ligand 
affinity chromatography was first excluded in order to get sufficient amounts of protein even if 
homogeneity might be reduced if compared to SEC-purified protein. The protein preparation 
was subsequently concentrated to a volume of 100-150 µL with a protein content of 5-8 mg/mL 
by using ultrafiltration with a MWCO of 10 kDa. Successful concentration and homogeneity of 
the protein was analysed by SDS-PAGE and SEC (Fig. 41). 
Fig. 41: Evaluation of ETA homogeneity after ultrafiltration. (A) Concentration by ultrafiltration was 
monitored by SDS-PAGE. Sample volumes of 1 µL of initial protein preparation and of samples collected 
during the concentration process were loaded on 12 % SDS-Tris-glycine gels and subsequently visualised 
by Coomassie staining. Arrows point at monomeric ETA and potential dimers. (B, C) The homogeneity 
of ETA before and after concentration was assessed by SEC on an analytical Superdex 200 3.2/30 
column. Approximately 10-30 µg were analysed. (B) Concentration without addition of the native ligand 
ET-1. (C) Concentration in presence of ET-1. Insets: Second order differentiation of concentrated (left) 
and non-concentrated (right) protein. M, marker proteins. 
Only a marginal loss of less than 5 % ETA could be observed upon average concentration. 
Furthermore, concentration of ETA to 3 mg/mL did not seem to result in excessive generation 
of higher- and lower-order aggregates as judged by SDS-PAGE (Fig.  41  A). SEC of ETA 
concentrated to 8 mg/mL in the presence of its ligand ET-1 further indicated only a minimal 
increase in lower-order aggregates by determination of second order differentiation if compared 
to the non-concentrated protein (Fig. 41 C). Those preliminary data suggest that addition of 
1 % glycerol and equal moles of ligand prior to the concentration process seemed to stabilize the 
receptor, because concentration of ETA to over 3  mg/mL without ligand generated micro-114   Results 
 
aggregation which could be observed by a SEC profile shift of the major fraction of protein to 
higher molecular weights (Fig. 41 B). 
 
4.6.2.  Set-up of basic crystallization trials for the evaluation of critical 
parameters for structural investigations of ETA 
Initial crystallization screens were accomplished with 150  µL each of ETA samples either 
concentrated to 5.2 mg/mL without ligand or concentrated to 8.0 mg/mL in presence of ET-1. 
Using the robotic platform “CrystalMation” (Rigaku, Berlin, Germany) volumes of 100  nL 
protein solution were provided in 96-well plates and incubated with 100 nL drops of different 
buffer compositions (see 3.10.). 18 different commercial or custom screens in 96-well formats 
for soluble proteins and MPs as well as classical vapour diffusion and cubic phase trials were 
performed with both receptor preparations. None of them yielded crystals yet after 83 days 
(ETA without ligand) and 41 days (ETA with ligand). For further reference and listing of the 
applied screens see 7.5.. 
At the given conditions of protein concentrations between 5 and 8 mg/mL, reduced to 
50 % due to the addition of the respective buffer volumes, ETA seemed to stay soluble hardly 
ever reaching the point of supersaturation or precipitation. Only in about 20-30  %  of the 
investigated conditions precipitates could be observed, suggesting that the protein concentration 
had to be increased in order to force ETA to precipitate by addition of various precipitants. 
Custom pH screens which were designed according to Koszelak-Rosenblum and collegues 
(2009) further did not reveal any pH preference of ETA in between pH  4.0 and pH  9.5 as 
precipitates occurred randomly, either at 4 °C or 18 °C. Similar observations were made for the 
cubic phase trials at 22 °C. 
However, besides salt crystals which were obtained with the MemGold
TM Screen 
(Molecular Dimensions Ltd., Suffolk, UK) (Fig.  42  B) changes in the precipitation state 
followed by the occurrence of structures of higher density could be detected in some of the 
drops over time, possibly pointing towards microcrystallization (Fig. 42 C, D, E). Those results 
were obtained with MemSys
TM, MemGold
TM and a combination of MemStart
TM and MemPlus
TM 
(Molecular Dimensions Ltd., Suffolk, UK). Furthermore, some of the cubic phase wells showed 
changes in their surface which might also point to preferable crystal growth conditions over 
time (Fig. 42 A, time course). Results   115 
 
Fig. 42: ETA precipitation in different crystallization conditions. ETA was expressed in the P-CF 
mode, resolubilized in 1 % LPPG and subsequently exchanged to 0.1 % B35 in 20 mM Tris, 150 mM 
NaCl, pH 7.5 upon IMAC purification. (A) ETA was mixed with cubic phase material and incubated at 
22 °C for 49 days. A clear change in the cubic phase surface could be detected. (B) Small needle shaped 
crystals arranged as a starlike complex indicating grown salt crystals. (C) Densified protein precipitate 
monitored after 83 days. (C, D,E) Possible formation of microcrystals after 83 days. 
 
4.7.  Analysis of the oligomerization potential of the CF expressed ET receptors 
As delineated in the introduction, the traditional view of a GPCR monomer acting as single unit 
on downstream effectors has changed. Homo- as well as hetero-oligomerization is common 
amongst GPCRs and there is evidence of clear physiological functions for oligomerization 
(see 1.3.4. and 1.5.5.). A variety of experimental data mostly determined by FRET and co-
immunoprecipitation on ET receptors in membranes of cultured cells also propose homo- and 
heterodimerization of both ET subtypes (see 1.5.5.). 
 
Fig.  43: Verification of ETA oligomers by 
ESI-mass spectrometry. 1.25  µg of purified ETA 
were loaded on precast 11  %  Bis-Tris gels, bands 
excised, digested and subjected to mass spectrometry. 
M, SeeBlue Plus-2 marker proteins. 
In this study, ETA seemed to form dimers and 
lower order oligomers in certain buffer 
conditions as observed in gel filtration profiles of 
LPPG and B35 or MALS analysis of ETA in 
B35 micelles (Fig. 20). Likewise, protein bands with molecular weights corresponding to lower 
order oligomers or dimers of full-length ETA which remain stable even during SDS-PAGE 
could be verified in cooperation with Dr. Julian Langer (group of Prof. Michel, Department of 116   Results 
 
Molecular Membrane Biology, Max-Planck Institute of Biophysics, Frankfurt/Main) by peptide 
mass fingerprinting (see 3.7.4.) in B35 with 12-15 % sequence coverage (Fig. 43). 
To characterize oligomerization of CF expressed ETB, Dr. Christian Klammt prepared a variety 
of truncations of the receptor which he used to analyse in vitro homo-oligomerization by 
different pull-down assays (see 1.6.) (Klammt et al. 2007c). Following these experiments on the 
ETB receptor three different ETA truncations were generated in order to analyse both homo- 
and hetero-oligomerization of ETA and ETA with ETB by pull-down assays taking advantage 
of poly(His)10-tag as well as strep-tag for cross-purification (Fig. 44 A). 
 
4.7.1.  Expression, purification and gel filtration analysis of CF expressed ETA 
truncations 
Protein synthesis resulted in the ETA variants with C-terminal poly(His)10- or strepII-tags. The 
truncations ETA197cHx (221 aa, 24.7 kDa) and ETA197strep (219 aa, 24.4 kDa) comprise the 
first three TMS of the full-length ETA receptor. ETA198strep (158 aa, 29.9 kDa) consists of the 
last four TMS. 
 
Fig. 44: Designed ETA 
truncations for the 
analysis of ETA/ETB 
oligomerization. (A) 
Predicted secondary 
structure of  truncated 
ETA constructs 
compared with the full-
length ETA receptor. 
The black part of the 
full-length protein, 
depicted in all 
truncations, was 
removed from the 
sequence leaving the 
green part. (B) P-CF 
expression screen of 
ETA truncations. 3  µL 
of RM were loaded, 
separated on 16 % SDS-
Tris-glycine gels and 
subsequently Coomassie 
stained. (C) 
Resolubilization of 
P-CF expressed 
precipitates in 
1 % LPPG.  3 µL  were 
loaded on 12  % SDS-
Tris-glycine gels and 
Coomassie stained. 
Arrows point at the 
expressed or 
resolubilized 
truncations. M, marker 
proteins; -RM, control 
RM before expression. Results   117 
 
Expression of ETA107cHx (133 aa, 14.5 kDa) and ETA107strep (131 aa, 14.5 kDa) resulted in 
constructs comprising the N-terminal region and first TMS of the full-length receptor 
(Fig. 44 A). 
All constructs were successfully expressed in the P-CF mode with final yields in the mg 
range per mL RM (Fig. 44 B). Exemplified with ETA197cHx as well as with ETA198strep, 
which were used in subsequent oligomerization studies, a resolubilization efficiency of 100 % 
was reached for all the truncated constructs thus displaying a solubilization behaviour similar to 
the full-length ETA receptor (Fig. 44 C). Sample preparation for further analysis was therefore 
performed according to the protocols established for ETAcHx (see 4.2.). 
Resolubilization in 1 % LPPG and subsequent affinity purification for both ETA197cHx 
and ETA198strep resulted in pure protein with final yields of 530 µg/mL and 250µg/mL RM, 
respectively, which was sufficient for interaction studies and gel filtration analysis on an 
analytical Superdex 200 3.2/30 column (Fig.  45  A, B, SDS-gel inset). The sample of 
ETA197cHx in 0.1 % B35 (~10 x CMC) displayed a very broad peak pattern after four days 
storage at 4 °C covering almost one third of the whole retention volume (Fig. 45 A). Likewise, 
it started to elute right following the void volume. The elution profile centred at approximately 
1.44 mL corresponding to ~200 kDa. A prominent shoulder at 1.25 mL (~520 kDa) indicated 
high molecular weight which might account for the formation of higher order oligomers of a 
considerable part of the protein. This assumption was supported by second order differentiation 
of the elution curve calculated by the Unicorn 5.11 software which detected one major 
minimum below the peak at 1.44 mL and a couple of smaller minima below the shoulder at 
1.25 mL (Fig. 45 A, inset on the right hand side). 
Fig. 45: Homogeneity of P-CF expressed ETA truncations exchanged to B35 upon purification. SEC 
elution profiles of purified ETA197cHx (A) and ETA198strep (B) in 0.1 % B35. The analysed detergents 
are indicated (1
st detergent/2
nd detergent). Samples containing 5-20 µg of protein were analysed on a 
Superdex 200 3.2/30 column. Protein absorbance was recorded at 280 nm. The elution peaks of ETA are 
indicated by thin arrows. The bold arrow indicates the void volume of the column in between 0.9 and 
1.0  mL. The retention volume indicated by an asterisk corresponds to approximately 150  kDa. Grey 
framed insets: 10 µL of elution fractions were loaded on 16 % SDS-Tris-glycine gels and subsequently 
Coomassie stained. The right hand side insets comprising blue and red curves represent initially smoothed 
curves (blue) subjected to second order differentiation (red) in the Unicorn 5.11 software. M, marker 
proteins; E, elution fraction. 118   Results 
 
Due to the apparently reduced stability of the ETA197 fragment over time it was only used in 
fresh preparations for subsequent experiments. 
ETA198strep in 0.1 % B35 showed a homogenous elution profile even after four days storage at 
4 °C which centred at approximately 1.53 mL (~120 kDa) (Fig. 45 B). Supposing a micellar 
contribution of B35 of 50-60 kDa ETA198strep could be present as lower order oligomer and 
potentially display dimeric character. Second order differentiation resulted in only one major 
protein fraction indicating a high degree of sample homogeneity (Fig. 45 B, inset on the right 
hand side). 
 
4.7.2.  Pull-down experiments with full-length ET receptors and truncations 
Two affinity pull-down approaches were used to investigate the oligomerization potential of the 
ETA and ETB receptors. On the one hand, the full-length strep-tagged ETA receptor was co-
expressed in the D-CF mode with 0.5 % B35 either together with full-length his-tagged ETA 
and ETB or with available his-tagged ETA and ETB truncations. Those preparations were 
incubated with the equilibrated matrix for 2 h at RT followed by o. n. incubation at 4 °C prior to 
purification by strep-affinity chromatography (see 3.5.4.). 
On the other hand, full-length receptors with poly(His)10- and strepII-tag were expressed 
separately either in P-CF mode and subsequently resolubilized or produced in D-CF mode using 
0.5 % B35. The single purified receptors were mixed and further treated as described above for 
the co-expression. 
In the co-expression assay, the synthesis of the receptors and the corresponding 
truncations as well as the subsequent pull-down analysis was always visualised by 
immunoblotting against the C-terminal poly(His)10-tag (Fig 46 A). 
After loading of the co-expressed RMs on the strep-matrix, the full-length receptors ETAcHx 
and ETB-signcHx which lacks its signal sequence (Fig.  46  A) as well as all analysed 
poly(His)10-tagged ETB truncations like ETB93a (15.4 kDa, TMS1-TMS3), ETB131 (14.4 kDa, 
first TMS with N-terminal part), ETB308 (18.8 kDa, TMS6-TMS7 with C-terminus) and the 
ETA fragment ETA197 (24.7 kDa, TMS1-TMS3 with complete N-terminal domain) (Fig. 46 B) 
were co-eluted with ETAstrep. 
No specificity could be detected in the co-expression approaches with respect to the TM 
domains potentially involved in heterodimerization. All TMSs seem important for the 
interaction of ETA and ETB since all fragments either with or without N- or C-terminal 
domains bound to the ETAstrep receptor. Therefore, no special interaction interface could be 
confined for ETA/ETB heterodimerization at this point like it was possible for the 
homodimerization of ETB (Klammt et al. 2007c). Results   119 
 
Fig.  46: Homo- and heterodimerization analysis of full-length receptors and of ETA and ETB 
fragments with ETAstrep. Co-expressed receptors and fragments containing a poly(His)10-tag have been 
analysed by pull-down experiments on strep-tactin matrix. Co-expression of ETAstrep, ETAcHx and 
ETB-signcHx (A) as well as of ETAstrep and various truncations (B) was performed in presence of 
0.5 % B35 and purification of the soluble part was achieved by strep-affinity chromatography. 5 µL of 
acetone precipitated material was subsequently loaded on 12 % (A) and 16 % (B) SDS-Tris-glycine gels 
and immunodetected by antibodies against the C-terminal His-tag. Black arrows indicate the relevant co-
eluted proteins. Co-detection of strep-tagged ETA by a specific anti-strep antibody is represented by red 
arrows. M, marker proteins; FT, flow-through; w, wash fractions; E, elution fractions. 
A variety of NCs were accomplished in order to investigate the specificity of the co-expression 
experiments. The cross-reactivity of the his-tagged full-length receptors (ETAcHx and ETB-
signcHx) and a selection of truncations (ETA197cHx, ETB93acHx, ETB308cHx) with the 
applied strep-matrix was analysed by loading separate protein preparations of the respective 
receptors on equilibrated matrix material (Fig.  47  A, B). None of the analysed fragments 
showed any affinity to the strep-matrix alone excluding the possibility of false positives. Every 
poly(His)10-tagged protein sample was already removed in the flow-through and the wash 
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Fig.  47: Analysis of cross-reactivity of poly(His)10-tagged ET receptor fragments with the 
strep-affinity matrix. Neither full-length receptors (A) nor ETB and ETA truncations (B) bound to the 
matrix if lacking the necessary strepII-tag. His-tagged ETA, ETB and their various truncations have been 
expressed in the D-CF mode in presence of 0.5 % B35. The soluble fractions of the RM have been 
purified by strep-tag affinity chromatography as performed with the co-expressed samples. All fractions 
were precipitated with acetone. 5 µL of resuspended protein samples were loaded on 12 % (A) and 16 % 
(B) SDS-Tris-glycine gels, respectively and subsequently immunodetected by western blotting against the 
C-terminal poly(His)10-tag. Receptors and fragment monomers are indicated by arrows. M, marker 
proteins; FT, flow-through; w, wash fractions; E, elution fractions. 
In a second NC, different unrelated poly(His)10-tagged MPs were co-expressed with ETAstrep 
to analyse if the detected protein-protein interactions were restricted to the ET receptors hinting 
at a specific interaction mechanism or if those co-elutions relied on a more general mechanism 
which would also be observable upon co-expression with other MPs. The poly(His)10-tagged 
N-terminal fragment of presenilin 1 (NTF, 33.25 kDa) as well as the N-terminal membrane 
domain of TAP-like (TMD0, 19.8  kDa), belonging to the ATP-cassette (ABC) transporter 
family, were chosen for the control experiments with ETAstrep. 
 
Fig.  48: Co-expression of unrelated his-tagged MPs with ETAstrep. D-CF co-expressed MPs in 
0.5 % B35 containing a poly(His)10-tag have been analysed by pull-down experiments on strep-tactin 
matrix. Both TMD0 (A) and NTF (B) did not display any interaction with the matrix itself but with 
ETAstrep as they could be co-eluted like observed for the ET receptors. All fractions were precipitated 
with acetone. 5 µL of resuspended protein samples were loaded on 12 % (A) and 16 % (B) SDS-Tris-
glycine gels, respectively and subsequently immunodetected by western blotting against the C-terminal 
His-tag. MPs are indicated by arrows. M, marker proteins; FT, flow-through; w, wash fractions; E, elution 
fractions. 
Cross-reactivity with the strep-matrix itself could again be excluded for all of the proteins 
(Fig.  48  A and B, left illustration). Nevertheless, co-expression resulted in a similar elution 
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proteins all interacted with ETAstrep suggesting a more general mechanism underlying the 
detected interactions between ETA and ETB (Fig. 48 A and B, right illustration). 
When expressed separately either in P-CF mode and resolubilized in 1 % LPPG or in 
D-CF mode in presence of 0.5 % B35, then subsequently mixed in equal volumes of RM and 
incubated with the strep matrix as mentioned above for the co-expression assay, only minor 
protein-protein interaction of the full-length ET receptors ETAstrep/ETB-signcHx could be 
observed (Fig. 49 A). An estimated fraction of 1-5 % of ETB-signcHx could be co-eluted with 
ETAstrep. Addition of the wild type ligand, often supposed to stabilize the oligomerization 
interface in GPCRs, did not increase the interaction potential of single ET receptors in this assay 
and addition of CHS during incubation did further reduce the binding capacity to the strep 
column for both assays (data not shown). 
The separately P-CF produced truncations ETA197cHx and ETB198strep, resolubilized 
in 1 % LPPG and purified by Co
2+-chelate or strep-affinity chromatography were also analysed 
with respect to their mutual interaction. Following their separate purification and subsequent 
dialysis to remove the competing imidazole and biotin, both truncations were mixed at equal 
concentrations and the pull-down of ETA198strep was assessed with ETA197cHx bound to 
Co
2+-NTA beads (Fig. 49 B). 
Fig. 49: Oligomerization studies with separately expressed ET receptors and ETA truncations. (A) 
Analysis of interaction of full-length receptors. The soluble fractions of the RM or the resolubilized 
samples were purified by strep-tag affinity chromatography as performed with the co-expressed samples. 
5  µL of acetone precipitated fractions were loaded on 12  % SDS-Tris-glycine gels. The gels were 
subsequently immunoblotted and the C-terminal His-tag of ETB-signcHx was detected. Co-eluted bands 
of ETB-signcHx are indicated by black arrows. (B) Pull-down of ETA truncations. The purified receptor 
fragments were mixed at a molar ratio of 1:1 and subsequently purified by Co
2+ affinity chromatography. 
13 µL of acetone precipitated  fractions were loaded on 16 % SDS-Tris-glycine gels and stained with 
Coomassie Blue. Black arrows point at co-eluted proteins. The blue arrow might indicate a 197/198 
heterodimer. M, marker proteins; FT, flow-through; w, wash fractions; E, elution fractions. 
ETA197cHx showed interaction with ETA198strep since both fragments were detected at their 
respective molecular weights of 24.7 kDa (ETA197cHx) and 29.9 kDa (ETA198strep) in the 
elution samples. In addition a third faint band at approximately 45 kDa undetectable in flow-
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resistant heterodimer of ETA197cHx and ETA198strep. However, a remarkable fraction of 
ETA198strep was already removed in the flow-through and in the more stringent washing steps 
suggesting that not every ETA197cHx was able to bind to ETA198strep at the given reaction 
conditions (Fig.  49 B). 
 
4.8.  Cell-free expression of the human ETB receptor: Functional analysis by SPR 
As SPR measurements were successfully applied for the functional investigations of CF 
produced detergent-solubilized ETB receptor and various truncations (Klammt et al. 2007c) this 
technique was used to compare ETB either generated in E. coli or in wheat germ extracts. SPR 
measurements were performed in cooperation with Dr. Michael Beyermann (FMP, Berlin, 
Germany) who provided all his expertise. 
 
4.8.1.  Wheat germ extract versus E. coli: Comparison of full-length ETB 
solubilization behaviour in the D-CF expression mode 
The presented work was performed in cooperation with the lab of Vladimir Shirokov (Institute 
of Protein Research, Russian Academy of Sciences, Pushchino, Moscow Region, Russia). 
Introduced into the technique of WGE preparation and expression of ETB in the WG system by 
Vladimir Shirokov, the initial set-up and all detergent screenings were further carried out by 
Gelina Kopeina and Zhanna Afonina (PhD students, Institute of Protein Research). Wheat germ 
CF expression of ETB for functional studies by SPR measurements was accomplished by the 
author of current thesis. 
The full-length ETB receptor was cloned into the pOBE-TMV vector as described in 
detail in experimental procedures (see 3.1.1.). CF synthesis was carried out in an uncoupled 
transcription/translation CECF system achieving highest expression rates at 3 mM Mg
2+ and 
105 mM  K
+ for the translation reaction (see 3.3.5.). A selection of detergents at various 
concentrations which already proved suitable for the D-CF expression of various MPs as well as 
of ETB in the E. coli CF system (Klammt et al. 2005, 2007b, 2007c) was analysed (Table 13). 
In contrast to the E. coli system the long chain phosphoglycerol LMPG could be used 
for direct soluble expression of ETB at concentrations up to 0.04 % (Fig. 50) but apparently 
resulted in either degradation or two different conformational states of ETB upon synthesis as 
the two detected bands upon western blotting might indicate (Fig. 50, black and red arrow). An 
increase in LMPG concentrations further reduced the overall expression yield tremendously. 
Synthesis of ETB in presence of DDM almost totally abolished its expression in the WGE, 
supposing a hampering effect of DDM on the translation process of ETB in wheat germs. In the 
E. coli system, DDM did likewise only result in insoluble expression of human ETB. However, 
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or similar alkyl glycosides in terms of protein synthesis for a variety of MPs (Klammt et al. 
2005) as well as for ETA (Junge et al. 2010b). 
Table 13: Detergent tolerance of WGE for the expression of full-length human ETB. Concentrations 
of the respective detergents in % and x CMC as well as the detected expression level are indicated. 
 
Detergent Concentration  Expression  level
a 
  (%) (x  CMC)    pellet  supernatant 
none -  -    +++  - 
Polyethylene glycol derivates 
Triton X-100  0.2  13.4  +  ++ 
 0.4  26.8  ++  ++ 
 0.8  53.6  ++  + 
 1.3  87.1  ++  +/- 
Steroid derivates 
Digitonin 0.1  1.12  +++  ++ 
 0.5  5.62  +  +++ 
 1.0  11.25  +/-  +++ 
Alkyl glycosides 
DDM 0.1  15.0  +  +/- 
 0.2  30.0  -  - 
 0.4  60.0  -  - 
Long chain phosphoglycerols 
LMPG 0.01  4.2  +++ ++ 
 0.02  8.4  ++  ++ 
 0.04  16.8  +/-  + 
Polyoxyethylene-alkyl-ethers 
Brij 35  0.01  1.04  +++  ++ 
 0.05  5.2  +  ++(+) 
 0.1  10.4  +  ++(+) 
 0.5  52  +  +++ 
 1.0  104  +  ++ 
Brij 78  0.01  1.89  ++  ++ 
 0.05  9.45  +  ++ 
 0.1  18.9  +/-  ++ 
 0.5  94.5  -  + 
 1.0  189.0  +/-  ++ 
Brij 98  0.01  3.48  +++  +(+) 
 0.05  17.4  ++  ++ 
 0.1  34.8  +  +++ 
 0.5  174.0  +  +++ 
 1.0  348.0  +/-  +++ 
a expression level: +++, high; ++, ++(+), medium; +, low; +/-, spurious detection; -, no yield 
Best expression with highest yield of up to 1.5 mg/mL of soluble ETB receptor was performed 
in presence of the steroid derivative digitonin and a variety of polyoxyethylene-alkyl-ethers 
(Brij). 1 % of digitonin, B78 and B98, respectively as well as 0.1 % and 0.5 % B35 resulted in 
the highest soluble amount of ETB (Fig. 50). These data are well in accordance with the D-CF 
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were produced with 0.4-0.6 % digitonin, 2 % B58, 1 % B78 and 0.1 % B35 (Klammt et al. 
2007b). 
Fig. 50: CF production of soluble human ETB in an individual WGE. Western blot analysis of ETB 
synthesized in presence of the optimized concentrations of the respective tested detergents. Samples of 
supernatant and pellet fractions (3 µL) were loaded on 12 % SDS-Tris-glycine polyacrylamide gels and 
subsequently immunodetected by antibodies against the C-terminal poly(His)10-tag. Black arrows indicate 
monomeric ETB. The red arrow points at possible degradation products or different conformations of 
ETB in LMPG. M, marker proteins; S, supernatant; P, pellet. 
In order to compare generated functional data of WGE expressed ETB with the published and 
analysed data of the ETB receptor expressed in the E. coli system (Klammt et al. 2007b, 2007c) 
1 % B78 was chosen as detergent for the expression of ETB in the WGE. 
 
4.8.2.  Functional analysis of human ETB receptors produced in different CF 
systems by SPR measurements 
To quantitate its ligand binding affinity in real time by calculation of the equilibrium 
dissociation constant (KD) via determination of both association (ka) and dissociation (kd) 
constants (KD = 1/KA = kd/ka) SPR measurements of detergent-solubilized ETB receptor were 
performed by Dr. Michael Beyermann (FMP, Berlin, Germany) as described in the experimental 
procedures (see 3.9.5.). Therefore, the human ETB receptor was D-CF expressed in presence of 
1 % B78 in both implemented CF systems, E. coli as well as WGE. Both different receptor 
preparations were subsequently purified to 0.1 % B78 upon Ni
2+-chelate chromatography and 
analysed on biosensor CM-5 chips on which ET-1 was immobilized by amide coupling. 
Both receptors, D-CF expressed either in E. coli or in WGE, seem to behave similarly 
with respect to their affinities to the wild type ET-1 ligand. KD values in between 10-100 nM 
were determined suggesting that the ET-1 ligand binds to the receptors with high affinity 
(Fig. 51 A, B). 
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Fig. 51: SPR measurements of human ETB CF expressed in E. coli or WGE extracts. SPR response 
curves for the ET-1/E. coli ETB and ET-1/WGE ETB interaction using ET-1 coated CM-5 chips. 700 RU 
(A) and 1200 RU (B) of ET-1 have been immobilized on the chips via amide coupling and respective 
proteins were analysed in 20 mM Tris, 100 mM NaCl, 0.005 % P-20, pH 8.0, 0.1 % B78 at 25 °C using a 
flowrate of 2 µL/min. (A) ETB was D-CF expressed in E. coli in presence of 1 % B78, purified and 
titrated between 1.8 µg/mL and 180 µg/mL to investigate the concentration dependency of ligand 
binding. (B) ETB was expressed in presence of 1 % B78 in WGE. 120 µg/mL of purified receptor were 
subsequently loaded on ligand-coated chips. The stability of binding over time was analysed in a time 
range of days to weeks. 
Moreover, the WGE receptor was very stable over time since a repetition of measurements of 
the same preparation after approximately three weeks resulted in comparable binding constants 
(Fig. 51 B). While association seems to be fast, dissociation of the ligand occurred very slowly 
assuming a tight binding to ETB. These values for the KD only display approximately 1-2 orders 
of magnitude less affinity than those obtained from crude membrane preparations which are in 
between 40  pM-10  nM (Elshourbagy et al. 1993, Schiller et al. 2000, Taylor et al. 2003). 
Published SPR data of CF expressed ETB by Christian Klammt are comparable with values of 
about 7 nM (Klammt et al. 2007c). In order to analyse the consistency of the determined values 
and to prove the applicability of SPR to the ET receptor system, different NCs were conducted 
in parallel to the respective measurements. Cross-binding of E. coli CF expressed ETB receptor 
to unrelated GPCR-specific peptide ligands such as sauvagine (40 aa, 4.6 kDa) and urocortin 
(40 aa, 4.7 kDa), known ligands of the CRF receptor, as well as unspecific binding of the chip-
bound ET-1 to two other CF expressed detergent-solubilized GPCRs, CRF and V2R, were 
investigated (Fig.  52  A, B, C). None of the employed, ET-1 substituting peptide ligands, 
showed any remarkable binding to the ETB receptor suggesting specific binding of ETB to 
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Fig.  52: Evaluation of ETB binding 
specificity to ET-1 coated CM-5 chips by SPR 
measurements. (A) Response curves of ETB 
with different ET-1 unrelated GPCR peptide 
agonists and ET-1 or (B) with CF expressed 
V2R  and (C) CRF receptor. The respective 
GPCRs were D-CF expressed, exchanged to 
Brij derivatives upon IMAC purification and 
concentrated. Amounts of 10 µg (A), and 5 µg 
(B, C) were analysed on chips loaded with 
1400 RU ET-1, 700 RU urocortin and 1000 RU 
vasopressin. Experiments were performed at 
25 °C and a flowrate of 2 µL/min. 
However, upon loading of the ET-1 coated chips with different GPCRs high cross-interaction 
between ET-1 and unrelated GPCRs was observed displaying comparable association and 
dissociation behaviour as seen for both ETB receptor preparations (Fig.  52  B, C). Those 
detected side-effects considerably hampered the evaluation and further questioned the reliability 
of the above gained binding data. Therefore, SPR data were not further used to determine 
binding constants, and the experimental set-up was so far excluded for future functional analysis 
of the ET-receptom. 
 
4.9.  CF expression of ETB intein fusion constructs for segmental isotope labelling 
With regard to the reasonable quality of the first recorded liquid-state NMR [
15N
1H]-TROSY-
HSQC spectra of the LMPG-solubilized ETB truncation ETB93a (15.4  kDa, TMS1-TMS3) 
performed by Dr. Christian Klammt (PhD thesis) which showed the least spectral overlap of all 
tested truncations, this fragment represented a potential candidate for structural investigations of 
a ligand-binding competent GPCR fragment (Klammt et al. 2007c) by liquid-state NMR 
spectroscopy. 
In order to further minimize the observed peak overlap, segmental labelling of single 
TMSs in combination with the CF expression technique was considered for ETB93a. An 
interesting approach for the introduction of selectively labelled TMSs into a MP is the use of so 
called split inteins (Fig.  53). Those inteins are protein introns which can self-excise in an 
autocatalytic manner in cis as well as in trans, rejoining two flanking peptides or proteins via 
native peptide bond formation (Brenzel et al. 2006, Hong et al. 2008, Mathys et al. 1999, Sun et Results   127 
 
al. 2004, Wu et al. 1998). This type of labelling would allow the structural characterization of a 
single protein domain in the context of a full-length protein without extensive signal overlaps 
generated by the other domains. 
 
 
Fig.  53: Representation of protein trans-
splicing (left) and of the two potential 
segmentally labelled ETB93a constructs 
(right). Labelled TMS segments are 
indicated in green. If spliced correctly either 
the 1
st TMS (I) or the 2
ndand 3
rd TMSs (II) 
can be isotopically labelled by CF 
expression and subsequently be fused to the 
native adjacent TMSs by autocatalytic 
trans-splicing. 
 
4.9.1.  CF expression of ETB intein fusions and evaluation of optimal 
solubilization 
The CF expression of the ETB93a intein fusion constructs pVSO 4.1 and pVSO 4.2 plasmids 
was accomplished in cooperation with the group of Prof. Mootz who provided cloning and 
splicing expertise (Technical University Dortmund, Germany) (see 3.11.). Expressed proteins 
from split intein fusions for the trans-splicing reaction were TMS 1 plus DnaE
N peptide from 
Nostoc punctiforme (ETB 4.1, ETB-TMS1 intein) with a molecular weight of 19.1 kDa as well 
as the corresponding split intein DnaE
C peptide plus TMS2+3 (ETB 4.2, ETB-TMS2+3 intein) 
with a calculated mass of 15.1  kDa. Both intein fusion constructs harboured an N-terminal 
T7-tag and a C-terminal poly(His)10-tag and could be produced in the P-CF mode at final yields 
of more than 1 mg/mL of RM (Fig. 54 A). 
D-CF expression screens of ETB 4.1 revealed a low overall solubilization potential of 
all detergents at the analysed concentrations of 0.1 % DDM, 0.1 % B35, 1 % B58, 1 % B78 and 
1 % B98, although Brij detergents were shown to result in quantitative solubilization of the 
full-length ETB receptor and various truncations (Klammt et al. 2007b, 2007c). All tested 
detergents failed. Only 1 % B98 generated marginally soluble ETB 4.1 at estimated values of 
less than 1 % (Fig. 54 B). ETB 4.2 displayed a higher detergent compatibility with regard to its 
solubilization behaviour. While 0.1  %  DDM completely abolished CF synthesis, the best 128   Results 
 
quantitative soluble expression was achieved in 1 % 58 and 1 % B78 with 30-50 % followed by 
0.1 % B35. B98 could not be used for the soluble production of ETB 4.2 (Fig. 54 C). 
 
Fig.  54: Production of ETB 
intein fusions in the P-CF and 
D-CF expression mode. Sample 
volumes of 1 µL (Western blot) or 
2 µL (Coomassie) were loaded on 
17  % SDS-Tris-glycine gels and 
immunodetected by anti-T7-tag 
antibodies or stained by 
Coomassie Blue. (A) P-CF 
produced intein precipitates. (B) 
D-CF expression of the inteine 
constructs in presence of various 
detergents at the indicated final 
concentrations (w/v). M, marker 
proteins; P, pellet; S, supernatant. 
Since D-CF expression resulted in very low final yields of both soluble ETB intein constructs 
this mode was not further considered. Instead, post-translational resolubilization was analysed 
to evaluate the overall amount of detergent-solubilized intein fusions (Fig. 55). 
Detergents were chosen with respect to their applicability in solution-state NMR 
spectroscopy. The lyso-phospholipid and long-chain phosphoglycerol LPPG, the phospholipid 
derivative Fos-12 as well as the short-chain phospholipid diC6PC are well accepted in the area 
of structural investigations by NMR (Arora et al. 2001, Krueger-Koplin et al. 2004). TX-100 
was used as a reference as it proved already successful in the resolubilization of MPs such as 
EmrE and Tsx (Klammt et al. 2005). 
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Fig.  55: Resolubilization of 
ETB intein fusions. Sample 
volumes of 1.5 µL in splicing 
buffer and detergent at the 
indicated concentrations 
(v/w) were loaded on 10  % 
Tris-Tricine-SDS gels and 
subsequently immunoblotted 
against the C-terminal 
poly(His)10-tag. Arrows 
indicate soluble fractions. M, 
marker proteins; P, pellet; S, 
supernatant. 
Resolubilization after P-CF mode resulted in higher recovery of solubilized intein fusions as 
compared to the co-translational solubilization in the D-CF mode (Fig. 54  and 55). ETB 4.1 
(ETB-TMS1 intein) could be produced as precipitate in high amounts. However, quantitative 
solublilization proved to be more difficult than expected. TX-100 and diC6PC resulted only in 
marginal yield of soluble ETB  4.1, followed by Fos-12 and LPPG which exhibited a 
resolubilization efficiency of 20 and 50 %, respectively (Fig. 55, left). A similar preference of 
detergents for resolubilization could be detected with ETB 4.2 (ETB TMS2+3 intein) although 
the overall expression rate was diminished compared to ETB 4.2 (Fig. 55, right). Summarizing 
the resolubilization experiments for both inteins from the P-CF mode, a list of suitable 
detergents (LPPG > Fos-12 > diC6PC >> TX-100) could be defined as basis for subsequent 
trans-splicing approaches. 
 
4.9.2.  Trans-splicing of detergent-solubilized ETB intein fusions 
Correct complete splicing of the two precursor ETB intein fusions should result in the potential 
products ETB93a consisting of 15.4 kDa with N-and C-terminal tags as well as the residual split 
intein DnaE
N peptide (13.1 kDa, without T7-tag, plus poly(His)10-tag) and the split intein DnaE
C 
peptide (5.6  kDa, characterized by the possession of a remaining T7-tag but lacking the 
poly(His)10-tag). 
In agreement with Prof. Mootz and under consideration of the published data of Hong et 
al. (2008), the parameters for the investigations of trans-splicing were chosen as follows. The 
intein cleavage buffer consisted of 50mM Tris, 100mM NaCl, 2mM DTT, 1mM EDTA and 2 % 
LPPG or 2 % Fos-12 showing the highest solubilization efficiency. The pH, optimal for the 
splicing between 6.5 and 7.0, was kept neutral at 7.0 as this reflects best the overall 
physiological conditions perceived by human GPCRs. The respective ETB intein fusions 
precursors ETB 4.1 and ETB 4.2 were expressed separately in P-CF mode, the precipitate was 
harvested by centrifugation, washed and resolubilized in the chosen detergents (see 3.11.). The 
single resolubilized targets were subsequently mixed at equal volume ratios (1:1, v/v) and 
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Three temperatures of 16 °C, 22 °C and 40 °C in combination with a variety of incubation times 
from 45 min to 65 h were tested (Fig. 56). Splicing was followed by immunodetection against 
both N-terminal T7-tag and C-terminal poly(His)10-tag as well as by autoradiography after CF 
expression in presence of 
35S-methionine (Fig. 57). 
One of the most difficult tasks was the differentiation between the uncleaved precursor 
ETB  4.2 with a mass of 
15.1  kDa and the potential 
splice product ETB93a with 
15.4  kDa since both proteins 
only differed in approximately 
200  Da which can hardly be 
resolved by SDS-PAGE. 
Furthermore, remaining 
inteins after complete 
cleavage could fuse again 
resulting in a protein with a 
molecular weight of 18.7 kDa 
again hardly distinguishable 
from the ETB  4.1 precursor 
with 19.1  kDa. Due to those 
similarities in protein mass it 
was almost impossible to 
evaluate the optimal time span 
and temperature for the 
splicing reactions for both chosen detergents by immunodetection (Fig. 56). 
Only a slight difference in the observed mass of the lower band at 15.1 kDa could be detected 
with 2 % Fos-12 at 16 °C. This observation was interpreted as a possible indication for ongoing 
splicing which resulted in the product after 18 h (Fig. 56 A, underlined in green and cyan). 
Since no such change in molecular mass was detected at 22 °C it was suggested that splicing 
might occur earlier at higher temperatures. Similar results pointing at successful trans-splicing 
were not achieved with 2  %  LPPG as all protein bands remained at the same positions 
(Fig. 56 B). 
As 2 % Fos-12 seemed suitable for further studies it was chosen for the investigation of 
splicing by a transfer of radioactive methionine from either ETB 4.1 or ETB 4.2 to the product 
during cleavage. P-CF expression of both precursors was successfully performed in presence of 
35S-methionine. Single protein bands in the autoradiogram further demonstrated the specificity 
of the methionine incorporation during CF reaction as no background was observed (Fig. 57). 
Fig. 56:  Evaluation  of  trans-splicing parameters for P-CF 
produced ETB intein fusions. ETB intein precursors were either 
resolubilized in 2  %  Fos-12 (A) or 2  %  LPPG (B). Sample 
volumes of 2.5 µL of a total reaction volume of 30 µL were taken 
at different time points, loaded on 12  %  Tris-Tricine-SDS gels 
and subsequently subjected to immunoblotting against the 
C-terminal His-tag. Black arrows point to ETB 4.1 bands while 
green arrows illustrate ETB  4.2. Possible mass shifts are 
underlined in green and cyan. M, marker proteins; v/v, 
volume/volume. Results   131 
 
Combination of equal volumes of radioactively labelled ETB  4.1 (
35S 4.1) with unlabelled 
ETB 4.2 resulted in an additional band at around 15 kDa arising upon incubation under splicing 
conditions after 1 h which increased in intensity over time reaching highest signal intensity after 
65 h. Simultaneously, the precursor band at 19.1 kDa became fainter suggesting a quantitative 
turnover in line with the occurrence of the lower band. Since the detected additional band 
displayed a mass of ~15 kDa, comparable to the mass of the precursor ETB 4.2 with 15.1 kDa, 
this band could rather be explained by the formation of ETB93a (15.4  kDa) than with the 
peptide split intein DnaE
N splicing intermediate (13.1 kDa) (Fig. 57). Radioactive labelling of 
intein constructs resolubilized in 2 % LPPG did not show any turnover (data not shown) which 
is in consistency to the above delineated results (Fig. 56). 
 
Fig. 57: Autoradiogram of ETB intein 
trans-splicing monitored by 
incorporation of 
35S-methionine by CF 
expression.  Sample volumes of 5  µL 
from single CF expression or various 
time points were loaded on 10  %  Tris-
Tricine-SDS gels and analysed after 
incubation on phosphoimager plates. Gel 
exposition was performed at RT for two 
days. The black arrow and triangle 
indicate the potential arising product 
ETB93a. 
 
In order to further monitor the occurrence of splicing 
intermediates in the ongoing process, the existence 
of different immunotags depending on which 
intermediate was formed was assessed by 
immunodetection against both tags (Fig.  58). The 
splicing process seemed to proceed under the 
evaluated conditions as the turnover of precursors as 
well as the formation of intermediates could be 
detected. The band at 19.1  kDa, representing 
ETB  4.1, decreased in intensity after 24  h which 
could be observed by immunodetection of both tags 
(Fig. 58, red arrows). Furthermore, a slight upward 
shift in the band at 15  kDa might indicate the 
formation of the product ETB93a (Fig.  58, green 
arrows). The band at a low molecular mass of 
estimated 6 kDa, which was only detectable by an 
antibody against the T7-tag, suggests the occurrence of the peptide split intein DnaE
C 
intermediate (5.6 kDa) (Fig. 58, blue arrow). The second peptide intermediate of the split intein 
DnaE
N was monitored at 13 kDa only by the antibody against the C-terminal poly(His)10-tag 
Fig.  58: Detection of splicing 
intermediates. Protein samples of 3 µL 
were applied to 12  %  Tris-Tricine-SDS 
gels and immunoblotted against N- and 
C-terminal tags. Various arrows point at 
splicing intermediates and potential 
products. M, marker proteins. 132   Results 
 
which is well in accordance with the calculated molecular weight of the intermediates. 
However, this band was also detectable in the single precursor sample ETB 4.2 which might be 
explained by an unstable state, in which the intein  already starts to excise itself without the 
presence of its counterpart (Fig. 58, black arrow). 
Although no complete assembly of the TMSs of ETB93a occurred by trans-splicing 
because precursors, intermediates and splice product seemed to persist in parallel in the RM, it 
was demonstrated with high probability that trans-splicing could successfully be applied to CF 
expressed MPs in a detergent environment. However, its applicability to NMR spectroscopy at 
this point remains questionable since the turnover was rather qualitative than quantitative and 
high amounts of product are needed for structural investigations which could not be achieved 
with the constructs and conditions at hand. Furthermore, the ETB93a product as well as the 
precursors displayed highly similar molecular masses together with the modification by the 
same immunotags which considerably hampered straightforward detection and purification 
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5.  Discussion 
 
5.1.  Protocol development for the preparative scale expression of functionally 
folded GPCRs in individual cell-free systems 
5.1.1.  Selecting CF expression systems based on E. coli for GPCR production: 
Basic considerations 
CF expression as alternative option for the preparative scale production of MPs is emerging for 
approximately the last five years with first reports starting in 2004 (Berrier et al. 2004, Elbaz et 
al. 2004, Klammt et al. 2004). Evident advantages of CF expression reside in the reduced 
system complexity eliminating many critical steps of conventional cell-based systems which 
allows fast protein production in small scale volumes with easy and reliable labelling techniques 
(Schwarz et al. 2007b, Koglin et al. 2006, Liguori et al. 2007, Reckel et al. 2008). PTMs of 
expressed targets such as glycosylation, lipidation or phosphorylation can a priori not be 
expected in CF systems based on E. coli extracts. This might affect stability and/or function of 
individual proteins, but on the other hand could result in more uniform sample qualities in terms 
of structural aspects. Specific chaperone systems or cellular quality control mechanisms that 
might scrutinize and remove misfolded MPs are also most likely absent in CF systems. Due to 
the lack of those cell-internal machineries, CF synthesis of MPs requires extensive evaluation of 
protein quality. 
Two major configurations exist for the CF production of proteins known as batch or 
CECF delineated in detail (see 1.2.2.). The highest productivity at the mg/mL of RM level is 
still obtained with the CECF system (Kigawa and Yokojama 1991, Shirokov et al. 2007, Spirin 
et al. 1988). Since the batch mode resulted in very moderate expression levels of GPCRs of 
approximately 160 µg/mL as analysed for the β2-adrenergic (AR), the muscarinic acetylcholine 
2 (AChM2) and the neurotensin receptors (NTR) (Ishihara et al. 2005) the CECF configuration 
is likely to be favoured for GPCRs with regard to relative production efficiencies. It was not 
only successfully used to achieve expression levels of up to 3 mg/mL of RM for human ETB 
but also for other GPCRs such as the human V2R, the rat corticotropin releasing factor receptor 
1 (CRF), the human melatonin (MTN) and neuropeptide Y receptors (NPY) (Klammt et al. 
2007b, 2007c), for the human histamine H1 receptor (HRH1) (Kamonchanok et al. 2008) and 
for olfactory receptors (Kaiser et al. 2008). Therefore, this configuration was chosen for the 
preparative scale expression of both members of the ET receptom in the current work. 
ETA and ETB constructs were designed by using expression vectors of the pET or the 
pIVEX series since they possess T7 promotors which rely on the highly processive and specific 
T7RNAP. Since low expression rates can mostly be connected to problems with peptide 134   Discussion 
 
elongation or especially translation initiation in which the approximately first ten nucleotides 
following the start codon play an important role (Gonzalez de Valdivia and Isaksson 2004), 
different strategies have been used to effectively circumvent initiation problems with GPCRs in 
CF systems. Most problems of initiation have successfully been avoided by fusion of small 
expression tags like the T7-tag (Klammt et al. 2005) or larger fusion partners such as Trx to the 
N-terminus of the target protein (Ishihara et al. 2005, Kamonchanok et al. 2008). Especially 
valuable for expression of GPCRs in our hands proved the T7-tag whose addition solely 
allowed their production in sufficient amounts (Klammt et al. 2007b, Schneider et al. 2010). 
This tag is advantageous over larger fusion partners like Trx due to its small size of only 
1.5  kDa and it might not even be necessarily removed for structural evaluations by X-ray 
crystallography. Choosing C- or N-terminal poly(His)x-tags or strep-tags additionally facilitate 
rapid purification by IMAC or other affinity matrices and has been applied to all CF expressed 
GPCRs. Beneficial for an increase in recovery of detergent-solubilized MPs seems an extension 
of the poly(His)6-tag provided by most of the standard CF expression vectors to a 
poly(His)10-tag which proved valuable for the purification of CF ETB achieving amounts of 
1.8  mg/mL final purified receptor (Klammt et al. 2007c). Furthermore the addition of 
immunodetectable tags on both ends simplifies the verification of full-length synthesis of 
expressed MPs as they tend to run faster than their predicted molecular weight on SDS-PAGE. 
The functional folding of MPs in general might furthermore not be affected by terminal fusion 
tags (Massotte et al. 1997, 1999). 
CF expression of ETA and ETB was conducted with an N-terminal T7-tag and a 
C-terminal poly(His)10-tag in the present thesis. Extensions with peptide tags like Flag-tag 
(1.0  kDa) or c-myc-tag (1.2  kDa) at the N-terminus were previously reported to have 
neglectable effects in the ETA receptor’s ligand binding affinity upon overexpression in Pichia 
pastoris (Cid et al. 2000). Likewise, the addition of poly(His)6-tags at both ends of the ETB 
receptor did not show a pronounced influence on functionality either (Doi et al. 1997) indicating 
that an addition of terminal tags can be regarded as acceptable strategy for functional receptor 
studies within the ET receptom. Both tags were successfully used in immunodetection to verify 
the full-length synthesis of ETAcHx and ETAstrep (Fig. 10). 
Regarding the choice of the optimal detergent there is no general rule as to which type is 
most suited for the functional conservation of individual GPCRs. Detergents should therefore be 
subject of intense investigations and optimization processes as discussed in detail (see 5.2.). 
However, some detergents have been shown to be preferred for the direct solubilization of 
GPCRs by D-CF expression as well as for the resolubilization out of P-CF precipitates. For the 
D-CF mode, the steroid derivative digitonin as well as representatives of the long chain 
polyoxyethylene-alkyl-ethers B35, B58, B78 and B98 resulted in the highest soluble yield of the 
majority of analysed GPCRs such as both human ET receptors ETA and ETB, human and rat 
V2R, the rat CRF 1, NPY4R and MTNR1B (Junge et al. 2010b, Klammt et al. 2007b), the Discussion   135 
 
human β2AR-GαS fusion, human AChM2 and the rat NTR (Ishihara et al. 2005) as well as the 
olfactory receptors human OR17-4 and mouse OR23 (Kaiser et al. 2008). The presence of those 
detergents yields soluble GPCRs of more than 3 mg/mL RM (Klammt et al. 2007b). Whereas 
Brij derivatives are applicable in a broad range of concentrations for the expression of GPCRs 
(Klammt et al. 2005), digitonin displays very defined optima, and increasing concentrations 
might impair production levels (Kaiser et al. 2008, Klammt et al. 2005). Other detergent classes 
such as polyoxyethylene sorbitane esters (Tween derivatives) and alkyl glucosides such as 
DDM, HDM and TDM resulted in considerably lower yield or even no co-translationally 
solubilized receptors (Ishihara et al. 2005, Kaiser et al. 2008, Klammt et al. 2005, Junge et al. 
2010b). Most effective resolubilization of P-CF produced GPCR precipitates was obtained in 
detergents such as LMPG and LPPG (Junge et al. 2010b, Klammt et al. 2005) and DDM in case 
of the human HRH1 (Kamonchanok et al. 2008). 
 
5.1.2.  Cell-free expression of the ET receptom using E. coli extracts: 
Comparison of protein production rates to cell-based systems 
Aiming at structural determination of proteins requires sufficient protein yields combined with 
functionality and intrinsic stability of the target receptor preferably in a detergent-solubilized 
state. In in vivo expression systems most of the MPs are either expressed purely in membranes 
or in form of IBs (Tate 2001). A high protein quality is an essential prerequisite for structural 
studies of the ET receptors. Different production strategies have been explored but none of them 
has apparently been successful in generating suitable samples in reasonable amounts as no 
structural data have been published so far. 
Heterologous expression hosts of mammalian background like COS, CHO or HEK293 
cells (Arai et al. 1990, Adachi et al. 1992, Gregan et al. 2004a, 2004b, Evans and Walker 2008) 
are mostly used for clinical studies and pharmacological characterization of novel receptor 
agonists and antagonists. Although those systems represent the natural environment of the 
receptors they do usually not allow for extensive overexpression in the range of mg amounts of 
soluble receptor and therefore are hardly suited for structural studies (Arai et al. 1990, Mondon 
et al. 1998, De Leon and Garcia 1995). Further heterologous in vivo expression systems like 
E. coli (Haendler et al. 1993), the methylotrophic yeast Pichia pastoris (Schiller et al. 2000, 
2001, Saravanan et al. 2004, 2007), and Spodoptera frugiperda Sf9 cells (Doi et al. 1997) have 
already been investigated with respect to overproduction efficiencies of ET receptors with 
varying degrees of success in terms of high yield, receptor purity, stability and receptor function 
(Table 14). 
With 41 receptors per cell ETB was overexpressed at low levels in E. coli. Membrane 
fractions were analysed for their binding behaviour. The receptor displayed equal binding 
properties of all three ligands with a dissociation constant to ET-1 of 100 pM which is in the 136   Discussion 
 
range of native receptors (Haendler et al. 1993). However, if comparing its overexpression rate 
to other GPCRs in E. coli, fusion of the NTR to MBP and Trx for instance resulted in the 
detection of up to 700 binding sites per cell (Tucker and Grisshammer 1996) which is 
considerably higher, implying that direct expression of ETB into E. coli membranes might not 
be a straightforward approach if high protein yield is required. 
The expression of N- and C-terminal tagged mutated ETB receptors in P. pastoris 
resulted in high expression levels of stacked membrane inserted receptor which could be 
up-scaled by fermentation with final yields of 9 mg/L. In its membrane environment it exhibited 
comparable pharmacological properties to the native ETB (Schiller et al. 2000, 2001). The 
expression in yeast therefore seems to be very promising for structural approaches. However, 
upon its extraction from ET-1 pre-saturated membranes at RT in DDM approximately 40 % of 
the receptor was lost although retaining monomeric character and high stability over a wide pH 
range. The determination of ligand binding capacity of 30 % final receptor yields (~3 mg/mL) in 
a detergent-solubilized state was only roughly determined. Radioactive ET-1 found in the 
supernatant after cell lysis was correlated to totally bound ligand (Schiller et al. 2001). 
However, as membrane solubilization is far from being a very mild procedure it might be 
critical to assume, that all membrane bound receptors keep the agonist and its functional 
conformation. 
Table  14: CF and heterologous non-mammalian expression systems for the production of ET 
receptors. Representative selection of published data on the production level as well as on functional ET 
receptor yield of the human ET system. 
 
Receptor 
subtype 
Expression 
system 
Production 
levels
A 
Final functional 
receptor yield in 
soluble form 
Assay
B  Reference 
ETB  E. coli  41 r/c  n. a.  m  Haendler et al. 1993 
ETB  P. pastoris  4-9 mg/L  n. a.  m  Schiller et al. 2000 
ETB  P. pastoris  9 mg/L  3 mg/mL  m  Schiller et al. 2001 
ETB  P. pastoris -  2.3–2.8  mg/L
  s  Saravanan et al. 2007 
ETB  Sf9 cells  ~0.7-1 mg/L  ~0.3 mg/L  s  Doi et al. 1997, 1999 
ETB  E. coli CF  3 mg/mL  0.9 mg/mL  s  Klammt et al. 2007b 
ETA  P. pastoris  ~0.6 mg/L  0.6 mg/L  s  Saravanan et al. 2004 
ETA  Sf9 cells  ~0.25 mg/L  < 0.05 mg/L
C  s  Doi et al. 1999 
ETA  E. coli CF  1.5 mg/mL  0.5 mg/mL  s  Junge et al. 2010b 
A Production levels either expressed as total amount of receptor per litre culture (mg/L), receptors per cell 
(r/c) or as mg/mL of CF RM. 
B Assays either performed on solubilized receptor preparation (s) or on membrane preparation (m) 
n. a., not analysed 
-, not stated 
C, estimated value determined based on the statement of 5-10 times lower efficiency for ETA as for ETB 
Likewise, the data by Saravanan et al. in Pichia seem very promising but they were produced 
using a completely new assay based on ligand affinity chromatography via hydroxyl apatite gels 
coupled to colour development (Saravanan et al. 2004). They could indeed show that binding of 
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ligand to native membranes. However, this assay was not applied to other GPCRs so far and 
therefore lacks a well-founded comparison to related receptors. In this work the immobilized 
ligand ET-1 has been shown to bind unspecifically to other detergent-solubilized GPCRs with 
very high affinity in SPR measurements, therefore tending to generate false positives in micellar 
environments (see 4.8.2.). 
ETA and ETB receptors as well as mutated variants were further expressed in 
considerable amounts in Sf9 cells, subsequently detergent-solubilized and ligand affinity 
purified to homogeneity with a loss of protein of approximately 90 % (Doi et al. 1997, Satoh et 
al. 1997). Furthermore, ETB was expressed more efficiently in insect cells than ETA. Besides 
their inherent ability to promote glycosylation, Sf9 cells also allowed Ca
2+ signalling indicating 
that, upon ligand binding, the ET receptors were capable of inducing downstream processes 
comparable to the wild-type environment (Doi et al. 1999, Satoh et al. 1997). Upon affinity 
purification, mostly performed by using a biotinylated (Lys9) ET-1 wild type variant (Doi et al. 
1997, 1999, Saravanan et al. 2004, 2007, Satoh et al. 1997), ligand binding activity of the 
receptors could be preserved to the same levels as in insect cell membranes (Satoh et al. 1997). 
  CF expressed ETB receptor was purified to levels of up to 1.8  mg/mL of RM in 
0.1  %  B78 and its ligand binding capacity upon co-elution studies by gel filtration with 
Cy3-labelled ET-1 was calculated to be approximately 50 % which would result in ~0.9 mg/mL 
of functional receptor (Klammt et al. 2007c). This is comparable to in vivo data from Sf9 cell 
produced receptor (Table 14). 
  In the present study, final CF expressed ETA receptor concentrations of up to 1 mg/mL 
after IMAC purification in 0.1 % B35 could be achieved under optimal conditions. Calculating 
with a loss of 50  % upon ligand affinity chromatography (see 4.5.1.) still 0.5  mg/mL of 
functional receptor can be obtained (Fig.  36). These data of final receptor yield of ETA 
produced in a self-made E. coli extract are highly competitive to most of the published values 
for ETA from in vivo expression (Doi et al. 1999, Saravanan et al. 2004) and therefore 
represents a promising approach for structural investigations. 
 
5.1.3.  Cell-free expression of ETB using wheat germ extracts 
Preparative scale expression achieving mg amounts of protein per mL of RM is currently 
possible by using E. coli or WGE (Endo and Sawasaki 2005, Zubay 1973). E. coli as well as 
wheat embryo extracts have similar efficiencies in the production of prokaryotic and eukaryotic 
MPs and even proteins far exceeding 100 kDa in size can be synthesized in both systems 
(Liguori et al. 2007, Schwarz et al. 2010). It is in discussion if eukaryotic MPs should be 
expressed in eukaryotic CF systems. Prokaryotic sources do not provide eukaryotic chaperone 
systems eventually necessary for a higher quality of eukaryotic target proteins (see 1.2.2.). 
Disulfide bond formation is generally feasible in all CF systems (Goerke et al. 2008) but other 138   Discussion 
 
PTMs like directed proteolytic processing, phosphorylation, prenylation and glycosylation can 
principally only take place if modifying enzymes or corresponding microsome fractions have 
been supplemented (Swartz 2006). 
ETB was chosen as target MP as it has been most extensively studied by E. coli CF 
expression before, and functional assays were readily available (Klammt et al. 2007b, 2007c). 
Basic investigations of production efficiencies as well as of detergent tolerances were performed 
along with a final comparison of the functionality of the ETB receptor isolated from both 
systems. In cooperation with Vladimir Shirokovs lab, the WGE system was established for the 
expression of the ETB receptor. In terms of productivity as well as detergent compatibility for 
high yield D-CF expression of ETB no major differences were revealed by intensive screenings 
(see 4.8.1.). The average yield of D-CF expressed ETB receptor using Brij derivatives in both 
systems achieved mg amounts per mL of RM being slightly reduced in WGE with 1.5 mg/mL 
as compared with 3 mg/mL in CF E. coli (Klammt et al. 2007b). Moreover, similar binding 
kinetics were determined by SPR measurements (see 4.8.2.). However, the detection of ETB 
glycosylation as an example for PTMs remained negative in our lab indicating that necessary 
modifications might not be performed in WGE either (data not shown). This is also in 
accordance with observations of Endo an co-workers who stated that glycosylation generally 
does not occur during CF expression using WGE (Takai et al. 2010). In WGE N-terminal 
lipoylation may only be possible if the necessary substrate is supplied (Lingappa et al. 1997). 
Insect cell as well as rabbit reticulocyte and Leishmania extracts might perform required PTMs 
if used for analytical scale protein production in the µg/mL range (Arduengo et al.2007, Ezure 
et al. 2006, Mureev et al. 2009, Ren et al. 1993, Tie et al. 2005). 
So far, the expression of ETB did not profit from any obvious advantages in a self-made 
WGE CF system. Since WGE preparation has the disadvantages of being relatively laborious 
and time consuming (Endo and Sawasaki 2005, Madin et al. 2000) and as its production 
efficiency is highly dependent on the choice of the wheat source, the more reliable E. coli 
extract was preferred for further functional and structural investigations of the ET receptors. 
 
5.2.  Development of target specific quality control protocols for CF expressed 
GPCRs: Case study ETA receptor 
The continuously growing diversity of options to design and modulate expression environments, 
protocol compositions and folding kinetics increasingly require rational strategies for the 
optimization of protein sample quality in CF expression systems. Quality control of the 
synthesized proteins is fundamental in order to obtain a necessary feedback on the design of 
appropriate expression protocols (Wagner et al. 2006, Junge et al. 2010a). MPs are likewise 
more difficult to handle than soluble proteins as detergents and lipids are major determinants in 
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predict as even closely related MPs seem to behave very differently like observed for CF 
expressed ETA and ETB (Junge et al. 2010b, Klammt et al. 2007b, 2007c). 
 
5.2.1.  Primary solubilization of CF expressed MPs: Considerations for the 
conservation of structural and functional features 
The preparative scale expression of MPs in the D-CF and P-CF modes are unique approaches 
for the rapid production of proteomicelles and it is tempting to speculate which of the two 
expression modes is more likely to result in correctly folded protein. 
The D-CF mode appears to have certain advantages as it avoids any initial precipitation 
of the synthesized MPs, provides an efficient solubilization approach independent from specific 
translocation systems and delivers MP samples that can directly be used for a variety of 
functional and structural assays. Although this mode appears to be more likely in resulting in 
non-aggregated MPs, some potential disadvantages have to be considered. Expression yields are 
usually lower if compared with the P-CF mode. Reduced translation rates caused by the 
detergents and incomplete solubilization of the synthesized MPs are possible reasons. With 
ETA, 50 % less purified protein was obtained after D-CF expression in presence of B35 if 
compared with P-CF expression and resolubilization in LPPG (see 4.2.3.). Furthermore, 
harvesting a P-CF produced MP precipitate by centrifugation already eliminates most 
contaminating cell extract proteins which stay in the supernatant. This represents already a first 
purification step and resolubilization of the precipitate can sometimes even result in apparently 
pure protein (Klammt et al. 2004). For instance, D-CF produced ETA was considerably less 
pure after IMAC than the P-CF expressed and purified receptor (Fig. 17 A, C). 
ETA was efficiently produced in the P-CF (see 4.1.1.) and in the D-CF mode 
(see 4.1.2.). However, while post-translational solubilization of ETA in 1  %  LPPG already 
generated a homogenous elution profile if compared with other analysed detergents (Fig. 15 A), 
the D-CF expression of ETA in 0.5 % B35 seemed to be less suited. In this case, the reduction 
in detergent concentration upon IMAC purification to 0.1 % B35 resulted in a Gaussian shaped 
peak which still covered a very broad range of the elution volume comprising at least four 
different oligomeric states (Fig. 19 A). Reduced B35 concentrations might cause the exposure 
of TMS parts which could then more easily form intermolecular aggregates. This behaviour 
suggests that the initial structure of ETA upon expression in B35 was not correctly packed or is 
unstable, so that a loss of detergent molecules increases aggregation. All other detergents used 
for the D-CF expression of ETA, including digitonin, resulted in a predominant loss of soluble 
receptor with the exception of B35 still yielding ~50 % of the P-CF production efficiencies. 
Therefore, they were considered less suited for the production of ETA due to the reduction in 
final receptor yield (see 4.1.2.). 140   Discussion 
 
One of the most frequent associations if working with P-CF produced proteins is that P-CF 
precipitates are similar to bacterial IBs. IB formation is a common mechanism observed upon 
expression of proteins in cell-based systems, especially in E. coli, and many GPCRs can be 
targeted into IBs upon overexpression (Michalke et al. 2009). The proteins in IBs are mostly 
inactive (Vallejo and Rinas 2004) and their functional folding has to be restored by often harsh 
refolding procedures which usually require solubilization in either a strong detergent, in a 
chaotrope or in organic solvents (Kiefer 2003). Those aggregates are therefore often undesired 
as successful refolding procedures in particular of GPCRs still remain the exception (Baneres et 
al. 2003, 2005, Bazarsuren et al. 2002, Dahmane et al. 2009). 
Although structural analyses of P-CF produced MP precipitates are still rare, 
accumulating evidence indicates that they behave differently if compared with MP inclusion 
bodies. Maslennikov et al. could show by magic angle spinning solid-state NMR that P-CF 
precipitates of the E. coli histidine kinase receptors ArcB and KdpD are characterized by 
α-helical folding. The recorded spectra were highly comparable to those recorded after 
lyophilization of the detergent-solublilized receptors. Proton-deuterium exchange measurements 
by solution NMR led the authors to the unambiguous interpretation that secondary structure 
elements must be generated during P-CF expression (Maslennikov et al. 2010). In cooperation 
with Karsten Mörs, similar preliminary evidence was obtained with P-CF expressed ETA 
receptor in current work (see 4.2.8.). Judged by the signal intensity of the CαCβ cross-peaks of 
alanine and isoleucine in two independent experiments, an estimated amount of 30-40 % of the 
secondary structure might already contain α-helical elements (Fig.  24). Those values are 
marginally lower than the predicted (51 %) and the determined values of samples in 0.1 % B35 
(46 %) which exhibited ligand binding capacity (see 4.2.7. and 4.5.1.). These findings support 
the potential of P-CF expression to result in correctly folded MPs after adequate solubilization. 
P-CF precipitates solubilize in a variety of relatively mild detergents without prior 
denaturation (Klammt et al. 2004, Schwarz et al. 2007b). The lyso-phosphatidylglycerols 
LMPG as well as the related LPPG were found to be almost universal in the efficient P-CF 
solubilization of diverse structural classes of MPs ranging from transporters to GPCRs (Keller 
et al. 2008, Klammt et al. 2005). P-CF expressed ETA was also found to be most effectively 
resolubilized in LPPG and moreover exhibited the highest degree of homogeneity in this 
detergent (see 4.2.2.). The reasons to choose lyso-phosphaditylglycerols for resolubilization of 
ETA are suggestive in that (I) they might be well suited for the solublilization of MPs due to 
their close structural resemblance to native membrane lipids although displaying micellar 
character (Williams et al. 1996). (II) Lyso-phosphatidylglycerols were used to isolate large MPs 
in a native and functional form before and are well suited to analyse small MPs by NMR 
spectroscopy (Krueger-Koplin et al. 2004, Williams et al. 1996). A survey of 25 different 
detergents singled out lyso-phosphaditylglycerols as superior in stabilizing native MP 
conformations and in preventing their aggregation at high concentrations (Krueger-Koplin et al. Discussion   141 
 
2004). (III) The anionic character of the phosphatidylglycerol might be necessary for the native 
folding of ET receptors. The zwitterionic lysophosphocholine LMPC generated a much broarder 
elution profil upon gel filtration analysis (Fig. 15 A) suggesting a variety of oligomeric states. 
As many cell types predominantly expressing ET receptors contain PG to an average value of 
5-10 % (Christie 1985) ETA might not only need zwitterionic phosphatidylcholine but also a 
negatively charged headgroup for homogenous folding. Predominant fatty acids in endothelial 
cells were additionally found to be oleate, stearate and palmitate (Cansell et al. 1997). 
Therefore, LPPG (- palmitoyl) is likely preferred over LMPG (-myristoyl). (IV) 
Retrospectively, BN-PAGE (Schägger et al. 1994, Wittig et al. 2006) performed on ETA 
directly after resolubilization in 1 % LPPG additionally supported the choice of this detergent. 
Most of the receptor seemed to display monomeric character with a faint band pointing at 
dimerization (Fig. 15 B). This behaviour is reported for native ET receptors as well as for other 
GPCRs (see 1.3.4. and 1.5.5.). Likewise, a number of further GPCRs and complex transporters 
have already been functionally reconstituted from solubilized P-CF precipitates. The Trx-β2 AR 
in fusion to its Gsα protein (Ishihara et al. 2005) as well as the HRH1 (Kamonchanok et al. 
2008) showed activities comparable to in vivo data. Keller et al. revealed the functional 
reconstitution of P-CF produced eukaryotic drug transporters solubilized in 2 % LMPG (Keller 
et al. 2008). In contrast human P-CF expressed ETB was highly aggregated in LMPG and did 
not show any co-elution with fluorescently labelled ET-1 upon gel filtration, while D-CF 
expressed ETB in B78 exhibited ligand binding (Klammt et al. 2007c). 
Further reports of non-related MPs support that not only the D-CF but also the P-CF 
mode result in functionally folded proteins as shown for EmrE (Elbaz et al. 2004, Klammt et al. 
2004), the bacterial mechanosensitive channel MscL (Berrier et al. 2004) and a bacterial light-
harvesting protein (Shimada et al. 2004). Furthermore, synthetic amphipathic polymers appear 
to have a considerable potential in the functional solubilization of GPCRs even out of IB 
material (Dahmane et al. 2009) The P-CF mode might therefore become increasingly important 
for the rapid production of MP samples and optimized resolubilization conditions implementing 
an increasing variety of compounds could significantly improve success rates in future. 
 
5.2.2.  Detergent exchange of ETA: Effects of secondary detergents on the 
quality of the receptor 
The type and the properties of detergents play an important role in the recovery of an active 
state MP as they effect homogeneity and secondary structure elements (Le Maire et al. 2000). 
Two options for detergent screening can be considered. The first screen focuses on the detergent 
selected for initial MP solubilization in the D-CF or P-CF mode (see 5.2.1.). Any selected 
primary detergent in the P-CF or D-CF mode can be exchanged with almost any other detergent 
preferred for downstream analyses upon MP immobilization during the initial IMAC 
purification, dialysis or gel filtration (Arnold and Linke 2008, Linke 2009). Hence, in the 142   Discussion 
 
second screen upon MP purification, the detergents most suitable for the desired downstream 
assays are selected. 
An important parameter for sample quality is its homogeneity monitored by different 
oligomeric states. SEC profiling is an established and relatively universal tool for the initial 
estimation of protein aggregation and heterogeneity, ideally suited to investigate the effect of 
detergents on MPs. The homogeneity of different ETA samples could be correlated to the 
different production conditions. P-CF produced samples generally displayed a more symmetric, 
narrower peak shape after detergent exchange. The broad elution profile of D-CF produced ETA 
in B35 is in strong contrast to the homogeneity of P-CF produced samples (Fig. 18 and 19). 
Negative staining electron micrographs of different ETA sample preparations generated from 
D-CF or P-CF mode supported those assumptions (see 4.2.6.). Purified P-CF produced ETA 
was characterized by a high degree of monodispersity with equally sized particles in LPPG/B35. 
D-CF ETA instead displayed a high degree of heterogeneity (Fig. 22). For the CF expressed 
ETB receptor the opposite picture was revealed by negative staining. Whereas LPMG 
resolubilized P-CF produced ETB was highly aggregated, no detectable signs of aggregation 
were found for D-CF synthesized ETB in B78, which indicated a high sample quality (Klammt 
et al. 2007b). 
For P-CF produced ETA precipitates, resolubilization with LPPG followed by exchange 
to B35 or Fos-16 was best suitable. Highest yield of purified protein in line with homogenous 
gel filtration profiles indicated both detergents for further analysis (see 4.2.3. and 4.2.4.). The 
obtained results in the present study show that P-CF expression of GPCRs in combination with 
appropriate solubilization detergents can result in apparently homogenous sample qualities. The 
expression mode (see 5.2.1.) as well as the secondary detergent upon detergent exchange could 
therefore be identified as major determinants for the quality of the ETA receptor. These findings 
correlate with previous results of secondary structure analysis of CF expressed Tsx protein and 
the porcine GPCR V2R by CD spectroscopy. They revealed considerable variations of the 
α-helical and β-sheet contents which were dependent on the mode of expression or on the added 
detergent during IMAC purification (Klammt et al. 2005). 
Another effect of detergents is their influence on the oligomerization potential of MPs. 
DDM and CHAPS for instance influenced the oligomer-dimer-monomer equilibrium of 
rhodopsin (Jastrzebska et al. 2004) and CF expression in presence of different detergents 
affected the apparent dimerization of porcine V2R and human ETB observed upon SDS-PAGE 
analysis (Klammt et al. 2007b). 
The oligomerization state of P-CF produced ETA samples were analysed with MALS 
(Slotboom et al. 2008). ETA appeared to be predominantly monomeric in Fos-16 micelles 
whereas monomeric as well as dimeric particles were present in B35 micelles (see 4.2.5.). D-CF 
produced ETA in B35 displayed such a high molecular mass with over 1 MDa that no reliable 
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therefore be triggered by the surrounding micelles but is also dependent on the expression 
mode. This option might be of primary importance to study GPCRs more closely in vitro. The 
formation of molecular assemblies composed of dimeric or higher oligomeric units among 
GPCRs is discussed as a common mechanism potentially involved in modulating receptor 
function (Milligan 2004, Rios et al. 2001). The possibility of individual in vitro manipulation of 
the oligomeric state of a GPCR by a micelle of distinct composition might therefore represent 
an interesting tool to study their structure in order to develop therapies for diseases caused by 
oligomerization (see 1.3.4.). 
 
5.2.3.  Evaluation of secondary structure stability of CF expressed ETA 
Thermostability is an essential prerequisite of MPs which are subjected to structural 
investigations by X-ray crystallography and liquid-state NMR spectroscopy. Therefore, the 
stability of ETA proteomicelles was analysed by gel filtration as well as by CD spectroscopy. 
The stability of P-CF synthesized ETA appeared to be considerably high as almost identical 
SEC elution profiles could be obtained in several conditions after one week storage at 4 °C. 
Even for the very broad peak of D-CF produced ETA the elution profile did not change over 
time (Fig. 18 and 19). Accordingly, the thermal stability of the secondary structural elements of 
D-CF produced ETA in B35 and of P-CF produced ETA exchanged to B35 was notably high 
and observable denaturation started above 50 °C with Tm values of approximately 72 °C and 
85 °C, respectively (see 4.2.7.). These values correspond to the thermal stability of dark-adapted 
rhodopsin in disc membranes of around 72 °C (Khan et al. 1991). 
Enhancing thermostability from initial values of 37 to 47 °C or from 23 to 40 °C upon 
mutation was an important parameter towards crystallization of recombinant bovine rhodopsin 
and human adenosine A2a receptor, respectively (Magnani et al. 2008, Standfuss et al. 2007). 
Alteration of receptors by point mutation also enhanced the thermostability of the β1-AR to 
~53 °C or of the NTR 1 to about 50 °C compared with its highest stability in ligand bound form 
(Serrano-Vega et al. 2008, Shibata et al. 2009). However, those denaturation temperatures are 
not directly comparable to the data obtained with CF expressed ETA as temperature induced 
loss of radioligand binding versus thermal unfolding were determined. Those measurements 
indicate the thermal stability of the active tertiary structure of a protein. Potentially different 
sensitivities of the applied techniques must therefore be considered. For ETA, the high thermal 
stability only characterizes its secondary structure but nothing is so far known about its tertiary 
structure stability. 
To investigate the thermostability of a GPCR by ligand binding requires a 
straightforward technique and an easy to handle ligand. Due to its complex structure with two 
disulfide bridges and a highly hydrophobic character, ET-1 is only limitedly suited to establish a 
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hydrophobic surfaces might occur, generating false positives, and the disulfide bridges might 
break in certain buffer conditions rendering this ligand unreliable for throughput evaluation 
approaches (see 5.3.3.). 
Alternatives to assess the tertiary structure thermostability of CF expressed ETA 
without using radioligand binding experiments would be differential scanning calorimetry 
(DSC) which measures the enthalpy of unfolding due to heat denaturation and was already 
successfully used for rhodopsin (Kahn et al. 1991). However, the major drawback of this 
technique is, that a standard DSC instrument needs large amounts of protein in a concentration 
range required for structural determination. With regard to quality optimization of recombinant 
MPs, this technique is not suited for throughput screening purposes. Differential scanning 
fluorimetry (DSF), a more recent approach to determine the thermal stability of a protein’s 
tertiary structure, neither requiring the monitoring of enzyme activity nor high protein 
concentrations, might therefore be more suited for the investigation of the CF expressed ETA 
receptor. DSF has been adapted to high throughput formats and bases on environmentally 
sensitive dyes whose emission properties change upon interaction with thermally denaturated 
proteins (Pantoliano et al. 2001, Poklar et al. 1997). It has already been successfully applied to 
more than 200 soluble human proteins (Vedadi et al. 2006) and although specific detergents 
might interact with the fluoroprobe (Ericsson et al. 2006, Senisterra et al. 2010), evaluation of 
the right detergent/protein ratio might enable the implementation on MPs. 
 
5.2.4.  Membrane insertion of CF expressed ETA by co- or post-translational 
reconstitution 
The functionality of MPs is commonly explored in native membranes or lipid bilayers as they 
represent their natural environment and are associated with correct folding of the respective 
target proteins. Comprehensive studies of either native or recombinant ET receptors in crude 
membrane fractions obtained from eukaryotic homologous or heterologous host cells have 
already been performed (Adachi et al. 1994, Arai et al. 1990, Doi et al. 1997, 1999, Haendler et 
al. 1993, Schiller et al. 2000, 2001). However, invesitgations of in vitro reconstituted ETA or 
ETB are still scarce with reports of incorporation efficiency by freeze-fracture (Klammt et al. 
2007b) or extrinsic fluorescence intensity (Saravanan et al. 2004, 2007). However, ligand 
binding of in vitro reconstituted CF expressed ET receptors has not been evaluated so far. 
Reconstitution of MPs, with special focus on CF expressed MPs and GPCRs, can be 
accomplished in two different ways. In the classical post-translational reconstitution approach, 
P-CF or D-CF mode generated MP proteomicelles are in vitro inserted into lipid bilayers by 
dilution of the solubilizing detergents below their CMC upon addition of liposome stocks 
(Rigaud et al. 1995). Preformed liposomes may alternatively be pre-destabilized by moderate 
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to hydrophobic resins like Biobeads (Rigaud et al. 1998). The reconstitution of CF expressed 
detergent-solubilized MPs and GPCRs by those conventional techniques is feasible and its 
success has been monitored by freeze-fracture analysis or ligand binding assays (Berrier et al. 
2004, Elbaz et al. 2004, Kamonchanok et al. 2008, Keller et al. 2008, Klammt et al. 2004, 
2007b). 
Alternatively, the L-CF expression mode in the presence of supplied lipids, which is 
unique for CF expression, offers a new option for the co-translational insertion of MPs. In this 
mode, lipids can be supplied into the CF RM in a variety of formulations (see 1.2.3.). One clear 
advantage of the L-CF mode might be a prevalent inside out orientation of the target MP as the 
translation happens outside of the vesicles (Schwarz et al. 2008) in contrast to the random 
orientation of conventional in vitro reconstitution approaches in which detergent to lipid ratios 
and types have to be carefully evaluated to trigger the direction of insertion (Knol et al.1998). 
Such a unidirectional insertion would simplify functionality assays and enhances their 
sensitivity. However, a couple of parameters have to be considered if applying the L-CF mode 
because the charge of the lipids can greatly affect transcription and translation efficiency in the 
CF systems (see 1.2.3.). Lipid and lipid mixtures are tolerated at often high concentrations in CF 
expression (Klammt at al. 2004) but their concentration may furthermore influence the obtained 
expression level as shown for GFP (Bui et al. 2008). In contrast to the commonly used P-CF and 
D-CF mode, the L-CF mode is just emerging, but recent reports of successfully integrated MPs 
in different lipid environments including nanodiscs clearly point at the high potential of this 
technique (see 1.2.3.). 
For both approaches, protocols have to be adapted to the respective target proteins as 
efficient translocation is target dependent and can be considered as major challenge that has to 
be overcome. The rate of successful MP integration can for instance be monitored by electron 
microscopic freeze-fracture analysis, immunodetection or ligand binding assays if available. 
Protease protection assays can further support the insertion of MPs by topological information 
but their implementation was not successful for ETA in the current work (data not shown). 
Freeze-fracture analysis revealed a homogenously dispersed character of the inserted 
ETA particles from post-translational insertion (Fig.  28) as is expected for functional 
reconstitution (Lindstrom et al. 1980). The observed reconstitution efficiency was however very 
low with only 5-10 particles per vesicle. Furthermore, the majority of the protein precipitated 
during reconstitution causing high background signals in subsequent radioligand experiments. 
Change of reconstitution conditions by evaluation of expression modes, protein detergents as 
well as liposome destabilizing detergents, lipid-to-protein ratios and lipid compositions enabled 
the suppression of high background in some cases and highlighted that reconstitution of ETA 
and ETB samples was only successful with P-CF produced samples out of LPPG or LMPG 
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GPCRs which were most effectively reconstituted from P-CF mode solubilized protein samples 
(Ishihara et al. 2005, Kamonchanok et al. 2008, Klammt et al. 2007b). 
A functional assay was further developed which allowed a correlation between insertion 
rate of liposomes either gained by co- or post-translational reconstitution and specifically bound 
ligand (see 4.3. and  4.3.1.). Highest activity of ETA was always measured at 1:1,000 molar 
protein-lipid ratio with artificial lipids composed of either eukaryotic asolectin PC, PC/PE 
mixtures or E. coli polar lipids (with major components PE and PG). 
L-CF expressed ETA, whose synthesis was always performed in presence of CHAPS 
pre-destabilized liposomes, was also evaluated by radioligand binding (see 4.4.2.). The best 
signal/background ratio was determined for a mixture of asolectin PC, PE and PG, which was 
higher than the apparent with pure aso-PC (Fig. 33). These results are in accordance with the 
evidence that lipid charge influences CF translation and that anionic lipids might be required for 
functional reconstitution of specific targets (Bui et al. 2008, Umakoshi et al. 2009, Van Dalen et 
al. 2002). Anionic LPPG resulted in the most homogenous profile of ETA supporting the 
assumption that ETA might need surrounding negative charges (see 5.2.1.). However, overall 
binding efficiencies were lower as compared with post-translational reconstitution. Whereas for 
the latter approach binding values of up to 60 % over background were calculated, only 30 % 
were reached with the best conditions in the L-CF mode. Protein precipitation or partial 
integration caused by detergent removal along with inefficient translocation through the lipid 
bilayer is most probably the reason for the observed high background. Approaches to wash the 
L-CF pellet with urea in order to remove attached proteins from the surface of the liposome 
failed, as the same high background was observed with or without urea treatment (data not 
shown). 
Reasons for problems with translocation are evident. Efficient insertion of MPs into the 
membrane is generally hampered by large terminal domains, extended hydrophilic loop regions 
or tags since those enlarge the hydrophilic MPs parts and with it the energy barrier which has to 
be surpassed to become inserted (Hessa et al. 2005). Furthermore, hydrophobic protein parts 
should be completely covered by detergent molecules which is essential for functional 
reconstitution (Jung et al. 1998, Padan et al. 2008) especially at the stage of detergent removal. 
Loosely covered hydrophobic patches will tend to aggregate faster resulting in precipitation 
instead of reconstitution. GPCRs are MPs with large hydrophilic domains whose integration in 
the membrane is processed by eukaryotic translation machineries (see 1.1.1.). The CF expressed 
ETA additionally comprises hydrophilic N- and C-terminal tags which enlarge those domains. 
Furthermore, detergent removal by Biobeads might not be suited for ETA with regard to 
rapidity or detergent compatibility. Careful evaluation of the right detergent and of the detergent 
removal technique in combination with changes in the speediness of removal might increase the 
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In order to improve the functional reconstitution of ETA in the L-CF mode, one of the first steps 
is the reduction of precipitated protein by lowering the amount of DNA template or by 
decreasing the expression temperature thus slowing down production kinetics. Addition of 
agents like non-delipidating detergents such as fluorinated surfactants (Park et al. 2007, Polidori 
et al. 2006), Brij derivatives or the addition of lipids like cholesterol, all likely stabilizing the 
MP prior to liposome insertion or acting as specifically bound co-factors for functional folding 
(Hunte and Richers 2008, Opekarova and Tanner 2003), might be further options to control and 
to enhance functional reconstitution in the L-CF mode. However, it is questionable if the L-CF 
mode is suitable for ligand binding assays of GPCRs. If one prevalent orientation of the MP 
upon insertion is generated (Schwarz et al. 2008), the N-terminus as well as all native ECLs of 
GPCRs could face the interior of the liposome. With most peptide ligands binding to 
extracellular domains and the upper parts of the TMSs (Ji et al. 1998, Kobilka 2007) effective 
ligand binding might then not be expected for the ET receptors if the ligand is not transported 
through the membrane. But even if functionality could not be approached, the reconstitution by 
L-CF mode would still be a promising option for techniques that require quantitative 
reconstitution as a prerequisite such atomic force microscopy (AFM) to study protein folding 
and stability. If efficient co-reconstitution of ETA and/or ETB can be obtained by L-CF 
expression this would further be a very fast, straightforward and competitive sample preparation 
method to investigate the oligomerization potential of CF expressed receptors by FRET 
measurements (see 5.5.). 
 
5.3.  Functional characterization of the ET receptors 
5.3.1.  Lipid based functional studies 
Functional studies of GPCRs have mostly been performed in native membranes or in artificial 
liposomes of defined composition. Specific antagonist binding for CF expressed GPCRs was 
measured with reconstituted synthetic Gsα-fusions of the human β2-AR expressed in the P-CF 
mode in E. coli extracts (Ishihara et al. 2005). The human HRH1 was synthesized in E. coli 
extracts in the P-CF mode, solubilized in DDM and reconstituted into proteoliposomes. 
Competition binding assays revealed pharmacological properties similar to the protein isolated 
from Sf9 cells or measured in mammalian COS-7 cells, although the binding affinity of one 
inverse agonist was found to be 100-fold reduced (Kamonchanok et al. 2008). Likewise, 
alprenolol showed up to 1000-fold reduced inhibition and an altered binding mechanism to the 
human β2-AR with thioredoxin and Gsα in two-site competition analyses if compared to the 
Sf9 positive control which showed one-site binding (Ishihara et al. 2005). The determined IC50 
values of reconstituted ETA and ETB in the present study with 2.17 µM are in between 10
3- and 
10
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only moderate ET-1 binding affinities (Desmarets et al. 1996, Desmarets and Frelin 1999, Saeki 
et al. 1991). Nevertheless, the IC50 values are in the same order of magnitude for both ET 
receptors (Junge et al. 2010b) which is in good agreement with previous studies, suggesting 
equal inhibition competence of unlabelled ET-1 (Saeki et al. 1991). KD values with CF 
expressed ETA receptors in artificial liposomes of varying composition were calculated by 
saturation binding of radioactively labelled ET-1. Equilibrium dissociation constants with 
positive cooperativity were determined at around 1.4 nM (see 4.3.3.). These binding data are on 
average only one or two orders of magnitude higher than in other heterologous membrane 
preparations (Table 15) and therefore well comparable to in vivo data except for the detection of 
cooperativity. 
Table 15: Heterologous expression systems for the production of ET receptors. KD determined by 
radioactive binding of 
125I-ET-1. Ki or IC50 values were determined with native peptides. The table was 
modified after Schiller et al. 2000. 
 
Receptor 
subtype 
Expression 
system 
Production 
levels
A 
Affinity 
(binding) 
Assay
B  Reference 
ETB  E.coli  41 r/c  100 pM [KD]  m  Haendler et al. 1993 
ETB  P. pastoris  20-60 pmol/mg  42 pM [KD]
a 
200-700 pM [Ki]
b 
m  Schiller et al. 2000 
ETB  P. pastoris  9 mg/L  40 pM [KD]  m  Schiller et al. 2001 
ETA  Sf9 cells  ~0.25 mg/L  50 – 80 pM [KD]
a  m  Doi et al. 1999 
ETB  CHO cells  0.82 pmol/mg  310 pM [KD]  m  Takagi et al. 1995 
ETB  CHO cells  0.02 pmol/mg  25.5 pM [KD]  m  Buchan et al. 1994 
ETA CC139 
fibroblasts 
-  30-400 pM [IC50] 
20 pM [KD] 
m  Desmarets et al. 
1996, 1999 
A Production levels either expressed as total number of binding sites (pmol/mg), as Bmax value calculated 
from the binding data (pmol/mg protein), total amount of receptor per litre culture (mg/L) or as receptors 
per cell (r/c) 
B Assays performed on membrane preparation (m) 
a saturation binding with 
125I-ET-1 (Schiller et al. 2000, 2001; Doi et al. 1999) 
b competition with ET-1, ET-2 or ET-3 
-, not indicated 
Prominent differences in IC50 and KD values of the same ligands to CF expressed receptors 
were observed for the human β2-AR with thioredoxin and Gsα (Ishihara et al. 2005) as well as 
for different ET receptor membrane preparations (Desmarets et al. 1996, Desmarets and Frelin 
1999). Copy number effects resulting from difficult to determine receptor concentrations might 
account for those diverging results in obtained ligand binding data (Desmarets et al. 1996). 
Competition experiments with ET-1 and ETA commonly result in a broad range of apparent KD 
values in between 20  pM and 1  nM. This oberservation is attributed to inaccuracy in the 
determination of receptor concentration rather than to the binding itself, as complex second-
order rate kinetics and ligand depletion control ligand association employing receptor 
concentrations higher than the apparent KD (Desmarets et al. 1996, Desmarets and Frelin 1999, 
Jacobs et al. 1975). The concentration of CF reconstituted ETA receptor was commonly only 
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micrographs (Fig.  28) as all other assays failed due to the residual precipitate presumably 
attached to the liposomes (see 5.2.4.). Therefore, imprecise determination of ETA concentration 
might be an explanation for the high difference of IC50 values from in vivo material. Similarly, 
positive cooperativity with Hill slopes of ~2 was found in saturation binding experiments of 
purified NTR  1 at high receptor concentrations whereas at low receptor concentrations Hill 
slopes of ~1 prevailed. The authors concluded that the receptor must exist as dimers or higher-
order oligomers at high concentrations to explain the positive cooperative effect (White et al. 
2007). Such oligomerization effects might cause the positive cooperativity observed in CF 
expressed ETA. 
Further explanations for those variations are related to the absence of a eukaryotic cell 
environment. PTMs such as glycosylations and palmitoylations are known as potential 
modulator of GPCR binding properties and could affect the interactions of ETA with ligands 
(Shraga-Levine and Sokolovsky 1998, Zhang et al. 2001). The C-terminal domain and the third 
cytoplasmic loop of ETA and ETB contain several putative phosphorylation sites and 
glycosylations and palmitoylations are further proposed modifications of both receptors. Quite 
pronounced is the role of G-protein coupling and association with GPCR interacting proteins in 
enhancing ligand binding (Fitzsimons et al. 2004, Hay et al., 2006). Dynamic interactions of 
ligand/receptor/G-proteins can be necessary for high affinity agonist binding. The production of 
unmodified receptors in the E. coli based CF system in combination with the absence of any 
accessory proteins or specific lipids after reconstitution into defined E. coli polar lipids could 
therefore contribute to modified binding properties or to incorrectly folded protein. 
 
5.3.2.  Working with detergent-solubilized ET receptors 
The most common objection against working with MPs in a micellar environment is the 
assumption, that their functionality is considerably changed or even completely abolished due to 
the lacking membrane environment. The absence of lateral pressure and the exposure of 
hydrophobic surfaces to aqueous solutions during MP solubilization are thought to considerably 
perturb their structures (Rosenbusch 2001). This is supported by the fact that ligand binding 
profiles of ETB in intact cells already differ from corresponding membrane fractions (Hara et al. 
1998). 
However, a variety of GPCRs has already been synthesized in CF systems in a 
detergent-solubilized state and their functional activity has subsequently been evaluated by in 
vitro analysis. Ligand binding of a human olfactory receptor was reported after D-CF 
production in WGE (Kaiser et al. 2008). Full-length and truncated derivatives of the human 
ETB receptor have been D-CF synthesized in presence of B78 and ligand binding of the agonist 
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SPR measurements, were shown to be only marginally different from in vivo data (Klammt et 
al. 2007b, 2007c). 
A first indication that CF expressed ET receptors in detergent micelles might behave 
similarly to receptors extracted out of native membranes has been gained in present work. Both 
CF expressed receptors displayed different receptor-ligand complex stabilities with b-ET-1 
upon separation via SDS-PAGE (Fig. 37). In contrast to ETA whose binding to b-ET-1 could 
not be detected by western blotting, human CF expressed ETB seems to form a tight complex 
with its ligand ET-1 which remains stable upon treatment with SDS. The same observations 
were made with receptors isolated from crude canine membranes and human placenta samples 
(Takasuka et al. 1992, 1994). 
Since detergents do not display static structures and the polydispersity of micelles 
commonly varies (Garavito and Ferguson-Miller 2001, Hauser 2000), functional folding of MPs 
most likely is considerably effected by the micellar environment generated by different types of 
detergents. Besides heterogeneity in oligomeric states, the presence of different folding 
conformations can become a major bottleneck for structural approaches. Purification of 
solubilized GPCRs by their ligand binding properties is therefore an essential step in quality 
control and represents a valuable tool to receive homogenous sample qualities. The ligand 
binding competence of solubilized ETA to immobilized b-ET-1 ligand ranged from 
approximately 1 % up to 50 % in B35 or DDM micelles (see 4.5.1.). Those relatively high 
binding capacities could be obtained from ETA expressed in the D-CF mode as well as in the 
P-CF mode, the P-CF quality in particular being in accordance with the comparable sample 
qualities obtained by SEC and MALS (see 4.2.4. and 4.2.5.). However, high batch variations of 
DDM along with decreasing yield of purified ETA in the course of the presented work made it 
impossible to proceed working with this detergent (see 4.2.3.). 
Corresponding GPCR ligand binding capacities after cellular expression in E. coli cells 
revealed 40 % for the human peripheral cannabinoid 2 receptor and only less than 1 % for the 
human  α2b-AR (Magnin et al. 2009). Large-scale fermentation of a NTR  1 fusion protein 
yielded in 90 mg functional fusion protein / 200 L of culture (White et al. 2004). Considering 
initial yields of purified ETA of approximately 1 mg/mL after P-CF expression and 0.5 mg/mL 
after D-CF expression, corresponding amounts of some 500  and  250  µg ligand-binding 
competent ETA could be isolated out of 1  mL RM with the described optimal conditions 
(see 4.5.1.). With P-CF expressed ETB, the ET-1 binding competence was found to be 
significantly lower within the range of less than 10 %. This corresponds to previous findings 
indicating that P-CF produced solubilized ETB still contains a high degree of aggregated 
inactive protein (Klammt et al. 2007c). It is therefore important to note that the ETA receptor 
behaves differently from ETB after P-CF expression in showing non-aggregated sample quality 
combined with high ligand binding competence. The P-CF as well as D-CF mode can thus be Discussion   151 
 
implemented for the preparative scale production of functional ETA. However, while the D-CF 
mode should be preferred for ETB, the P-CF mode is highly suited for ETA. 
The dissociation constant of the linear f-4-Ala-ET-1 ligand in ETA proteomicelles was, 
corrected by a factor of 50 % binding capacity, determined at around 1.2 µM by fluorescence 
anisotropy, compared with 0.57 µM in crude membranes of human tissue (Saeki et al. 1991) or 
4.52  µM reported by Molenaar in cardic membranes (Molenaar et al. 1992). This marginal 
variation might be explained by different assay conditions, fluorescence anisotropy versus 
radioligand binding to membranes, and the use of differently labelled ligand derivatives. 
Specificity of the binding was controlled with the ETA receptor/b-ET-1 complex eluted from 
the monomeric avidin matrix, which did not show any increase in anisotropy (see 4.5.3.). 
Recent reports show that fluorescence anisotropy was also successfully applied to membrane 
preparations of melanocortin 4 (Veiksina et al. 2010) and muscarinic M1 receptors (Huwiler et 
al. 2010) and might therefore represent a valuable alternative to SPR measurements to study 
ligand binding of detergent-solubilized GPCRs. 
 
5.3.3.  Troubleshooting for functional studies: Structural complexity of ET-1 
One of the most prominent problems working with ET peptide ligands is their intrinsic 
hydrophobicity along with a very complex structure formed by two disulfide bridges (see 1.5.2.) 
and a high aggregation potential in aqueous solution (Bennes et al. 1990, 1991), so that the 
peptide has to be solubilized in an organic solvent like DMSO. The physiological necessity of 
the ET-1 peptide of being partly hydrophobic might reside in the mechanism of receptor-ligand 
binding. It might at least partially need to integrate into the membrane to reach its binding 
region as peptide ligands smaller than 40 aa are thought to bind to parts of ECLs and the upper 
parts of the TMSs of GPCRs (Ji et al. 1998, Kobilka 2007). For ET-1 and ETB it has been 
proposed that TMS 1 (Klammt et al. 2007c) and parts of the fifth TMS (Boivin et al. 2005) are 
essential. ET-1 might interact with ETA at parts of ECL 1, IL 3 and TMS 4 and 6 (Aubin et al. 
2008) with a histidine residue in the sixth helix binding to the essential tryptophan 21 of the 
ligand. Modelling studies further proposes a hydrophobic binding cleft for the C-terminus of the 
ligand confined by aromatic residues in helices 3, 5 and 6 (Huggins et al. 1993). 
Difficulties which presumably arise from the ligand’s complex structure have been 
encountered in this thesis. Scintillation proximity assays (SPA) with ET-1 and CF expressed 
ETB failed due to unspecific interactions of the ligand with empty scintillation beads of 
different types (cooperation with Dr. Michael Beyermann, data not shown). Likewise, the 
competitive displacement of monomeric avidin matrix bound ETA/b-ET-1 with ET-1 tried as 
alternative to elution with biotin was not possible, most probably due to a high interaction of 
ET-1 with the matrix material alone, monitored with 
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have considerably reduced its quantitative potency to displace the b-ET-1 derivative from its 
binding site on ETA. 
Fig. 59: Unspecific interaction of 
125I-ET-1 with the monomeric avidin agarose beads. (A) Elution 
profile of 
125I-ET-1 from MAM. (B) Radioactive ligand retained on MAM beads. The fraction of ligand, 
removed by washing and elution with biotin is very small (300-1000 cpm) although no receptor 
interaction partner is bound to the matrix. The retained total counts on the matrix after washing and 
elution are suggestive for high unspecific matrix/ligand interaction (25000-260000 cpm). 
Unspecific interaction of ET-1 with the surrounding micelles or with similar hydrophobic 
binding pockets of the prepared CF expressed GPCRs, due to its hydrophobic C-terminus, might 
have been one of the reasons why cross-interactions with V2R (aromatic residues at similar 
positions, see above), CRF and ETB at equal binding kinetics were observed upon SPR 
measurements (see 4.8.2.). Those encountered difficulties rendered it highly necessary to 
perform excessive NCs for all presented functional assays with detergent-solubilized ETA. 
High background binding which was always observed when using liposome reconstituted 
CF expressed ETA (Fig. 27 and 33) might also result from hydrophobic interactions of ET-1 
with partially integrated, misfolded receptor or with liposome-attached receptor precipitate. Due 
to detergent removal, the hydrophobic patches of precipitated ETA are completely accessible 
and may offer many unspecific binding sites for ET-1. 
 
5.4.  Structural investigations of CF expressed human ETA receptor 
5.4.1.  Using CF expression for structural studies of GPCRs by X-ray 
crystallography 
CF expression could offer a high potential for the structural analysis of MPs by NMR 
spectroscopy as well as by X-ray crystallography. The set-up is ideally suited for rapid screens 
of optimal expression and resolubilization conditions, and protein samples can be obtained in 
less than 24 hours. Besides the efficient incorporation of isotopically labelled amino acids 
(Ozawa  et al. 2005, Reckel et al. 2008, Trbovic et al. 2005), non-natural and chemically 
modified amino acids can become incorporated quantitatively into CF-synthesised proteins 
(Kanda et al. 2000, Kiga et al. 2000, Sengupta et al. 2003). This can also be utilised in order to Discussion   153 
 
include selenomethionine in protein samples for X-ray crystallography (Kigawa et al. 2002). In 
addition, beneficial supplements which can enhance protein stability for crystallization attempts 
like ligands, cofactors or substrates can be added directly, without considering transport or 
metabolic conversion problems. Furthermore, problems of heterogenous sample quality upon 
inefficient or differing glycosylation patterns often present in in vivo systems are avoided 
(Okamoto et al. 1998, Shraga-Levine et al. 1998). Crystals of CF expressed MPs were recently 
obtained with EmrE and VDAC1 (Chen et al. 2007, Deniaud et al. 2010, Nguyen et al. 2010) 
clearly demonstrating that the quality of CF-produced MP samples can be sufficient for 
crystallization. 
ETA was judged suitable for initial screenings of critical parameters for structural 
analysis by X-ray crystallography as it fulfilled a variety of essential prerequisites. (I) In the 
present work, ETA could be expressed in the P-CF mode in high amounts of 1.5  mg/mL 
average yield. (II) After resolubilization in 1 % LPPG and subsequent IMAC purification to 
0.1 % B35 a purity of approximately 98 % was achieved (Fig. 17 A and Table 11). (III) SEC 
and MALS analyses pointed at homogenous sample qualities (see 4.2.4. and 4.2.5.) which was 
supported by negative staining EM (see 4.2.6.). Samples are furthermore stable after purification 
for at least one week at 4 °C. (IV) Its secondary structure exhibited high thermostability at 
around 85 °C investigated by CD spectroscopy (see 4.2.7.). This enabled crystal screening not 
only at 4 °C but also at 18 °C as well as at 22 °C required for lipid-based cubic phase trials. 
Higher temperatures than 4 °C were prevalent in solving most of the recent crystal structures of 
GPCRs (Cherezov et al. 2007, Hanson et al. 2008, Jaakola et al. 2008, Rasmussen et al. 2007, 
Warne et al. 2008). (V) The ligand binding competence of ETA in 0.1 % B35 was successfully 
proven by fluorescence anisotropy and ligand affinity chromatography (see 4.5.1. and 4.5.3.). 
Most of the GPCR structures (Cherezov et al. 2007, Hanson et al. 2008, Jaakola et al. 2008, 
Warne et al. 2008) needed co-crystallization of agonists or antagonists to stabilize the active and 
homogenous receptor conformation. Binding of ETA to its ligand ET-1 at up to 50 %  which 
could be performed in 0.1  %  B35 might therefore be a requirement for successful 
crystallization. (VI) ETA could be concentrated in absence and in particular in presence of the 
ligand to >5  mg/mL without loosing its overall homogeneity as monitored by gel filtration 
(see 4.6.1.). 
Detergents in type and concentration are one of the most critical parameters in MP 
crystallization as they have to keep the protein in a soluble form, provide the necessary stability, 
allow an active conformation and should not impair the formation of rigid crystal contacts 
largely based on hydrophilic domains of the protein protruding from the proteomicelle (Hunte 
and Michel 2002). Commonly used detergents such as DDM or Foscholine-derivatives (Fos-16 
in this case) which were investigated in this study upon detergent exchange of CF expressed 
ETA did not provide the necessary combination of all parameters like long-term stability, 
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detergent used for crystallization of ETA was therefore primarily not guided by those detergents 
which most often yield ordered crystals but rather based on the fact that the Brij derivative B35 
showed the best overall compatibility with ETA. Initial crystallization screens were 
accomplished with 150 µL each of ETA either concentrated to 5.2 mg/mL without ligand or 
concentrated to 8.0 mg/mL in presence of ET-1 with the sitting drop vapour diffusion method. 
The screens were performed on the CrsytalMation
TM automatic platform in 96-well formats (in 
cooperation with Dr. Yvonne Thielmann) with crystal drops of 200 nL volume. Therefore, it 
was possible to apply over 18 commercial as well as custom screens not only comprising 
classical vapour diffusion but also cubic phase trials with only two ETA sample preparations of 
150 µL each (see 7.5.). 
So far, no crystals were observed in any of the analysed conditions. Neither a certain pH 
nor certain precipitants or additives could be qualified as essential until now but some tendency 
towards microcrystallization of ETA could be observed with MemSys
TM, MemGold
TM and 
MemStart+MemPlus
TM (see 4.6.2.). 
 
5.4.2.  Getting CF expressed human ETA to crystallize 
Engineering MPs by the insertion of mutations to enhance the receptor’s thermostability, 
integration of T4 lysozyme or binding of antibody fragments to the receptor in order to enlarge 
the available crystal contact surface was essential for crystallization of all recent recombinant 
GPCR structures (see 1.3.5.) (Hunte and Michel 2002, Rosenbaum et al. 2009, Serrano-Vega et 
al. 2008). Those approaches should be among the first choice if the non-engineered ETA 
receptor does not crystallize as they base on extensive fundamental research and high expertise. 
There are however still a variety of options to improve the quality of non-engineered 
ETA. Crystallization is a result of supersaturation. 5-8 mg/mL is considered as the lower limit 
of an initial desirable concentration for crystal growth. This could hence be one of the first steps 
to be approached, as ETA did not show any remarkable tendency to high-order aggregates upon 
concentration which could further be modulated and controlled by the addition of ET-1 during 
concentration (see 4.6.1. and 4.6.2.). The choice of detergent also plays an important role. B35 
is not commonly used in crystallization since it generates very large micelles tending to impair 
crystal contact formation. There is a long list of common non-ionic and zwitterionic detergents 
used for crystallization which have to be tested in future in terms of quantity, quality and 
functionality of the receptor like the preferred alkyl maltosides with the CYMAL series, the 
alkyl glucosides as well as alkyl dimethylamine-oxides like LDAO (Hunte and Michel 2003). 
However, due to the observation that the shortest of the long-chain Brij derivatives B35 seemed 
optimally suited for the generation of crystallization-grade ETA by CF synthesis, a variety of 
short-chain alkyl polyoxyethylenes like C8E5, C8E4, C12E9 or C12E8, also commonly utilized 
in crystallization trials, could further be suited for the receptor. Around 7-12 carbons in length Discussion   155 
 
are at least needed to mimic the thickness of the hydrophobic part of native membranes (Wiener 
2004). It might therefore be an interesting option to mix short- and long-chain Brij derivatives 
for the crystallization of ETA. Overall, it is crucial to retain its ligand-binding capacity which 
might be reduced the shorter the alkyl chains get. Successful exchange to those detergents 
should therefore be analysed first by SEC and ligand affinity chromatography which is a 
valuable tool that will greatly facilitate the evaluation of the alternative detergents. 
Other options to enhance the receptor’s stability and homogeneity -which were not 
investigated so far due to a pronounced loss in sample quantity of up to 50 %- are secondary 
purification steps of ETA either by ligand affinity chromatography or by gel filtration which are 
also commonly applied techniques in receptor preparation for crystallization (White et al. 2004). 
The upcoming method of lipid cubic phase crystallization (Caffrey and Cherezov 2009), doped 
with cholesterol, was successfully applied in the structural determination of the human β2-AR 
(Cherezov et al. 2007, Hanson et al. 2008) and the human adenosine A2a receptor (Jaakola et al. 
2008). This approach might further be a very interesting alternative to the classical vapour 
diffusion crystallization of ETA as it stabilizes the receptor in a more native-like environment 
and the addition of cholesterol could influence ETA receptor stability (Burger et al. 2000, Couet 
et al. 1997). Brij  derivatives as well as fluorinated surfactants which showed reasonable 
(fluorinated surfactants) to high ETA receptor quality (B35) (see 4.5.1.) might in this case be 
ideally suited for the partitioning of the protein into the provided lipid bilayers since they are 
very mild and do not disintegrate membranes (Park et al. 2007, Polidori et al. 2006). 
 
5.5.  Interaction of the individual CF expressed ET receptors 
5.5.1.  Oligomerization behaviour of CF  expressed ET receptors in the context 
of current models 
Homo- and hetero-dimerization/oligomerization of rhodopsin-like GPCRs is an increasingly 
recognized mechanism and investigations thereof are a growing field in science. It has been 
shown in different receptor systems that both types of interaction have enormous physiological 
and pathophysiological implications (Chabre and Le Maire 2005, Jastrzebska et al. 2006, Lee 
S.P. 2004) and might therefore represent an important platform for the modulation of GPCR 
activities such as ligand binding, signalling or trafficking (Rios et al. 2001, Schöneberg et al. 
1999). Understanding the mode in which different or the same protomers of the complex 
interact as well as revealing their interaction interface is essential for the development of totally 
new therapies for a variety of diseases related to receptor complex formation (George et al. 
2002, Milligan 2007). 
The underlying structural interaction mechanism in homo- and heterodimers of the ET 
receptors has not been elucidated yet and is still a matter of debate. Bivalent ligands have been 
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this hypothesis has been contrasted by the findings that indeed neither agonists nor antagonists 
did show any influence on dimer formation or dissociation (Evans and Walker 2008, Gregan et 
al. 2004a, 2004b) and single-particle analysis strongly suggests ETB dimer formation in the 
absence of the ligand (Klammt et al. 2007b). In the rhodopsin-like family, to which the ET 
receptom belongs, the model of robust hydrophobic interaction between the TMSs is favoured 
as SDS-resistant oligomers are often observed (Lemmon et al. 1992) and involvements of 
almost all TM helices (1, 2, 4, 5, 6) including parts of extracellular domains have been analysed 
for a variety of different GPCRs (Milligan 2007). 
Recently, it has been proposed by pull-down experiments of D-CF expressed full-length 
human ETB receptor and truncations thereof that the TMS 1 is involved in the essential 
interface for intermolecular interactions between single ETB monomers as the two fragments 
ETB131 and ETB93a, which overlapped in that region, did still form dimers with full-length 
ETB (Klammt et al. 2007c). 
In accordance with the studies performed by Dr. Christian Klammt, investigations of CF 
expressed human full-length ETA and ETB as well as various designed truncations should allow 
further characterization of the molecular interaction and possible interfaces between ETA 
homodimers as well as ETA/ETB heterodimers in the current study. Synthesizing truncated 
derivatives of MPs for the analysis of receptor interactions is a very straightforward approach 
and largely facilitated by using CF expression. Truncations might be toxic in cell-based systems 
resulting in low expression yields or even cell-death. Alternatively, they might be recognized by 
cellular regulatory machineries as aberrant or damaged, subsequently degraded by the 
proteasome or single proteases. Small-sized MPs, like truncations in this case, are readily 
synthesized in CF systems in high amounts often surpassing the yields of large proteins 
(Schwarz et al. 2010). This has already been shown for the human ETB receptor (Klammt et al. 
2007c). Similar results were obtained with the synthesis of ETA truncations in this work 
(see 4.7.1.). All derivatives were expressed at high levels and were characterized by the same 
resolubilization behaviour as the full-length ETA construct (Fig. 44). 
The potential of CF produced full-length ETA to homodimerize was already observed 
by different techniques during quality analysis. Apparently stable SDS-resistant dimers of ETA 
in 0.1 % B35 were detected by ESI-mass spectrometry of in-gel trypsin digested receptor bands 
and by MALS combined with SEC (see 4.7. and 4.2.5.). Furthermore, protein bands at the 
approximate size of the calculated dimers were also observed by BN-PAGE analysis of directly 
resolubilized ETA in 1 % LPPG (see 4.2.2.). 
Pull-down experiments with differently tagged receptors served as tool for the analysis 
of ETA and ETB interactions in the present thesis (see 4.7.2.). Pull-down assays require stable 
interactions with low dissociation constants to ensure that the interacting partners do not 
disassemble during the washing steps. This stable interaction might be hampered by large 
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analysed by two different CF expression approaches followed by pull-down via strep-affinity 
chromatography. Either the full-length receptors were co-expressed during CF synthesis or they 
were expressed separately and subsequently mixed as individual components. The 
co-expression assay was favoured, as it has been hypothesized that at least homo-
oligomerization already occurs at the level of protein synthesis in the ER or during maturation 
of the GPCR prior to cell surface delivery (Bulenger et al. 2005). B35 was chosen as most 
promising detergent since ETA already showed possible dimerization in it (Fig. 20, 40 and 41) 
and since it further allowed the expression of all interaction partners. 
Co-expression resulted in a quantitative pull-down of the his-tagged ETB and ETA 
receptor with full-length ETAstrep indicating homo- and heterodimerization of both ET 
receptors (Fig.  46  A). Likewise, receptor interaction could also be observed with the 
combination ETAstrep/ETA197cHx which would suppose that at least the first three TMSs with 
adjacent loops and the N-terminal region might be sufficient for homodimerization (Fig. 46 B). 
Since all tested ETBcHx truncations, some harbouring N-terminal segments (ETB131, 
ETB93a), some only consisting of C-terminal receptor parts (ETB308) could further be 
co-eluted with the full-length ETAstrep receptor under the chosen conditions, it is likely that 
more than only one defined region may be necessary for the heterodimerization of ETA with 
ETB. The interaction interface might be allocated to different parts without any detectable 
preference for distinct TMSs. This is in accordance with the existing model of ‘contact’ dimers 
for a variety of other GPCRs (see 1.3.4.) indicating involvements of almost all TMS (1, 2, 4, 5, 
6) for their interaction (Milligan 2007). In a co-expression approach of single helix bundles of 
rhodopsin it was further possible to reassemble a functional receptor (Yu et al. 1995) indicating 
a specific interaction within the helix bundle itself, most likely due to hydrophobic interactions 
(Yeagle and Albert 2007). 
The obtained results are however highly questionable at this point. Supposed NCs of 
ETAstrep with unrelated his-tagged MPs (NTF as well as TMD0), which were performed in 
parallel, also resulted in co-elution of latter proteins with the ETA receptor showing the same 
elution behaviour like the interacting ET derived partners (Fig. 48). Analysis of all single his-
tagged components with regard to their affinity to the strep-matrix could in fact exclude cross-
reactivity as possible explanation of the results (Fig.  47). Therefore, it was assumed that 
hydrophobic interactions between the TMSs themselves might be the reason for the obtained 
results since those associations can readily occur either in a specific (for the ET receptor 
combinations) or a totally unspecific (for ETA and unrelated MPs) manner. Other possible 
molecular mechanisms like the formation of covalent disulfide bridges or ionic interactions in 
the loop regions would be too specific, most likely requiring a special amino acid motif, than to 
occur as artefacts with unrelated MPs. 
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5.5.2.  Troubleshooting and suggestions for future experiments 
The problem which clearly arose from such false positives was the question how those 
nonspecific artefacts were generated. One possible explanation might reside in the choice of 
co-expression for the analysis of oligomerization. Co-expression of MPs in presence of high 
concentrations of detergents such as 0.5 % B35 used in the present study (~46 x CMC) might be 
ideally suited for the promotion of hydrophobic interactions. Unrelated proteins might be 
co-translationally expressed into the same micelle due to the excess of detergent. The possibility 
to form hydrophobic interactions might be caused by their spatial proximity that is kept tight by 
the micellar environment. Native interaction partners will show the same behaviour, rendering it 
impossible to differentiate between specific interaction and nonspecific association. 
The idea of artificially generated spatial proximity by the surrounding micelle being 
responsible for those artefacts is supported by the observation that the interactions gained from 
individually CF expressed ET receptors mixed directly from separate RM (Fig.  49) or 
truncations which were purified beforehand (Fig. 49 B), is reduced to only estimated 1-10 %. 
The combination of separately expressed interaction partners might however also have 
draw-backs with regard to the decreased interaction intensity with ETA. While the 
co-expression assay might generate artificial proximity, the individual expression of supposed 
interaction partners might create such large micelles around the single receptors, tumbling in 
three dimensions, that they can hardly find each other. In addition, the necessary interaction 
interfaces, especially if those contact areas are confined to the TMSs, are completely surrounded 
by detergent molecules. Not only the micellar dimensions which can be very large with B35 
(additional 50-100 kDa), but also the net charge of the detergent would play an important role in 
this case. Negatively charged micelles surrounding the protein such as LPPG might 
electrostatically repel each other with a high probability (Krueger-Koplin et al. 2004) so that the 
interacting proteins could hardly come into such a close contact necessary for homo- or hetero-
oligomerization (Fig. 49 left illustration). 
In order to identify specific interactions between the CF-expressed detergent-solubilized 
ET receptors with the given pull-down assay, different approaches are possible. (I) If the 
detergent itself creates spatial proximity in the co-expression approach and keeps the MPs 
tightly associated by its presence, detergent exchange breaking the influence of the previous 
detergent might remove unspecific association while stable specific interactions are preserved. 
(II) Specific interactions are supposed to be more stable than nonspecific association. 
Displacing an unspecifically bound MP by an interaction partner with a predicted higher affinity 
might therefore be a further option. 
Given the problems caused by the micellar environment, a more reasonable approach for this 
type of investigation is to go into membranes. FRET measurements already show a potential for 
the analysis of GPCR oligomerization (Overton and Blumer 2002). Physiological insertion Discussion   159 
 
levels are usually sufficient for FRET sensitivity (Patel et al. 2002), so that moderate 
reconstitution could already meet the requirements. The interaction between the single 
protomers would then occur in the 2-dimensional space of the natural lipid bilayer, in which the 
mobility of the receptors is much more directed than in the 3-dimensional space of the micelles. 
Specific interactions of ET receptors were already determined in crude membranes by FRET 
(Evans and Walker, 2008, Gregan et al. 2004a, 2004b). Single molecule FRET with 
co-reconstituted CF expressed ET receptors either obtained by classical post-translational or by 
co-translational reconstitution using the L-CF mode might therefore more reliably allow the 
determination of their specific homo- or hetero-oligomerization potential. 
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7.  Appendix 
 
7.1.  Primer sequences 
The respective restriction sites are indicated in bold letters. 
7.1.1.  Sequencing primers for pET-Vectors 
 
7.1.2.  Cloning primers for ETB without signal sequence and truncations 
 
 
7.1.3.  Cloning primers for site-directed mutagenesis in the ETA full-length 
receptor 
 
Vector Tag  Name  Sequence  TM 
[°C] 
pET -  T7-prom  5’ TAA TAC GAC TCA CTA TAG GG 
3’ 
54 
pET -  T7-term  5’ CTA GTT ATT GCT CAG CGG T 3’  55 
Vector Tag  Name  Sequence  TM 
[°C] 
pET 
21a(+) 
T7 (N) 
His10 (C) 
ETB1-bam_up  5’ CGG GGA TCC GAG GAG AGA 
GGC TTC CCG CCT GAC AGG 3’ 
75 
pET 
21a(+) 
T7 (N) 
His10 (C) 
ETB93_up  5’ CGG GGA TCC CCC ATC GAG 
ATC AAG GAG ACT TTC AAA 3’ 
68 
pET 
21a(+) 
T7 (N) 
His10 (C) 
ETB131_low  5’ CGG CTC GAG GCA CTT GTT 
CTT GTA GAT AAT TCT CAG AAG 3’ 
67 
pET 
21a(+) 
T7 (N) 
His10 (C) 
ETB131_lowstop  5’ CGG CTC GAG TTA CTT GTT CTT 
GTA GAT AAT TCT CAG AAG 3’ 
64 
pET 
21a(+) 
T7 (N) 
His10 (C) 
ETB_low_wo_ 
Cterm 
5’ CGG CTC GAG GCA TGA CTT 
AAA GCA GTT TTT GAA TCT 3’ 
64 
Vector Tag  Name  Sequence  TM 
[°C] 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA C/A 158_up  5’ GGC GTA TTT CTT GCC AGG CTG 
TTC CCC 3’ 
71 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA C/A 
158_low  
5’ GGG GAA CAG CTT GGC AAG 
AAA TAC GCC 3’ 
71 
pET 21a(+)  T7 (N) 
strep (C) 
ETA C/A 239_up  5’ CAG CAT AAA ACC GCT ATG 
GGC 3’ 
68 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA 
C/A239_low 
5’GCC ATT GAG CAT AGC GGT TTT 
ATG CTG 3’ 
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7.1.4.  Cloning primers for ETA full-length and truncations 
 
 
7.2.  Vector map of pET21a(+) used for the CF expression of the ET receptom 
 
Fig.  60: Schematic vector table of 
pET21a(+). The pET21a(His)10 
plasmid used in present study is a 
modified pET21a(+) vector. It contains 
additional four histidine codons 
downstream of the present six histidine 
codons resulting in a C-terminal 
poly(His)10-tag. The additional codons 
were inserted by site-directed 
mutagenesis by Dr. Christian Klammt. 
The vector carries a gene for ampicillin 
resistance. The black arrow represents 
the multiple cloning site.  
 
 
 
 
 
 
 
 
Vector Tag  Name  Sequence  TM 
[°C] 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA_up  5’ CCG AGA TCT ATG GAA ACC 
CTT TGC CTC AGG GCA TCC 3’ 
69 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA_low  5’ CCG CTC GAG GTT CAT GCT 
GTC CTT ATG GCT GCT CCG 3’ 
71 
pET 21a(+)  T7 (N) 
strep (C) 
ETAlow strep  5’ CCG CCA TGG CAT GCT GTC CTT 
ATG GCT GCT CCG 3’ 
71 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA107_low  5’ CCG CTC GAG CTG GTA AAT 
GAT CCT GAG CAG AGT TGC 3’ 
69 
pET 21a(+)  T7 (N) 
strep (C) 
ETA107_low 
strep 
5’ CGA CCA TGG CTG GTA AAT 
GAT CCT GAG CAG AGT TGC 3’ 
66 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA198_up  5’ CGA AGA TCT ATT GGG ATT 
CCT TTG GTA ACT GCC 3’ 
63 
pET 21a(+)  T7 (N) 
His10 (C) 
ETA197_low   5’ CCG CTC GAG TCC CTG AAC 
ACG ACT CCA GGA GGC 3’ 
73 
pET 21a(+)  T7 (N) 
strep (C) 
ETA197_low 
strep 
5’ CGA CCA TGG TCC CTG AAC 
ACG ACT CCA GGA GGC 3’ 
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7.3.  Primary sequences and labels of peptide ligands used for the functional 
analysis of CF expressed ET receptors 
 
 
 
 
 
 
Fig.  61: ETA ligand overview. Schematic illustration of ET-1 derivatives successfully used in the 
functional analysis of detergent-solubilized and reconstituted ETA. Type and sites of the various labels 
are indicated. The circular ET-1 was used as WT variant without any label, as commercial radioligand or 
as biotinylated ligand. The linear ET-1 was used in its fluorescein labelled form. All ligands except for 
the 
125I-ET-1 were kindly provided by Dr. Michael Beyermann (FMP, Berlin). 
 
7.4.  Standard curves for the calibration of size exclusion chromatography 
columns for the analysis of homogeneity and MALS 
 
 
Fig. 62: Calibration curves used for the 
quality analysis of ETA. (A, B) The old 
and new analytical scale Superdex 200 
3.2/30 columns were used for the gel 
filtration analysis. The semi-preparative 
scale Superdex 200 10/300 was applied to 
MALS analysis. 
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7.5.  List of crystallization screens used in the CrystalMation automated robotic 
parameter screening of CF expressed ETA 
7.5.1.  Commercially available screens 
The CubicPhase I Suite (Qiagen GmbH ,Germany), 22 °C 
The CubicPhase II Suite (Qiagen GmbH ,Germany), 22 °C 
The MbClass Suite (Qiagen GmbH ,Germany), 4 °C 
The MbClass II Suite (Qiagen GmbH ,Germany), 4 °C 
MemGold
TM (Molecular Dimensions Ltd., UK), 4 and 18 °C 
MemStart and MemPlus
TM (Molecular Dimensions Ltd., UK), 4 and 18 °C 
MemSys
TM and Sigma Membrane Kit (Molecular Dimensions Ltd., UK and Sigma-Aldrich 
Chemie GmbH, Germany), 4 and 18 °C 
PGA Screen
TM (Molecular Dimensions Ltd., UK), 4 °C 
JBScreen Pentaerythritol HTS (Jena Bioscience GmbH, Germany), 4 °C 
 
7.5.2.  Custom MPI screens 
Those screens were partly set up after Koszelak-Rosenblum et al. 2009 for crystallization in the 
MPI of Biophysics, Frankfurt/Main, Germany. 
Custom MPI pH Screen from 4 to 9.5, 4 °C and 18 °C 
MPI Custom Screen pH 5.6 A, 4 °C 
MPI Custom Screen pH 5.6 B, 4 °C 
MPI Custom Screen pH 5.6 C, 4 °C 
MPI Custom Screen pH 5.6 D, 4 °C 
MPI Custom Screen pH 7.0 A, 4 °C 
MPI Custom Screen pH 7.0 B, 4 °C 
MPI Custom Screen pH 7.0 C, 4 °C 
MPI Custom Screen pH 7.0 D, 4 °C 
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